nct_id,adverse_event_term,organ_system,serious,frequency_threshold,assessed_participants,affected_participants,events,event_type,antibody_name,antibody_category,indication,phase,enrollment
NCT36359049,Infusion related reaction,General disorders and administration site conditions,No,15%,245,1,2,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 1,245
NCT36359049,Infection,Infections and infestations,Yes,10%,245,7,13,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 1,245
NCT36359049,Infusion related reaction,General disorders and administration site conditions,No,15%,245,15,25,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 1,245
NCT36359049,Cytopenia,Blood and lymphatic system disorders,No,15%,245,1,2,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 1,245
NCT36359049,Infection,Infections and infestations,Yes,15%,245,13,24,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 1,245
NCT36359049,Infusion related reaction,General disorders and administration site conditions,No,5%,245,14,21,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 1,245
NCT36359049,Infusion related reaction,General disorders and administration site conditions,No,15%,245,10,20,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 1,245
NCT36359049,Cytopenia,Blood and lymphatic system disorders,No,5%,245,5,9,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 1,245
NCT36359049,Cytopenia,Blood and lymphatic system disorders,No,15%,245,12,20,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 1,245
NCT48729418,Infusion related reaction,General disorders and administration site conditions,No,5%,865,1,1,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 1,865
NCT48729418,Cytopenia,Blood and lymphatic system disorders,No,5%,865,24,42,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 1,865
NCT48729418,Infection,Infections and infestations,Yes,15%,865,12,18,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 1,865
NCT48729418,Infusion related reaction,General disorders and administration site conditions,No,15%,865,4,6,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 1,865
NCT48729418,Cytopenia,Blood and lymphatic system disorders,No,15%,865,42,70,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 1,865
NCT48729418,Infection,Infections and infestations,Yes,10%,865,47,66,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 1,865
NCT32734633,Cytopenia,Blood and lymphatic system disorders,No,15%,673,11,16,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 1,673
NCT32734633,Infection,Infections and infestations,Yes,10%,673,38,54,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 1,673
NCT32734633,Cytopenia,Blood and lymphatic system disorders,No,5%,673,18,19,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 1,673
NCT32734633,Cytopenia,Blood and lymphatic system disorders,No,5%,673,7,12,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 1,673
NCT32734633,Cytopenia,Blood and lymphatic system disorders,No,10%,673,9,9,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 1,673
NCT32734633,Infection,Infections and infestations,Yes,10%,673,21,21,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 1,673
NCT32734633,Infusion related reaction,General disorders and administration site conditions,No,5%,673,48,54,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 1,673
NCT32734633,Infection,Infections and infestations,Yes,10%,673,14,22,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 1,673
NCT57871801,Infection,Infections and infestations,Yes,10%,310,7,10,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 2,310
NCT57871801,Infection,Infections and infestations,Yes,5%,310,31,54,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 2,310
NCT57871801,Infection,Infections and infestations,Yes,5%,310,12,21,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 2,310
NCT57871801,Infection,Infections and infestations,Yes,10%,310,11,15,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 2,310
NCT57871801,Cytopenia,Blood and lymphatic system disorders,No,10%,310,12,21,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 2,310
NCT57871801,Infection,Infections and infestations,Yes,15%,310,22,41,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 2,310
NCT57871801,Cytopenia,Blood and lymphatic system disorders,No,15%,310,29,43,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 2,310
NCT83581942,Infection,Infections and infestations,Yes,10%,72,4,6,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 2,72
NCT83581942,Cytopenia,Blood and lymphatic system disorders,No,10%,72,6,6,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 2,72
NCT83581942,Infection,Infections and infestations,Yes,10%,72,5,9,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 2,72
NCT83581942,Infusion related reaction,General disorders and administration site conditions,No,15%,72,6,6,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 2,72
NCT83581942,Infusion related reaction,General disorders and administration site conditions,No,15%,72,2,4,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 2,72
NCT83581942,Infection,Infections and infestations,Yes,15%,72,7,8,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 2,72
NCT83581942,Cytopenia,Blood and lymphatic system disorders,No,5%,72,5,6,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 2,72
NCT83581942,Infusion related reaction,General disorders and administration site conditions,No,10%,72,5,5,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 2,72
NCT83581942,Infection,Infections and infestations,Yes,10%,72,5,7,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 2,72
NCT23823136,Infection,Infections and infestations,Yes,10%,230,13,25,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 3,230
NCT23823136,Infection,Infections and infestations,Yes,10%,230,9,9,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 3,230
NCT23823136,Infection,Infections and infestations,Yes,15%,230,10,14,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 3,230
NCT23823136,Infusion related reaction,General disorders and administration site conditions,No,15%,230,19,20,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 3,230
NCT23823136,Cytopenia,Blood and lymphatic system disorders,No,15%,230,12,22,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 3,230
NCT23823136,Cytopenia,Blood and lymphatic system disorders,No,5%,230,1,2,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 3,230
NCT23823136,Infusion related reaction,General disorders and administration site conditions,No,10%,230,21,28,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 3,230
NCT23823136,Cytopenia,Blood and lymphatic system disorders,No,15%,230,4,5,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 3,230
NCT23823136,Infusion related reaction,General disorders and administration site conditions,No,15%,230,10,17,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 3,230
NCT23823136,Cytopenia,Blood and lymphatic system disorders,No,10%,230,15,21,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 3,230
NCT23823136,Infusion related reaction,General disorders and administration site conditions,No,5%,230,4,4,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 3,230
NCT93654326,Infusion related reaction,General disorders and administration site conditions,No,10%,412,25,40,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 3,412
NCT93654326,Infection,Infections and infestations,Yes,5%,412,3,4,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 3,412
NCT93654326,Cytopenia,Blood and lymphatic system disorders,No,15%,412,30,60,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 3,412
NCT93654326,Infusion related reaction,General disorders and administration site conditions,No,15%,412,29,55,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 3,412
NCT64586623,Infection,Infections and infestations,Yes,15%,396,14,27,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 3,396
NCT64586623,Cytopenia,Blood and lymphatic system disorders,No,10%,396,2,4,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 3,396
NCT64586623,Infection,Infections and infestations,Yes,15%,396,23,38,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 3,396
NCT64586623,Infusion related reaction,General disorders and administration site conditions,No,15%,396,21,37,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 3,396
NCT64586623,Infusion related reaction,General disorders and administration site conditions,No,5%,396,11,11,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 3,396
NCT64586623,Cytopenia,Blood and lymphatic system disorders,No,5%,396,18,26,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 3,396
NCT64586623,Cytopenia,Blood and lymphatic system disorders,No,15%,396,32,32,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 3,396
NCT64586623,Infection,Infections and infestations,Yes,5%,396,22,22,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 3,396
NCT64586623,Infusion related reaction,General disorders and administration site conditions,No,5%,396,23,30,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 3,396
NCT64586623,Cytopenia,Blood and lymphatic system disorders,No,15%,396,7,8,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 3,396
NCT64586623,Infusion related reaction,General disorders and administration site conditions,No,15%,396,12,22,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 3,396
NCT17057020,Infection,Infections and infestations,Yes,10%,639,2,3,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 4,639
NCT17057020,Cytopenia,Blood and lymphatic system disorders,No,10%,639,47,76,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 4,639
NCT17057020,Infection,Infections and infestations,Yes,10%,639,30,34,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 4,639
NCT17057020,Infection,Infections and infestations,Yes,15%,639,42,42,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 4,639
NCT44586030,Infection,Infections and infestations,Yes,15%,206,5,7,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 4,206
NCT44586030,Cytopenia,Blood and lymphatic system disorders,No,15%,206,1,2,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 4,206
NCT44586030,Cytopenia,Blood and lymphatic system disorders,No,5%,206,14,20,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 4,206
NCT44586030,Cytopenia,Blood and lymphatic system disorders,No,5%,206,4,5,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 4,206
NCT44586030,Cytopenia,Blood and lymphatic system disorders,No,5%,206,7,9,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 4,206
NCT67064918,Infection,Infections and infestations,Yes,5%,812,30,55,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 4,812
NCT67064918,Infusion related reaction,General disorders and administration site conditions,No,15%,812,20,37,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 4,812
NCT67064918,Infection,Infections and infestations,Yes,5%,812,2,2,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 4,812
NCT67064918,Cytopenia,Blood and lymphatic system disorders,No,5%,812,19,26,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 4,812
NCT67064918,Infusion related reaction,General disorders and administration site conditions,No,10%,812,43,47,All Causality,Rituximab,Anti-CD20,Lymphoma,Phase 4,812
NCT67064918,Cytopenia,Blood and lymphatic system disorders,No,10%,812,45,59,Treatment Emergent,Rituximab,Anti-CD20,Lymphoma,Phase 4,812
NCT98784408,Cytopenia,Blood and lymphatic system disorders,No,10%,907,20,22,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 1,907
NCT98784408,Infusion related reaction,General disorders and administration site conditions,No,5%,907,36,64,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 1,907
NCT98784408,Cytopenia,Blood and lymphatic system disorders,No,15%,907,41,51,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 1,907
NCT98784408,Infusion related reaction,General disorders and administration site conditions,No,15%,907,49,52,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 1,907
NCT98784408,Cytopenia,Blood and lymphatic system disorders,No,10%,907,8,8,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 1,907
NCT98784408,Infusion related reaction,General disorders and administration site conditions,No,10%,907,45,83,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 1,907
NCT98784408,Infection,Infections and infestations,Yes,15%,907,49,94,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 1,907
NCT98784408,Infection,Infections and infestations,Yes,5%,907,43,44,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 1,907
NCT98784408,Infection,Infections and infestations,Yes,5%,907,16,18,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 1,907
NCT98784408,Cytopenia,Blood and lymphatic system disorders,No,15%,907,13,17,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 1,907
NCT98784408,Cytopenia,Blood and lymphatic system disorders,No,5%,907,11,21,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 1,907
NCT98784408,Infection,Infections and infestations,Yes,15%,907,44,81,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 1,907
NCT16782352,Infection,Infections and infestations,Yes,10%,777,6,9,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 1,777
NCT16782352,Infection,Infections and infestations,Yes,10%,777,29,34,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 1,777
NCT16782352,Infusion related reaction,General disorders and administration site conditions,No,5%,777,30,38,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 1,777
NCT16782352,Cytopenia,Blood and lymphatic system disorders,No,5%,777,33,48,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 1,777
NCT16782352,Infection,Infections and infestations,Yes,15%,777,6,7,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 1,777
NCT16782352,Cytopenia,Blood and lymphatic system disorders,No,5%,777,15,18,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 1,777
NCT16782352,Infection,Infections and infestations,Yes,15%,777,50,59,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 1,777
NCT16782352,Infection,Infections and infestations,Yes,15%,777,29,50,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 1,777
NCT16782352,Infection,Infections and infestations,Yes,10%,777,27,53,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 1,777
NCT16782352,Infection,Infections and infestations,Yes,10%,777,30,44,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 1,777
NCT16782352,Infusion related reaction,General disorders and administration site conditions,No,15%,777,17,17,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 1,777
NCT85076861,Infusion related reaction,General disorders and administration site conditions,No,5%,870,35,41,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 1,870
NCT85076861,Infection,Infections and infestations,Yes,10%,870,25,44,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 1,870
NCT85076861,Cytopenia,Blood and lymphatic system disorders,No,10%,870,19,34,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 1,870
NCT85076861,Cytopenia,Blood and lymphatic system disorders,No,10%,870,19,35,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 1,870
NCT85076861,Cytopenia,Blood and lymphatic system disorders,No,10%,870,27,48,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 1,870
NCT85076861,Infusion related reaction,General disorders and administration site conditions,No,5%,870,10,18,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 1,870
NCT85076861,Infection,Infections and infestations,Yes,15%,870,17,21,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 1,870
NCT85076861,Infusion related reaction,General disorders and administration site conditions,No,5%,870,50,65,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 1,870
NCT85076861,Cytopenia,Blood and lymphatic system disorders,No,10%,870,6,8,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 1,870
NCT85076861,Infection,Infections and infestations,Yes,15%,870,27,50,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 1,870
NCT82030671,Infusion related reaction,General disorders and administration site conditions,No,15%,579,17,19,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 2,579
NCT82030671,Cytopenia,Blood and lymphatic system disorders,No,10%,579,43,54,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 2,579
NCT82030671,Infection,Infections and infestations,Yes,5%,579,3,6,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 2,579
NCT82030671,Cytopenia,Blood and lymphatic system disorders,No,15%,579,1,2,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 2,579
NCT82030671,Infusion related reaction,General disorders and administration site conditions,No,5%,579,32,34,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 2,579
NCT82030671,Infection,Infections and infestations,Yes,10%,579,41,44,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 2,579
NCT82030671,Cytopenia,Blood and lymphatic system disorders,No,15%,579,25,33,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 2,579
NCT82030671,Infection,Infections and infestations,Yes,5%,579,38,66,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 2,579
NCT82030671,Cytopenia,Blood and lymphatic system disorders,No,5%,579,22,30,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 2,579
NCT82030671,Infection,Infections and infestations,Yes,10%,579,22,22,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 2,579
NCT82030671,Cytopenia,Blood and lymphatic system disorders,No,15%,579,40,45,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 2,579
NCT82030671,Cytopenia,Blood and lymphatic system disorders,No,10%,579,35,46,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 2,579
NCT82030671,Infection,Infections and infestations,Yes,10%,579,14,18,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 2,579
NCT82030671,Cytopenia,Blood and lymphatic system disorders,No,10%,579,14,25,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 2,579
NCT82030671,Cytopenia,Blood and lymphatic system disorders,No,10%,579,28,56,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 2,579
NCT68989080,Cytopenia,Blood and lymphatic system disorders,No,10%,646,50,52,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 3,646
NCT68989080,Infusion related reaction,General disorders and administration site conditions,No,5%,646,30,33,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 3,646
NCT68989080,Infusion related reaction,General disorders and administration site conditions,No,15%,646,12,16,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 3,646
NCT68989080,Infusion related reaction,General disorders and administration site conditions,No,15%,646,50,83,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 3,646
NCT68989080,Cytopenia,Blood and lymphatic system disorders,No,5%,646,25,42,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 3,646
NCT68989080,Cytopenia,Blood and lymphatic system disorders,No,5%,646,22,34,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 3,646
NCT68989080,Infusion related reaction,General disorders and administration site conditions,No,10%,646,9,18,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 3,646
NCT68989080,Infection,Infections and infestations,Yes,15%,646,2,2,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 3,646
NCT68989080,Cytopenia,Blood and lymphatic system disorders,No,10%,646,5,8,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 3,646
NCT68989080,Infection,Infections and infestations,Yes,10%,646,28,42,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 3,646
NCT68989080,Cytopenia,Blood and lymphatic system disorders,No,10%,646,27,50,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 3,646
NCT69137751,Infection,Infections and infestations,Yes,15%,983,13,26,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 3,983
NCT69137751,Infusion related reaction,General disorders and administration site conditions,No,10%,983,7,10,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 3,983
NCT69137751,Cytopenia,Blood and lymphatic system disorders,No,15%,983,1,1,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 3,983
NCT69137751,Infection,Infections and infestations,Yes,15%,983,10,11,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 3,983
NCT48835969,Cytopenia,Blood and lymphatic system disorders,No,15%,766,39,49,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 4,766
NCT48835969,Infusion related reaction,General disorders and administration site conditions,No,5%,766,31,47,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 4,766
NCT48835969,Infusion related reaction,General disorders and administration site conditions,No,10%,766,25,50,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 4,766
NCT48835969,Cytopenia,Blood and lymphatic system disorders,No,15%,766,4,6,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 4,766
NCT48835969,Infusion related reaction,General disorders and administration site conditions,No,5%,766,1,2,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 4,766
NCT48835969,Cytopenia,Blood and lymphatic system disorders,No,15%,766,21,23,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 4,766
NCT48835969,Cytopenia,Blood and lymphatic system disorders,No,5%,766,31,32,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 4,766
NCT48835969,Infection,Infections and infestations,Yes,15%,766,19,32,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 4,766
NCT48835969,Cytopenia,Blood and lymphatic system disorders,No,15%,766,21,24,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 4,766
NCT48835969,Cytopenia,Blood and lymphatic system disorders,No,5%,766,46,51,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 4,766
NCT48835969,Infection,Infections and infestations,Yes,15%,766,21,41,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 4,766
NCT48835969,Infection,Infections and infestations,Yes,15%,766,24,33,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 4,766
NCT48835969,Infection,Infections and infestations,Yes,15%,766,32,59,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 4,766
NCT59816313,Infection,Infections and infestations,Yes,10%,526,9,16,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 4,526
NCT59816313,Infusion related reaction,General disorders and administration site conditions,No,5%,526,27,30,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 4,526
NCT59816313,Infusion related reaction,General disorders and administration site conditions,No,10%,526,1,2,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 4,526
NCT59816313,Infusion related reaction,General disorders and administration site conditions,No,15%,526,37,52,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 4,526
NCT59816313,Infection,Infections and infestations,Yes,15%,526,24,30,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 4,526
NCT59816313,Infusion related reaction,General disorders and administration site conditions,No,15%,526,34,67,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 4,526
NCT57743063,Infusion related reaction,General disorders and administration site conditions,No,10%,149,6,11,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 4,149
NCT57743063,Cytopenia,Blood and lymphatic system disorders,No,10%,149,7,7,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 4,149
NCT57743063,Infusion related reaction,General disorders and administration site conditions,No,15%,149,5,5,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 4,149
NCT57743063,Infusion related reaction,General disorders and administration site conditions,No,15%,149,11,11,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 4,149
NCT57743063,Infection,Infections and infestations,Yes,15%,149,14,16,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 4,149
NCT57743063,Cytopenia,Blood and lymphatic system disorders,No,10%,149,14,24,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 4,149
NCT57743063,Cytopenia,Blood and lymphatic system disorders,No,5%,149,3,4,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 4,149
NCT57743063,Cytopenia,Blood and lymphatic system disorders,No,5%,149,10,16,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 4,149
NCT57743063,Cytopenia,Blood and lymphatic system disorders,No,15%,149,9,10,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 4,149
NCT57743063,Infusion related reaction,General disorders and administration site conditions,No,15%,149,2,2,All Causality,Rituximab,Anti-CD20,Leukemia,Phase 4,149
NCT57743063,Infusion related reaction,General disorders and administration site conditions,No,10%,149,3,4,Treatment Emergent,Rituximab,Anti-CD20,Leukemia,Phase 4,149
NCT91513091,Infusion related reaction,General disorders and administration site conditions,No,10%,480,30,31,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 1,480
NCT91513091,Cytopenia,Blood and lymphatic system disorders,No,5%,480,35,66,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 1,480
NCT91513091,Cytopenia,Blood and lymphatic system disorders,No,5%,480,11,19,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 1,480
NCT91513091,Infection,Infections and infestations,Yes,10%,480,19,31,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 1,480
NCT91513091,Cytopenia,Blood and lymphatic system disorders,No,15%,480,34,62,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 1,480
NCT91513091,Infusion related reaction,General disorders and administration site conditions,No,10%,480,9,18,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 1,480
NCT91513091,Infection,Infections and infestations,Yes,10%,480,38,50,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 1,480
NCT91513091,Cytopenia,Blood and lymphatic system disorders,No,15%,480,41,68,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 1,480
NCT91513091,Infusion related reaction,General disorders and administration site conditions,No,5%,480,46,58,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 1,480
NCT91513091,Cytopenia,Blood and lymphatic system disorders,No,10%,480,48,81,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 1,480
NCT91513091,Cytopenia,Blood and lymphatic system disorders,No,10%,480,34,55,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 1,480
NCT91513091,Infusion related reaction,General disorders and administration site conditions,No,5%,480,20,22,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 1,480
NCT91513091,Infusion related reaction,General disorders and administration site conditions,No,15%,480,40,54,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 1,480
NCT91513091,Infusion related reaction,General disorders and administration site conditions,No,5%,480,3,3,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 1,480
NCT91513091,Cytopenia,Blood and lymphatic system disorders,No,15%,480,41,53,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 1,480
NCT24762298,Infusion related reaction,General disorders and administration site conditions,No,10%,390,13,25,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 1,390
NCT24762298,Infection,Infections and infestations,Yes,5%,390,20,40,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 1,390
NCT24762298,Infusion related reaction,General disorders and administration site conditions,No,15%,390,30,55,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 1,390
NCT24762298,Infusion related reaction,General disorders and administration site conditions,No,10%,390,14,21,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 1,390
NCT24762298,Cytopenia,Blood and lymphatic system disorders,No,10%,390,32,55,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 1,390
NCT24762298,Infection,Infections and infestations,Yes,15%,390,15,17,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 1,390
NCT24762298,Infusion related reaction,General disorders and administration site conditions,No,5%,390,10,14,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 1,390
NCT24762298,Infusion related reaction,General disorders and administration site conditions,No,10%,390,27,51,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 1,390
NCT29922611,Infection,Infections and infestations,Yes,10%,288,23,26,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 2,288
NCT29922611,Cytopenia,Blood and lymphatic system disorders,No,15%,288,6,10,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 2,288
NCT29922611,Cytopenia,Blood and lymphatic system disorders,No,10%,288,18,23,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 2,288
NCT29922611,Infusion related reaction,General disorders and administration site conditions,No,15%,288,4,4,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 2,288
NCT29922611,Infection,Infections and infestations,Yes,10%,288,4,8,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 2,288
NCT29922611,Cytopenia,Blood and lymphatic system disorders,No,10%,288,19,27,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 2,288
NCT29922611,Cytopenia,Blood and lymphatic system disorders,No,15%,288,16,23,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 2,288
NCT29922611,Infusion related reaction,General disorders and administration site conditions,No,5%,288,16,21,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 2,288
NCT29922611,Infusion related reaction,General disorders and administration site conditions,No,10%,288,2,4,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 2,288
NCT29922611,Infection,Infections and infestations,Yes,15%,288,11,15,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 2,288
NCT70687198,Infection,Infections and infestations,Yes,10%,970,22,31,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 2,970
NCT70687198,Cytopenia,Blood and lymphatic system disorders,No,10%,970,2,4,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 2,970
NCT70687198,Infusion related reaction,General disorders and administration site conditions,No,10%,970,50,98,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 2,970
NCT70687198,Cytopenia,Blood and lymphatic system disorders,No,10%,970,1,1,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 2,970
NCT65627719,Infusion related reaction,General disorders and administration site conditions,No,10%,36,2,2,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 3,36
NCT65627719,Infection,Infections and infestations,Yes,5%,36,1,2,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 3,36
NCT65627719,Infection,Infections and infestations,Yes,10%,36,2,3,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 3,36
NCT65627719,Cytopenia,Blood and lymphatic system disorders,No,5%,36,1,2,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 3,36
NCT65627719,Infection,Infections and infestations,Yes,15%,36,2,4,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 3,36
NCT65627719,Cytopenia,Blood and lymphatic system disorders,No,10%,36,2,2,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 3,36
NCT65627719,Cytopenia,Blood and lymphatic system disorders,No,5%,36,1,2,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 3,36
NCT65627719,Cytopenia,Blood and lymphatic system disorders,No,10%,36,3,5,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 3,36
NCT39275439,Cytopenia,Blood and lymphatic system disorders,No,15%,525,4,5,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 3,525
NCT39275439,Infusion related reaction,General disorders and administration site conditions,No,5%,525,42,66,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 3,525
NCT39275439,Infusion related reaction,General disorders and administration site conditions,No,5%,525,11,14,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 3,525
NCT39275439,Infusion related reaction,General disorders and administration site conditions,No,10%,525,12,17,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 3,525
NCT39275439,Cytopenia,Blood and lymphatic system disorders,No,5%,525,22,42,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 3,525
NCT39275439,Cytopenia,Blood and lymphatic system disorders,No,5%,525,31,55,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 3,525
NCT39275439,Cytopenia,Blood and lymphatic system disorders,No,10%,525,16,28,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 3,525
NCT39275439,Infusion related reaction,General disorders and administration site conditions,No,5%,525,16,29,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 3,525
NCT39275439,Infusion related reaction,General disorders and administration site conditions,No,5%,525,5,7,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 3,525
NCT39275439,Infection,Infections and infestations,Yes,15%,525,45,81,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 3,525
NCT13086082,Cytopenia,Blood and lymphatic system disorders,No,10%,196,18,20,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 4,196
NCT13086082,Infection,Infections and infestations,Yes,10%,196,18,29,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 4,196
NCT13086082,Cytopenia,Blood and lymphatic system disorders,No,10%,196,15,22,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 4,196
NCT13086082,Cytopenia,Blood and lymphatic system disorders,No,5%,196,15,17,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 4,196
NCT13086082,Infusion related reaction,General disorders and administration site conditions,No,5%,196,2,2,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 4,196
NCT13086082,Infusion related reaction,General disorders and administration site conditions,No,10%,196,19,30,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 4,196
NCT13086082,Cytopenia,Blood and lymphatic system disorders,No,15%,196,17,28,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 4,196
NCT16210378,Cytopenia,Blood and lymphatic system disorders,No,5%,911,50,61,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 4,911
NCT16210378,Cytopenia,Blood and lymphatic system disorders,No,5%,911,6,10,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 4,911
NCT16210378,Infection,Infections and infestations,Yes,10%,911,43,56,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 4,911
NCT16210378,Cytopenia,Blood and lymphatic system disorders,No,15%,911,34,63,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 4,911
NCT16210378,Infection,Infections and infestations,Yes,5%,911,7,12,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 4,911
NCT16210378,Infusion related reaction,General disorders and administration site conditions,No,10%,911,24,45,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 4,911
NCT16210378,Infection,Infections and infestations,Yes,15%,911,12,21,All Causality,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 4,911
NCT16210378,Infection,Infections and infestations,Yes,5%,911,33,66,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 4,911
NCT16210378,Infusion related reaction,General disorders and administration site conditions,No,15%,911,26,31,Treatment Emergent,Rituximab,Anti-CD20,Multiple Sclerosis,Phase 4,911
NCT24962589,Infusion related reaction,General disorders and administration site conditions,No,5%,88,6,12,Treatment Emergent,Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,88
NCT24962589,Infection,Infections and infestations,Yes,10%,88,2,3,Treatment Emergent,Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,88
NCT24962589,Infection,Infections and infestations,Yes,10%,88,3,6,Treatment Emergent,Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,88
NCT24962589,Infection,Infections and infestations,Yes,5%,88,7,14,All Causality,Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,88
NCT24962589,Infusion related reaction,General disorders and administration site conditions,No,10%,88,1,1,Treatment Emergent,Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,88
NCT24962589,Infection,Infections and infestations,Yes,10%,88,1,2,All Causality,Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,88
NCT24962589,Infection,Infections and infestations,Yes,15%,88,4,5,Treatment Emergent,Obinutuzumab,Anti-CD20,Lymphoma,Phase 1,88
NCT32126806,Infusion related reaction,General disorders and administration site conditions,No,15%,74,6,6,Treatment Emergent,Obinutuzumab,Anti-CD20,Lymphoma,Phase 2,74
NCT32126806,Infection,Infections and infestations,Yes,5%,74,3,6,All Causality,Obinutuzumab,Anti-CD20,Lymphoma,Phase 2,74
NCT32126806,Cytopenia,Blood and lymphatic system disorders,No,10%,74,6,11,All Causality,Obinutuzumab,Anti-CD20,Lymphoma,Phase 2,74
NCT32126806,Infection,Infections and infestations,Yes,10%,74,7,8,All Causality,Obinutuzumab,Anti-CD20,Lymphoma,Phase 2,74
NCT32126806,Infusion related reaction,General disorders and administration site conditions,No,10%,74,6,8,Treatment Emergent,Obinutuzumab,Anti-CD20,Lymphoma,Phase 2,74
NCT32126806,Infusion related reaction,General disorders and administration site conditions,No,5%,74,6,11,Treatment Emergent,Obinutuzumab,Anti-CD20,Lymphoma,Phase 2,74
NCT32126806,Cytopenia,Blood and lymphatic system disorders,No,15%,74,4,7,Treatment Emergent,Obinutuzumab,Anti-CD20,Lymphoma,Phase 2,74
NCT40778145,Cytopenia,Blood and lymphatic system disorders,No,15%,514,16,31,All Causality,Obinutuzumab,Anti-CD20,Lymphoma,Phase 2,514
NCT40778145,Infusion related reaction,General disorders and administration site conditions,No,15%,514,6,11,Treatment Emergent,Obinutuzumab,Anti-CD20,Lymphoma,Phase 2,514
NCT40778145,Infusion related reaction,General disorders and administration site conditions,No,10%,514,18,23,Treatment Emergent,Obinutuzumab,Anti-CD20,Lymphoma,Phase 2,514
NCT40778145,Infusion related reaction,General disorders and administration site conditions,No,10%,514,48,74,All Causality,Obinutuzumab,Anti-CD20,Lymphoma,Phase 2,514
NCT40778145,Cytopenia,Blood and lymphatic system disorders,No,15%,514,15,29,All Causality,Obinutuzumab,Anti-CD20,Lymphoma,Phase 2,514
NCT27960108,Cytopenia,Blood and lymphatic system disorders,No,15%,340,7,12,All Causality,Obinutuzumab,Anti-CD20,Lymphoma,Phase 3,340
NCT27960108,Cytopenia,Blood and lymphatic system disorders,No,5%,340,12,14,Treatment Emergent,Obinutuzumab,Anti-CD20,Lymphoma,Phase 3,340
NCT27960108,Cytopenia,Blood and lymphatic system disorders,No,10%,340,21,29,Treatment Emergent,Obinutuzumab,Anti-CD20,Lymphoma,Phase 3,340
NCT27960108,Cytopenia,Blood and lymphatic system disorders,No,15%,340,22,37,All Causality,Obinutuzumab,Anti-CD20,Lymphoma,Phase 3,340
NCT27960108,Infusion related reaction,General disorders and administration site conditions,No,10%,340,30,49,All Causality,Obinutuzumab,Anti-CD20,Lymphoma,Phase 3,340
NCT27960108,Cytopenia,Blood and lymphatic system disorders,No,10%,340,18,36,All Causality,Obinutuzumab,Anti-CD20,Lymphoma,Phase 3,340
NCT27960108,Infusion related reaction,General disorders and administration site conditions,No,10%,340,25,30,All Causality,Obinutuzumab,Anti-CD20,Lymphoma,Phase 3,340
NCT27960108,Infection,Infections and infestations,Yes,15%,340,7,14,Treatment Emergent,Obinutuzumab,Anti-CD20,Lymphoma,Phase 3,340
NCT27960108,Infusion related reaction,General disorders and administration site conditions,No,10%,340,19,29,All Causality,Obinutuzumab,Anti-CD20,Lymphoma,Phase 3,340
NCT27960108,Cytopenia,Blood and lymphatic system disorders,No,10%,340,19,35,Treatment Emergent,Obinutuzumab,Anti-CD20,Lymphoma,Phase 3,340
NCT18105917,Cytopenia,Blood and lymphatic system disorders,No,5%,783,24,26,Treatment Emergent,Obinutuzumab,Anti-CD20,Lymphoma,Phase 3,783
NCT18105917,Infusion related reaction,General disorders and administration site conditions,No,10%,783,7,12,All Causality,Obinutuzumab,Anti-CD20,Lymphoma,Phase 3,783
NCT18105917,Cytopenia,Blood and lymphatic system disorders,No,15%,783,9,15,Treatment Emergent,Obinutuzumab,Anti-CD20,Lymphoma,Phase 3,783
NCT18105917,Cytopenia,Blood and lymphatic system disorders,No,5%,783,21,42,Treatment Emergent,Obinutuzumab,Anti-CD20,Lymphoma,Phase 3,783
NCT18105917,Infection,Infections and infestations,Yes,10%,783,46,61,All Causality,Obinutuzumab,Anti-CD20,Lymphoma,Phase 3,783
NCT18105917,Cytopenia,Blood and lymphatic system disorders,No,15%,783,41,81,Treatment Emergent,Obinutuzumab,Anti-CD20,Lymphoma,Phase 3,783
NCT18105917,Infusion related reaction,General disorders and administration site conditions,No,15%,783,45,45,Treatment Emergent,Obinutuzumab,Anti-CD20,Lymphoma,Phase 3,783
NCT18105917,Infusion related reaction,General disorders and administration site conditions,No,15%,783,25,49,All Causality,Obinutuzumab,Anti-CD20,Lymphoma,Phase 3,783
NCT18105917,Infection,Infections and infestations,Yes,10%,783,26,51,All Causality,Obinutuzumab,Anti-CD20,Lymphoma,Phase 3,783
NCT47616921,Cytopenia,Blood and lymphatic system disorders,No,15%,346,19,27,Treatment Emergent,Obinutuzumab,Anti-CD20,Lymphoma,Phase 4,346
NCT47616921,Infusion related reaction,General disorders and administration site conditions,No,10%,346,7,13,Treatment Emergent,Obinutuzumab,Anti-CD20,Lymphoma,Phase 4,346
NCT47616921,Cytopenia,Blood and lymphatic system disorders,No,5%,346,8,16,All Causality,Obinutuzumab,Anti-CD20,Lymphoma,Phase 4,346
NCT47616921,Infusion related reaction,General disorders and administration site conditions,No,5%,346,12,12,All Causality,Obinutuzumab,Anti-CD20,Lymphoma,Phase 4,346
NCT47616921,Cytopenia,Blood and lymphatic system disorders,No,10%,346,34,60,Treatment Emergent,Obinutuzumab,Anti-CD20,Lymphoma,Phase 4,346
NCT63782469,Infusion related reaction,General disorders and administration site conditions,No,10%,620,23,43,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 1,620
NCT63782469,Infection,Infections and infestations,Yes,10%,620,1,1,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 1,620
NCT63782469,Cytopenia,Blood and lymphatic system disorders,No,15%,620,9,15,Treatment Emergent,Obinutuzumab,Anti-CD20,Leukemia,Phase 1,620
NCT63782469,Infusion related reaction,General disorders and administration site conditions,No,5%,620,18,22,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 1,620
NCT63782469,Infection,Infections and infestations,Yes,10%,620,27,39,Treatment Emergent,Obinutuzumab,Anti-CD20,Leukemia,Phase 1,620
NCT63782469,Cytopenia,Blood and lymphatic system disorders,No,10%,620,35,39,Treatment Emergent,Obinutuzumab,Anti-CD20,Leukemia,Phase 1,620
NCT63782469,Infusion related reaction,General disorders and administration site conditions,No,5%,620,11,16,Treatment Emergent,Obinutuzumab,Anti-CD20,Leukemia,Phase 1,620
NCT63782469,Infusion related reaction,General disorders and administration site conditions,No,15%,620,23,35,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 1,620
NCT63782469,Cytopenia,Blood and lymphatic system disorders,No,5%,620,18,21,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 1,620
NCT63782469,Infection,Infections and infestations,Yes,10%,620,39,39,Treatment Emergent,Obinutuzumab,Anti-CD20,Leukemia,Phase 1,620
NCT63782469,Infusion related reaction,General disorders and administration site conditions,No,15%,620,7,13,Treatment Emergent,Obinutuzumab,Anti-CD20,Leukemia,Phase 1,620
NCT63782469,Cytopenia,Blood and lymphatic system disorders,No,15%,620,3,5,Treatment Emergent,Obinutuzumab,Anti-CD20,Leukemia,Phase 1,620
NCT63782469,Cytopenia,Blood and lymphatic system disorders,No,5%,620,47,68,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 1,620
NCT63782469,Cytopenia,Blood and lymphatic system disorders,No,5%,620,23,27,Treatment Emergent,Obinutuzumab,Anti-CD20,Leukemia,Phase 1,620
NCT20258271,Cytopenia,Blood and lymphatic system disorders,No,5%,900,26,32,Treatment Emergent,Obinutuzumab,Anti-CD20,Leukemia,Phase 1,900
NCT20258271,Cytopenia,Blood and lymphatic system disorders,No,5%,900,28,56,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 1,900
NCT20258271,Infusion related reaction,General disorders and administration site conditions,No,5%,900,13,18,Treatment Emergent,Obinutuzumab,Anti-CD20,Leukemia,Phase 1,900
NCT20258271,Infection,Infections and infestations,Yes,15%,900,32,55,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 1,900
NCT20258271,Infusion related reaction,General disorders and administration site conditions,No,10%,900,7,12,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 1,900
NCT20258271,Infection,Infections and infestations,Yes,10%,900,50,85,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 1,900
NCT20258271,Infection,Infections and infestations,Yes,10%,900,49,86,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 1,900
NCT20258271,Cytopenia,Blood and lymphatic system disorders,No,5%,900,21,26,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 1,900
NCT20258271,Infusion related reaction,General disorders and administration site conditions,No,10%,900,15,27,Treatment Emergent,Obinutuzumab,Anti-CD20,Leukemia,Phase 1,900
NCT20258271,Infusion related reaction,General disorders and administration site conditions,No,10%,900,9,16,Treatment Emergent,Obinutuzumab,Anti-CD20,Leukemia,Phase 1,900
NCT20258271,Infection,Infections and infestations,Yes,15%,900,48,52,Treatment Emergent,Obinutuzumab,Anti-CD20,Leukemia,Phase 1,900
NCT20258271,Infection,Infections and infestations,Yes,15%,900,16,20,Treatment Emergent,Obinutuzumab,Anti-CD20,Leukemia,Phase 1,900
NCT94625568,Infection,Infections and infestations,Yes,5%,160,16,22,Treatment Emergent,Obinutuzumab,Anti-CD20,Leukemia,Phase 2,160
NCT94625568,Infusion related reaction,General disorders and administration site conditions,No,10%,160,10,12,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 2,160
NCT94625568,Cytopenia,Blood and lymphatic system disorders,No,15%,160,11,18,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 2,160
NCT94625568,Infusion related reaction,General disorders and administration site conditions,No,5%,160,4,6,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 2,160
NCT94625568,Cytopenia,Blood and lymphatic system disorders,No,5%,160,1,1,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 2,160
NCT94625568,Cytopenia,Blood and lymphatic system disorders,No,10%,160,4,8,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 2,160
NCT94625568,Infection,Infections and infestations,Yes,5%,160,7,7,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 2,160
NCT94625568,Cytopenia,Blood and lymphatic system disorders,No,5%,160,7,9,Treatment Emergent,Obinutuzumab,Anti-CD20,Leukemia,Phase 2,160
NCT94625568,Infusion related reaction,General disorders and administration site conditions,No,15%,160,14,27,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 2,160
NCT94625568,Cytopenia,Blood and lymphatic system disorders,No,15%,160,7,14,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 2,160
NCT94625568,Infection,Infections and infestations,Yes,15%,160,7,13,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 2,160
NCT94625568,Cytopenia,Blood and lymphatic system disorders,No,5%,160,5,9,Treatment Emergent,Obinutuzumab,Anti-CD20,Leukemia,Phase 2,160
NCT51289540,Cytopenia,Blood and lymphatic system disorders,No,5%,236,20,36,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 3,236
NCT51289540,Infection,Infections and infestations,Yes,10%,236,7,11,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 3,236
NCT51289540,Infection,Infections and infestations,Yes,5%,236,1,2,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 3,236
NCT51289540,Infection,Infections and infestations,Yes,5%,236,8,10,Treatment Emergent,Obinutuzumab,Anti-CD20,Leukemia,Phase 3,236
NCT51289540,Infusion related reaction,General disorders and administration site conditions,No,5%,236,13,21,Treatment Emergent,Obinutuzumab,Anti-CD20,Leukemia,Phase 3,236
NCT51289540,Infection,Infections and infestations,Yes,10%,236,1,1,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 3,236
NCT51289540,Infection,Infections and infestations,Yes,5%,236,3,3,Treatment Emergent,Obinutuzumab,Anti-CD20,Leukemia,Phase 3,236
NCT51289540,Cytopenia,Blood and lymphatic system disorders,No,5%,236,22,40,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 3,236
NCT51289540,Infection,Infections and infestations,Yes,10%,236,21,41,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 3,236
NCT51289540,Infection,Infections and infestations,Yes,5%,236,10,12,Treatment Emergent,Obinutuzumab,Anti-CD20,Leukemia,Phase 3,236
NCT51289540,Infection,Infections and infestations,Yes,5%,236,14,26,Treatment Emergent,Obinutuzumab,Anti-CD20,Leukemia,Phase 3,236
NCT51289540,Infection,Infections and infestations,Yes,15%,236,15,27,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 3,236
NCT51289540,Infection,Infections and infestations,Yes,15%,236,3,3,Treatment Emergent,Obinutuzumab,Anti-CD20,Leukemia,Phase 3,236
NCT51289540,Cytopenia,Blood and lymphatic system disorders,No,5%,236,16,18,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 3,236
NCT51289540,Cytopenia,Blood and lymphatic system disorders,No,5%,236,15,23,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 3,236
NCT45429745,Infection,Infections and infestations,Yes,15%,788,25,32,Treatment Emergent,Obinutuzumab,Anti-CD20,Leukemia,Phase 4,788
NCT45429745,Cytopenia,Blood and lymphatic system disorders,No,15%,788,27,30,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 4,788
NCT45429745,Infection,Infections and infestations,Yes,10%,788,9,16,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 4,788
NCT45429745,Infusion related reaction,General disorders and administration site conditions,No,5%,788,6,8,Treatment Emergent,Obinutuzumab,Anti-CD20,Leukemia,Phase 4,788
NCT45429745,Infection,Infections and infestations,Yes,5%,788,9,17,Treatment Emergent,Obinutuzumab,Anti-CD20,Leukemia,Phase 4,788
NCT15896378,Infusion related reaction,General disorders and administration site conditions,No,15%,428,26,39,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 4,428
NCT15896378,Infusion related reaction,General disorders and administration site conditions,No,10%,428,35,59,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 4,428
NCT15896378,Cytopenia,Blood and lymphatic system disorders,No,5%,428,8,13,Treatment Emergent,Obinutuzumab,Anti-CD20,Leukemia,Phase 4,428
NCT15896378,Infusion related reaction,General disorders and administration site conditions,No,5%,428,18,20,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 4,428
NCT15896378,Infection,Infections and infestations,Yes,10%,428,6,9,All Causality,Obinutuzumab,Anti-CD20,Leukemia,Phase 4,428
NCT15896378,Infusion related reaction,General disorders and administration site conditions,No,15%,428,39,62,Treatment Emergent,Obinutuzumab,Anti-CD20,Leukemia,Phase 4,428
NCT93671633,Infection,Infections and infestations,Yes,15%,684,19,29,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,684
NCT93671633,Infusion related reaction,General disorders and administration site conditions,No,5%,684,24,31,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,684
NCT93671633,Infection,Infections and infestations,Yes,10%,684,19,25,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,684
NCT93671633,Infusion related reaction,General disorders and administration site conditions,No,10%,684,38,68,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,684
NCT93671633,Cytopenia,Blood and lymphatic system disorders,No,15%,684,9,16,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,684
NCT93671633,Cytopenia,Blood and lymphatic system disorders,No,15%,684,18,28,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,684
NCT93671633,Infusion related reaction,General disorders and administration site conditions,No,10%,684,37,65,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,684
NCT93671633,Infection,Infections and infestations,Yes,15%,684,21,31,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,684
NCT93671633,Cytopenia,Blood and lymphatic system disorders,No,5%,684,9,9,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,684
NCT93671633,Cytopenia,Blood and lymphatic system disorders,No,15%,684,23,36,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,684
NCT93671633,Cytopenia,Blood and lymphatic system disorders,No,10%,684,9,11,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,684
NCT93671633,Infusion related reaction,General disorders and administration site conditions,No,5%,684,41,66,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,684
NCT93671633,Infusion related reaction,General disorders and administration site conditions,No,5%,684,11,20,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,684
NCT93671633,Infusion related reaction,General disorders and administration site conditions,No,15%,684,12,14,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,684
NCT93671633,Cytopenia,Blood and lymphatic system disorders,No,15%,684,26,40,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,684
NCT93467774,Infection,Infections and infestations,Yes,10%,735,49,83,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,735
NCT93467774,Infection,Infections and infestations,Yes,5%,735,3,4,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,735
NCT93467774,Cytopenia,Blood and lymphatic system disorders,No,5%,735,4,5,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,735
NCT93467774,Infusion related reaction,General disorders and administration site conditions,No,10%,735,41,43,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,735
NCT93467774,Infection,Infections and infestations,Yes,15%,735,2,4,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,735
NCT93467774,Infection,Infections and infestations,Yes,10%,735,22,29,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,735
NCT93467774,Cytopenia,Blood and lymphatic system disorders,No,10%,735,8,16,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,735
NCT93467774,Infection,Infections and infestations,Yes,5%,735,44,81,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,735
NCT93467774,Infusion related reaction,General disorders and administration site conditions,No,5%,735,42,55,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,735
NCT93467774,Cytopenia,Blood and lymphatic system disorders,No,15%,735,1,1,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,735
NCT93467774,Cytopenia,Blood and lymphatic system disorders,No,5%,735,46,88,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,735
NCT93467774,Cytopenia,Blood and lymphatic system disorders,No,10%,735,42,46,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,735
NCT93947495,Infection,Infections and infestations,Yes,5%,92,9,10,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,92
NCT93947495,Infusion related reaction,General disorders and administration site conditions,No,5%,92,5,8,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,92
NCT93947495,Cytopenia,Blood and lymphatic system disorders,No,10%,92,2,4,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,92
NCT93947495,Cytopenia,Blood and lymphatic system disorders,No,15%,92,3,6,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,92
NCT93947495,Cytopenia,Blood and lymphatic system disorders,No,10%,92,1,2,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,92
NCT93947495,Cytopenia,Blood and lymphatic system disorders,No,10%,92,7,7,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,92
NCT93947495,Cytopenia,Blood and lymphatic system disorders,No,10%,92,8,16,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,92
NCT93947495,Cytopenia,Blood and lymphatic system disorders,No,10%,92,7,9,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,92
NCT93947495,Cytopenia,Blood and lymphatic system disorders,No,5%,92,4,8,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,92
NCT93947495,Infusion related reaction,General disorders and administration site conditions,No,15%,92,9,10,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,92
NCT93947495,Infection,Infections and infestations,Yes,15%,92,8,10,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 1,92
NCT21889641,Cytopenia,Blood and lymphatic system disorders,No,5%,722,49,69,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 2,722
NCT21889641,Infusion related reaction,General disorders and administration site conditions,No,10%,722,26,36,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 2,722
NCT21889641,Infusion related reaction,General disorders and administration site conditions,No,15%,722,33,36,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 2,722
NCT21889641,Infection,Infections and infestations,Yes,15%,722,40,70,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 2,722
NCT21889641,Cytopenia,Blood and lymphatic system disorders,No,5%,722,30,43,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 2,722
NCT21889641,Infection,Infections and infestations,Yes,10%,722,9,14,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 2,722
NCT21889641,Infusion related reaction,General disorders and administration site conditions,No,5%,722,12,23,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 2,722
NCT21889641,Infection,Infections and infestations,Yes,15%,722,11,17,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 2,722
NCT32396804,Cytopenia,Blood and lymphatic system disorders,No,5%,73,6,11,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 2,73
NCT32396804,Cytopenia,Blood and lymphatic system disorders,No,15%,73,7,8,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 2,73
NCT32396804,Infusion related reaction,General disorders and administration site conditions,No,15%,73,1,1,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 2,73
NCT32396804,Cytopenia,Blood and lymphatic system disorders,No,10%,73,2,4,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 2,73
NCT32396804,Infection,Infections and infestations,Yes,5%,73,7,11,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 2,73
NCT32396804,Infusion related reaction,General disorders and administration site conditions,No,15%,73,1,2,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 2,73
NCT32396804,Infusion related reaction,General disorders and administration site conditions,No,10%,73,4,5,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 2,73
NCT32396804,Cytopenia,Blood and lymphatic system disorders,No,5%,73,2,2,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 2,73
NCT32396804,Cytopenia,Blood and lymphatic system disorders,No,10%,73,3,6,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 2,73
NCT32396804,Cytopenia,Blood and lymphatic system disorders,No,5%,73,6,6,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 2,73
NCT32396804,Infusion related reaction,General disorders and administration site conditions,No,5%,73,2,2,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 2,73
NCT32396804,Cytopenia,Blood and lymphatic system disorders,No,10%,73,3,6,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 2,73
NCT99144820,Cytopenia,Blood and lymphatic system disorders,No,10%,410,31,41,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 3,410
NCT99144820,Infection,Infections and infestations,Yes,15%,410,10,11,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 3,410
NCT99144820,Infection,Infections and infestations,Yes,5%,410,6,8,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 3,410
NCT23459864,Infusion related reaction,General disorders and administration site conditions,No,10%,355,5,7,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 4,355
NCT23459864,Cytopenia,Blood and lymphatic system disorders,No,15%,355,25,47,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 4,355
NCT23459864,Infection,Infections and infestations,Yes,5%,355,24,47,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 4,355
NCT23459864,Cytopenia,Blood and lymphatic system disorders,No,15%,355,10,16,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 4,355
NCT23459864,Infection,Infections and infestations,Yes,10%,355,27,47,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 4,355
NCT23459864,Infection,Infections and infestations,Yes,15%,355,7,11,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 4,355
NCT23459864,Infusion related reaction,General disorders and administration site conditions,No,5%,355,26,41,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 4,355
NCT23459864,Cytopenia,Blood and lymphatic system disorders,No,15%,355,14,23,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 4,355
NCT23459864,Infection,Infections and infestations,Yes,10%,355,28,34,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 4,355
NCT23459864,Cytopenia,Blood and lymphatic system disorders,No,5%,355,34,34,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 4,355
NCT23459864,Cytopenia,Blood and lymphatic system disorders,No,5%,355,33,49,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 4,355
NCT23459864,Cytopenia,Blood and lymphatic system disorders,No,15%,355,31,57,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 4,355
NCT23459864,Infection,Infections and infestations,Yes,15%,355,27,46,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 4,355
NCT29029783,Cytopenia,Blood and lymphatic system disorders,No,5%,977,36,68,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 4,977
NCT29029783,Infusion related reaction,General disorders and administration site conditions,No,5%,977,35,66,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 4,977
NCT29029783,Cytopenia,Blood and lymphatic system disorders,No,15%,977,21,35,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 4,977
NCT84463325,Infusion related reaction,General disorders and administration site conditions,No,5%,543,13,15,All Causality,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 4,543
NCT84463325,Infusion related reaction,General disorders and administration site conditions,No,10%,543,32,61,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 4,543
NCT84463325,Infusion related reaction,General disorders and administration site conditions,No,15%,543,14,17,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 4,543
NCT84463325,Infusion related reaction,General disorders and administration site conditions,No,15%,543,31,36,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 4,543
NCT84463325,Infusion related reaction,General disorders and administration site conditions,No,5%,543,36,54,Treatment Emergent,Obinutuzumab,Anti-CD20,Multiple Sclerosis,Phase 4,543
NCT27329313,Infusion related reaction,General disorders and administration site conditions,No,10%,693,31,41,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 1,693
NCT27329313,Infusion related reaction,General disorders and administration site conditions,No,5%,693,17,19,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 1,693
NCT27329313,Cytopenia,Blood and lymphatic system disorders,No,15%,693,39,47,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 1,693
NCT27329313,Infection,Infections and infestations,Yes,5%,693,47,56,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 1,693
NCT27329313,Infusion related reaction,General disorders and administration site conditions,No,10%,693,37,41,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 1,693
NCT27329313,Cytopenia,Blood and lymphatic system disorders,No,10%,693,19,20,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 1,693
NCT27329313,Infection,Infections and infestations,Yes,15%,693,8,15,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 1,693
NCT27329313,Infection,Infections and infestations,Yes,5%,693,10,16,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 1,693
NCT27329313,Infusion related reaction,General disorders and administration site conditions,No,10%,693,10,19,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 1,693
NCT27329313,Infusion related reaction,General disorders and administration site conditions,No,5%,693,11,11,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 1,693
NCT27329313,Cytopenia,Blood and lymphatic system disorders,No,5%,693,6,10,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 1,693
NCT27329313,Infection,Infections and infestations,Yes,15%,693,29,38,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 1,693
NCT27329313,Cytopenia,Blood and lymphatic system disorders,No,10%,693,41,67,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 1,693
NCT37540896,Infection,Infections and infestations,Yes,15%,351,28,34,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 2,351
NCT37540896,Infusion related reaction,General disorders and administration site conditions,No,10%,351,21,40,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 2,351
NCT37540896,Cytopenia,Blood and lymphatic system disorders,No,10%,351,16,22,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 2,351
NCT37540896,Infection,Infections and infestations,Yes,5%,351,10,18,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 2,351
NCT37540896,Infection,Infections and infestations,Yes,15%,351,21,27,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 2,351
NCT37540896,Infusion related reaction,General disorders and administration site conditions,No,5%,351,21,31,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 2,351
NCT37540896,Infection,Infections and infestations,Yes,15%,351,4,6,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 2,351
NCT37540896,Cytopenia,Blood and lymphatic system disorders,No,15%,351,25,35,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 2,351
NCT37540896,Cytopenia,Blood and lymphatic system disorders,No,5%,351,19,33,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 2,351
NCT37540896,Infusion related reaction,General disorders and administration site conditions,No,5%,351,35,70,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 2,351
NCT37540896,Infection,Infections and infestations,Yes,10%,351,11,20,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 2,351
NCT37540896,Infusion related reaction,General disorders and administration site conditions,No,10%,351,1,1,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 2,351
NCT37540896,Infection,Infections and infestations,Yes,10%,351,27,31,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 2,351
NCT89973394,Cytopenia,Blood and lymphatic system disorders,No,5%,466,33,66,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 2,466
NCT89973394,Cytopenia,Blood and lymphatic system disorders,No,15%,466,16,32,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 2,466
NCT89973394,Infection,Infections and infestations,Yes,15%,466,36,39,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 2,466
NCT89973394,Cytopenia,Blood and lymphatic system disorders,No,10%,466,31,53,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 2,466
NCT89973394,Infusion related reaction,General disorders and administration site conditions,No,10%,466,26,37,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 2,466
NCT89973394,Infusion related reaction,General disorders and administration site conditions,No,5%,466,46,71,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 2,466
NCT89973394,Infection,Infections and infestations,Yes,5%,466,25,31,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 2,466
NCT77548914,Infusion related reaction,General disorders and administration site conditions,No,10%,295,26,41,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 3,295
NCT77548914,Infusion related reaction,General disorders and administration site conditions,No,10%,295,9,17,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 3,295
NCT77548914,Cytopenia,Blood and lymphatic system disorders,No,5%,295,27,35,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 3,295
NCT77548914,Infusion related reaction,General disorders and administration site conditions,No,5%,295,6,7,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 3,295
NCT77548914,Cytopenia,Blood and lymphatic system disorders,No,15%,295,2,4,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 3,295
NCT77548914,Infusion related reaction,General disorders and administration site conditions,No,5%,295,16,25,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 3,295
NCT77548914,Infusion related reaction,General disorders and administration site conditions,No,10%,295,14,25,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 3,295
NCT77548914,Infusion related reaction,General disorders and administration site conditions,No,15%,295,25,33,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 3,295
NCT77548914,Infection,Infections and infestations,Yes,15%,295,5,9,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 3,295
NCT77548914,Infection,Infections and infestations,Yes,10%,295,2,3,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 3,295
NCT77548914,Cytopenia,Blood and lymphatic system disorders,No,5%,295,3,6,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 3,295
NCT77548914,Cytopenia,Blood and lymphatic system disorders,No,15%,295,18,26,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 3,295
NCT77548914,Infection,Infections and infestations,Yes,15%,295,17,17,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 3,295
NCT77548914,Infection,Infections and infestations,Yes,10%,295,16,19,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 3,295
NCT64988149,Cytopenia,Blood and lymphatic system disorders,No,15%,692,28,38,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 4,692
NCT64988149,Infection,Infections and infestations,Yes,5%,692,10,11,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 4,692
NCT64988149,Cytopenia,Blood and lymphatic system disorders,No,10%,692,41,41,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 4,692
NCT69249820,Infusion related reaction,General disorders and administration site conditions,No,5%,459,16,22,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 4,459
NCT69249820,Infusion related reaction,General disorders and administration site conditions,No,10%,459,25,38,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 4,459
NCT69249820,Infection,Infections and infestations,Yes,15%,459,30,53,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 4,459
NCT69249820,Infection,Infections and infestations,Yes,10%,459,17,29,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 4,459
NCT69249820,Infusion related reaction,General disorders and administration site conditions,No,10%,459,31,52,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 4,459
NCT69249820,Infection,Infections and infestations,Yes,10%,459,43,82,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 4,459
NCT69249820,Infusion related reaction,General disorders and administration site conditions,No,15%,459,8,11,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 4,459
NCT69249820,Cytopenia,Blood and lymphatic system disorders,No,5%,459,41,71,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 4,459
NCT69249820,Infection,Infections and infestations,Yes,10%,459,44,78,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 4,459
NCT78462301,Cytopenia,Blood and lymphatic system disorders,No,10%,379,6,7,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 4,379
NCT78462301,Infection,Infections and infestations,Yes,15%,379,22,25,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 4,379
NCT78462301,Cytopenia,Blood and lymphatic system disorders,No,10%,379,9,11,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 4,379
NCT78462301,Infection,Infections and infestations,Yes,15%,379,2,4,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 4,379
NCT78462301,Infusion related reaction,General disorders and administration site conditions,No,15%,379,26,52,All Causality,Ofatumumab,Anti-CD20,Lymphoma,Phase 4,379
NCT78462301,Infusion related reaction,General disorders and administration site conditions,No,15%,379,14,26,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 4,379
NCT78462301,Cytopenia,Blood and lymphatic system disorders,No,10%,379,34,55,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 4,379
NCT78462301,Infection,Infections and infestations,Yes,10%,379,11,11,Treatment Emergent,Ofatumumab,Anti-CD20,Lymphoma,Phase 4,379
NCT98305573,Cytopenia,Blood and lymphatic system disorders,No,15%,642,31,48,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 1,642
NCT98305573,Cytopenia,Blood and lymphatic system disorders,No,15%,642,11,22,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 1,642
NCT98305573,Infection,Infections and infestations,Yes,5%,642,1,1,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 1,642
NCT25684850,Cytopenia,Blood and lymphatic system disorders,No,15%,474,45,64,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 1,474
NCT25684850,Infection,Infections and infestations,Yes,5%,474,3,3,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 1,474
NCT25684850,Cytopenia,Blood and lymphatic system disorders,No,10%,474,17,24,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 1,474
NCT25684850,Infection,Infections and infestations,Yes,10%,474,17,26,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 1,474
NCT25684850,Infusion related reaction,General disorders and administration site conditions,No,15%,474,4,4,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 1,474
NCT25684850,Infusion related reaction,General disorders and administration site conditions,No,5%,474,31,51,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 1,474
NCT25684850,Infection,Infections and infestations,Yes,5%,474,43,71,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 1,474
NCT25684850,Infection,Infections and infestations,Yes,10%,474,1,2,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 1,474
NCT25684850,Cytopenia,Blood and lymphatic system disorders,No,10%,474,39,76,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 1,474
NCT25684850,Infection,Infections and infestations,Yes,5%,474,26,37,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 1,474
NCT25684850,Infection,Infections and infestations,Yes,10%,474,47,90,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 1,474
NCT25684850,Cytopenia,Blood and lymphatic system disorders,No,15%,474,28,30,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 1,474
NCT25684850,Cytopenia,Blood and lymphatic system disorders,No,15%,474,40,80,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 1,474
NCT25684850,Cytopenia,Blood and lymphatic system disorders,No,15%,474,28,45,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 1,474
NCT25684850,Cytopenia,Blood and lymphatic system disorders,No,10%,474,28,31,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 1,474
NCT35402693,Cytopenia,Blood and lymphatic system disorders,No,5%,364,16,21,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 1,364
NCT35402693,Infection,Infections and infestations,Yes,10%,364,14,21,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 1,364
NCT35402693,Cytopenia,Blood and lymphatic system disorders,No,15%,364,2,2,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 1,364
NCT35402693,Infusion related reaction,General disorders and administration site conditions,No,5%,364,1,1,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 1,364
NCT35402693,Infection,Infections and infestations,Yes,15%,364,20,25,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 1,364
NCT35402693,Infection,Infections and infestations,Yes,10%,364,30,35,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 1,364
NCT35402693,Infusion related reaction,General disorders and administration site conditions,No,10%,364,9,13,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 1,364
NCT35402693,Infusion related reaction,General disorders and administration site conditions,No,15%,364,31,46,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 1,364
NCT10712776,Infection,Infections and infestations,Yes,5%,215,3,5,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 2,215
NCT10712776,Cytopenia,Blood and lymphatic system disorders,No,15%,215,4,5,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 2,215
NCT10712776,Cytopenia,Blood and lymphatic system disorders,No,5%,215,1,2,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 2,215
NCT10712776,Infection,Infections and infestations,Yes,15%,215,5,6,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 2,215
NCT25015027,Infusion related reaction,General disorders and administration site conditions,No,15%,267,23,45,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 2,267
NCT25015027,Cytopenia,Blood and lymphatic system disorders,No,10%,267,23,35,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 2,267
NCT25015027,Infusion related reaction,General disorders and administration site conditions,No,5%,267,8,16,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 2,267
NCT25015027,Infection,Infections and infestations,Yes,5%,267,23,32,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 2,267
NCT25015027,Infection,Infections and infestations,Yes,10%,267,20,28,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 2,267
NCT25015027,Infection,Infections and infestations,Yes,10%,267,10,13,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 2,267
NCT25015027,Cytopenia,Blood and lymphatic system disorders,No,5%,267,14,21,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 2,267
NCT11694638,Infection,Infections and infestations,Yes,5%,658,4,4,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 3,658
NCT11694638,Infusion related reaction,General disorders and administration site conditions,No,15%,658,32,60,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 3,658
NCT11694638,Cytopenia,Blood and lymphatic system disorders,No,5%,658,39,67,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 3,658
NCT11694638,Infusion related reaction,General disorders and administration site conditions,No,15%,658,6,11,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 3,658
NCT11694638,Infusion related reaction,General disorders and administration site conditions,No,15%,658,49,73,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 3,658
NCT11694638,Infusion related reaction,General disorders and administration site conditions,No,5%,658,23,43,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 3,658
NCT11694638,Infection,Infections and infestations,Yes,10%,658,15,21,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 3,658
NCT76832648,Cytopenia,Blood and lymphatic system disorders,No,15%,609,22,35,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 3,609
NCT76832648,Infusion related reaction,General disorders and administration site conditions,No,10%,609,29,55,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 3,609
NCT76832648,Infusion related reaction,General disorders and administration site conditions,No,5%,609,29,30,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 3,609
NCT76832648,Cytopenia,Blood and lymphatic system disorders,No,15%,609,28,51,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 3,609
NCT76832648,Infusion related reaction,General disorders and administration site conditions,No,15%,609,23,32,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 3,609
NCT76832648,Infusion related reaction,General disorders and administration site conditions,No,5%,609,44,52,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 3,609
NCT76832648,Cytopenia,Blood and lymphatic system disorders,No,5%,609,19,20,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 3,609
NCT35783129,Infusion related reaction,General disorders and administration site conditions,No,10%,939,14,24,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 3,939
NCT35783129,Cytopenia,Blood and lymphatic system disorders,No,5%,939,21,32,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 3,939
NCT35783129,Infection,Infections and infestations,Yes,15%,939,35,64,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 3,939
NCT35783129,Cytopenia,Blood and lymphatic system disorders,No,10%,939,39,73,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 3,939
NCT35783129,Infection,Infections and infestations,Yes,15%,939,23,43,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 3,939
NCT35783129,Cytopenia,Blood and lymphatic system disorders,No,5%,939,28,47,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 3,939
NCT35783129,Cytopenia,Blood and lymphatic system disorders,No,5%,939,41,59,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 3,939
NCT35783129,Infection,Infections and infestations,Yes,5%,939,40,60,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 3,939
NCT35783129,Infection,Infections and infestations,Yes,10%,939,14,24,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 3,939
NCT36392133,Cytopenia,Blood and lymphatic system disorders,No,15%,976,4,6,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 4,976
NCT36392133,Cytopenia,Blood and lymphatic system disorders,No,10%,976,38,73,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 4,976
NCT36392133,Cytopenia,Blood and lymphatic system disorders,No,5%,976,17,24,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 4,976
NCT36392133,Cytopenia,Blood and lymphatic system disorders,No,15%,976,9,14,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 4,976
NCT36392133,Cytopenia,Blood and lymphatic system disorders,No,15%,976,5,8,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 4,976
NCT36392133,Infection,Infections and infestations,Yes,10%,976,19,21,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 4,976
NCT36392133,Infection,Infections and infestations,Yes,15%,976,37,58,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 4,976
NCT36392133,Infection,Infections and infestations,Yes,5%,976,25,50,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 4,976
NCT36392133,Infection,Infections and infestations,Yes,10%,976,21,38,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 4,976
NCT36392133,Cytopenia,Blood and lymphatic system disorders,No,10%,976,18,19,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 4,976
NCT36392133,Infusion related reaction,General disorders and administration site conditions,No,5%,976,8,12,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 4,976
NCT36392133,Infection,Infections and infestations,Yes,15%,976,26,47,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 4,976
NCT36392133,Cytopenia,Blood and lymphatic system disorders,No,15%,976,5,7,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 4,976
NCT36392133,Infection,Infections and infestations,Yes,10%,976,38,72,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 4,976
NCT49566743,Infusion related reaction,General disorders and administration site conditions,No,15%,342,19,25,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 4,342
NCT49566743,Cytopenia,Blood and lymphatic system disorders,No,5%,342,20,23,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 4,342
NCT49566743,Infusion related reaction,General disorders and administration site conditions,No,5%,342,10,20,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 4,342
NCT49566743,Infusion related reaction,General disorders and administration site conditions,No,15%,342,15,23,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 4,342
NCT49566743,Infusion related reaction,General disorders and administration site conditions,No,10%,342,34,39,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 4,342
NCT49566743,Cytopenia,Blood and lymphatic system disorders,No,15%,342,15,30,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 4,342
NCT49566743,Cytopenia,Blood and lymphatic system disorders,No,10%,342,7,8,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 4,342
NCT49566743,Infection,Infections and infestations,Yes,5%,342,34,50,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 4,342
NCT49566743,Infusion related reaction,General disorders and administration site conditions,No,10%,342,1,1,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 4,342
NCT49566743,Cytopenia,Blood and lymphatic system disorders,No,5%,342,1,1,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 4,342
NCT49566743,Cytopenia,Blood and lymphatic system disorders,No,15%,342,19,23,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 4,342
NCT49566743,Infection,Infections and infestations,Yes,15%,342,27,30,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 4,342
NCT49566743,Infection,Infections and infestations,Yes,15%,342,32,49,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 4,342
NCT49566743,Cytopenia,Blood and lymphatic system disorders,No,15%,342,11,21,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 4,342
NCT49566743,Cytopenia,Blood and lymphatic system disorders,No,10%,342,27,50,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 4,342
NCT66807541,Infection,Infections and infestations,Yes,5%,498,45,80,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 4,498
NCT66807541,Infusion related reaction,General disorders and administration site conditions,No,5%,498,45,51,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 4,498
NCT66807541,Cytopenia,Blood and lymphatic system disorders,No,15%,498,16,27,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 4,498
NCT66807541,Infusion related reaction,General disorders and administration site conditions,No,5%,498,27,54,Treatment Emergent,Ofatumumab,Anti-CD20,Leukemia,Phase 4,498
NCT66807541,Infection,Infections and infestations,Yes,15%,498,44,76,All Causality,Ofatumumab,Anti-CD20,Leukemia,Phase 4,498
NCT17616731,Cytopenia,Blood and lymphatic system disorders,No,10%,463,10,14,Treatment Emergent,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 1,463
NCT17616731,Infection,Infections and infestations,Yes,15%,463,20,22,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 1,463
NCT17616731,Infection,Infections and infestations,Yes,10%,463,26,51,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 1,463
NCT17616731,Infusion related reaction,General disorders and administration site conditions,No,15%,463,12,23,Treatment Emergent,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 1,463
NCT17616731,Infusion related reaction,General disorders and administration site conditions,No,10%,463,24,29,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 1,463
NCT17616731,Cytopenia,Blood and lymphatic system disorders,No,10%,463,26,28,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 1,463
NCT17616731,Cytopenia,Blood and lymphatic system disorders,No,5%,463,25,45,Treatment Emergent,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 1,463
NCT15397926,Cytopenia,Blood and lymphatic system disorders,No,5%,96,7,7,Treatment Emergent,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 2,96
NCT15397926,Infusion related reaction,General disorders and administration site conditions,No,15%,96,5,10,Treatment Emergent,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 2,96
NCT15397926,Infusion related reaction,General disorders and administration site conditions,No,10%,96,3,4,Treatment Emergent,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 2,96
NCT15397926,Infection,Infections and infestations,Yes,10%,96,3,4,Treatment Emergent,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 2,96
NCT15397926,Infection,Infections and infestations,Yes,5%,96,3,4,Treatment Emergent,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 2,96
NCT15397926,Cytopenia,Blood and lymphatic system disorders,No,5%,96,9,11,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 2,96
NCT97402885,Infection,Infections and infestations,Yes,10%,569,22,33,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 2,569
NCT97402885,Cytopenia,Blood and lymphatic system disorders,No,15%,569,46,49,Treatment Emergent,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 2,569
NCT97402885,Cytopenia,Blood and lymphatic system disorders,No,5%,569,12,21,Treatment Emergent,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 2,569
NCT97402885,Infusion related reaction,General disorders and administration site conditions,No,15%,569,3,5,Treatment Emergent,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 2,569
NCT97402885,Cytopenia,Blood and lymphatic system disorders,No,15%,569,44,54,Treatment Emergent,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 2,569
NCT97402885,Infusion related reaction,General disorders and administration site conditions,No,5%,569,23,46,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 2,569
NCT97402885,Infusion related reaction,General disorders and administration site conditions,No,15%,569,35,38,Treatment Emergent,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 2,569
NCT86890998,Infusion related reaction,General disorders and administration site conditions,No,15%,291,28,50,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 3,291
NCT86890998,Infection,Infections and infestations,Yes,5%,291,2,3,Treatment Emergent,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 3,291
NCT86890998,Infection,Infections and infestations,Yes,15%,291,4,4,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 3,291
NCT86890998,Cytopenia,Blood and lymphatic system disorders,No,10%,291,13,23,Treatment Emergent,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 3,291
NCT86890998,Infection,Infections and infestations,Yes,10%,291,21,27,Treatment Emergent,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 3,291
NCT86890998,Infection,Infections and infestations,Yes,15%,291,11,17,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 3,291
NCT86890998,Infection,Infections and infestations,Yes,5%,291,18,21,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 3,291
NCT86890998,Infection,Infections and infestations,Yes,5%,291,19,21,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 3,291
NCT13167781,Infusion related reaction,General disorders and administration site conditions,No,10%,986,43,72,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 3,986
NCT13167781,Infection,Infections and infestations,Yes,5%,986,44,80,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 3,986
NCT13167781,Infusion related reaction,General disorders and administration site conditions,No,5%,986,21,36,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 3,986
NCT13167781,Infection,Infections and infestations,Yes,15%,986,10,17,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 3,986
NCT13167781,Cytopenia,Blood and lymphatic system disorders,No,5%,986,48,68,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 3,986
NCT13167781,Cytopenia,Blood and lymphatic system disorders,No,15%,986,11,14,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 3,986
NCT76528896,Cytopenia,Blood and lymphatic system disorders,No,10%,155,12,20,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 4,155
NCT76528896,Infection,Infections and infestations,Yes,15%,155,11,16,Treatment Emergent,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 4,155
NCT76528896,Infection,Infections and infestations,Yes,5%,155,1,2,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 4,155
NCT76528896,Infection,Infections and infestations,Yes,5%,155,14,24,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 4,155
NCT76528896,Infusion related reaction,General disorders and administration site conditions,No,10%,155,14,28,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 4,155
NCT76528896,Cytopenia,Blood and lymphatic system disorders,No,5%,155,13,24,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 4,155
NCT76528896,Cytopenia,Blood and lymphatic system disorders,No,15%,155,7,8,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 4,155
NCT76528896,Infusion related reaction,General disorders and administration site conditions,No,15%,155,3,4,Treatment Emergent,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 4,155
NCT76528896,Infusion related reaction,General disorders and administration site conditions,No,10%,155,11,15,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 4,155
NCT63286949,Infusion related reaction,General disorders and administration site conditions,No,10%,869,27,50,Treatment Emergent,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 4,869
NCT63286949,Infusion related reaction,General disorders and administration site conditions,No,5%,869,3,4,Treatment Emergent,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 4,869
NCT63286949,Infusion related reaction,General disorders and administration site conditions,No,5%,869,15,23,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 4,869
NCT63286949,Infusion related reaction,General disorders and administration site conditions,No,15%,869,45,90,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 4,869
NCT63286949,Infusion related reaction,General disorders and administration site conditions,No,10%,869,4,4,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 4,869
NCT63286949,Infusion related reaction,General disorders and administration site conditions,No,10%,869,17,20,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 4,869
NCT63286949,Infection,Infections and infestations,Yes,15%,869,44,81,All Causality,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 4,869
NCT63286949,Cytopenia,Blood and lymphatic system disorders,No,10%,869,29,39,Treatment Emergent,Ofatumumab,Anti-CD20,Multiple Sclerosis,Phase 4,869
NCT86109948,Infusion related reaction,General disorders and administration site conditions,No,10%,985,32,33,All Causality,Ocrelizumab,Anti-CD20,Lymphoma,Phase 1,985
NCT86109948,Cytopenia,Blood and lymphatic system disorders,No,10%,985,41,77,Treatment Emergent,Ocrelizumab,Anti-CD20,Lymphoma,Phase 1,985
NCT86109948,Infection,Infections and infestations,Yes,5%,985,2,4,All Causality,Ocrelizumab,Anti-CD20,Lymphoma,Phase 1,985
NCT86109948,Infusion related reaction,General disorders and administration site conditions,No,5%,985,4,4,All Causality,Ocrelizumab,Anti-CD20,Lymphoma,Phase 1,985
NCT86109948,Infusion related reaction,General disorders and administration site conditions,No,10%,985,41,73,All Causality,Ocrelizumab,Anti-CD20,Lymphoma,Phase 1,985
NCT86109948,Cytopenia,Blood and lymphatic system disorders,No,5%,985,34,47,All Causality,Ocrelizumab,Anti-CD20,Lymphoma,Phase 1,985
NCT86109948,Cytopenia,Blood and lymphatic system disorders,No,10%,985,26,40,All Causality,Ocrelizumab,Anti-CD20,Lymphoma,Phase 1,985
NCT86109948,Infusion related reaction,General disorders and administration site conditions,No,10%,985,22,40,All Causality,Ocrelizumab,Anti-CD20,Lymphoma,Phase 1,985
NCT86109948,Infection,Infections and infestations,Yes,5%,985,33,58,All Causality,Ocrelizumab,Anti-CD20,Lymphoma,Phase 1,985
NCT86109948,Infection,Infections and infestations,Yes,10%,985,25,34,All Causality,Ocrelizumab,Anti-CD20,Lymphoma,Phase 1,985
NCT86915742,Cytopenia,Blood and lymphatic system disorders,No,10%,41,3,5,All Causality,Ocrelizumab,Anti-CD20,Lymphoma,Phase 2,41
NCT86915742,Infection,Infections and infestations,Yes,5%,41,1,2,Treatment Emergent,Ocrelizumab,Anti-CD20,Lymphoma,Phase 2,41
NCT86915742,Infection,Infections and infestations,Yes,15%,41,4,7,All Causality,Ocrelizumab,Anti-CD20,Lymphoma,Phase 2,41
NCT86915742,Cytopenia,Blood and lymphatic system disorders,No,15%,41,2,2,Treatment Emergent,Ocrelizumab,Anti-CD20,Lymphoma,Phase 2,41
NCT86915742,Cytopenia,Blood and lymphatic system disorders,No,5%,41,2,3,Treatment Emergent,Ocrelizumab,Anti-CD20,Lymphoma,Phase 2,41
NCT86915742,Infusion related reaction,General disorders and administration site conditions,No,15%,41,3,6,Treatment Emergent,Ocrelizumab,Anti-CD20,Lymphoma,Phase 2,41
NCT86915742,Cytopenia,Blood and lymphatic system disorders,No,15%,41,3,4,Treatment Emergent,Ocrelizumab,Anti-CD20,Lymphoma,Phase 2,41
NCT86915742,Cytopenia,Blood and lymphatic system disorders,No,10%,41,1,2,Treatment Emergent,Ocrelizumab,Anti-CD20,Lymphoma,Phase 2,41
NCT86915742,Infusion related reaction,General disorders and administration site conditions,No,5%,41,4,6,Treatment Emergent,Ocrelizumab,Anti-CD20,Lymphoma,Phase 2,41
NCT86915742,Cytopenia,Blood and lymphatic system disorders,No,5%,41,3,3,All Causality,Ocrelizumab,Anti-CD20,Lymphoma,Phase 2,41
NCT86915742,Infection,Infections and infestations,Yes,5%,41,3,4,All Causality,Ocrelizumab,Anti-CD20,Lymphoma,Phase 2,41
NCT41400974,Infection,Infections and infestations,Yes,15%,158,5,7,Treatment Emergent,Ocrelizumab,Anti-CD20,Lymphoma,Phase 2,158
NCT41400974,Infusion related reaction,General disorders and administration site conditions,No,5%,158,1,2,All Causality,Ocrelizumab,Anti-CD20,Lymphoma,Phase 2,158
NCT41400974,Cytopenia,Blood and lymphatic system disorders,No,15%,158,6,11,Treatment Emergent,Ocrelizumab,Anti-CD20,Lymphoma,Phase 2,158
NCT41400974,Infusion related reaction,General disorders and administration site conditions,No,15%,158,4,4,Treatment Emergent,Ocrelizumab,Anti-CD20,Lymphoma,Phase 2,158
NCT57661992,Infusion related reaction,General disorders and administration site conditions,No,5%,112,11,18,All Causality,Ocrelizumab,Anti-CD20,Lymphoma,Phase 3,112
NCT57661992,Cytopenia,Blood and lymphatic system disorders,No,10%,112,2,3,All Causality,Ocrelizumab,Anti-CD20,Lymphoma,Phase 3,112
NCT57661992,Cytopenia,Blood and lymphatic system disorders,No,15%,112,3,4,All Causality,Ocrelizumab,Anti-CD20,Lymphoma,Phase 3,112
NCT57661992,Infection,Infections and infestations,Yes,15%,112,9,10,Treatment Emergent,Ocrelizumab,Anti-CD20,Lymphoma,Phase 3,112
NCT57661992,Cytopenia,Blood and lymphatic system disorders,No,5%,112,7,8,Treatment Emergent,Ocrelizumab,Anti-CD20,Lymphoma,Phase 3,112
NCT57661992,Infection,Infections and infestations,Yes,15%,112,4,4,All Causality,Ocrelizumab,Anti-CD20,Lymphoma,Phase 3,112
NCT57661992,Infection,Infections and infestations,Yes,10%,112,4,8,All Causality,Ocrelizumab,Anti-CD20,Lymphoma,Phase 3,112
NCT57661992,Infection,Infections and infestations,Yes,15%,112,9,14,All Causality,Ocrelizumab,Anti-CD20,Lymphoma,Phase 3,112
NCT57661992,Infection,Infections and infestations,Yes,5%,112,9,11,Treatment Emergent,Ocrelizumab,Anti-CD20,Lymphoma,Phase 3,112
NCT57661992,Infection,Infections and infestations,Yes,10%,112,7,9,Treatment Emergent,Ocrelizumab,Anti-CD20,Lymphoma,Phase 3,112
NCT57661992,Cytopenia,Blood and lymphatic system disorders,No,15%,112,10,13,Treatment Emergent,Ocrelizumab,Anti-CD20,Lymphoma,Phase 3,112
NCT57661992,Cytopenia,Blood and lymphatic system disorders,No,5%,112,2,2,Treatment Emergent,Ocrelizumab,Anti-CD20,Lymphoma,Phase 3,112
NCT39141575,Cytopenia,Blood and lymphatic system disorders,No,15%,118,3,4,All Causality,Ocrelizumab,Anti-CD20,Lymphoma,Phase 4,118
NCT39141575,Infection,Infections and infestations,Yes,10%,118,7,9,Treatment Emergent,Ocrelizumab,Anti-CD20,Lymphoma,Phase 4,118
NCT39141575,Cytopenia,Blood and lymphatic system disorders,No,10%,118,4,8,All Causality,Ocrelizumab,Anti-CD20,Lymphoma,Phase 4,118
NCT39141575,Infusion related reaction,General disorders and administration site conditions,No,5%,118,9,17,All Causality,Ocrelizumab,Anti-CD20,Lymphoma,Phase 4,118
NCT39141575,Infection,Infections and infestations,Yes,15%,118,10,12,All Causality,Ocrelizumab,Anti-CD20,Lymphoma,Phase 4,118
NCT39141575,Infection,Infections and infestations,Yes,10%,118,5,9,Treatment Emergent,Ocrelizumab,Anti-CD20,Lymphoma,Phase 4,118
NCT39141575,Infusion related reaction,General disorders and administration site conditions,No,10%,118,3,5,Treatment Emergent,Ocrelizumab,Anti-CD20,Lymphoma,Phase 4,118
NCT39141575,Infection,Infections and infestations,Yes,5%,118,2,4,All Causality,Ocrelizumab,Anti-CD20,Lymphoma,Phase 4,118
NCT39141575,Infection,Infections and infestations,Yes,10%,118,7,8,All Causality,Ocrelizumab,Anti-CD20,Lymphoma,Phase 4,118
NCT39141575,Infection,Infections and infestations,Yes,5%,118,10,17,Treatment Emergent,Ocrelizumab,Anti-CD20,Lymphoma,Phase 4,118
NCT39141575,Infusion related reaction,General disorders and administration site conditions,No,10%,118,3,3,All Causality,Ocrelizumab,Anti-CD20,Lymphoma,Phase 4,118
NCT39141575,Infection,Infections and infestations,Yes,5%,118,2,2,All Causality,Ocrelizumab,Anti-CD20,Lymphoma,Phase 4,118
NCT39141575,Infusion related reaction,General disorders and administration site conditions,No,15%,118,8,8,Treatment Emergent,Ocrelizumab,Anti-CD20,Lymphoma,Phase 4,118
NCT73360696,Infection,Infections and infestations,Yes,10%,617,49,84,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 1,617
NCT73360696,Infusion related reaction,General disorders and administration site conditions,No,15%,617,41,67,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 1,617
NCT73360696,Infusion related reaction,General disorders and administration site conditions,No,5%,617,40,71,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 1,617
NCT73360696,Infusion related reaction,General disorders and administration site conditions,No,5%,617,43,54,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 1,617
NCT72416710,Cytopenia,Blood and lymphatic system disorders,No,15%,559,2,4,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 1,559
NCT72416710,Cytopenia,Blood and lymphatic system disorders,No,5%,559,29,50,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 1,559
NCT72416710,Infusion related reaction,General disorders and administration site conditions,No,10%,559,6,7,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 1,559
NCT42921792,Infection,Infections and infestations,Yes,10%,758,20,27,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 1,758
NCT42921792,Infection,Infections and infestations,Yes,15%,758,1,2,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 1,758
NCT42921792,Cytopenia,Blood and lymphatic system disorders,No,5%,758,15,26,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 1,758
NCT42921792,Cytopenia,Blood and lymphatic system disorders,No,15%,758,30,36,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 1,758
NCT42921792,Infusion related reaction,General disorders and administration site conditions,No,15%,758,50,93,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 1,758
NCT42921792,Cytopenia,Blood and lymphatic system disorders,No,15%,758,9,15,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 1,758
NCT42921792,Infection,Infections and infestations,Yes,10%,758,11,11,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 1,758
NCT42921792,Infusion related reaction,General disorders and administration site conditions,No,15%,758,40,79,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 1,758
NCT42921792,Infusion related reaction,General disorders and administration site conditions,No,5%,758,50,67,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 1,758
NCT42921792,Infection,Infections and infestations,Yes,15%,758,30,57,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 1,758
NCT67285403,Cytopenia,Blood and lymphatic system disorders,No,10%,949,30,59,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 2,949
NCT67285403,Infusion related reaction,General disorders and administration site conditions,No,10%,949,32,35,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 2,949
NCT67285403,Infection,Infections and infestations,Yes,5%,949,24,32,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 2,949
NCT67285403,Infusion related reaction,General disorders and administration site conditions,No,10%,949,12,13,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 2,949
NCT67285403,Cytopenia,Blood and lymphatic system disorders,No,10%,949,43,83,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 2,949
NCT67285403,Cytopenia,Blood and lymphatic system disorders,No,10%,949,34,67,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 2,949
NCT67285403,Infection,Infections and infestations,Yes,15%,949,33,48,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 2,949
NCT67285403,Cytopenia,Blood and lymphatic system disorders,No,5%,949,28,42,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 2,949
NCT67285403,Cytopenia,Blood and lymphatic system disorders,No,15%,949,37,47,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 2,949
NCT67285403,Infusion related reaction,General disorders and administration site conditions,No,15%,949,40,40,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 2,949
NCT67285403,Cytopenia,Blood and lymphatic system disorders,No,10%,949,22,44,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 2,949
NCT16510682,Infection,Infections and infestations,Yes,5%,888,43,78,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 2,888
NCT16510682,Infusion related reaction,General disorders and administration site conditions,No,10%,888,14,15,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 2,888
NCT16510682,Infusion related reaction,General disorders and administration site conditions,No,5%,888,16,23,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 2,888
NCT16510682,Infusion related reaction,General disorders and administration site conditions,No,5%,888,41,62,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 2,888
NCT62742948,Infection,Infections and infestations,Yes,5%,653,1,1,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 2,653
NCT62742948,Infusion related reaction,General disorders and administration site conditions,No,10%,653,8,15,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 2,653
NCT62742948,Infusion related reaction,General disorders and administration site conditions,No,5%,653,19,30,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 2,653
NCT99184747,Infusion related reaction,General disorders and administration site conditions,No,15%,573,2,4,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 3,573
NCT99184747,Cytopenia,Blood and lymphatic system disorders,No,5%,573,50,72,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 3,573
NCT99184747,Infusion related reaction,General disorders and administration site conditions,No,5%,573,21,26,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 3,573
NCT99184747,Cytopenia,Blood and lymphatic system disorders,No,15%,573,42,80,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 3,573
NCT99184747,Infection,Infections and infestations,Yes,5%,573,12,17,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 3,573
NCT99184747,Infection,Infections and infestations,Yes,5%,573,35,47,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 3,573
NCT99184747,Infusion related reaction,General disorders and administration site conditions,No,10%,573,38,57,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 3,573
NCT99184747,Infusion related reaction,General disorders and administration site conditions,No,10%,573,28,41,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 3,573
NCT33886240,Cytopenia,Blood and lymphatic system disorders,No,5%,53,2,2,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 3,53
NCT33886240,Infection,Infections and infestations,Yes,10%,53,2,2,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 3,53
NCT33886240,Infusion related reaction,General disorders and administration site conditions,No,5%,53,4,6,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 3,53
NCT33886240,Infusion related reaction,General disorders and administration site conditions,No,10%,53,4,8,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 3,53
NCT33886240,Cytopenia,Blood and lymphatic system disorders,No,15%,53,2,3,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 3,53
NCT33886240,Cytopenia,Blood and lymphatic system disorders,No,5%,53,2,2,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 3,53
NCT33886240,Cytopenia,Blood and lymphatic system disorders,No,5%,53,2,4,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 3,53
NCT33886240,Infusion related reaction,General disorders and administration site conditions,No,15%,53,4,5,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 3,53
NCT33886240,Infection,Infections and infestations,Yes,10%,53,5,5,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 3,53
NCT33886240,Infusion related reaction,General disorders and administration site conditions,No,10%,53,3,5,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 3,53
NCT33886240,Cytopenia,Blood and lymphatic system disorders,No,5%,53,1,1,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 3,53
NCT33886240,Cytopenia,Blood and lymphatic system disorders,No,5%,53,1,2,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 3,53
NCT33886240,Cytopenia,Blood and lymphatic system disorders,No,15%,53,5,9,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 3,53
NCT89092666,Cytopenia,Blood and lymphatic system disorders,No,15%,563,50,96,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 3,563
NCT89092666,Infusion related reaction,General disorders and administration site conditions,No,10%,563,19,21,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 3,563
NCT89092666,Infection,Infections and infestations,Yes,5%,563,35,44,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 3,563
NCT89092666,Infection,Infections and infestations,Yes,10%,563,3,6,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 3,563
NCT89092666,Cytopenia,Blood and lymphatic system disorders,No,15%,563,47,80,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 3,563
NCT89092666,Infusion related reaction,General disorders and administration site conditions,No,15%,563,25,47,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 3,563
NCT58611678,Cytopenia,Blood and lymphatic system disorders,No,15%,975,1,2,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 4,975
NCT58611678,Cytopenia,Blood and lymphatic system disorders,No,10%,975,42,71,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 4,975
NCT58611678,Cytopenia,Blood and lymphatic system disorders,No,5%,975,28,37,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 4,975
NCT58611678,Infection,Infections and infestations,Yes,5%,975,13,26,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 4,975
NCT58611678,Infusion related reaction,General disorders and administration site conditions,No,5%,975,28,45,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 4,975
NCT58611678,Infusion related reaction,General disorders and administration site conditions,No,5%,975,9,9,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 4,975
NCT58611678,Infection,Infections and infestations,Yes,15%,975,4,6,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 4,975
NCT58611678,Infusion related reaction,General disorders and administration site conditions,No,5%,975,42,64,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 4,975
NCT58611678,Infusion related reaction,General disorders and administration site conditions,No,15%,975,30,49,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 4,975
NCT58611678,Cytopenia,Blood and lymphatic system disorders,No,5%,975,42,61,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 4,975
NCT58611678,Infusion related reaction,General disorders and administration site conditions,No,5%,975,25,32,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 4,975
NCT58611678,Infection,Infections and infestations,Yes,10%,975,5,5,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 4,975
NCT58611678,Infection,Infections and infestations,Yes,10%,975,50,59,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 4,975
NCT58611678,Cytopenia,Blood and lymphatic system disorders,No,15%,975,18,33,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 4,975
NCT58611678,Cytopenia,Blood and lymphatic system disorders,No,15%,975,10,20,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 4,975
NCT15614833,Infection,Infections and infestations,Yes,15%,888,4,5,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 4,888
NCT15614833,Cytopenia,Blood and lymphatic system disorders,No,15%,888,15,15,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 4,888
NCT15614833,Infection,Infections and infestations,Yes,5%,888,10,16,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 4,888
NCT15614833,Infection,Infections and infestations,Yes,10%,888,2,4,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 4,888
NCT15614833,Infection,Infections and infestations,Yes,15%,888,32,57,Treatment Emergent,Ocrelizumab,Anti-CD20,Leukemia,Phase 4,888
NCT15614833,Infusion related reaction,General disorders and administration site conditions,No,10%,888,34,56,All Causality,Ocrelizumab,Anti-CD20,Leukemia,Phase 4,888
NCT74925460,Infusion related reaction,General disorders and administration site conditions,No,5%,584,5,6,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 1,584
NCT74925460,Infection,Infections and infestations,Yes,15%,584,36,49,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 1,584
NCT74925460,Cytopenia,Blood and lymphatic system disorders,No,10%,584,43,77,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 1,584
NCT74925460,Infection,Infections and infestations,Yes,5%,584,50,89,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 1,584
NCT74925460,Cytopenia,Blood and lymphatic system disorders,No,5%,584,27,51,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 1,584
NCT89346782,Infusion related reaction,General disorders and administration site conditions,No,15%,368,27,34,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 1,368
NCT89346782,Infection,Infections and infestations,Yes,10%,368,2,3,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 1,368
NCT89346782,Cytopenia,Blood and lymphatic system disorders,No,15%,368,26,26,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 1,368
NCT89346782,Cytopenia,Blood and lymphatic system disorders,No,15%,368,30,36,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 1,368
NCT89346782,Infusion related reaction,General disorders and administration site conditions,No,15%,368,19,29,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 1,368
NCT89346782,Infusion related reaction,General disorders and administration site conditions,No,15%,368,31,50,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 1,368
NCT89346782,Cytopenia,Blood and lymphatic system disorders,No,5%,368,22,30,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 1,368
NCT89346782,Infusion related reaction,General disorders and administration site conditions,No,5%,368,7,11,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 1,368
NCT89346782,Infection,Infections and infestations,Yes,15%,368,30,38,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 1,368
NCT56705534,Infection,Infections and infestations,Yes,15%,400,2,2,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 2,400
NCT56705534,Infection,Infections and infestations,Yes,5%,400,38,51,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 2,400
NCT56705534,Cytopenia,Blood and lymphatic system disorders,No,10%,400,24,24,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 2,400
NCT56705534,Infusion related reaction,General disorders and administration site conditions,No,10%,400,25,44,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 2,400
NCT56705534,Cytopenia,Blood and lymphatic system disorders,No,15%,400,2,4,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 2,400
NCT68759844,Cytopenia,Blood and lymphatic system disorders,No,5%,757,22,22,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 2,757
NCT68759844,Cytopenia,Blood and lymphatic system disorders,No,10%,757,8,15,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 2,757
NCT68759844,Infection,Infections and infestations,Yes,15%,757,9,11,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 2,757
NCT68759844,Infection,Infections and infestations,Yes,5%,757,46,82,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 2,757
NCT68759844,Cytopenia,Blood and lymphatic system disorders,No,5%,757,14,21,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 2,757
NCT68759844,Infusion related reaction,General disorders and administration site conditions,No,10%,757,14,25,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 2,757
NCT68759844,Infusion related reaction,General disorders and administration site conditions,No,10%,757,25,25,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 2,757
NCT68759844,Infection,Infections and infestations,Yes,15%,757,49,73,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 2,757
NCT68759844,Cytopenia,Blood and lymphatic system disorders,No,15%,757,22,37,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 2,757
NCT68759844,Infusion related reaction,General disorders and administration site conditions,No,5%,757,20,31,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 2,757
NCT68759844,Cytopenia,Blood and lymphatic system disorders,No,10%,757,14,26,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 2,757
NCT68759844,Infusion related reaction,General disorders and administration site conditions,No,15%,757,49,72,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 2,757
NCT68759844,Infusion related reaction,General disorders and administration site conditions,No,15%,757,26,37,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 2,757
NCT68759844,Infusion related reaction,General disorders and administration site conditions,No,15%,757,21,27,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 2,757
NCT79393535,Cytopenia,Blood and lymphatic system disorders,No,10%,900,28,50,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 3,900
NCT79393535,Infusion related reaction,General disorders and administration site conditions,No,5%,900,17,17,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 3,900
NCT79393535,Infusion related reaction,General disorders and administration site conditions,No,10%,900,30,57,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 3,900
NCT24029614,Cytopenia,Blood and lymphatic system disorders,No,5%,566,10,17,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 3,566
NCT24029614,Infusion related reaction,General disorders and administration site conditions,No,10%,566,17,24,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 3,566
NCT24029614,Cytopenia,Blood and lymphatic system disorders,No,15%,566,38,70,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 3,566
NCT30495566,Infusion related reaction,General disorders and administration site conditions,No,15%,544,41,62,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 3,544
NCT30495566,Cytopenia,Blood and lymphatic system disorders,No,15%,544,13,23,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 3,544
NCT30495566,Infusion related reaction,General disorders and administration site conditions,No,15%,544,45,68,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 3,544
NCT82052914,Infusion related reaction,General disorders and administration site conditions,No,10%,949,34,62,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 4,949
NCT82052914,Infusion related reaction,General disorders and administration site conditions,No,5%,949,50,97,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 4,949
NCT82052914,Infection,Infections and infestations,Yes,5%,949,19,27,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 4,949
NCT82052914,Infusion related reaction,General disorders and administration site conditions,No,5%,949,45,78,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 4,949
NCT82052914,Infusion related reaction,General disorders and administration site conditions,No,5%,949,37,48,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 4,949
NCT82052914,Infection,Infections and infestations,Yes,10%,949,9,18,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 4,949
NCT86855955,Cytopenia,Blood and lymphatic system disorders,No,10%,669,12,23,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 4,669
NCT86855955,Infusion related reaction,General disorders and administration site conditions,No,10%,669,32,37,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 4,669
NCT86855955,Cytopenia,Blood and lymphatic system disorders,No,10%,669,16,25,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 4,669
NCT86855955,Infection,Infections and infestations,Yes,15%,669,29,34,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 4,669
NCT86855955,Infusion related reaction,General disorders and administration site conditions,No,15%,669,36,36,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 4,669
NCT86855955,Infection,Infections and infestations,Yes,15%,669,20,29,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 4,669
NCT86855955,Infusion related reaction,General disorders and administration site conditions,No,10%,669,24,47,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 4,669
NCT86855955,Cytopenia,Blood and lymphatic system disorders,No,5%,669,32,60,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 4,669
NCT86855955,Cytopenia,Blood and lymphatic system disorders,No,15%,669,50,58,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 4,669
NCT86855955,Infusion related reaction,General disorders and administration site conditions,No,5%,669,36,38,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 4,669
NCT86855955,Infection,Infections and infestations,Yes,15%,669,27,28,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 4,669
NCT86855955,Infection,Infections and infestations,Yes,10%,669,2,3,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 4,669
NCT86855955,Infusion related reaction,General disorders and administration site conditions,No,5%,669,32,32,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 4,669
NCT86855955,Infection,Infections and infestations,Yes,10%,669,7,9,All Causality,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 4,669
NCT86855955,Cytopenia,Blood and lymphatic system disorders,No,15%,669,35,63,Treatment Emergent,Ocrelizumab,Anti-CD20,Multiple Sclerosis,Phase 4,669
NCT92491261,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,183,3,5,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,183
NCT92491261,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,183,11,17,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,183
NCT92491261,Infusion related reaction,General disorders and administration site conditions,No,15%,183,2,2,All Causality,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,183
NCT18101054,Cardiac failure,Cardiac disorders,Yes,10%,835,22,39,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,835
NCT18101054,Infusion related reaction,General disorders and administration site conditions,No,5%,835,31,46,All Causality,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,835
NCT18101054,Infusion related reaction,General disorders and administration site conditions,No,5%,835,13,25,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,835
NCT18101054,Cardiac failure,Cardiac disorders,Yes,15%,835,10,13,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,835
NCT18101054,Infusion related reaction,General disorders and administration site conditions,No,15%,835,7,8,All Causality,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,835
NCT18101054,Infusion related reaction,General disorders and administration site conditions,No,10%,835,33,50,All Causality,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,835
NCT18101054,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,835,16,21,All Causality,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,835
NCT18101054,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,835,16,31,All Causality,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,835
NCT18101054,Cardiac failure,Cardiac disorders,Yes,15%,835,47,53,All Causality,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,835
NCT18101054,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,835,38,64,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,835
NCT18101054,Infusion related reaction,General disorders and administration site conditions,No,10%,835,4,6,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,835
NCT18101054,Infusion related reaction,General disorders and administration site conditions,No,15%,835,48,49,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,835
NCT18101054,Cardiac failure,Cardiac disorders,Yes,10%,835,37,73,All Causality,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,835
NCT18101054,Cardiac failure,Cardiac disorders,Yes,15%,835,6,8,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,835
NCT38706919,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,734,49,88,All Causality,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,734
NCT38706919,Cardiac failure,Cardiac disorders,Yes,15%,734,44,58,All Causality,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,734
NCT38706919,Cardiac failure,Cardiac disorders,Yes,10%,734,45,73,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,734
NCT38706919,Infusion related reaction,General disorders and administration site conditions,No,15%,734,39,72,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,734
NCT38706919,Cardiac failure,Cardiac disorders,Yes,10%,734,34,53,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,734
NCT38706919,Infusion related reaction,General disorders and administration site conditions,No,5%,734,44,60,All Causality,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,734
NCT38706919,Cardiac failure,Cardiac disorders,Yes,5%,734,38,58,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,734
NCT38706919,Cardiac failure,Cardiac disorders,Yes,15%,734,20,39,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 1,734
NCT24725663,Cardiac failure,Cardiac disorders,Yes,5%,77,2,4,All Causality,Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,77
NCT24725663,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,77,6,10,All Causality,Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,77
NCT24725663,Cardiac failure,Cardiac disorders,Yes,10%,77,1,2,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,77
NCT24725663,Infusion related reaction,General disorders and administration site conditions,No,10%,77,3,5,All Causality,Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,77
NCT24725663,Infusion related reaction,General disorders and administration site conditions,No,5%,77,4,5,All Causality,Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,77
NCT24725663,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,77,3,6,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,77
NCT24725663,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,77,6,11,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,77
NCT24725663,Cardiac failure,Cardiac disorders,Yes,5%,77,5,5,All Causality,Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,77
NCT24725663,Infusion related reaction,General disorders and administration site conditions,No,10%,77,1,1,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 2,77
NCT50442191,Cardiac failure,Cardiac disorders,Yes,10%,714,15,27,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,714
NCT50442191,Infusion related reaction,General disorders and administration site conditions,No,5%,714,29,32,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,714
NCT50442191,Cardiac failure,Cardiac disorders,Yes,5%,714,36,39,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,714
NCT50442191,Cardiac failure,Cardiac disorders,Yes,10%,714,30,41,All Causality,Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,714
NCT50442191,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,714,45,71,All Causality,Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,714
NCT50442191,Infusion related reaction,General disorders and administration site conditions,No,10%,714,7,7,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,714
NCT50442191,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,714,2,3,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,714
NCT50442191,Infusion related reaction,General disorders and administration site conditions,No,10%,714,34,50,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,714
NCT50442191,Cardiac failure,Cardiac disorders,Yes,15%,714,48,69,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,714
NCT50442191,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,714,39,68,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,714
NCT50442191,Cardiac failure,Cardiac disorders,Yes,5%,714,46,80,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,714
NCT50442191,Cardiac failure,Cardiac disorders,Yes,15%,714,11,18,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,714
NCT50442191,Infusion related reaction,General disorders and administration site conditions,No,5%,714,18,27,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,714
NCT50442191,Cardiac failure,Cardiac disorders,Yes,5%,714,43,76,All Causality,Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,714
NCT50442191,Cardiac failure,Cardiac disorders,Yes,15%,714,17,22,All Causality,Trastuzumab,Anti-HER2,Breast Cancer,Phase 3,714
NCT53460629,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,982,48,91,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 4,982
NCT53460629,Cardiac failure,Cardiac disorders,Yes,5%,982,5,5,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 4,982
NCT53460629,Cardiac failure,Cardiac disorders,Yes,15%,982,27,41,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 4,982
NCT53460629,Cardiac failure,Cardiac disorders,Yes,15%,982,3,6,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 4,982
NCT53460629,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,982,1,1,All Causality,Trastuzumab,Anti-HER2,Breast Cancer,Phase 4,982
NCT53460629,Infusion related reaction,General disorders and administration site conditions,No,15%,982,46,90,Treatment Emergent,Trastuzumab,Anti-HER2,Breast Cancer,Phase 4,982
NCT94079951,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,421,20,23,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,421
NCT94079951,Infusion related reaction,General disorders and administration site conditions,No,15%,421,5,6,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,421
NCT94079951,Infusion related reaction,General disorders and administration site conditions,No,15%,421,36,43,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,421
NCT94079951,Infusion related reaction,General disorders and administration site conditions,No,10%,421,22,25,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,421
NCT94079951,Cardiac failure,Cardiac disorders,Yes,5%,421,17,20,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,421
NCT94079951,Cardiac failure,Cardiac disorders,Yes,10%,421,40,51,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,421
NCT94079951,Infusion related reaction,General disorders and administration site conditions,No,5%,421,41,50,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,421
NCT94079951,Infusion related reaction,General disorders and administration site conditions,No,15%,421,10,14,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,421
NCT94079951,Cardiac failure,Cardiac disorders,Yes,10%,421,35,47,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,421
NCT94079951,Cardiac failure,Cardiac disorders,Yes,5%,421,11,21,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,421
NCT94079951,Infusion related reaction,General disorders and administration site conditions,No,15%,421,30,36,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,421
NCT94079951,Infusion related reaction,General disorders and administration site conditions,No,5%,421,25,32,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,421
NCT94079951,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,421,16,17,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 1,421
NCT39777525,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,42,1,1,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,42
NCT39777525,Infusion related reaction,General disorders and administration site conditions,No,15%,42,4,4,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,42
NCT39777525,Cardiac failure,Cardiac disorders,Yes,10%,42,3,5,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,42
NCT39777525,Cardiac failure,Cardiac disorders,Yes,10%,42,4,5,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,42
NCT39777525,Infusion related reaction,General disorders and administration site conditions,No,5%,42,3,4,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,42
NCT39777525,Cardiac failure,Cardiac disorders,Yes,10%,42,2,4,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,42
NCT39777525,Cardiac failure,Cardiac disorders,Yes,15%,42,4,7,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,42
NCT39777525,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,42,1,1,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,42
NCT39777525,Cardiac failure,Cardiac disorders,Yes,5%,42,1,1,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,42
NCT39777525,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,42,2,4,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,42
NCT39777525,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,42,3,4,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,42
NCT39777525,Cardiac failure,Cardiac disorders,Yes,5%,42,1,2,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,42
NCT33301017,Infusion related reaction,General disorders and administration site conditions,No,10%,840,16,18,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,840
NCT33301017,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,840,39,75,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,840
NCT33301017,Cardiac failure,Cardiac disorders,Yes,10%,840,42,82,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,840
NCT76979198,Infusion related reaction,General disorders and administration site conditions,No,5%,747,13,22,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,747
NCT76979198,Cardiac failure,Cardiac disorders,Yes,15%,747,7,8,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,747
NCT76979198,Cardiac failure,Cardiac disorders,Yes,10%,747,30,56,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,747
NCT76979198,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,747,12,14,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,747
NCT76979198,Cardiac failure,Cardiac disorders,Yes,15%,747,24,37,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,747
NCT76979198,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,747,12,17,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,747
NCT76979198,Cardiac failure,Cardiac disorders,Yes,15%,747,33,39,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,747
NCT76979198,Infusion related reaction,General disorders and administration site conditions,No,15%,747,9,18,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,747
NCT76979198,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,747,35,59,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,747
NCT76979198,Infusion related reaction,General disorders and administration site conditions,No,15%,747,29,43,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,747
NCT76979198,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,747,1,1,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 2,747
NCT45563241,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,491,3,5,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,491
NCT45563241,Cardiac failure,Cardiac disorders,Yes,15%,491,13,22,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,491
NCT45563241,Infusion related reaction,General disorders and administration site conditions,No,5%,491,19,19,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,491
NCT45563241,Cardiac failure,Cardiac disorders,Yes,5%,491,18,20,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,491
NCT45563241,Infusion related reaction,General disorders and administration site conditions,No,10%,491,12,12,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,491
NCT45563241,Infusion related reaction,General disorders and administration site conditions,No,10%,491,29,56,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,491
NCT45563241,Infusion related reaction,General disorders and administration site conditions,No,5%,491,49,73,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,491
NCT45563241,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,491,34,38,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,491
NCT94231093,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,42,2,2,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,42
NCT94231093,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,42,1,1,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,42
NCT94231093,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,42,4,5,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,42
NCT94231093,Infusion related reaction,General disorders and administration site conditions,No,5%,42,3,4,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,42
NCT94231093,Cardiac failure,Cardiac disorders,Yes,5%,42,4,6,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,42
NCT94231093,Cardiac failure,Cardiac disorders,Yes,15%,42,2,4,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,42
NCT94231093,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,42,1,2,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,42
NCT94231093,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,42,4,4,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,42
NCT94231093,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,42,2,3,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,42
NCT94231093,Cardiac failure,Cardiac disorders,Yes,10%,42,1,1,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,42
NCT68557517,Cardiac failure,Cardiac disorders,Yes,5%,264,20,28,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,264
NCT68557517,Cardiac failure,Cardiac disorders,Yes,5%,264,26,34,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,264
NCT68557517,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,264,20,38,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,264
NCT68557517,Cardiac failure,Cardiac disorders,Yes,15%,264,15,27,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,264
NCT68557517,Cardiac failure,Cardiac disorders,Yes,15%,264,15,23,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,264
NCT68557517,Infusion related reaction,General disorders and administration site conditions,No,15%,264,12,15,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,264
NCT68557517,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,264,21,37,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,264
NCT68557517,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,264,5,6,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,264
NCT68557517,Infusion related reaction,General disorders and administration site conditions,No,15%,264,23,46,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 3,264
NCT69340701,Cardiac failure,Cardiac disorders,Yes,10%,760,41,68,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 4,760
NCT69340701,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,760,6,6,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 4,760
NCT69340701,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,760,36,51,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 4,760
NCT69340701,Infusion related reaction,General disorders and administration site conditions,No,10%,760,35,62,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 4,760
NCT69340701,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,760,42,61,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 4,760
NCT69340701,Cardiac failure,Cardiac disorders,Yes,10%,760,22,33,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 4,760
NCT69340701,Infusion related reaction,General disorders and administration site conditions,No,15%,760,36,65,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 4,760
NCT69340701,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,760,30,58,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 4,760
NCT69340701,Cardiac failure,Cardiac disorders,Yes,15%,760,40,61,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 4,760
NCT69340701,Cardiac failure,Cardiac disorders,Yes,15%,760,33,56,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 4,760
NCT69340701,Cardiac failure,Cardiac disorders,Yes,5%,760,30,51,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 4,760
NCT69340701,Infusion related reaction,General disorders and administration site conditions,No,15%,760,11,15,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 4,760
NCT69340701,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,760,30,58,All Causality,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 4,760
NCT69340701,Infusion related reaction,General disorders and administration site conditions,No,5%,760,5,6,Treatment Emergent,Trastuzumab,Anti-HER2,Gastric Cancer,Phase 4,760
NCT36116932,Infusion related reaction,General disorders and administration site conditions,No,5%,522,16,30,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 1,522
NCT36116932,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,522,31,40,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 1,522
NCT36116932,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,522,10,14,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 1,522
NCT36116932,Cardiac failure,Cardiac disorders,Yes,15%,522,50,83,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 1,522
NCT36116932,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,522,49,51,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 1,522
NCT36116932,Cardiac failure,Cardiac disorders,Yes,5%,522,39,45,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 1,522
NCT36116932,Infusion related reaction,General disorders and administration site conditions,No,15%,522,36,47,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 1,522
NCT36116932,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,522,29,43,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 1,522
NCT36116932,Infusion related reaction,General disorders and administration site conditions,No,5%,522,35,67,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 1,522
NCT36116932,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,522,50,83,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 1,522
NCT36116932,Cardiac failure,Cardiac disorders,Yes,10%,522,30,54,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 1,522
NCT36116932,Infusion related reaction,General disorders and administration site conditions,No,5%,522,30,31,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 1,522
NCT36116932,Cardiac failure,Cardiac disorders,Yes,5%,522,45,76,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 1,522
NCT36116932,Cardiac failure,Cardiac disorders,Yes,15%,522,6,12,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 1,522
NCT78005094,Cardiac failure,Cardiac disorders,Yes,5%,806,31,43,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 1,806
NCT78005094,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,806,9,18,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 1,806
NCT78005094,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,806,20,37,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 1,806
NCT78005094,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,806,45,81,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 1,806
NCT78005094,Infusion related reaction,General disorders and administration site conditions,No,10%,806,19,34,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 1,806
NCT78005094,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,806,5,5,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 1,806
NCT78005094,Infusion related reaction,General disorders and administration site conditions,No,10%,806,5,10,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 1,806
NCT78005094,Cardiac failure,Cardiac disorders,Yes,5%,806,40,52,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 1,806
NCT78005094,Infusion related reaction,General disorders and administration site conditions,No,5%,806,35,47,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 1,806
NCT78005094,Infusion related reaction,General disorders and administration site conditions,No,15%,806,34,38,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 1,806
NCT79923711,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,323,17,24,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 1,323
NCT79923711,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,323,15,16,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 1,323
NCT79923711,Cardiac failure,Cardiac disorders,Yes,5%,323,13,18,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 1,323
NCT29469432,Cardiac failure,Cardiac disorders,Yes,5%,676,45,48,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 2,676
NCT29469432,Infusion related reaction,General disorders and administration site conditions,No,15%,676,21,21,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 2,676
NCT29469432,Cardiac failure,Cardiac disorders,Yes,15%,676,31,56,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 2,676
NCT29469432,Cardiac failure,Cardiac disorders,Yes,5%,676,36,51,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 2,676
NCT29469432,Infusion related reaction,General disorders and administration site conditions,No,15%,676,10,13,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 2,676
NCT29469432,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,676,16,19,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 2,676
NCT29469432,Cardiac failure,Cardiac disorders,Yes,15%,676,3,4,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 2,676
NCT29469432,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,676,50,64,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 2,676
NCT29469432,Infusion related reaction,General disorders and administration site conditions,No,5%,676,25,34,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 2,676
NCT46616575,Cardiac failure,Cardiac disorders,Yes,5%,499,31,31,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 2,499
NCT46616575,Cardiac failure,Cardiac disorders,Yes,10%,499,14,26,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 2,499
NCT46616575,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,499,28,45,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 2,499
NCT46616575,Infusion related reaction,General disorders and administration site conditions,No,5%,499,2,2,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 2,499
NCT84496688,Cardiac failure,Cardiac disorders,Yes,10%,281,22,38,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 3,281
NCT84496688,Cardiac failure,Cardiac disorders,Yes,10%,281,19,23,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 3,281
NCT84496688,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,281,25,43,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 3,281
NCT12976838,Infusion related reaction,General disorders and administration site conditions,No,10%,752,7,7,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 4,752
NCT12976838,Infusion related reaction,General disorders and administration site conditions,No,15%,752,36,47,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 4,752
NCT12976838,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,752,9,13,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 4,752
NCT71697507,Cardiac failure,Cardiac disorders,Yes,10%,160,13,22,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 4,160
NCT71697507,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,160,2,2,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 4,160
NCT71697507,Cardiac failure,Cardiac disorders,Yes,5%,160,8,15,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 4,160
NCT71697507,Cardiac failure,Cardiac disorders,Yes,10%,160,9,11,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 4,160
NCT71697507,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,160,12,15,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 4,160
NCT71697507,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,160,9,9,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 4,160
NCT71697507,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,160,1,2,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 4,160
NCT71697507,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,160,7,11,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 4,160
NCT71697507,Cardiac failure,Cardiac disorders,Yes,5%,160,5,5,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 4,160
NCT71697507,Infusion related reaction,General disorders and administration site conditions,No,10%,160,5,8,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 4,160
NCT71697507,Cardiac failure,Cardiac disorders,Yes,10%,160,8,16,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 4,160
NCT71697507,Infusion related reaction,General disorders and administration site conditions,No,10%,160,10,11,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 4,160
NCT71697507,Infusion related reaction,General disorders and administration site conditions,No,10%,160,10,14,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 4,160
NCT31880841,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,270,17,17,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 4,270
NCT31880841,Infusion related reaction,General disorders and administration site conditions,No,10%,270,8,8,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 4,270
NCT31880841,Infusion related reaction,General disorders and administration site conditions,No,10%,270,20,29,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 4,270
NCT31880841,Cardiac failure,Cardiac disorders,Yes,10%,270,6,11,Treatment Emergent,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 4,270
NCT31880841,Cardiac failure,Cardiac disorders,Yes,5%,270,8,11,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 4,270
NCT31880841,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,270,12,20,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 4,270
NCT31880841,Cardiac failure,Cardiac disorders,Yes,10%,270,17,23,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 4,270
NCT31880841,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,270,26,35,All Causality,Trastuzumab,Anti-HER2,Esophageal Cancer,Phase 4,270
NCT43793287,Cardiac failure,Cardiac disorders,Yes,15%,579,36,51,Treatment Emergent,Pertuzumab,Anti-HER2,Breast Cancer,Phase 1,579
NCT43793287,Infusion related reaction,General disorders and administration site conditions,No,15%,579,21,38,All Causality,Pertuzumab,Anti-HER2,Breast Cancer,Phase 1,579
NCT43793287,Cardiac failure,Cardiac disorders,Yes,15%,579,49,92,All Causality,Pertuzumab,Anti-HER2,Breast Cancer,Phase 1,579
NCT43793287,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,579,31,51,All Causality,Pertuzumab,Anti-HER2,Breast Cancer,Phase 1,579
NCT43793287,Cardiac failure,Cardiac disorders,Yes,15%,579,17,18,All Causality,Pertuzumab,Anti-HER2,Breast Cancer,Phase 1,579
NCT43793287,Cardiac failure,Cardiac disorders,Yes,10%,579,12,23,All Causality,Pertuzumab,Anti-HER2,Breast Cancer,Phase 1,579
NCT43793287,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,579,25,36,Treatment Emergent,Pertuzumab,Anti-HER2,Breast Cancer,Phase 1,579
NCT24407969,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,105,5,10,Treatment Emergent,Pertuzumab,Anti-HER2,Breast Cancer,Phase 2,105
NCT24407969,Infusion related reaction,General disorders and administration site conditions,No,5%,105,5,5,Treatment Emergent,Pertuzumab,Anti-HER2,Breast Cancer,Phase 2,105
NCT24407969,Cardiac failure,Cardiac disorders,Yes,5%,105,10,20,All Causality,Pertuzumab,Anti-HER2,Breast Cancer,Phase 2,105
NCT24407969,Cardiac failure,Cardiac disorders,Yes,10%,105,3,4,All Causality,Pertuzumab,Anti-HER2,Breast Cancer,Phase 2,105
NCT24407969,Cardiac failure,Cardiac disorders,Yes,10%,105,8,12,Treatment Emergent,Pertuzumab,Anti-HER2,Breast Cancer,Phase 2,105
NCT77108827,Cardiac failure,Cardiac disorders,Yes,15%,610,17,20,All Causality,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,610
NCT77108827,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,610,21,24,All Causality,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,610
NCT77108827,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,610,26,31,All Causality,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,610
NCT77108827,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,610,10,11,All Causality,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,610
NCT77108827,Cardiac failure,Cardiac disorders,Yes,5%,610,49,59,Treatment Emergent,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,610
NCT77108827,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,610,38,58,Treatment Emergent,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,610
NCT77108827,Infusion related reaction,General disorders and administration site conditions,No,10%,610,47,56,All Causality,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,610
NCT77108827,Cardiac failure,Cardiac disorders,Yes,5%,610,26,41,Treatment Emergent,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,610
NCT58387230,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,976,3,4,All Causality,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,976
NCT58387230,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,976,10,12,Treatment Emergent,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,976
NCT58387230,Cardiac failure,Cardiac disorders,Yes,15%,976,8,14,Treatment Emergent,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,976
NCT58387230,Infusion related reaction,General disorders and administration site conditions,No,5%,976,21,33,Treatment Emergent,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,976
NCT58387230,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,976,47,88,All Causality,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,976
NCT58387230,Infusion related reaction,General disorders and administration site conditions,No,5%,976,36,47,Treatment Emergent,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,976
NCT58387230,Cardiac failure,Cardiac disorders,Yes,15%,976,39,70,All Causality,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,976
NCT58387230,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,976,43,81,All Causality,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,976
NCT58387230,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,976,18,33,All Causality,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,976
NCT58387230,Infusion related reaction,General disorders and administration site conditions,No,15%,976,42,64,All Causality,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,976
NCT58387230,Cardiac failure,Cardiac disorders,Yes,15%,976,40,43,Treatment Emergent,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,976
NCT58387230,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,976,5,8,All Causality,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,976
NCT58387230,Infusion related reaction,General disorders and administration site conditions,No,5%,976,48,93,Treatment Emergent,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,976
NCT30700714,Infusion related reaction,General disorders and administration site conditions,No,5%,944,33,59,Treatment Emergent,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,944
NCT30700714,Cardiac failure,Cardiac disorders,Yes,5%,944,13,16,Treatment Emergent,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,944
NCT30700714,Cardiac failure,Cardiac disorders,Yes,10%,944,7,12,Treatment Emergent,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,944
NCT30700714,Cardiac failure,Cardiac disorders,Yes,5%,944,9,15,Treatment Emergent,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,944
NCT30700714,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,944,18,29,Treatment Emergent,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,944
NCT30700714,Infusion related reaction,General disorders and administration site conditions,No,15%,944,27,41,All Causality,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,944
NCT30700714,Cardiac failure,Cardiac disorders,Yes,15%,944,18,23,Treatment Emergent,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,944
NCT30700714,Infusion related reaction,General disorders and administration site conditions,No,5%,944,28,48,All Causality,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,944
NCT30700714,Cardiac failure,Cardiac disorders,Yes,10%,944,47,65,All Causality,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,944
NCT30700714,Infusion related reaction,General disorders and administration site conditions,No,10%,944,41,52,Treatment Emergent,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,944
NCT30700714,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,944,42,79,All Causality,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,944
NCT30700714,Cardiac failure,Cardiac disorders,Yes,10%,944,37,69,Treatment Emergent,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,944
NCT30700714,Cardiac failure,Cardiac disorders,Yes,15%,944,1,1,All Causality,Pertuzumab,Anti-HER2,Breast Cancer,Phase 3,944
NCT80130999,Cardiac failure,Cardiac disorders,Yes,10%,86,4,6,All Causality,Pertuzumab,Anti-HER2,Breast Cancer,Phase 4,86
NCT80130999,Cardiac failure,Cardiac disorders,Yes,10%,86,8,8,Treatment Emergent,Pertuzumab,Anti-HER2,Breast Cancer,Phase 4,86
NCT80130999,Infusion related reaction,General disorders and administration site conditions,No,15%,86,4,5,Treatment Emergent,Pertuzumab,Anti-HER2,Breast Cancer,Phase 4,86
NCT80130999,Cardiac failure,Cardiac disorders,Yes,15%,86,1,2,Treatment Emergent,Pertuzumab,Anti-HER2,Breast Cancer,Phase 4,86
NCT23534320,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,722,6,12,Treatment Emergent,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 1,722
NCT23534320,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,722,43,80,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 1,722
NCT23534320,Infusion related reaction,General disorders and administration site conditions,No,10%,722,1,1,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 1,722
NCT23534320,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,722,48,48,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 1,722
NCT90006506,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,937,7,12,Treatment Emergent,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 2,937
NCT90006506,Infusion related reaction,General disorders and administration site conditions,No,5%,937,18,21,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 2,937
NCT90006506,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,937,49,73,Treatment Emergent,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 2,937
NCT90006506,Cardiac failure,Cardiac disorders,Yes,5%,937,7,8,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 2,937
NCT90006506,Infusion related reaction,General disorders and administration site conditions,No,10%,937,31,42,Treatment Emergent,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 2,937
NCT90006506,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,937,35,67,Treatment Emergent,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 2,937
NCT90006506,Infusion related reaction,General disorders and administration site conditions,No,10%,937,49,63,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 2,937
NCT90006506,Infusion related reaction,General disorders and administration site conditions,No,15%,937,46,79,Treatment Emergent,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 2,937
NCT90006506,Cardiac failure,Cardiac disorders,Yes,5%,937,3,4,Treatment Emergent,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 2,937
NCT97858564,Cardiac failure,Cardiac disorders,Yes,5%,369,6,10,Treatment Emergent,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 2,369
NCT97858564,Cardiac failure,Cardiac disorders,Yes,10%,369,26,45,Treatment Emergent,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 2,369
NCT97858564,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,369,2,4,Treatment Emergent,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 2,369
NCT97858564,Infusion related reaction,General disorders and administration site conditions,No,10%,369,20,27,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 2,369
NCT97858564,Infusion related reaction,General disorders and administration site conditions,No,5%,369,32,34,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 2,369
NCT16058594,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,294,22,36,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 2,294
NCT16058594,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,294,20,29,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 2,294
NCT16058594,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,294,27,29,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 2,294
NCT16058594,Infusion related reaction,General disorders and administration site conditions,No,10%,294,4,7,Treatment Emergent,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 2,294
NCT16058594,Infusion related reaction,General disorders and administration site conditions,No,5%,294,21,28,Treatment Emergent,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 2,294
NCT16058594,Cardiac failure,Cardiac disorders,Yes,10%,294,12,12,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 2,294
NCT16058594,Cardiac failure,Cardiac disorders,Yes,5%,294,21,30,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 2,294
NCT16058594,Cardiac failure,Cardiac disorders,Yes,5%,294,18,32,Treatment Emergent,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 2,294
NCT16058594,Cardiac failure,Cardiac disorders,Yes,5%,294,14,17,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 2,294
NCT55337370,Cardiac failure,Cardiac disorders,Yes,10%,867,33,60,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 3,867
NCT55337370,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,867,4,6,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 3,867
NCT55337370,Infusion related reaction,General disorders and administration site conditions,No,5%,867,22,39,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 3,867
NCT55337370,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,867,23,30,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 3,867
NCT55337370,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,867,15,29,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 3,867
NCT55337370,Infusion related reaction,General disorders and administration site conditions,No,10%,867,1,1,Treatment Emergent,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 3,867
NCT55337370,Cardiac failure,Cardiac disorders,Yes,15%,867,14,24,Treatment Emergent,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 3,867
NCT55337370,Cardiac failure,Cardiac disorders,Yes,5%,867,10,16,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 3,867
NCT55337370,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,867,28,55,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 3,867
NCT55337370,Cardiac failure,Cardiac disorders,Yes,5%,867,38,46,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 3,867
NCT55337370,Infusion related reaction,General disorders and administration site conditions,No,5%,867,28,33,Treatment Emergent,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 3,867
NCT97183937,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,714,9,14,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 3,714
NCT97183937,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,714,5,7,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 3,714
NCT97183937,Cardiac failure,Cardiac disorders,Yes,10%,714,20,30,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 3,714
NCT97183937,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,714,39,65,Treatment Emergent,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 3,714
NCT97183937,Cardiac failure,Cardiac disorders,Yes,5%,714,25,41,Treatment Emergent,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 3,714
NCT97183937,Cardiac failure,Cardiac disorders,Yes,15%,714,28,55,Treatment Emergent,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 3,714
NCT97183937,Cardiac failure,Cardiac disorders,Yes,5%,714,30,52,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 3,714
NCT97183937,Cardiac failure,Cardiac disorders,Yes,15%,714,41,46,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 3,714
NCT24473171,Infusion related reaction,General disorders and administration site conditions,No,5%,268,19,27,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 4,268
NCT24473171,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,268,23,23,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 4,268
NCT24473171,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,268,10,18,All Causality,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 4,268
NCT24473171,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,268,9,11,Treatment Emergent,Pertuzumab,Anti-HER2,Gastric Cancer,Phase 4,268
NCT37128190,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,104,9,18,All Causality,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,104
NCT37128190,Infusion related reaction,General disorders and administration site conditions,No,5%,104,9,15,Treatment Emergent,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,104
NCT37128190,Cardiac failure,Cardiac disorders,Yes,10%,104,10,20,All Causality,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,104
NCT37128190,Cardiac failure,Cardiac disorders,Yes,5%,104,4,4,Treatment Emergent,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,104
NCT37128190,Infusion related reaction,General disorders and administration site conditions,No,5%,104,3,5,All Causality,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,104
NCT37128190,Infusion related reaction,General disorders and administration site conditions,No,10%,104,2,4,All Causality,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,104
NCT37128190,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,104,9,9,Treatment Emergent,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,104
NCT37128190,Cardiac failure,Cardiac disorders,Yes,5%,104,5,5,All Causality,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,104
NCT29347995,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,261,24,41,All Causality,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,261
NCT29347995,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,261,24,30,All Causality,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,261
NCT29347995,Cardiac failure,Cardiac disorders,Yes,5%,261,5,9,All Causality,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,261
NCT29347995,Infusion related reaction,General disorders and administration site conditions,No,10%,261,23,32,All Causality,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,261
NCT29347995,Infusion related reaction,General disorders and administration site conditions,No,5%,261,5,8,All Causality,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,261
NCT29347995,Infusion related reaction,General disorders and administration site conditions,No,15%,261,13,23,Treatment Emergent,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,261
NCT29347995,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,261,9,15,All Causality,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,261
NCT29347995,Infusion related reaction,General disorders and administration site conditions,No,10%,261,13,13,Treatment Emergent,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,261
NCT29347995,Infusion related reaction,General disorders and administration site conditions,No,10%,261,17,25,Treatment Emergent,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,261
NCT29347995,Infusion related reaction,General disorders and administration site conditions,No,10%,261,1,1,Treatment Emergent,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,261
NCT29347995,Cardiac failure,Cardiac disorders,Yes,5%,261,17,34,Treatment Emergent,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,261
NCT29347995,Infusion related reaction,General disorders and administration site conditions,No,5%,261,11,14,All Causality,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,261
NCT29347995,Cardiac failure,Cardiac disorders,Yes,15%,261,1,1,All Causality,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,261
NCT28830407,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,923,13,26,Treatment Emergent,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,923
NCT28830407,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,923,25,49,Treatment Emergent,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,923
NCT28830407,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,923,35,53,Treatment Emergent,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,923
NCT28830407,Infusion related reaction,General disorders and administration site conditions,No,5%,923,4,5,Treatment Emergent,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,923
NCT28830407,Cardiac failure,Cardiac disorders,Yes,10%,923,31,34,All Causality,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,923
NCT28830407,Cardiac failure,Cardiac disorders,Yes,10%,923,33,35,All Causality,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,923
NCT28830407,Infusion related reaction,General disorders and administration site conditions,No,15%,923,43,84,Treatment Emergent,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,923
NCT28830407,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,923,15,28,All Causality,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 1,923
NCT60563372,Infusion related reaction,General disorders and administration site conditions,No,10%,931,28,47,All Causality,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 2,931
NCT60563372,Infusion related reaction,General disorders and administration site conditions,No,10%,931,15,18,Treatment Emergent,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 2,931
NCT60563372,Infusion related reaction,General disorders and administration site conditions,No,5%,931,8,12,Treatment Emergent,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 2,931
NCT60563372,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,931,1,1,All Causality,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 2,931
NCT60563372,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,931,49,50,All Causality,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 2,931
NCT43322529,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,53,4,4,Treatment Emergent,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 3,53
NCT43322529,Infusion related reaction,General disorders and administration site conditions,No,10%,53,2,2,All Causality,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 3,53
NCT43322529,Cardiac failure,Cardiac disorders,Yes,5%,53,1,1,Treatment Emergent,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 3,53
NCT43322529,Infusion related reaction,General disorders and administration site conditions,No,10%,53,4,4,All Causality,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 3,53
NCT43322529,Infusion related reaction,General disorders and administration site conditions,No,15%,53,2,2,Treatment Emergent,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 3,53
NCT43322529,Cardiac failure,Cardiac disorders,Yes,5%,53,5,6,All Causality,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 3,53
NCT43322529,Cardiac failure,Cardiac disorders,Yes,10%,53,1,1,Treatment Emergent,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 3,53
NCT43322529,Cardiac failure,Cardiac disorders,Yes,5%,53,5,7,Treatment Emergent,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 3,53
NCT43322529,Infusion related reaction,General disorders and administration site conditions,No,5%,53,3,4,Treatment Emergent,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 3,53
NCT43322529,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,53,4,4,Treatment Emergent,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 3,53
NCT43322529,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,53,1,1,All Causality,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 3,53
NCT43322529,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,53,1,2,Treatment Emergent,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 3,53
NCT43322529,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,53,3,3,All Causality,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 3,53
NCT79211980,Cardiac failure,Cardiac disorders,Yes,10%,81,8,16,Treatment Emergent,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 4,81
NCT79211980,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,81,4,5,Treatment Emergent,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 4,81
NCT79211980,Cardiac failure,Cardiac disorders,Yes,15%,81,2,2,Treatment Emergent,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 4,81
NCT79211980,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,81,3,6,Treatment Emergent,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 4,81
NCT79211980,Cardiac failure,Cardiac disorders,Yes,5%,81,7,13,Treatment Emergent,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 4,81
NCT79211980,Cardiac failure,Cardiac disorders,Yes,10%,81,2,2,All Causality,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 4,81
NCT79211980,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,81,8,8,All Causality,Pertuzumab,Anti-HER2,Esophageal Cancer,Phase 4,81
NCT58590759,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,85,7,13,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,85
NCT58590759,Cardiac failure,Cardiac disorders,Yes,15%,85,7,14,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,85
NCT58590759,Cardiac failure,Cardiac disorders,Yes,5%,85,6,11,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,85
NCT58590759,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,85,4,7,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,85
NCT58590759,Infusion related reaction,General disorders and administration site conditions,No,10%,85,8,16,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,85
NCT58590759,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,85,3,4,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,85
NCT58590759,Cardiac failure,Cardiac disorders,Yes,5%,85,7,8,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,85
NCT58590759,Cardiac failure,Cardiac disorders,Yes,15%,85,6,9,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,85
NCT58590759,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,85,3,4,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,85
NCT58590759,Infusion related reaction,General disorders and administration site conditions,No,10%,85,5,7,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,85
NCT58590759,Infusion related reaction,General disorders and administration site conditions,No,5%,85,5,6,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,85
NCT58590759,Cardiac failure,Cardiac disorders,Yes,5%,85,3,4,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,85
NCT58590759,Infusion related reaction,General disorders and administration site conditions,No,10%,85,1,1,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,85
NCT85983103,Infusion related reaction,General disorders and administration site conditions,No,5%,707,30,55,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,707
NCT85983103,Infusion related reaction,General disorders and administration site conditions,No,5%,707,32,61,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,707
NCT85983103,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,707,18,28,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,707
NCT85983103,Cardiac failure,Cardiac disorders,Yes,15%,707,47,80,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,707
NCT85983103,Infusion related reaction,General disorders and administration site conditions,No,10%,707,7,13,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,707
NCT85983103,Cardiac failure,Cardiac disorders,Yes,10%,707,8,9,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,707
NCT85983103,Infusion related reaction,General disorders and administration site conditions,No,5%,707,49,93,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,707
NCT85983103,Cardiac failure,Cardiac disorders,Yes,15%,707,14,24,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,707
NCT85983103,Cardiac failure,Cardiac disorders,Yes,10%,707,47,62,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,707
NCT85983103,Cardiac failure,Cardiac disorders,Yes,15%,707,22,24,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,707
NCT85983103,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,707,9,11,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,707
NCT85983103,Infusion related reaction,General disorders and administration site conditions,No,15%,707,8,12,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,707
NCT85983103,Cardiac failure,Cardiac disorders,Yes,15%,707,47,73,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,707
NCT85983103,Cardiac failure,Cardiac disorders,Yes,10%,707,3,4,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,707
NCT85983103,Infusion related reaction,General disorders and administration site conditions,No,15%,707,10,11,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 1,707
NCT11430383,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,921,42,73,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 2,921
NCT11430383,Infusion related reaction,General disorders and administration site conditions,No,15%,921,16,20,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 2,921
NCT11430383,Infusion related reaction,General disorders and administration site conditions,No,5%,921,45,89,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 2,921
NCT11430383,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,921,28,33,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 2,921
NCT11430383,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,921,25,34,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 2,921
NCT11430383,Cardiac failure,Cardiac disorders,Yes,10%,921,39,60,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 2,921
NCT11430383,Cardiac failure,Cardiac disorders,Yes,15%,921,25,29,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 2,921
NCT11430383,Cardiac failure,Cardiac disorders,Yes,10%,921,5,9,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 2,921
NCT11430383,Infusion related reaction,General disorders and administration site conditions,No,15%,921,14,23,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 2,921
NCT11430383,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,921,3,4,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 2,921
NCT11430383,Cardiac failure,Cardiac disorders,Yes,15%,921,40,71,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 2,921
NCT11430383,Infusion related reaction,General disorders and administration site conditions,No,10%,921,44,66,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 2,921
NCT11430383,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,921,35,45,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 2,921
NCT11430383,Infusion related reaction,General disorders and administration site conditions,No,10%,921,14,19,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 2,921
NCT18866819,Cardiac failure,Cardiac disorders,Yes,15%,488,30,42,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 2,488
NCT18866819,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,488,48,79,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 2,488
NCT18866819,Cardiac failure,Cardiac disorders,Yes,5%,488,35,50,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 2,488
NCT52824323,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,134,10,11,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 3,134
NCT52824323,Cardiac failure,Cardiac disorders,Yes,10%,134,5,5,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 3,134
NCT52824323,Infusion related reaction,General disorders and administration site conditions,No,5%,134,4,4,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 3,134
NCT52824323,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,134,5,5,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 3,134
NCT52824323,Cardiac failure,Cardiac disorders,Yes,5%,134,9,17,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 3,134
NCT52824323,Infusion related reaction,General disorders and administration site conditions,No,15%,134,12,22,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 3,134
NCT52824323,Infusion related reaction,General disorders and administration site conditions,No,10%,134,6,8,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 3,134
NCT52824323,Infusion related reaction,General disorders and administration site conditions,No,10%,134,12,14,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 3,134
NCT43413000,Cardiac failure,Cardiac disorders,Yes,5%,133,7,7,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 3,133
NCT43413000,Cardiac failure,Cardiac disorders,Yes,10%,133,9,12,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 3,133
NCT43413000,Cardiac failure,Cardiac disorders,Yes,15%,133,2,3,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 3,133
NCT43413000,Cardiac failure,Cardiac disorders,Yes,5%,133,11,15,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 3,133
NCT43413000,Cardiac failure,Cardiac disorders,Yes,15%,133,2,2,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 3,133
NCT43413000,Cardiac failure,Cardiac disorders,Yes,10%,133,7,10,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 3,133
NCT43413000,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,133,12,14,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 3,133
NCT43413000,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,133,9,14,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 3,133
NCT12062929,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,956,27,35,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,956
NCT12062929,Cardiac failure,Cardiac disorders,Yes,10%,956,20,31,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,956
NCT12062929,Cardiac failure,Cardiac disorders,Yes,5%,956,24,24,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,956
NCT12062929,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,956,17,26,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,956
NCT12062929,Infusion related reaction,General disorders and administration site conditions,No,10%,956,29,29,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,956
NCT88116734,Cardiac failure,Cardiac disorders,Yes,10%,120,4,5,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,120
NCT88116734,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,120,5,6,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,120
NCT88116734,Infusion related reaction,General disorders and administration site conditions,No,5%,120,9,14,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,120
NCT88116734,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,120,10,17,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,120
NCT88116734,Cardiac failure,Cardiac disorders,Yes,10%,120,12,23,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,120
NCT88116734,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,120,6,7,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,120
NCT88116734,Infusion related reaction,General disorders and administration site conditions,No,5%,120,11,13,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,120
NCT88116734,Cardiac failure,Cardiac disorders,Yes,15%,120,4,6,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,120
NCT88116734,Infusion related reaction,General disorders and administration site conditions,No,5%,120,9,16,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,120
NCT88116734,Cardiac failure,Cardiac disorders,Yes,5%,120,10,10,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,120
NCT88116734,Infusion related reaction,General disorders and administration site conditions,No,15%,120,12,13,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,120
NCT88116734,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,120,6,10,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,120
NCT88116734,Infusion related reaction,General disorders and administration site conditions,No,5%,120,8,14,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,120
NCT88116734,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,120,11,19,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,120
NCT73872146,Cardiac failure,Cardiac disorders,Yes,15%,757,19,38,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,757
NCT73872146,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,757,16,19,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,757
NCT73872146,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,757,27,35,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,757
NCT73872146,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,757,26,34,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,757
NCT73872146,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,757,32,34,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,757
NCT73872146,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,757,41,74,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,757
NCT73872146,Infusion related reaction,General disorders and administration site conditions,No,5%,757,10,17,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,757
NCT73872146,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,757,1,1,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,757
NCT73872146,Cardiac failure,Cardiac disorders,Yes,15%,757,20,26,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,757
NCT73872146,Cardiac failure,Cardiac disorders,Yes,15%,757,3,4,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,757
NCT73872146,Infusion related reaction,General disorders and administration site conditions,No,15%,757,27,38,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,757
NCT73872146,Infusion related reaction,General disorders and administration site conditions,No,10%,757,2,3,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,757
NCT73872146,Cardiac failure,Cardiac disorders,Yes,5%,757,35,52,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Breast Cancer,Phase 4,757
NCT44433687,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,358,26,47,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 1,358
NCT44433687,Cardiac failure,Cardiac disorders,Yes,5%,358,9,10,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 1,358
NCT44433687,Infusion related reaction,General disorders and administration site conditions,No,5%,358,35,67,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 1,358
NCT44433687,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,358,5,10,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 1,358
NCT44433687,Infusion related reaction,General disorders and administration site conditions,No,5%,358,2,2,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 1,358
NCT44433687,Cardiac failure,Cardiac disorders,Yes,15%,358,10,19,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 1,358
NCT66133386,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,371,2,3,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 1,371
NCT66133386,Cardiac failure,Cardiac disorders,Yes,5%,371,8,16,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 1,371
NCT66133386,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,371,13,22,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 1,371
NCT66133386,Cardiac failure,Cardiac disorders,Yes,10%,371,20,28,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 1,371
NCT66133386,Infusion related reaction,General disorders and administration site conditions,No,5%,371,7,12,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 1,371
NCT66133386,Infusion related reaction,General disorders and administration site conditions,No,15%,371,33,34,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 1,371
NCT66133386,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,371,10,19,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 1,371
NCT25951363,Cardiac failure,Cardiac disorders,Yes,15%,229,20,30,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,229
NCT25951363,Cardiac failure,Cardiac disorders,Yes,15%,229,2,4,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,229
NCT25951363,Infusion related reaction,General disorders and administration site conditions,No,10%,229,16,28,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,229
NCT25951363,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,229,21,25,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,229
NCT25951363,Infusion related reaction,General disorders and administration site conditions,No,15%,229,10,14,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,229
NCT25951363,Cardiac failure,Cardiac disorders,Yes,15%,229,8,13,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,229
NCT25951363,Cardiac failure,Cardiac disorders,Yes,10%,229,2,3,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,229
NCT25951363,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,229,11,19,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,229
NCT25951363,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,229,18,20,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,229
NCT25951363,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,229,6,11,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,229
NCT25951363,Cardiac failure,Cardiac disorders,Yes,15%,229,2,2,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,229
NCT25951363,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,229,12,15,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,229
NCT52669879,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,189,2,2,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,189
NCT52669879,Infusion related reaction,General disorders and administration site conditions,No,10%,189,11,16,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,189
NCT52669879,Cardiac failure,Cardiac disorders,Yes,5%,189,2,4,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,189
NCT52669879,Cardiac failure,Cardiac disorders,Yes,5%,189,9,16,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,189
NCT52669879,Cardiac failure,Cardiac disorders,Yes,10%,189,13,21,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,189
NCT52669879,Infusion related reaction,General disorders and administration site conditions,No,15%,189,12,16,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,189
NCT52669879,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,189,12,14,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,189
NCT52669879,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,189,9,15,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,189
NCT52669879,Infusion related reaction,General disorders and administration site conditions,No,5%,189,3,5,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,189
NCT52669879,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,189,18,19,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,189
NCT52669879,Infusion related reaction,General disorders and administration site conditions,No,5%,189,2,3,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,189
NCT52669879,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,189,7,14,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,189
NCT87151190,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,569,24,40,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,569
NCT87151190,Cardiac failure,Cardiac disorders,Yes,10%,569,42,64,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,569
NCT87151190,Infusion related reaction,General disorders and administration site conditions,No,5%,569,39,69,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,569
NCT87151190,Cardiac failure,Cardiac disorders,Yes,15%,569,21,23,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,569
NCT87151190,Cardiac failure,Cardiac disorders,Yes,5%,569,12,17,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,569
NCT87151190,Cardiac failure,Cardiac disorders,Yes,5%,569,25,41,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 2,569
NCT96037081,Cardiac failure,Cardiac disorders,Yes,5%,880,6,11,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 3,880
NCT96037081,Infusion related reaction,General disorders and administration site conditions,No,10%,880,50,62,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 3,880
NCT96037081,Cardiac failure,Cardiac disorders,Yes,10%,880,10,17,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 3,880
NCT96037081,Infusion related reaction,General disorders and administration site conditions,No,5%,880,47,74,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 3,880
NCT96037081,Infusion related reaction,General disorders and administration site conditions,No,5%,880,43,71,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 3,880
NCT96037081,Cardiac failure,Cardiac disorders,Yes,5%,880,40,42,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 3,880
NCT96037081,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,880,1,1,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 3,880
NCT96037081,Infusion related reaction,General disorders and administration site conditions,No,5%,880,9,16,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 3,880
NCT96037081,Infusion related reaction,General disorders and administration site conditions,No,15%,880,42,71,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 3,880
NCT96037081,Infusion related reaction,General disorders and administration site conditions,No,5%,880,25,27,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 3,880
NCT96037081,Infusion related reaction,General disorders and administration site conditions,No,5%,880,28,54,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 3,880
NCT96037081,Infusion related reaction,General disorders and administration site conditions,No,10%,880,31,46,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 3,880
NCT96037081,Infusion related reaction,General disorders and administration site conditions,No,5%,880,1,1,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 3,880
NCT96037081,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,880,17,32,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 3,880
NCT96037081,Cardiac failure,Cardiac disorders,Yes,15%,880,25,32,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 3,880
NCT66539686,Infusion related reaction,General disorders and administration site conditions,No,15%,47,2,4,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 3,47
NCT66539686,Infusion related reaction,General disorders and administration site conditions,No,5%,47,3,5,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 3,47
NCT66539686,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,47,4,7,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 3,47
NCT16257188,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,594,47,54,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 3,594
NCT16257188,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,594,34,58,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 3,594
NCT16257188,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,594,12,19,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 3,594
NCT16257188,Cardiac failure,Cardiac disorders,Yes,15%,594,15,21,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 3,594
NCT16257188,Cardiac failure,Cardiac disorders,Yes,10%,594,44,71,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 3,594
NCT11260808,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,905,48,78,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 4,905
NCT11260808,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,905,31,55,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 4,905
NCT11260808,Cardiac failure,Cardiac disorders,Yes,15%,905,4,5,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 4,905
NCT11260808,Infusion related reaction,General disorders and administration site conditions,No,15%,905,13,19,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 4,905
NCT58072648,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,279,17,18,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 4,279
NCT58072648,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,279,2,4,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 4,279
NCT58072648,Cardiac failure,Cardiac disorders,Yes,15%,279,8,11,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 4,279
NCT58072648,Cardiac failure,Cardiac disorders,Yes,15%,279,24,31,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 4,279
NCT58072648,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,279,23,27,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Gastric Cancer,Phase 4,279
NCT66352181,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,251,15,18,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 1,251
NCT66352181,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,251,17,21,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 1,251
NCT66352181,Infusion related reaction,General disorders and administration site conditions,No,10%,251,14,21,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 1,251
NCT66991801,Cardiac failure,Cardiac disorders,Yes,5%,84,7,9,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 1,84
NCT66991801,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,84,4,8,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 1,84
NCT66991801,Infusion related reaction,General disorders and administration site conditions,No,10%,84,5,7,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 1,84
NCT66991801,Infusion related reaction,General disorders and administration site conditions,No,15%,84,2,2,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 1,84
NCT66991801,Infusion related reaction,General disorders and administration site conditions,No,15%,84,6,12,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 1,84
NCT66991801,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,84,2,2,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 1,84
NCT66991801,Infusion related reaction,General disorders and administration site conditions,No,15%,84,8,14,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 1,84
NCT66991801,Cardiac failure,Cardiac disorders,Yes,10%,84,8,14,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 1,84
NCT66991801,Infusion related reaction,General disorders and administration site conditions,No,10%,84,6,11,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 1,84
NCT66991801,Cardiac failure,Cardiac disorders,Yes,10%,84,6,7,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 1,84
NCT66991801,Infusion related reaction,General disorders and administration site conditions,No,5%,84,2,4,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 1,84
NCT38764835,Cardiac failure,Cardiac disorders,Yes,5%,714,17,21,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 1,714
NCT38764835,Infusion related reaction,General disorders and administration site conditions,No,15%,714,7,13,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 1,714
NCT38764835,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,714,12,13,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 1,714
NCT38764835,Cardiac failure,Cardiac disorders,Yes,15%,714,22,35,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 1,714
NCT38764835,Cardiac failure,Cardiac disorders,Yes,15%,714,11,21,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 1,714
NCT38764835,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,714,36,69,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 1,714
NCT38764835,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,714,8,12,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 1,714
NCT33237170,Infusion related reaction,General disorders and administration site conditions,No,10%,997,27,47,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 2,997
NCT33237170,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,997,43,70,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 2,997
NCT33237170,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,997,50,100,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 2,997
NCT33237170,Infusion related reaction,General disorders and administration site conditions,No,15%,997,24,48,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 2,997
NCT33237170,Cardiac failure,Cardiac disorders,Yes,5%,997,48,77,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 2,997
NCT33237170,Cardiac failure,Cardiac disorders,Yes,15%,997,33,53,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 2,997
NCT33237170,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,997,15,28,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 2,997
NCT33237170,Infusion related reaction,General disorders and administration site conditions,No,15%,997,45,51,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 2,997
NCT33237170,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,997,28,28,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 2,997
NCT33237170,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,997,34,46,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 2,997
NCT49181561,Cardiac failure,Cardiac disorders,Yes,15%,339,10,12,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 2,339
NCT49181561,Infusion related reaction,General disorders and administration site conditions,No,5%,339,3,3,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 2,339
NCT49181561,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,339,12,12,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 2,339
NCT49181561,Cardiac failure,Cardiac disorders,Yes,5%,339,16,21,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 2,339
NCT49181561,Infusion related reaction,General disorders and administration site conditions,No,15%,339,6,7,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 2,339
NCT49181561,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,339,29,49,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 2,339
NCT49181561,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,339,16,22,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 2,339
NCT49181561,Cardiac failure,Cardiac disorders,Yes,10%,339,4,8,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 2,339
NCT49181561,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,339,25,43,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 2,339
NCT49181561,Infusion related reaction,General disorders and administration site conditions,No,5%,339,12,21,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 2,339
NCT49181561,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,339,23,45,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 2,339
NCT77286202,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,291,7,9,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 3,291
NCT77286202,Infusion related reaction,General disorders and administration site conditions,No,15%,291,27,29,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 3,291
NCT77286202,Infusion related reaction,General disorders and administration site conditions,No,10%,291,2,2,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 3,291
NCT77286202,Infusion related reaction,General disorders and administration site conditions,No,15%,291,29,47,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 3,291
NCT21048793,Cardiac failure,Cardiac disorders,Yes,15%,689,43,65,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 3,689
NCT21048793,Cardiac failure,Cardiac disorders,Yes,5%,689,35,41,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 3,689
NCT21048793,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,689,48,63,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 3,689
NCT21048793,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,5%,689,49,54,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 3,689
NCT21048793,Cardiac failure,Cardiac disorders,Yes,5%,689,24,46,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 3,689
NCT21048793,Infusion related reaction,General disorders and administration site conditions,No,15%,689,49,66,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 3,689
NCT21048793,Cardiac failure,Cardiac disorders,Yes,5%,689,22,34,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 3,689
NCT36169219,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,82,8,9,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 3,82
NCT36169219,Infusion related reaction,General disorders and administration site conditions,No,10%,82,8,15,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 3,82
NCT36169219,Infusion related reaction,General disorders and administration site conditions,No,15%,82,3,3,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 3,82
NCT36169219,Infusion related reaction,General disorders and administration site conditions,No,10%,82,6,12,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 3,82
NCT36169219,Infusion related reaction,General disorders and administration site conditions,No,10%,82,2,3,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 3,82
NCT36169219,Cardiac failure,Cardiac disorders,Yes,15%,82,6,11,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 3,82
NCT36169219,Cardiac failure,Cardiac disorders,Yes,5%,82,5,7,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 3,82
NCT36169219,Cardiac failure,Cardiac disorders,Yes,10%,82,1,2,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 3,82
NCT36169219,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,10%,82,1,1,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 3,82
NCT17708466,Cardiac failure,Cardiac disorders,Yes,5%,149,6,9,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 4,149
NCT17708466,Infusion related reaction,General disorders and administration site conditions,No,10%,149,2,3,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 4,149
NCT17708466,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,149,9,9,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 4,149
NCT17708466,Dyspnea,"Respiratory, thoracic and mediastinal disorders",Yes,15%,149,1,2,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 4,149
NCT17708466,Infusion related reaction,General disorders and administration site conditions,No,15%,149,3,5,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 4,149
NCT37664544,Cardiac failure,Cardiac disorders,Yes,10%,267,21,33,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 4,267
NCT37664544,Cardiac failure,Cardiac disorders,Yes,15%,267,19,19,Treatment Emergent,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 4,267
NCT37664544,Infusion related reaction,General disorders and administration site conditions,No,10%,267,12,22,All Causality,Ado-trastuzumab emtansine,Anti-HER2,Esophageal Cancer,Phase 4,267
NCT29066790,Proteinuria,Renal and urinary disorders,No,10%,639,11,16,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,639
NCT29066790,Proteinuria,Renal and urinary disorders,No,15%,639,50,58,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,639
NCT29066790,Hypertension,Vascular disorders,No,10%,639,12,21,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,639
NCT29066790,Hypertension,Vascular disorders,No,15%,639,2,2,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,639
NCT29066790,Proteinuria,Renal and urinary disorders,No,5%,639,36,67,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,639
NCT29066790,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,639,4,6,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,639
NCT29066790,Hypertension,Vascular disorders,No,15%,639,21,32,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,639
NCT29066790,Hypertension,Vascular disorders,No,10%,639,46,60,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,639
NCT29066790,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,639,14,17,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,639
NCT29066790,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,639,12,18,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,639
NCT29066790,Hypertension,Vascular disorders,No,5%,639,1,2,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,639
NCT29066790,Proteinuria,Renal and urinary disorders,No,5%,639,3,3,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,639
NCT29066790,Hypertension,Vascular disorders,No,15%,639,9,10,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 1,639
NCT83403465,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,84,3,3,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,84
NCT83403465,Proteinuria,Renal and urinary disorders,No,15%,84,2,4,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,84
NCT83403465,Hypertension,Vascular disorders,No,5%,84,2,3,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,84
NCT83403465,Proteinuria,Renal and urinary disorders,No,5%,84,7,8,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,84
NCT83403465,Hypertension,Vascular disorders,No,5%,84,3,3,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,84
NCT83403465,Hypertension,Vascular disorders,No,10%,84,1,1,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,84
NCT83403465,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,84,4,8,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,84
NCT83403465,Hypertension,Vascular disorders,No,15%,84,7,10,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,84
NCT83403465,Hypertension,Vascular disorders,No,10%,84,7,8,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,84
NCT83403465,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,84,7,13,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,84
NCT83403465,Proteinuria,Renal and urinary disorders,No,5%,84,5,10,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,84
NCT83403465,Hypertension,Vascular disorders,No,15%,84,5,5,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,84
NCT83403465,Proteinuria,Renal and urinary disorders,No,5%,84,5,5,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,84
NCT83403465,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,84,1,1,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,84
NCT64315172,Hypertension,Vascular disorders,No,15%,142,4,5,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,142
NCT64315172,Proteinuria,Renal and urinary disorders,No,15%,142,1,2,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,142
NCT64315172,Proteinuria,Renal and urinary disorders,No,15%,142,2,3,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,142
NCT99506370,Proteinuria,Renal and urinary disorders,No,5%,274,8,8,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,274
NCT99506370,Proteinuria,Renal and urinary disorders,No,5%,274,11,18,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,274
NCT99506370,Hypertension,Vascular disorders,No,15%,274,17,34,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,274
NCT99506370,Proteinuria,Renal and urinary disorders,No,10%,274,24,47,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,274
NCT99506370,Proteinuria,Renal and urinary disorders,No,15%,274,27,29,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,274
NCT99506370,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,274,17,20,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,274
NCT99506370,Proteinuria,Renal and urinary disorders,No,10%,274,5,5,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,274
NCT99506370,Hypertension,Vascular disorders,No,5%,274,6,6,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,274
NCT99506370,Proteinuria,Renal and urinary disorders,No,5%,274,12,20,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,274
NCT99506370,Hypertension,Vascular disorders,No,10%,274,16,30,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,274
NCT99506370,Hypertension,Vascular disorders,No,15%,274,16,27,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,274
NCT99506370,Proteinuria,Renal and urinary disorders,No,10%,274,24,36,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,274
NCT99506370,Hypertension,Vascular disorders,No,15%,274,15,21,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,274
NCT99506370,Proteinuria,Renal and urinary disorders,No,10%,274,13,15,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 2,274
NCT82032992,Proteinuria,Renal and urinary disorders,No,15%,945,34,42,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,945
NCT82032992,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,945,34,54,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,945
NCT82032992,Proteinuria,Renal and urinary disorders,No,10%,945,29,53,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,945
NCT62713148,Hypertension,Vascular disorders,No,5%,744,22,37,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,744
NCT62713148,Hypertension,Vascular disorders,No,15%,744,11,18,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,744
NCT62713148,Proteinuria,Renal and urinary disorders,No,15%,744,47,88,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 3,744
NCT46207933,Hypertension,Vascular disorders,No,5%,542,22,44,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,542
NCT46207933,Proteinuria,Renal and urinary disorders,No,5%,542,45,77,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,542
NCT46207933,Hypertension,Vascular disorders,No,15%,542,42,75,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,542
NCT46207933,Proteinuria,Renal and urinary disorders,No,15%,542,29,32,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,542
NCT46207933,Proteinuria,Renal and urinary disorders,No,10%,542,6,9,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,542
NCT46207933,Proteinuria,Renal and urinary disorders,No,5%,542,39,56,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,542
NCT46207933,Hypertension,Vascular disorders,No,5%,542,47,68,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,542
NCT46207933,Proteinuria,Renal and urinary disorders,No,10%,542,23,42,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,542
NCT46207933,Proteinuria,Renal and urinary disorders,No,5%,542,15,21,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,542
NCT46207933,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,542,49,49,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,542
NCT46207933,Proteinuria,Renal and urinary disorders,No,10%,542,35,37,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,542
NCT46207933,Proteinuria,Renal and urinary disorders,No,15%,542,10,15,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,542
NCT46207933,Proteinuria,Renal and urinary disorders,No,15%,542,33,34,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,542
NCT46207933,Hypertension,Vascular disorders,No,5%,542,27,43,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,542
NCT46207933,Proteinuria,Renal and urinary disorders,No,15%,542,10,15,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,542
NCT78174268,Proteinuria,Renal and urinary disorders,No,10%,187,5,5,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,187
NCT78174268,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,187,16,28,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,187
NCT78174268,Proteinuria,Renal and urinary disorders,No,15%,187,2,3,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,187
NCT78174268,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,187,18,35,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,187
NCT78174268,Hypertension,Vascular disorders,No,10%,187,8,10,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,187
NCT78174268,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,187,16,16,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,187
NCT78174268,Proteinuria,Renal and urinary disorders,No,15%,187,10,10,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,187
NCT78174268,Hypertension,Vascular disorders,No,15%,187,5,6,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,187
NCT78174268,Proteinuria,Renal and urinary disorders,No,10%,187,4,4,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,187
NCT78174268,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,187,3,6,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,187
NCT78174268,Proteinuria,Renal and urinary disorders,No,5%,187,15,24,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,187
NCT78174268,Proteinuria,Renal and urinary disorders,No,15%,187,11,20,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,187
NCT77476911,Hypertension,Vascular disorders,No,5%,36,2,2,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,36
NCT77476911,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,36,2,4,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,36
NCT77476911,Proteinuria,Renal and urinary disorders,No,10%,36,1,2,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,36
NCT77476911,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,36,1,2,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,36
NCT77476911,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,36,2,3,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,36
NCT77476911,Proteinuria,Renal and urinary disorders,No,15%,36,1,2,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,36
NCT77476911,Hypertension,Vascular disorders,No,5%,36,1,2,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,36
NCT77476911,Proteinuria,Renal and urinary disorders,No,15%,36,1,2,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,36
NCT77476911,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,36,2,3,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,36
NCT77476911,Hypertension,Vascular disorders,No,15%,36,1,1,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,36
NCT77476911,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,36,3,4,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,36
NCT77476911,Proteinuria,Renal and urinary disorders,No,15%,36,1,2,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,36
NCT77476911,Proteinuria,Renal and urinary disorders,No,15%,36,3,4,All Causality,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,36
NCT77476911,Proteinuria,Renal and urinary disorders,No,10%,36,2,2,Treatment Emergent,Bevacizumab,Anti-VEGF,Colorectal Cancer,Phase 4,36
NCT71882375,Hypertension,Vascular disorders,No,10%,883,40,49,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,883
NCT71882375,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,883,22,42,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,883
NCT71882375,Hypertension,Vascular disorders,No,10%,883,34,64,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,883
NCT71882375,Hypertension,Vascular disorders,No,5%,883,24,47,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,883
NCT71882375,Hypertension,Vascular disorders,No,5%,883,33,37,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,883
NCT71882375,Hypertension,Vascular disorders,No,10%,883,19,34,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,883
NCT71882375,Proteinuria,Renal and urinary disorders,No,10%,883,25,31,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,883
NCT71882375,Hypertension,Vascular disorders,No,15%,883,10,10,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,883
NCT71882375,Hypertension,Vascular disorders,No,5%,883,36,44,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,883
NCT71882375,Proteinuria,Renal and urinary disorders,No,5%,883,19,21,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,883
NCT67291452,Proteinuria,Renal and urinary disorders,No,5%,155,10,18,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,155
NCT67291452,Hypertension,Vascular disorders,No,10%,155,15,17,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,155
NCT67291452,Proteinuria,Renal and urinary disorders,No,10%,155,2,2,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,155
NCT67291452,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,155,8,12,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,155
NCT67291452,Proteinuria,Renal and urinary disorders,No,10%,155,7,9,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,155
NCT67291452,Proteinuria,Renal and urinary disorders,No,15%,155,11,18,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,155
NCT67291452,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,155,11,17,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,155
NCT67291452,Proteinuria,Renal and urinary disorders,No,5%,155,1,2,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,155
NCT67291452,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,155,11,13,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 1,155
NCT10154072,Proteinuria,Renal and urinary disorders,No,5%,452,13,23,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,452
NCT10154072,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,452,41,56,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,452
NCT10154072,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,452,41,60,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,452
NCT10154072,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,452,26,27,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,452
NCT10154072,Hypertension,Vascular disorders,No,15%,452,23,39,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,452
NCT10154072,Hypertension,Vascular disorders,No,10%,452,19,30,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,452
NCT10154072,Proteinuria,Renal and urinary disorders,No,5%,452,2,2,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,452
NCT10154072,Hypertension,Vascular disorders,No,10%,452,5,8,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,452
NCT10154072,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,452,24,48,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,452
NCT12243516,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,821,16,26,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,821
NCT12243516,Proteinuria,Renal and urinary disorders,No,5%,821,2,2,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,821
NCT12243516,Proteinuria,Renal and urinary disorders,No,10%,821,11,21,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,821
NCT12243516,Proteinuria,Renal and urinary disorders,No,5%,821,23,33,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,821
NCT12243516,Hypertension,Vascular disorders,No,15%,821,48,56,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,821
NCT12243516,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,821,35,36,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,821
NCT12243516,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,821,39,72,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,821
NCT12243516,Hypertension,Vascular disorders,No,15%,821,46,46,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,821
NCT12243516,Proteinuria,Renal and urinary disorders,No,10%,821,7,11,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,821
NCT12243516,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,821,22,44,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,821
NCT12243516,Proteinuria,Renal and urinary disorders,No,10%,821,27,44,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,821
NCT52650141,Hypertension,Vascular disorders,No,10%,827,38,45,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,827
NCT52650141,Proteinuria,Renal and urinary disorders,No,10%,827,16,29,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,827
NCT52650141,Proteinuria,Renal and urinary disorders,No,15%,827,19,36,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,827
NCT52650141,Hypertension,Vascular disorders,No,15%,827,2,4,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 2,827
NCT11919204,Proteinuria,Renal and urinary disorders,No,5%,375,14,26,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,375
NCT11919204,Hypertension,Vascular disorders,No,5%,375,4,4,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,375
NCT11919204,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,375,12,23,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,375
NCT11919204,Hypertension,Vascular disorders,No,15%,375,1,1,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,375
NCT11919204,Proteinuria,Renal and urinary disorders,No,10%,375,2,3,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,375
NCT11919204,Proteinuria,Renal and urinary disorders,No,10%,375,14,20,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,375
NCT11919204,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,375,21,38,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,375
NCT11919204,Hypertension,Vascular disorders,No,15%,375,6,7,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,375
NCT11919204,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,375,34,52,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,375
NCT11919204,Proteinuria,Renal and urinary disorders,No,15%,375,33,35,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,375
NCT11919204,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,375,4,6,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,375
NCT11919204,Hypertension,Vascular disorders,No,15%,375,32,33,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 3,375
NCT61859305,Hypertension,Vascular disorders,No,10%,298,16,20,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 4,298
NCT61859305,Proteinuria,Renal and urinary disorders,No,15%,298,13,15,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 4,298
NCT61859305,Hypertension,Vascular disorders,No,15%,298,4,4,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 4,298
NCT61859305,Hypertension,Vascular disorders,No,15%,298,4,7,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 4,298
NCT61859305,Hypertension,Vascular disorders,No,5%,298,10,20,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 4,298
NCT61859305,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,298,19,29,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 4,298
NCT61859305,Hypertension,Vascular disorders,No,10%,298,9,11,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 4,298
NCT61859305,Hypertension,Vascular disorders,No,15%,298,15,20,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 4,298
NCT61859305,Proteinuria,Renal and urinary disorders,No,10%,298,26,40,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 4,298
NCT61859305,Proteinuria,Renal and urinary disorders,No,10%,298,3,3,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 4,298
NCT61859305,Proteinuria,Renal and urinary disorders,No,15%,298,8,16,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 4,298
NCT61859305,Hypertension,Vascular disorders,No,10%,298,15,29,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 4,298
NCT61859305,Proteinuria,Renal and urinary disorders,No,5%,298,6,9,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 4,298
NCT61859305,Proteinuria,Renal and urinary disorders,No,10%,298,14,20,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 4,298
NCT61859305,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,298,27,33,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 4,298
NCT62533883,Hypertension,Vascular disorders,No,5%,329,11,12,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 4,329
NCT62533883,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,329,18,30,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 4,329
NCT62533883,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,329,1,2,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 4,329
NCT62533883,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,329,28,41,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 4,329
NCT62533883,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,329,16,25,All Causality,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 4,329
NCT62533883,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,329,10,20,Treatment Emergent,Bevacizumab,Anti-VEGF,Lung Cancer,Phase 4,329
NCT10274697,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,463,11,14,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,463
NCT10274697,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,463,31,54,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,463
NCT10274697,Hypertension,Vascular disorders,No,10%,463,39,76,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,463
NCT10274697,Proteinuria,Renal and urinary disorders,No,5%,463,33,39,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,463
NCT10274697,Hypertension,Vascular disorders,No,5%,463,42,46,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,463
NCT10274697,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,463,36,62,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,463
NCT10274697,Hypertension,Vascular disorders,No,5%,463,34,47,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,463
NCT10274697,Proteinuria,Renal and urinary disorders,No,15%,463,9,15,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,463
NCT10274697,Proteinuria,Renal and urinary disorders,No,5%,463,15,26,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,463
NCT10274697,Hypertension,Vascular disorders,No,10%,463,22,30,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,463
NCT10274697,Proteinuria,Renal and urinary disorders,No,5%,463,45,84,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,463
NCT10274697,Proteinuria,Renal and urinary disorders,No,10%,463,21,32,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,463
NCT10274697,Proteinuria,Renal and urinary disorders,No,15%,463,31,42,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,463
NCT10274697,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,463,10,19,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,463
NCT10274697,Hypertension,Vascular disorders,No,10%,463,7,14,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,463
NCT76174895,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,418,8,9,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,418
NCT76174895,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,418,20,30,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,418
NCT76174895,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,418,9,15,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,418
NCT76174895,Hypertension,Vascular disorders,No,15%,418,34,64,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,418
NCT76174895,Proteinuria,Renal and urinary disorders,No,15%,418,36,52,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,418
NCT76174895,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,418,30,32,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,418
NCT76174895,Proteinuria,Renal and urinary disorders,No,15%,418,29,41,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,418
NCT76174895,Proteinuria,Renal and urinary disorders,No,15%,418,34,35,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,418
NCT76174895,Proteinuria,Renal and urinary disorders,No,15%,418,17,20,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,418
NCT76174895,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,418,20,37,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,418
NCT76174895,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,418,15,21,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 1,418
NCT17855717,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,901,14,27,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,901
NCT17855717,Hypertension,Vascular disorders,No,15%,901,4,6,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,901
NCT17855717,Proteinuria,Renal and urinary disorders,No,15%,901,20,36,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,901
NCT17855717,Hypertension,Vascular disorders,No,5%,901,7,13,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,901
NCT17855717,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,901,33,47,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,901
NCT17855717,Proteinuria,Renal and urinary disorders,No,15%,901,22,42,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,901
NCT44443320,Hypertension,Vascular disorders,No,5%,537,16,20,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,537
NCT44443320,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,537,5,5,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,537
NCT44443320,Proteinuria,Renal and urinary disorders,No,15%,537,4,5,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,537
NCT44443320,Hypertension,Vascular disorders,No,5%,537,46,85,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,537
NCT44443320,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,537,37,46,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,537
NCT44443320,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,537,37,40,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,537
NCT44443320,Proteinuria,Renal and urinary disorders,No,15%,537,30,57,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,537
NCT44443320,Hypertension,Vascular disorders,No,10%,537,6,7,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,537
NCT44443320,Proteinuria,Renal and urinary disorders,No,15%,537,37,73,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,537
NCT44443320,Proteinuria,Renal and urinary disorders,No,10%,537,22,32,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,537
NCT44443320,Proteinuria,Renal and urinary disorders,No,15%,537,5,9,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,537
NCT44443320,Hypertension,Vascular disorders,No,5%,537,31,62,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,537
NCT57372270,Proteinuria,Renal and urinary disorders,No,15%,320,21,37,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,320
NCT57372270,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,320,10,12,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,320
NCT57372270,Hypertension,Vascular disorders,No,5%,320,17,27,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,320
NCT57372270,Proteinuria,Renal and urinary disorders,No,5%,320,13,22,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,320
NCT57372270,Hypertension,Vascular disorders,No,10%,320,10,14,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,320
NCT57372270,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,320,3,5,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,320
NCT57372270,Hypertension,Vascular disorders,No,10%,320,3,5,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 2,320
NCT22593637,Hypertension,Vascular disorders,No,15%,678,2,4,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,678
NCT22593637,Hypertension,Vascular disorders,No,10%,678,4,8,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,678
NCT22593637,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,678,44,71,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,678
NCT22593637,Hypertension,Vascular disorders,No,5%,678,32,34,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,678
NCT22593637,Hypertension,Vascular disorders,No,10%,678,15,22,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,678
NCT22593637,Proteinuria,Renal and urinary disorders,No,15%,678,42,65,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,678
NCT22593637,Hypertension,Vascular disorders,No,15%,678,11,12,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,678
NCT22593637,Hypertension,Vascular disorders,No,15%,678,38,59,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,678
NCT22593637,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,678,31,32,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,678
NCT22593637,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,678,43,84,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,678
NCT22593637,Hypertension,Vascular disorders,No,10%,678,23,37,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,678
NCT22593637,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,678,10,15,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,678
NCT22593637,Proteinuria,Renal and urinary disorders,No,10%,678,2,4,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,678
NCT22593637,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,678,26,34,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,678
NCT22593637,Proteinuria,Renal and urinary disorders,No,5%,678,4,6,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,678
NCT40222790,Hypertension,Vascular disorders,No,15%,215,5,9,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,215
NCT40222790,Proteinuria,Renal and urinary disorders,No,10%,215,12,15,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,215
NCT40222790,Hypertension,Vascular disorders,No,15%,215,4,6,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,215
NCT40222790,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,215,21,26,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,215
NCT40222790,Proteinuria,Renal and urinary disorders,No,15%,215,10,14,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,215
NCT40222790,Hypertension,Vascular disorders,No,15%,215,13,17,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,215
NCT40222790,Proteinuria,Renal and urinary disorders,No,15%,215,18,32,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,215
NCT40222790,Proteinuria,Renal and urinary disorders,No,10%,215,1,2,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,215
NCT40222790,Hypertension,Vascular disorders,No,5%,215,4,8,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,215
NCT40222790,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,215,15,28,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,215
NCT40222790,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,215,16,31,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,215
NCT40222790,Proteinuria,Renal and urinary disorders,No,5%,215,8,13,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 3,215
NCT29125103,Proteinuria,Renal and urinary disorders,No,5%,876,5,9,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 4,876
NCT29125103,Hypertension,Vascular disorders,No,10%,876,24,35,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 4,876
NCT29125103,Hypertension,Vascular disorders,No,5%,876,4,7,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 4,876
NCT29125103,Hypertension,Vascular disorders,No,10%,876,3,6,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 4,876
NCT29125103,Hypertension,Vascular disorders,No,10%,876,20,27,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 4,876
NCT29125103,Hypertension,Vascular disorders,No,15%,876,42,55,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 4,876
NCT29125103,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,876,26,51,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 4,876
NCT29125103,Proteinuria,Renal and urinary disorders,No,15%,876,1,1,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 4,876
NCT29125103,Hypertension,Vascular disorders,No,15%,876,46,71,Treatment Emergent,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 4,876
NCT29125103,Hypertension,Vascular disorders,No,15%,876,32,43,All Causality,Bevacizumab,Anti-VEGF,Ovarian Cancer,Phase 4,876
NCT15911018,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,472,29,46,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 1,472
NCT15911018,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,472,9,17,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 1,472
NCT15911018,Proteinuria,Renal and urinary disorders,No,15%,472,4,6,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 1,472
NCT15911018,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,472,27,47,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 1,472
NCT15911018,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,472,40,75,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 1,472
NCT15911018,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,472,44,73,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 1,472
NCT15911018,Proteinuria,Renal and urinary disorders,No,5%,472,5,5,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 1,472
NCT15911018,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,472,36,49,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 1,472
NCT15911018,Hypertension,Vascular disorders,No,15%,472,33,37,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 1,472
NCT79899332,Proteinuria,Renal and urinary disorders,No,10%,645,35,58,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 1,645
NCT79899332,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,645,48,50,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 1,645
NCT79899332,Proteinuria,Renal and urinary disorders,No,15%,645,20,21,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 1,645
NCT79899332,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,645,31,61,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 1,645
NCT79899332,Proteinuria,Renal and urinary disorders,No,10%,645,17,17,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 1,645
NCT79899332,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,645,19,30,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 1,645
NCT79899332,Hypertension,Vascular disorders,No,5%,645,10,19,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 1,645
NCT79899332,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,645,22,34,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 1,645
NCT79899332,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,645,16,19,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 1,645
NCT56800937,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,726,32,37,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 2,726
NCT56800937,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,726,46,83,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 2,726
NCT56800937,Hypertension,Vascular disorders,No,15%,726,47,80,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 2,726
NCT56800937,Proteinuria,Renal and urinary disorders,No,10%,726,11,17,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 2,726
NCT56800937,Proteinuria,Renal and urinary disorders,No,5%,726,46,62,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 2,726
NCT56800937,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,726,21,23,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 2,726
NCT56800937,Hypertension,Vascular disorders,No,5%,726,49,54,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 2,726
NCT56800937,Hypertension,Vascular disorders,No,15%,726,24,25,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 2,726
NCT56800937,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,726,23,30,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 2,726
NCT56800937,Proteinuria,Renal and urinary disorders,No,5%,726,11,13,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 2,726
NCT56800937,Hypertension,Vascular disorders,No,15%,726,9,10,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 2,726
NCT56800937,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,726,13,24,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 2,726
NCT56800937,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,726,14,24,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 2,726
NCT56800937,Proteinuria,Renal and urinary disorders,No,5%,726,2,4,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 2,726
NCT42097829,Proteinuria,Renal and urinary disorders,No,5%,90,6,8,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 2,90
NCT42097829,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,90,1,2,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 2,90
NCT42097829,Proteinuria,Renal and urinary disorders,No,10%,90,8,8,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 2,90
NCT42097829,Proteinuria,Renal and urinary disorders,No,5%,90,1,2,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 2,90
NCT42097829,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,90,2,4,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 2,90
NCT42097829,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,90,8,8,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 2,90
NCT59772960,Proteinuria,Renal and urinary disorders,No,10%,441,21,21,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 2,441
NCT59772960,Hypertension,Vascular disorders,No,10%,441,23,38,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 2,441
NCT59772960,Hypertension,Vascular disorders,No,15%,441,29,29,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 2,441
NCT59772960,Proteinuria,Renal and urinary disorders,No,10%,441,22,35,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 2,441
NCT59772960,Proteinuria,Renal and urinary disorders,No,10%,441,14,26,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 2,441
NCT43823427,Proteinuria,Renal and urinary disorders,No,15%,39,3,5,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 3,39
NCT43823427,Proteinuria,Renal and urinary disorders,No,15%,39,1,2,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 3,39
NCT43823427,Proteinuria,Renal and urinary disorders,No,5%,39,1,1,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 3,39
NCT43823427,Proteinuria,Renal and urinary disorders,No,5%,39,1,1,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 3,39
NCT43823427,Hypertension,Vascular disorders,No,15%,39,3,3,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 3,39
NCT43823427,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,39,2,2,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 3,39
NCT43823427,Proteinuria,Renal and urinary disorders,No,10%,39,1,1,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 3,39
NCT43823427,Proteinuria,Renal and urinary disorders,No,15%,39,3,5,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 3,39
NCT43823427,Hypertension,Vascular disorders,No,15%,39,2,2,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 3,39
NCT43823427,Hypertension,Vascular disorders,No,15%,39,2,3,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 3,39
NCT43823427,Proteinuria,Renal and urinary disorders,No,5%,39,1,1,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 3,39
NCT43823427,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,39,3,3,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 3,39
NCT43823427,Proteinuria,Renal and urinary disorders,No,10%,39,2,2,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 3,39
NCT43823427,Hypertension,Vascular disorders,No,10%,39,3,3,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 3,39
NCT43823427,Proteinuria,Renal and urinary disorders,No,5%,39,2,4,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 3,39
NCT18471639,Hypertension,Vascular disorders,No,15%,582,4,5,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 3,582
NCT18471639,Proteinuria,Renal and urinary disorders,No,10%,582,34,45,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 3,582
NCT18471639,Hypertension,Vascular disorders,No,15%,582,22,44,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 3,582
NCT65835095,Hypertension,Vascular disorders,No,5%,161,4,5,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 3,161
NCT65835095,Hypertension,Vascular disorders,No,5%,161,2,2,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 3,161
NCT65835095,Proteinuria,Renal and urinary disorders,No,5%,161,8,15,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 3,161
NCT65835095,Proteinuria,Renal and urinary disorders,No,15%,161,4,5,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 3,161
NCT65835095,Hypertension,Vascular disorders,No,10%,161,2,2,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 3,161
NCT65835095,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,161,2,2,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 3,161
NCT65835095,Proteinuria,Renal and urinary disorders,No,5%,161,12,17,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 3,161
NCT65835095,Proteinuria,Renal and urinary disorders,No,5%,161,14,18,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 3,161
NCT65835095,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,161,2,2,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 3,161
NCT71331350,Proteinuria,Renal and urinary disorders,No,10%,947,41,47,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,947
NCT71331350,Hypertension,Vascular disorders,No,5%,947,27,30,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,947
NCT71331350,Hypertension,Vascular disorders,No,15%,947,21,42,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,947
NCT71331350,Hypertension,Vascular disorders,No,15%,947,49,84,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,947
NCT71331350,Hypertension,Vascular disorders,No,10%,947,4,7,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,947
NCT71331350,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,947,48,92,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,947
NCT71331350,Hypertension,Vascular disorders,No,10%,947,39,41,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,947
NCT71331350,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,947,35,38,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,947
NCT71331350,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,947,12,17,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,947
NCT71331350,Hypertension,Vascular disorders,No,10%,947,25,38,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,947
NCT71331350,Hypertension,Vascular disorders,No,5%,947,18,29,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,947
NCT71331350,Proteinuria,Renal and urinary disorders,No,15%,947,34,62,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,947
NCT71331350,Hypertension,Vascular disorders,No,10%,947,17,22,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,947
NCT71331350,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,947,49,69,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,947
NCT71331350,Hypertension,Vascular disorders,No,10%,947,1,1,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,947
NCT83319508,Hypertension,Vascular disorders,No,5%,288,25,36,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,288
NCT83319508,Hypertension,Vascular disorders,No,5%,288,16,23,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,288
NCT83319508,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,288,3,6,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,288
NCT83319508,Proteinuria,Renal and urinary disorders,No,10%,288,17,20,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,288
NCT83319508,Proteinuria,Renal and urinary disorders,No,10%,288,25,32,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,288
NCT83319508,Hypertension,Vascular disorders,No,5%,288,25,47,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,288
NCT83319508,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,288,18,21,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,288
NCT83319508,Hypertension,Vascular disorders,No,5%,288,13,20,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,288
NCT83319508,Hypertension,Vascular disorders,No,10%,288,8,14,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,288
NCT83319508,Hypertension,Vascular disorders,No,5%,288,18,23,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,288
NCT83319508,Hypertension,Vascular disorders,No,5%,288,26,41,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,288
NCT83319508,Proteinuria,Renal and urinary disorders,No,15%,288,1,2,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,288
NCT83319508,Proteinuria,Renal and urinary disorders,No,10%,288,10,13,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,288
NCT83319508,Proteinuria,Renal and urinary disorders,No,15%,288,23,40,All Causality,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,288
NCT83319508,Proteinuria,Renal and urinary disorders,No,15%,288,24,40,Treatment Emergent,Ranibizumab,Anti-VEGF,Colorectal Cancer,Phase 4,288
NCT80748979,Proteinuria,Renal and urinary disorders,No,10%,730,11,17,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 1,730
NCT80748979,Proteinuria,Renal and urinary disorders,No,15%,730,9,15,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 1,730
NCT80748979,Hypertension,Vascular disorders,No,15%,730,42,74,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 1,730
NCT80748979,Proteinuria,Renal and urinary disorders,No,15%,730,6,12,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 1,730
NCT80748979,Proteinuria,Renal and urinary disorders,No,10%,730,9,14,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 1,730
NCT80748979,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,730,3,6,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 1,730
NCT80748979,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,730,12,14,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 1,730
NCT80748979,Proteinuria,Renal and urinary disorders,No,10%,730,50,56,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 1,730
NCT80748979,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,730,11,22,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 1,730
NCT80748979,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,730,37,44,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 1,730
NCT80748979,Proteinuria,Renal and urinary disorders,No,10%,730,4,6,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 1,730
NCT80748979,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,730,6,6,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 1,730
NCT80748979,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,730,9,15,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 1,730
NCT86164621,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,859,15,23,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 1,859
NCT86164621,Hypertension,Vascular disorders,No,5%,859,9,9,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 1,859
NCT86164621,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,859,44,49,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 1,859
NCT86164621,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,859,18,28,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 1,859
NCT86164621,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,859,47,51,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 1,859
NCT86164621,Proteinuria,Renal and urinary disorders,No,10%,859,48,81,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 1,859
NCT86164621,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,859,14,18,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 1,859
NCT86164621,Hypertension,Vascular disorders,No,5%,859,27,53,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 1,859
NCT15283476,Proteinuria,Renal and urinary disorders,No,15%,299,3,5,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 1,299
NCT15283476,Proteinuria,Renal and urinary disorders,No,10%,299,26,42,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 1,299
NCT15283476,Hypertension,Vascular disorders,No,10%,299,24,31,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 1,299
NCT15283476,Proteinuria,Renal and urinary disorders,No,5%,299,10,12,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 1,299
NCT15283476,Proteinuria,Renal and urinary disorders,No,10%,299,6,8,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 1,299
NCT15283476,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,299,8,8,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 1,299
NCT79560343,Hypertension,Vascular disorders,No,10%,225,21,24,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 2,225
NCT79560343,Hypertension,Vascular disorders,No,5%,225,12,15,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 2,225
NCT79560343,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,225,15,16,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 2,225
NCT79560343,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,225,1,1,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 2,225
NCT79560343,Proteinuria,Renal and urinary disorders,No,5%,225,15,22,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 2,225
NCT79560343,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,225,14,24,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 2,225
NCT79560343,Proteinuria,Renal and urinary disorders,No,5%,225,15,19,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 2,225
NCT79560343,Proteinuria,Renal and urinary disorders,No,10%,225,13,26,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 2,225
NCT79560343,Hypertension,Vascular disorders,No,15%,225,2,2,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 2,225
NCT30751078,Proteinuria,Renal and urinary disorders,No,15%,173,1,2,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 2,173
NCT30751078,Hypertension,Vascular disorders,No,15%,173,13,26,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 2,173
NCT30751078,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,173,8,13,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 2,173
NCT30751078,Proteinuria,Renal and urinary disorders,No,5%,173,9,15,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 2,173
NCT30751078,Proteinuria,Renal and urinary disorders,No,15%,173,17,22,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 2,173
NCT30751078,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,173,7,13,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 2,173
NCT30751078,Hypertension,Vascular disorders,No,10%,173,6,12,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 2,173
NCT30751078,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,173,8,8,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 2,173
NCT30751078,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,173,16,16,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 2,173
NCT30751078,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,173,6,6,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 2,173
NCT30751078,Hypertension,Vascular disorders,No,5%,173,15,29,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 2,173
NCT30751078,Proteinuria,Renal and urinary disorders,No,5%,173,17,19,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 2,173
NCT30751078,Proteinuria,Renal and urinary disorders,No,5%,173,16,20,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 2,173
NCT85616530,Proteinuria,Renal and urinary disorders,No,10%,531,1,1,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 2,531
NCT85616530,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,531,21,36,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 2,531
NCT85616530,Hypertension,Vascular disorders,No,10%,531,42,82,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 2,531
NCT85616530,Proteinuria,Renal and urinary disorders,No,10%,531,30,44,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 2,531
NCT85616530,Proteinuria,Renal and urinary disorders,No,5%,531,48,70,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 2,531
NCT53998641,Proteinuria,Renal and urinary disorders,No,10%,434,22,38,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 3,434
NCT53998641,Proteinuria,Renal and urinary disorders,No,5%,434,33,49,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 3,434
NCT53998641,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,434,15,22,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 3,434
NCT53998641,Hypertension,Vascular disorders,No,5%,434,17,33,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 3,434
NCT53998641,Proteinuria,Renal and urinary disorders,No,15%,434,40,64,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 3,434
NCT53998641,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,434,7,11,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 3,434
NCT71515230,Hypertension,Vascular disorders,No,10%,252,3,4,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 3,252
NCT71515230,Hypertension,Vascular disorders,No,5%,252,19,23,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 3,252
NCT71515230,Hypertension,Vascular disorders,No,15%,252,17,30,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 3,252
NCT71515230,Hypertension,Vascular disorders,No,15%,252,16,25,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 3,252
NCT71515230,Proteinuria,Renal and urinary disorders,No,5%,252,18,33,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 3,252
NCT71515230,Hypertension,Vascular disorders,No,15%,252,2,4,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 3,252
NCT71515230,Hypertension,Vascular disorders,No,5%,252,9,10,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 3,252
NCT71515230,Hypertension,Vascular disorders,No,5%,252,6,9,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 3,252
NCT71515230,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,252,22,35,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 3,252
NCT65927640,Proteinuria,Renal and urinary disorders,No,10%,227,16,29,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 4,227
NCT65927640,Hypertension,Vascular disorders,No,10%,227,2,4,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 4,227
NCT65927640,Hypertension,Vascular disorders,No,10%,227,22,25,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 4,227
NCT65927640,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,227,16,32,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 4,227
NCT65927640,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,227,21,34,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 4,227
NCT65927640,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,227,5,6,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 4,227
NCT65927640,Hypertension,Vascular disorders,No,15%,227,19,33,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 4,227
NCT65927640,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,227,6,7,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 4,227
NCT12503048,Proteinuria,Renal and urinary disorders,No,10%,918,50,90,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 4,918
NCT12503048,Proteinuria,Renal and urinary disorders,No,15%,918,48,61,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 4,918
NCT12503048,Hypertension,Vascular disorders,No,15%,918,2,4,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 4,918
NCT12503048,Hypertension,Vascular disorders,No,15%,918,47,75,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 4,918
NCT12503048,Hypertension,Vascular disorders,No,5%,918,18,22,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 4,918
NCT12503048,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,918,13,14,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 4,918
NCT12503048,Hypertension,Vascular disorders,No,5%,918,19,26,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 4,918
NCT12503048,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,918,25,33,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 4,918
NCT12503048,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,918,1,1,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 4,918
NCT12503048,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,918,23,26,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 4,918
NCT12503048,Hypertension,Vascular disorders,No,5%,918,22,37,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 4,918
NCT12503048,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,918,13,23,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 4,918
NCT12503048,Proteinuria,Renal and urinary disorders,No,15%,918,4,8,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 4,918
NCT12503048,Hypertension,Vascular disorders,No,15%,918,10,11,Treatment Emergent,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 4,918
NCT12503048,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,918,30,51,All Causality,Ranibizumab,Anti-VEGF,Lung Cancer,Phase 4,918
NCT33948851,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,574,37,54,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 1,574
NCT33948851,Proteinuria,Renal and urinary disorders,No,10%,574,41,48,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 1,574
NCT33948851,Hypertension,Vascular disorders,No,15%,574,16,22,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 1,574
NCT33948851,Hypertension,Vascular disorders,No,5%,574,34,64,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 1,574
NCT33948851,Hypertension,Vascular disorders,No,10%,574,37,68,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 1,574
NCT21950629,Proteinuria,Renal and urinary disorders,No,5%,701,14,21,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 1,701
NCT21950629,Proteinuria,Renal and urinary disorders,No,15%,701,38,76,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 1,701
NCT21950629,Proteinuria,Renal and urinary disorders,No,10%,701,41,56,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 1,701
NCT21950629,Hypertension,Vascular disorders,No,5%,701,37,64,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 1,701
NCT66231169,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,612,32,41,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 2,612
NCT66231169,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,612,21,21,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 2,612
NCT66231169,Hypertension,Vascular disorders,No,15%,612,18,31,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 2,612
NCT66231169,Hypertension,Vascular disorders,No,10%,612,32,32,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 2,612
NCT66231169,Hypertension,Vascular disorders,No,10%,612,43,74,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 2,612
NCT66231169,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,612,41,80,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 2,612
NCT66231169,Proteinuria,Renal and urinary disorders,No,15%,612,48,86,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 2,612
NCT66231169,Hypertension,Vascular disorders,No,15%,612,40,60,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 2,612
NCT66231169,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,612,10,19,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 2,612
NCT66231169,Proteinuria,Renal and urinary disorders,No,10%,612,42,67,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 2,612
NCT92095482,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,904,43,58,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,904
NCT92095482,Hypertension,Vascular disorders,No,15%,904,40,69,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,904
NCT92095482,Proteinuria,Renal and urinary disorders,No,15%,904,3,5,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,904
NCT92095482,Proteinuria,Renal and urinary disorders,No,15%,904,2,3,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,904
NCT92095482,Hypertension,Vascular disorders,No,15%,904,6,6,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,904
NCT92095482,Hypertension,Vascular disorders,No,10%,904,6,7,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,904
NCT92095482,Proteinuria,Renal and urinary disorders,No,10%,904,34,38,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,904
NCT92095482,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,904,7,14,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,904
NCT92095482,Proteinuria,Renal and urinary disorders,No,10%,904,29,35,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,904
NCT92095482,Proteinuria,Renal and urinary disorders,No,10%,904,47,59,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,904
NCT92095482,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,904,46,54,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,904
NCT92095482,Hypertension,Vascular disorders,No,10%,904,39,76,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,904
NCT92095482,Hypertension,Vascular disorders,No,10%,904,35,56,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,904
NCT92095482,Proteinuria,Renal and urinary disorders,No,15%,904,42,51,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,904
NCT92095482,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,904,24,36,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,904
NCT46905073,Proteinuria,Renal and urinary disorders,No,5%,106,1,1,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,106
NCT46905073,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,106,7,9,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,106
NCT46905073,Hypertension,Vascular disorders,No,15%,106,5,9,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,106
NCT46905073,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,106,5,8,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,106
NCT46905073,Hypertension,Vascular disorders,No,15%,106,9,14,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,106
NCT46905073,Proteinuria,Renal and urinary disorders,No,15%,106,1,2,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,106
NCT46905073,Hypertension,Vascular disorders,No,5%,106,5,5,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,106
NCT46905073,Proteinuria,Renal and urinary disorders,No,15%,106,7,9,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,106
NCT46905073,Proteinuria,Renal and urinary disorders,No,15%,106,5,7,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,106
NCT46905073,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,106,6,9,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,106
NCT46905073,Proteinuria,Renal and urinary disorders,No,10%,106,7,13,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,106
NCT46905073,Proteinuria,Renal and urinary disorders,No,10%,106,1,1,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,106
NCT46905073,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,106,8,8,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,106
NCT46905073,Hypertension,Vascular disorders,No,10%,106,9,15,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,106
NCT50887043,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,368,8,10,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,368
NCT50887043,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,368,22,22,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,368
NCT50887043,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,368,10,10,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 3,368
NCT32940316,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,647,25,39,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 4,647
NCT32940316,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,647,32,63,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 4,647
NCT32940316,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,647,20,25,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 4,647
NCT32940316,Proteinuria,Renal and urinary disorders,No,5%,647,36,67,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 4,647
NCT32940316,Hypertension,Vascular disorders,No,10%,647,36,69,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 4,647
NCT32940316,Proteinuria,Renal and urinary disorders,No,10%,647,16,17,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 4,647
NCT32940316,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,647,9,11,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 4,647
NCT32940316,Hypertension,Vascular disorders,No,15%,647,33,65,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 4,647
NCT32940316,Proteinuria,Renal and urinary disorders,No,15%,647,15,27,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 4,647
NCT32940316,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,647,37,46,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 4,647
NCT32940316,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,647,42,48,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 4,647
NCT32940316,Proteinuria,Renal and urinary disorders,No,5%,647,8,14,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 4,647
NCT32940316,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,647,50,60,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 4,647
NCT32427062,Proteinuria,Renal and urinary disorders,No,10%,839,5,5,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 4,839
NCT32427062,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,839,4,6,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 4,839
NCT32427062,Proteinuria,Renal and urinary disorders,No,10%,839,5,5,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 4,839
NCT32427062,Proteinuria,Renal and urinary disorders,No,5%,839,22,24,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 4,839
NCT32427062,Proteinuria,Renal and urinary disorders,No,15%,839,9,13,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 4,839
NCT30875486,Proteinuria,Renal and urinary disorders,No,10%,637,29,55,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 4,637
NCT30875486,Hypertension,Vascular disorders,No,10%,637,12,14,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 4,637
NCT30875486,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,637,37,51,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 4,637
NCT30875486,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,637,42,73,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 4,637
NCT30875486,Hypertension,Vascular disorders,No,10%,637,4,7,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 4,637
NCT30875486,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,637,26,41,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 4,637
NCT30875486,Proteinuria,Renal and urinary disorders,No,10%,637,25,40,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 4,637
NCT30875486,Hypertension,Vascular disorders,No,10%,637,20,23,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 4,637
NCT30875486,Proteinuria,Renal and urinary disorders,No,10%,637,43,45,All Causality,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 4,637
NCT30875486,Proteinuria,Renal and urinary disorders,No,10%,637,9,13,Treatment Emergent,Ranibizumab,Anti-VEGF,Ovarian Cancer,Phase 4,637
NCT89856329,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,188,16,28,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 1,188
NCT89856329,Hypertension,Vascular disorders,No,15%,188,18,36,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 1,188
NCT89856329,Hypertension,Vascular disorders,No,15%,188,17,17,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 1,188
NCT89856329,Proteinuria,Renal and urinary disorders,No,10%,188,16,22,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 1,188
NCT89856329,Hypertension,Vascular disorders,No,15%,188,9,13,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 1,188
NCT89856329,Hypertension,Vascular disorders,No,10%,188,6,12,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 1,188
NCT89856329,Proteinuria,Renal and urinary disorders,No,10%,188,11,21,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 1,188
NCT89856329,Hypertension,Vascular disorders,No,5%,188,9,16,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 1,188
NCT89856329,Hypertension,Vascular disorders,No,15%,188,5,8,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 1,188
NCT89856329,Proteinuria,Renal and urinary disorders,No,15%,188,3,5,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 1,188
NCT89856329,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,188,15,29,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 1,188
NCT38428726,Proteinuria,Renal and urinary disorders,No,15%,807,42,55,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 1,807
NCT38428726,Hypertension,Vascular disorders,No,5%,807,12,12,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 1,807
NCT38428726,Hypertension,Vascular disorders,No,10%,807,41,66,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 1,807
NCT38428726,Proteinuria,Renal and urinary disorders,No,15%,807,32,43,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 1,807
NCT38428726,Hypertension,Vascular disorders,No,5%,807,16,24,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 1,807
NCT38428726,Hypertension,Vascular disorders,No,15%,807,48,84,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 1,807
NCT38428726,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,807,45,81,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 1,807
NCT38428726,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,807,27,36,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 1,807
NCT38428726,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,807,25,35,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 1,807
NCT38428726,Proteinuria,Renal and urinary disorders,No,15%,807,35,49,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 1,807
NCT38428726,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,807,27,46,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 1,807
NCT38428726,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,807,40,67,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 1,807
NCT38428726,Proteinuria,Renal and urinary disorders,No,15%,807,45,47,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 1,807
NCT38428726,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,807,17,21,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 1,807
NCT69062284,Proteinuria,Renal and urinary disorders,No,15%,307,20,32,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 1,307
NCT69062284,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,307,12,18,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 1,307
NCT69062284,Proteinuria,Renal and urinary disorders,No,10%,307,20,38,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 1,307
NCT60969132,Hypertension,Vascular disorders,No,5%,951,33,43,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 2,951
NCT60969132,Proteinuria,Renal and urinary disorders,No,5%,951,13,24,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 2,951
NCT60969132,Hypertension,Vascular disorders,No,5%,951,19,25,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 2,951
NCT60969132,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,951,6,10,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 2,951
NCT60969132,Hypertension,Vascular disorders,No,10%,951,18,21,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 2,951
NCT93347085,Proteinuria,Renal and urinary disorders,No,15%,227,1,1,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 2,227
NCT93347085,Hypertension,Vascular disorders,No,15%,227,11,21,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 2,227
NCT93347085,Proteinuria,Renal and urinary disorders,No,15%,227,16,18,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 2,227
NCT93347085,Hypertension,Vascular disorders,No,10%,227,22,28,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 2,227
NCT93347085,Hypertension,Vascular disorders,No,5%,227,2,2,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 2,227
NCT93347085,Hypertension,Vascular disorders,No,10%,227,4,8,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 2,227
NCT93347085,Proteinuria,Renal and urinary disorders,No,15%,227,10,12,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 2,227
NCT93347085,Hypertension,Vascular disorders,No,10%,227,1,2,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 2,227
NCT93347085,Proteinuria,Renal and urinary disorders,No,5%,227,17,33,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 2,227
NCT93347085,Proteinuria,Renal and urinary disorders,No,15%,227,6,8,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 2,227
NCT93347085,Proteinuria,Renal and urinary disorders,No,15%,227,3,4,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 2,227
NCT42621682,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,554,44,49,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,554
NCT42621682,Proteinuria,Renal and urinary disorders,No,5%,554,18,24,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,554
NCT42621682,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,554,34,46,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,554
NCT42621682,Hypertension,Vascular disorders,No,15%,554,6,10,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,554
NCT42621682,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,554,43,83,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,554
NCT42621682,Hypertension,Vascular disorders,No,10%,554,50,81,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,554
NCT42621682,Hypertension,Vascular disorders,No,15%,554,3,4,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,554
NCT42621682,Proteinuria,Renal and urinary disorders,No,5%,554,16,30,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,554
NCT42621682,Hypertension,Vascular disorders,No,10%,554,22,35,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,554
NCT42621682,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,554,37,60,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,554
NCT42621682,Proteinuria,Renal and urinary disorders,No,10%,554,47,90,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,554
NCT42621682,Hypertension,Vascular disorders,No,15%,554,1,1,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,554
NCT42621682,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,554,14,22,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,554
NCT42621682,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,554,32,50,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,554
NCT46851208,Proteinuria,Renal and urinary disorders,No,15%,940,8,9,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,940
NCT46851208,Proteinuria,Renal and urinary disorders,No,10%,940,42,59,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,940
NCT46851208,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,940,34,44,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,940
NCT46851208,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,940,10,20,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,940
NCT46851208,Proteinuria,Renal and urinary disorders,No,10%,940,34,67,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,940
NCT46851208,Hypertension,Vascular disorders,No,5%,940,27,31,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,940
NCT46851208,Proteinuria,Renal and urinary disorders,No,10%,940,1,1,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,940
NCT46851208,Hypertension,Vascular disorders,No,15%,940,34,46,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,940
NCT46851208,Hypertension,Vascular disorders,No,5%,940,28,29,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,940
NCT46851208,Hypertension,Vascular disorders,No,15%,940,25,28,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,940
NCT46851208,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,940,49,67,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,940
NCT46851208,Hypertension,Vascular disorders,No,10%,940,7,13,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,940
NCT46851208,Proteinuria,Renal and urinary disorders,No,5%,940,16,17,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,940
NCT46851208,Hypertension,Vascular disorders,No,5%,940,31,33,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,940
NCT71538311,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,526,45,58,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,526
NCT71538311,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,526,4,8,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,526
NCT71538311,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,526,17,34,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,526
NCT71538311,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,526,34,60,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 3,526
NCT22125377,Proteinuria,Renal and urinary disorders,No,15%,389,15,25,Treatment Emergent,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 4,389
NCT22125377,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,389,26,50,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 4,389
NCT22125377,Hypertension,Vascular disorders,No,5%,389,17,17,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 4,389
NCT22125377,Hypertension,Vascular disorders,No,10%,389,38,62,All Causality,Aflibercept,Anti-VEGF,Colorectal Cancer,Phase 4,389
NCT38335861,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,458,11,12,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 1,458
NCT38335861,Proteinuria,Renal and urinary disorders,No,5%,458,19,33,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 1,458
NCT38335861,Hypertension,Vascular disorders,No,10%,458,14,19,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 1,458
NCT38335861,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,458,34,67,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 1,458
NCT38335861,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,458,31,40,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 1,458
NCT38335861,Proteinuria,Renal and urinary disorders,No,5%,458,39,56,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 1,458
NCT38335861,Proteinuria,Renal and urinary disorders,No,5%,458,5,7,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 1,458
NCT38335861,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,458,14,18,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 1,458
NCT38335861,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,458,9,14,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 1,458
NCT38335861,Proteinuria,Renal and urinary disorders,No,5%,458,16,16,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 1,458
NCT63206947,Proteinuria,Renal and urinary disorders,No,5%,737,50,91,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 1,737
NCT63206947,Hypertension,Vascular disorders,No,10%,737,41,67,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 1,737
NCT63206947,Proteinuria,Renal and urinary disorders,No,5%,737,41,44,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 1,737
NCT63206947,Proteinuria,Renal and urinary disorders,No,5%,737,14,15,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 1,737
NCT63206947,Hypertension,Vascular disorders,No,15%,737,43,77,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 1,737
NCT63206947,Hypertension,Vascular disorders,No,15%,737,10,15,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 1,737
NCT63206947,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,737,11,15,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 1,737
NCT63206947,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,737,33,33,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 1,737
NCT63206947,Hypertension,Vascular disorders,No,5%,737,33,41,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 1,737
NCT63206947,Hypertension,Vascular disorders,No,10%,737,45,73,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 1,737
NCT63206947,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,737,47,50,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 1,737
NCT53563341,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,319,3,4,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 2,319
NCT53563341,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,319,13,13,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 2,319
NCT53563341,Hypertension,Vascular disorders,No,10%,319,14,19,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 2,319
NCT53563341,Hypertension,Vascular disorders,No,15%,319,16,31,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 2,319
NCT53563341,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,319,12,23,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 2,319
NCT53563341,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,319,23,30,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 2,319
NCT94925643,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,472,29,30,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 2,472
NCT94925643,Hypertension,Vascular disorders,No,15%,472,16,28,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 2,472
NCT94925643,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,472,44,53,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 2,472
NCT94925643,Proteinuria,Renal and urinary disorders,No,10%,472,2,4,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 2,472
NCT94925643,Hypertension,Vascular disorders,No,15%,472,3,3,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 2,472
NCT94925643,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,472,16,23,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 2,472
NCT94925643,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,472,18,30,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 2,472
NCT94925643,Hypertension,Vascular disorders,No,15%,472,22,29,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 2,472
NCT38572955,Proteinuria,Renal and urinary disorders,No,15%,391,36,38,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 2,391
NCT38572955,Hypertension,Vascular disorders,No,15%,391,17,27,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 2,391
NCT38572955,Proteinuria,Renal and urinary disorders,No,5%,391,27,43,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 2,391
NCT38572955,Proteinuria,Renal and urinary disorders,No,5%,391,4,5,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 2,391
NCT38572955,Hypertension,Vascular disorders,No,15%,391,4,7,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 2,391
NCT38572955,Proteinuria,Renal and urinary disorders,No,15%,391,18,27,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 2,391
NCT44754290,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,490,23,46,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 3,490
NCT44754290,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,490,2,3,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 3,490
NCT44754290,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,490,18,30,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 3,490
NCT44754290,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,490,7,13,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 3,490
NCT44754290,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,490,34,45,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 3,490
NCT44754290,Proteinuria,Renal and urinary disorders,No,5%,490,36,59,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 3,490
NCT44754290,Hypertension,Vascular disorders,No,5%,490,24,47,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 3,490
NCT44754290,Proteinuria,Renal and urinary disorders,No,5%,490,48,68,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 3,490
NCT44754290,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,490,48,83,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 3,490
NCT44754290,Hypertension,Vascular disorders,No,5%,490,3,5,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 3,490
NCT44754290,Hypertension,Vascular disorders,No,5%,490,14,19,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 3,490
NCT44754290,Hypertension,Vascular disorders,No,10%,490,27,29,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 3,490
NCT65193257,Hypertension,Vascular disorders,No,10%,890,3,3,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 3,890
NCT65193257,Proteinuria,Renal and urinary disorders,No,15%,890,38,39,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 3,890
NCT65193257,Hypertension,Vascular disorders,No,10%,890,5,6,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 3,890
NCT65193257,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,890,23,30,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 3,890
NCT65193257,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,890,24,48,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 3,890
NCT65193257,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,890,28,33,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 3,890
NCT65193257,Hypertension,Vascular disorders,No,10%,890,23,36,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 3,890
NCT65193257,Proteinuria,Renal and urinary disorders,No,10%,890,43,50,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 3,890
NCT65193257,Hypertension,Vascular disorders,No,15%,890,11,19,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 3,890
NCT58362627,Proteinuria,Renal and urinary disorders,No,5%,443,14,16,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,443
NCT58362627,Hypertension,Vascular disorders,No,5%,443,33,36,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,443
NCT58362627,Proteinuria,Renal and urinary disorders,No,5%,443,14,27,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,443
NCT58362627,Proteinuria,Renal and urinary disorders,No,15%,443,37,68,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,443
NCT58362627,Proteinuria,Renal and urinary disorders,No,5%,443,41,68,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,443
NCT58362627,Proteinuria,Renal and urinary disorders,No,15%,443,10,16,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,443
NCT58362627,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,443,1,1,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,443
NCT58362627,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,443,41,61,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,443
NCT58362627,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,443,22,24,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,443
NCT58362627,Hypertension,Vascular disorders,No,5%,443,32,42,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,443
NCT58362627,Proteinuria,Renal and urinary disorders,No,5%,443,12,19,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,443
NCT58362627,Proteinuria,Renal and urinary disorders,No,5%,443,11,14,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,443
NCT58362627,Proteinuria,Renal and urinary disorders,No,5%,443,41,43,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,443
NCT58416245,Hypertension,Vascular disorders,No,15%,695,35,47,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,695
NCT58416245,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,695,6,9,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,695
NCT58416245,Hypertension,Vascular disorders,No,10%,695,49,85,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,695
NCT58416245,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,695,29,55,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,695
NCT58416245,Proteinuria,Renal and urinary disorders,No,10%,695,44,81,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,695
NCT58416245,Hypertension,Vascular disorders,No,5%,695,15,16,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,695
NCT58416245,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,695,46,76,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,695
NCT58416245,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,695,32,56,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,695
NCT58416245,Proteinuria,Renal and urinary disorders,No,15%,695,22,40,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,695
NCT58416245,Hypertension,Vascular disorders,No,5%,695,15,17,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,695
NCT68466127,Proteinuria,Renal and urinary disorders,No,5%,574,31,47,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,574
NCT68466127,Hypertension,Vascular disorders,No,15%,574,43,48,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,574
NCT68466127,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,574,35,46,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,574
NCT68466127,Hypertension,Vascular disorders,No,5%,574,43,49,Treatment Emergent,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,574
NCT68466127,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,574,38,69,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,574
NCT68466127,Hypertension,Vascular disorders,No,5%,574,26,31,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,574
NCT68466127,Hypertension,Vascular disorders,No,10%,574,1,1,All Causality,Aflibercept,Anti-VEGF,Lung Cancer,Phase 4,574
NCT93609410,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,178,8,11,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 1,178
NCT93609410,Proteinuria,Renal and urinary disorders,No,5%,178,2,2,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 1,178
NCT93609410,Proteinuria,Renal and urinary disorders,No,15%,178,11,17,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 1,178
NCT93609410,Proteinuria,Renal and urinary disorders,No,10%,178,3,4,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 1,178
NCT93609410,Proteinuria,Renal and urinary disorders,No,15%,178,3,4,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 1,178
NCT93609410,Proteinuria,Renal and urinary disorders,No,15%,178,16,27,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 1,178
NCT93609410,Proteinuria,Renal and urinary disorders,No,5%,178,16,30,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 1,178
NCT93609410,Hypertension,Vascular disorders,No,5%,178,12,12,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 1,178
NCT93609410,Proteinuria,Renal and urinary disorders,No,5%,178,17,22,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 1,178
NCT93609410,Hypertension,Vascular disorders,No,10%,178,2,3,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 1,178
NCT93609410,Hypertension,Vascular disorders,No,5%,178,5,8,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 1,178
NCT93609410,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,178,15,26,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 1,178
NCT93609410,Hypertension,Vascular disorders,No,10%,178,8,15,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 1,178
NCT64850646,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,873,11,19,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 2,873
NCT64850646,Proteinuria,Renal and urinary disorders,No,10%,873,24,26,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 2,873
NCT64850646,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,873,37,38,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 2,873
NCT64850646,Hypertension,Vascular disorders,No,10%,873,23,45,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 2,873
NCT64850646,Proteinuria,Renal and urinary disorders,No,10%,873,46,65,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 2,873
NCT64850646,Hypertension,Vascular disorders,No,10%,873,18,22,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 2,873
NCT64850646,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,873,17,20,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 2,873
NCT64850646,Hypertension,Vascular disorders,No,15%,873,24,29,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 2,873
NCT64850646,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,873,36,55,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 2,873
NCT64850646,Proteinuria,Renal and urinary disorders,No,5%,873,37,72,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 2,873
NCT79583245,Hypertension,Vascular disorders,No,15%,54,2,4,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 3,54
NCT79583245,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,54,2,3,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 3,54
NCT79583245,Hypertension,Vascular disorders,No,5%,54,4,5,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 3,54
NCT79583245,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,54,5,10,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 3,54
NCT79583245,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,54,3,4,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 3,54
NCT79583245,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,54,1,1,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 3,54
NCT79583245,Proteinuria,Renal and urinary disorders,No,5%,54,4,6,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 3,54
NCT79583245,Proteinuria,Renal and urinary disorders,No,5%,54,3,3,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 3,54
NCT79583245,Hypertension,Vascular disorders,No,5%,54,5,10,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 3,54
NCT79583245,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,54,5,7,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 3,54
NCT79583245,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,54,1,1,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 3,54
NCT79583245,Hypertension,Vascular disorders,No,15%,54,3,4,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 3,54
NCT79583245,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,54,4,8,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 3,54
NCT79583245,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,54,3,3,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 3,54
NCT79583245,Proteinuria,Renal and urinary disorders,No,10%,54,3,3,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 3,54
NCT85193572,Hypertension,Vascular disorders,No,5%,592,50,53,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 4,592
NCT85193572,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,592,15,18,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 4,592
NCT85193572,Hypertension,Vascular disorders,No,15%,592,45,50,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 4,592
NCT85193572,Proteinuria,Renal and urinary disorders,No,15%,592,14,15,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 4,592
NCT85193572,Proteinuria,Renal and urinary disorders,No,15%,592,11,14,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 4,592
NCT85193572,Hypertension,Vascular disorders,No,10%,592,7,10,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 4,592
NCT85193572,Hypertension,Vascular disorders,No,15%,592,30,51,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 4,592
NCT85193572,Hypertension,Vascular disorders,No,5%,592,48,88,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 4,592
NCT85193572,Hypertension,Vascular disorders,No,10%,592,49,56,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 4,592
NCT85193572,Proteinuria,Renal and urinary disorders,No,5%,592,44,50,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 4,592
NCT85193572,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,592,35,40,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 4,592
NCT61798014,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,764,9,17,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 4,764
NCT61798014,Hypertension,Vascular disorders,No,5%,764,24,34,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 4,764
NCT61798014,Hypertension,Vascular disorders,No,10%,764,50,66,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 4,764
NCT61798014,Proteinuria,Renal and urinary disorders,No,5%,764,33,58,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 4,764
NCT61798014,Haemorrhage,Blood and lymphatic system disorders,Yes,10%,764,37,52,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 4,764
NCT61798014,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,764,18,25,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 4,764
NCT61798014,Proteinuria,Renal and urinary disorders,No,10%,764,9,18,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 4,764
NCT61798014,Haemorrhage,Blood and lymphatic system disorders,Yes,15%,764,16,25,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 4,764
NCT61798014,Hypertension,Vascular disorders,No,5%,764,47,56,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 4,764
NCT61798014,Proteinuria,Renal and urinary disorders,No,15%,764,22,32,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 4,764
NCT61798014,Haemorrhage,Blood and lymphatic system disorders,Yes,5%,764,9,17,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 4,764
NCT61798014,Hypertension,Vascular disorders,No,5%,764,29,36,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 4,764
NCT20608576,Proteinuria,Renal and urinary disorders,No,5%,947,5,10,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 4,947
NCT20608576,Hypertension,Vascular disorders,No,5%,947,8,16,Treatment Emergent,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 4,947
NCT20608576,Proteinuria,Renal and urinary disorders,No,5%,947,49,69,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 4,947
NCT20608576,Proteinuria,Renal and urinary disorders,No,10%,947,15,17,All Causality,Aflibercept,Anti-VEGF,Ovarian Cancer,Phase 4,947
NCT16668712,Colitis,Gastrointestinal disorders,Yes,5%,563,13,22,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,563
NCT16668712,Colitis,Gastrointestinal disorders,Yes,15%,563,17,28,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,563
NCT16668712,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,563,15,18,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,563
NCT16668712,Colitis,Gastrointestinal disorders,Yes,10%,563,47,67,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,563
NCT16668712,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,563,47,62,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,563
NCT21782304,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,949,37,55,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,949
NCT21782304,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,949,14,14,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,949
NCT21782304,Hepatitis,Hepatobiliary disorders,Yes,5%,949,4,8,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,949
NCT21782304,Colitis,Gastrointestinal disorders,Yes,5%,949,45,69,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,949
NCT21782304,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,949,3,3,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,949
NCT44376605,Hepatitis,Hepatobiliary disorders,Yes,5%,883,48,49,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,883
NCT44376605,Colitis,Gastrointestinal disorders,Yes,10%,883,2,3,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,883
NCT44376605,Hepatitis,Hepatobiliary disorders,Yes,5%,883,16,18,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,883
NCT44376605,Colitis,Gastrointestinal disorders,Yes,15%,883,11,11,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,883
NCT44376605,Colitis,Gastrointestinal disorders,Yes,5%,883,32,61,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,883
NCT44376605,Hepatitis,Hepatobiliary disorders,Yes,5%,883,43,67,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,883
NCT44376605,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,883,21,37,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,883
NCT44376605,Hepatitis,Hepatobiliary disorders,Yes,10%,883,28,53,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,883
NCT44376605,Colitis,Gastrointestinal disorders,Yes,5%,883,37,74,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,883
NCT44376605,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,883,6,10,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,883
NCT44376605,Colitis,Gastrointestinal disorders,Yes,10%,883,39,73,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,883
NCT44376605,Colitis,Gastrointestinal disorders,Yes,15%,883,32,59,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,883
NCT44376605,Hepatitis,Hepatobiliary disorders,Yes,15%,883,24,26,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 1,883
NCT36962884,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,223,12,18,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,223
NCT36962884,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,223,11,21,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,223
NCT36962884,Colitis,Gastrointestinal disorders,Yes,10%,223,2,2,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,223
NCT36962884,Hepatitis,Hepatobiliary disorders,Yes,10%,223,4,5,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,223
NCT36962884,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,223,1,1,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,223
NCT36962884,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,223,5,6,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,223
NCT21130707,Hepatitis,Hepatobiliary disorders,Yes,15%,443,25,40,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,443
NCT21130707,Colitis,Gastrointestinal disorders,Yes,10%,443,25,28,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,443
NCT21130707,Hepatitis,Hepatobiliary disorders,Yes,5%,443,8,13,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,443
NCT21130707,Colitis,Gastrointestinal disorders,Yes,5%,443,17,33,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,443
NCT21130707,Colitis,Gastrointestinal disorders,Yes,5%,443,13,17,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,443
NCT21130707,Hepatitis,Hepatobiliary disorders,Yes,10%,443,9,11,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,443
NCT21130707,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,443,24,29,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,443
NCT21130707,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,443,8,16,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,443
NCT21130707,Colitis,Gastrointestinal disorders,Yes,5%,443,10,12,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,443
NCT21130707,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,443,44,58,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,443
NCT63699390,Colitis,Gastrointestinal disorders,Yes,5%,171,15,17,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,171
NCT63699390,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,171,16,32,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,171
NCT63699390,Hepatitis,Hepatobiliary disorders,Yes,5%,171,10,16,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,171
NCT63699390,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,171,4,4,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,171
NCT63699390,Hepatitis,Hepatobiliary disorders,Yes,10%,171,16,32,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,171
NCT63699390,Hepatitis,Hepatobiliary disorders,Yes,5%,171,2,2,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,171
NCT63699390,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,171,5,8,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 2,171
NCT29932113,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,236,16,25,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,236
NCT29932113,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,236,14,14,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,236
NCT29932113,Hepatitis,Hepatobiliary disorders,Yes,15%,236,3,6,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,236
NCT29932113,Colitis,Gastrointestinal disorders,Yes,15%,236,2,3,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,236
NCT29932113,Hepatitis,Hepatobiliary disorders,Yes,10%,236,10,13,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,236
NCT29932113,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,236,20,33,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,236
NCT29932113,Hepatitis,Hepatobiliary disorders,Yes,10%,236,20,34,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,236
NCT29738899,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,279,4,5,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,279
NCT29738899,Colitis,Gastrointestinal disorders,Yes,10%,279,18,27,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,279
NCT29738899,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,279,10,15,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,279
NCT29738899,Hepatitis,Hepatobiliary disorders,Yes,15%,279,1,1,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,279
NCT29738899,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,279,24,40,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,279
NCT29738899,Colitis,Gastrointestinal disorders,Yes,5%,279,7,11,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,279
NCT29738899,Hepatitis,Hepatobiliary disorders,Yes,5%,279,1,2,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,279
NCT29738899,Colitis,Gastrointestinal disorders,Yes,5%,279,20,36,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,279
NCT90042183,Hepatitis,Hepatobiliary disorders,Yes,5%,268,20,31,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,268
NCT90042183,Hepatitis,Hepatobiliary disorders,Yes,10%,268,9,13,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,268
NCT90042183,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,268,9,15,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,268
NCT90042183,Hepatitis,Hepatobiliary disorders,Yes,5%,268,8,8,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,268
NCT90042183,Colitis,Gastrointestinal disorders,Yes,10%,268,23,44,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,268
NCT90042183,Colitis,Gastrointestinal disorders,Yes,10%,268,13,22,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,268
NCT90042183,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,268,21,41,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,268
NCT90042183,Hepatitis,Hepatobiliary disorders,Yes,15%,268,14,15,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 3,268
NCT15817360,Colitis,Gastrointestinal disorders,Yes,15%,396,23,27,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,396
NCT15817360,Hepatitis,Hepatobiliary disorders,Yes,10%,396,11,15,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,396
NCT15817360,Colitis,Gastrointestinal disorders,Yes,5%,396,22,31,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,396
NCT15817360,Colitis,Gastrointestinal disorders,Yes,10%,396,30,40,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,396
NCT15817360,Hepatitis,Hepatobiliary disorders,Yes,15%,396,17,32,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,396
NCT15817360,Hepatitis,Hepatobiliary disorders,Yes,5%,396,27,54,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,396
NCT15817360,Colitis,Gastrointestinal disorders,Yes,10%,396,32,37,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,396
NCT15817360,Hepatitis,Hepatobiliary disorders,Yes,10%,396,31,38,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,396
NCT15817360,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,396,31,58,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,396
NCT15817360,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,396,8,15,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,396
NCT15817360,Colitis,Gastrointestinal disorders,Yes,10%,396,6,6,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,396
NCT15817360,Hepatitis,Hepatobiliary disorders,Yes,15%,396,23,40,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,396
NCT15817360,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,396,29,57,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,396
NCT15817360,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,396,25,29,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,396
NCT15817360,Hepatitis,Hepatobiliary disorders,Yes,5%,396,29,40,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,396
NCT50144995,Colitis,Gastrointestinal disorders,Yes,15%,406,17,28,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,406
NCT50144995,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,406,4,6,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,406
NCT50144995,Hepatitis,Hepatobiliary disorders,Yes,10%,406,5,8,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,406
NCT64224792,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,502,46,73,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,502
NCT64224792,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,502,10,15,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,502
NCT64224792,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,502,31,44,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,502
NCT64224792,Colitis,Gastrointestinal disorders,Yes,15%,502,18,21,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,502
NCT64224792,Hepatitis,Hepatobiliary disorders,Yes,15%,502,21,40,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,502
NCT64224792,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,502,7,12,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,502
NCT64224792,Hepatitis,Hepatobiliary disorders,Yes,15%,502,4,7,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,502
NCT64224792,Colitis,Gastrointestinal disorders,Yes,15%,502,7,11,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,502
NCT64224792,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,502,35,63,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,502
NCT64224792,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,502,14,18,Treatment Emergent,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,502
NCT64224792,Hepatitis,Hepatobiliary disorders,Yes,10%,502,10,10,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,502
NCT64224792,Hepatitis,Hepatobiliary disorders,Yes,10%,502,2,4,All Causality,Pembrolizumab,Anti-PD-1,Melanoma,Phase 4,502
NCT31924506,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,959,13,19,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 1,959
NCT31924506,Hepatitis,Hepatobiliary disorders,Yes,10%,959,11,16,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 1,959
NCT31924506,Colitis,Gastrointestinal disorders,Yes,15%,959,39,53,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 1,959
NCT31924506,Colitis,Gastrointestinal disorders,Yes,5%,959,1,1,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 1,959
NCT31924506,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,959,38,71,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 1,959
NCT31924506,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,959,14,28,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 1,959
NCT31924506,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,959,40,53,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 1,959
NCT31924506,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,959,19,30,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 1,959
NCT31924506,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,959,44,66,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 1,959
NCT31924506,Hepatitis,Hepatobiliary disorders,Yes,5%,959,27,39,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 1,959
NCT31924506,Colitis,Gastrointestinal disorders,Yes,10%,959,33,61,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 1,959
NCT31924506,Hepatitis,Hepatobiliary disorders,Yes,15%,959,25,28,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 1,959
NCT31924506,Colitis,Gastrointestinal disorders,Yes,15%,959,19,30,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 1,959
NCT31924506,Hepatitis,Hepatobiliary disorders,Yes,15%,959,33,40,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 1,959
NCT31924506,Colitis,Gastrointestinal disorders,Yes,15%,959,2,2,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 1,959
NCT29868322,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,874,38,59,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,874
NCT29868322,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,874,5,10,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,874
NCT29868322,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,874,24,38,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,874
NCT29868322,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,874,36,66,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,874
NCT29868322,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,874,9,17,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,874
NCT29868322,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,874,26,45,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,874
NCT29868322,Colitis,Gastrointestinal disorders,Yes,10%,874,27,33,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,874
NCT29868322,Colitis,Gastrointestinal disorders,Yes,5%,874,19,34,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,874
NCT29868322,Hepatitis,Hepatobiliary disorders,Yes,10%,874,8,14,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,874
NCT29868322,Hepatitis,Hepatobiliary disorders,Yes,5%,874,14,20,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,874
NCT29868322,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,874,39,47,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,874
NCT34939790,Hepatitis,Hepatobiliary disorders,Yes,10%,765,25,46,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,765
NCT34939790,Hepatitis,Hepatobiliary disorders,Yes,5%,765,4,4,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,765
NCT34939790,Colitis,Gastrointestinal disorders,Yes,15%,765,43,65,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,765
NCT34939790,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,765,6,9,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,765
NCT34939790,Colitis,Gastrointestinal disorders,Yes,15%,765,46,48,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,765
NCT34939790,Hepatitis,Hepatobiliary disorders,Yes,10%,765,25,26,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,765
NCT34939790,Colitis,Gastrointestinal disorders,Yes,5%,765,44,44,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,765
NCT34939790,Hepatitis,Hepatobiliary disorders,Yes,15%,765,9,18,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,765
NCT34939790,Colitis,Gastrointestinal disorders,Yes,15%,765,46,55,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,765
NCT34939790,Colitis,Gastrointestinal disorders,Yes,15%,765,33,60,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,765
NCT34939790,Hepatitis,Hepatobiliary disorders,Yes,15%,765,8,8,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,765
NCT34939790,Hepatitis,Hepatobiliary disorders,Yes,10%,765,39,45,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,765
NCT81489568,Hepatitis,Hepatobiliary disorders,Yes,10%,863,9,12,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,863
NCT81489568,Colitis,Gastrointestinal disorders,Yes,10%,863,47,51,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,863
NCT81489568,Colitis,Gastrointestinal disorders,Yes,5%,863,43,62,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,863
NCT81489568,Colitis,Gastrointestinal disorders,Yes,5%,863,10,16,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,863
NCT81489568,Hepatitis,Hepatobiliary disorders,Yes,10%,863,5,5,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,863
NCT81489568,Colitis,Gastrointestinal disorders,Yes,5%,863,32,51,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,863
NCT81489568,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,863,46,48,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 2,863
NCT37990206,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,78,7,12,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,78
NCT37990206,Colitis,Gastrointestinal disorders,Yes,5%,78,7,10,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,78
NCT37990206,Hepatitis,Hepatobiliary disorders,Yes,10%,78,2,2,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,78
NCT37990206,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,78,7,8,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,78
NCT37990206,Colitis,Gastrointestinal disorders,Yes,5%,78,1,1,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,78
NCT10545464,Hepatitis,Hepatobiliary disorders,Yes,5%,45,4,7,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,45
NCT10545464,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,45,1,2,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,45
NCT10545464,Hepatitis,Hepatobiliary disorders,Yes,5%,45,1,2,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,45
NCT10545464,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,45,3,6,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,45
NCT10545464,Colitis,Gastrointestinal disorders,Yes,15%,45,3,6,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,45
NCT10545464,Hepatitis,Hepatobiliary disorders,Yes,10%,45,4,5,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,45
NCT10545464,Colitis,Gastrointestinal disorders,Yes,15%,45,3,3,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,45
NCT10545464,Colitis,Gastrointestinal disorders,Yes,5%,45,4,8,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,45
NCT10545464,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,45,2,3,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,45
NCT97611651,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,125,7,10,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,125
NCT97611651,Colitis,Gastrointestinal disorders,Yes,5%,125,5,5,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,125
NCT97611651,Colitis,Gastrointestinal disorders,Yes,15%,125,11,18,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,125
NCT97611651,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,125,5,9,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,125
NCT97611651,Hepatitis,Hepatobiliary disorders,Yes,15%,125,1,1,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,125
NCT97611651,Hepatitis,Hepatobiliary disorders,Yes,10%,125,6,10,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,125
NCT97611651,Colitis,Gastrointestinal disorders,Yes,10%,125,2,3,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,125
NCT97611651,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,125,3,6,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,125
NCT97611651,Hepatitis,Hepatobiliary disorders,Yes,10%,125,12,21,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,125
NCT97611651,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,125,3,5,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,125
NCT97611651,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,125,11,14,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,125
NCT97611651,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,125,7,11,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,125
NCT97611651,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,125,7,10,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 3,125
NCT14202147,Hepatitis,Hepatobiliary disorders,Yes,5%,39,1,1,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 4,39
NCT14202147,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,39,3,6,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 4,39
NCT14202147,Hepatitis,Hepatobiliary disorders,Yes,5%,39,3,6,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 4,39
NCT14202147,Colitis,Gastrointestinal disorders,Yes,10%,39,1,1,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 4,39
NCT14202147,Hepatitis,Hepatobiliary disorders,Yes,10%,39,3,4,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 4,39
NCT14202147,Colitis,Gastrointestinal disorders,Yes,15%,39,3,6,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 4,39
NCT14202147,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,39,1,1,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 4,39
NCT14202147,Colitis,Gastrointestinal disorders,Yes,15%,39,2,3,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 4,39
NCT14202147,Colitis,Gastrointestinal disorders,Yes,15%,39,3,4,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 4,39
NCT14202147,Hepatitis,Hepatobiliary disorders,Yes,5%,39,2,2,All Causality,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 4,39
NCT14202147,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,39,2,2,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lung Cancer,Phase 4,39
NCT50717175,Colitis,Gastrointestinal disorders,Yes,15%,816,33,33,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,816
NCT50717175,Colitis,Gastrointestinal disorders,Yes,15%,816,17,23,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,816
NCT50717175,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,816,49,74,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,816
NCT50717175,Colitis,Gastrointestinal disorders,Yes,15%,816,13,16,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,816
NCT50717175,Colitis,Gastrointestinal disorders,Yes,10%,816,48,57,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,816
NCT62099161,Colitis,Gastrointestinal disorders,Yes,10%,647,12,14,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,647
NCT62099161,Colitis,Gastrointestinal disorders,Yes,15%,647,24,39,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,647
NCT62099161,Colitis,Gastrointestinal disorders,Yes,15%,647,26,43,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,647
NCT62099161,Hepatitis,Hepatobiliary disorders,Yes,5%,647,45,78,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,647
NCT62099161,Hepatitis,Hepatobiliary disorders,Yes,5%,647,40,68,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,647
NCT62099161,Colitis,Gastrointestinal disorders,Yes,15%,647,7,14,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,647
NCT62099161,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,647,28,33,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,647
NCT28982172,Colitis,Gastrointestinal disorders,Yes,5%,876,15,21,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,876
NCT28982172,Hepatitis,Hepatobiliary disorders,Yes,5%,876,47,72,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,876
NCT28982172,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,876,28,34,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,876
NCT28982172,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,876,3,5,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,876
NCT28982172,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,876,1,2,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,876
NCT28982172,Hepatitis,Hepatobiliary disorders,Yes,15%,876,19,23,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,876
NCT28982172,Colitis,Gastrointestinal disorders,Yes,10%,876,19,38,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,876
NCT28982172,Hepatitis,Hepatobiliary disorders,Yes,15%,876,35,69,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,876
NCT28982172,Colitis,Gastrointestinal disorders,Yes,5%,876,26,46,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,876
NCT28982172,Hepatitis,Hepatobiliary disorders,Yes,5%,876,26,47,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 1,876
NCT63954740,Colitis,Gastrointestinal disorders,Yes,15%,770,13,16,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,770
NCT63954740,Colitis,Gastrointestinal disorders,Yes,10%,770,50,56,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,770
NCT63954740,Hepatitis,Hepatobiliary disorders,Yes,10%,770,34,49,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,770
NCT63954740,Colitis,Gastrointestinal disorders,Yes,5%,770,9,13,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,770
NCT63954740,Colitis,Gastrointestinal disorders,Yes,10%,770,33,60,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,770
NCT63954740,Colitis,Gastrointestinal disorders,Yes,5%,770,9,13,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,770
NCT63954740,Colitis,Gastrointestinal disorders,Yes,10%,770,44,78,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,770
NCT37315303,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,755,42,82,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,755
NCT37315303,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,755,16,31,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,755
NCT37315303,Hepatitis,Hepatobiliary disorders,Yes,5%,755,4,4,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,755
NCT37315303,Hepatitis,Hepatobiliary disorders,Yes,10%,755,40,66,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,755
NCT37315303,Hepatitis,Hepatobiliary disorders,Yes,15%,755,4,6,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,755
NCT37315303,Hepatitis,Hepatobiliary disorders,Yes,15%,755,19,20,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,755
NCT37315303,Colitis,Gastrointestinal disorders,Yes,10%,755,15,16,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,755
NCT37315303,Hepatitis,Hepatobiliary disorders,Yes,10%,755,39,69,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,755
NCT37315303,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,755,29,32,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,755
NCT85480230,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,538,16,29,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,538
NCT85480230,Hepatitis,Hepatobiliary disorders,Yes,10%,538,6,9,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,538
NCT85480230,Colitis,Gastrointestinal disorders,Yes,5%,538,13,26,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 2,538
NCT23711365,Hepatitis,Hepatobiliary disorders,Yes,5%,251,13,15,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,251
NCT23711365,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,251,14,16,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,251
NCT23711365,Colitis,Gastrointestinal disorders,Yes,10%,251,5,6,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,251
NCT23711365,Colitis,Gastrointestinal disorders,Yes,10%,251,14,19,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,251
NCT23711365,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,251,8,15,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,251
NCT23711365,Hepatitis,Hepatobiliary disorders,Yes,15%,251,1,1,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,251
NCT23711365,Hepatitis,Hepatobiliary disorders,Yes,15%,251,12,15,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,251
NCT23711365,Colitis,Gastrointestinal disorders,Yes,10%,251,24,32,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,251
NCT23711365,Colitis,Gastrointestinal disorders,Yes,5%,251,17,18,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,251
NCT23711365,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,251,7,7,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,251
NCT23711365,Colitis,Gastrointestinal disorders,Yes,5%,251,12,23,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,251
NCT23711365,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,251,11,13,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,251
NCT23711365,Hepatitis,Hepatobiliary disorders,Yes,10%,251,14,20,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,251
NCT23711365,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,251,24,32,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,251
NCT23711365,Colitis,Gastrointestinal disorders,Yes,15%,251,12,23,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,251
NCT35260372,Colitis,Gastrointestinal disorders,Yes,15%,303,5,8,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,303
NCT35260372,Hepatitis,Hepatobiliary disorders,Yes,5%,303,28,42,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,303
NCT35260372,Colitis,Gastrointestinal disorders,Yes,10%,303,20,37,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,303
NCT35260372,Hepatitis,Hepatobiliary disorders,Yes,5%,303,1,1,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 3,303
NCT82427229,Hepatitis,Hepatobiliary disorders,Yes,5%,868,25,38,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,868
NCT82427229,Colitis,Gastrointestinal disorders,Yes,15%,868,36,59,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,868
NCT82427229,Colitis,Gastrointestinal disorders,Yes,5%,868,45,51,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,868
NCT82427229,Hepatitis,Hepatobiliary disorders,Yes,10%,868,1,1,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,868
NCT82427229,Hepatitis,Hepatobiliary disorders,Yes,15%,868,8,13,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,868
NCT82427229,Colitis,Gastrointestinal disorders,Yes,10%,868,3,3,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,868
NCT82427229,Hepatitis,Hepatobiliary disorders,Yes,15%,868,12,12,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,868
NCT82427229,Hepatitis,Hepatobiliary disorders,Yes,15%,868,28,48,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,868
NCT82427229,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,868,21,22,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,868
NCT82427229,Hepatitis,Hepatobiliary disorders,Yes,15%,868,17,27,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,868
NCT82427229,Colitis,Gastrointestinal disorders,Yes,5%,868,1,2,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,868
NCT82427229,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,868,45,72,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,868
NCT82427229,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,868,1,2,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,868
NCT83392707,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,323,9,17,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,323
NCT83392707,Colitis,Gastrointestinal disorders,Yes,5%,323,26,30,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,323
NCT83392707,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,323,27,49,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,323
NCT83392707,Colitis,Gastrointestinal disorders,Yes,5%,323,4,5,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,323
NCT83392707,Hepatitis,Hepatobiliary disorders,Yes,5%,323,7,12,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,323
NCT83392707,Hepatitis,Hepatobiliary disorders,Yes,10%,323,12,18,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,323
NCT83392707,Hepatitis,Hepatobiliary disorders,Yes,5%,323,14,26,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,323
NCT83392707,Hepatitis,Hepatobiliary disorders,Yes,15%,323,2,2,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,323
NCT83392707,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,323,29,51,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,323
NCT35460790,Colitis,Gastrointestinal disorders,Yes,10%,30,1,2,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,30
NCT35460790,Colitis,Gastrointestinal disorders,Yes,15%,30,1,1,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,30
NCT35460790,Colitis,Gastrointestinal disorders,Yes,10%,30,3,6,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,30
NCT35460790,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,30,1,2,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,30
NCT35460790,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,30,2,2,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,30
NCT35460790,Hepatitis,Hepatobiliary disorders,Yes,5%,30,3,6,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,30
NCT35460790,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,30,3,5,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,30
NCT35460790,Colitis,Gastrointestinal disorders,Yes,10%,30,3,5,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,30
NCT35460790,Colitis,Gastrointestinal disorders,Yes,15%,30,2,4,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,30
NCT35460790,Hepatitis,Hepatobiliary disorders,Yes,15%,30,2,3,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,30
NCT35460790,Colitis,Gastrointestinal disorders,Yes,10%,30,1,2,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,30
NCT35460790,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,30,1,2,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,30
NCT35460790,Hepatitis,Hepatobiliary disorders,Yes,15%,30,1,1,All Causality,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,30
NCT35460790,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,30,1,1,Treatment Emergent,Pembrolizumab,Anti-PD-1,Lymphoma,Phase 4,30
NCT75842185,Colitis,Gastrointestinal disorders,Yes,15%,525,1,2,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 1,525
NCT75842185,Colitis,Gastrointestinal disorders,Yes,10%,525,48,48,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 1,525
NCT75842185,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,525,48,85,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 1,525
NCT75842185,Hepatitis,Hepatobiliary disorders,Yes,10%,525,23,31,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 1,525
NCT75842185,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,525,12,16,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 1,525
NCT75842185,Hepatitis,Hepatobiliary disorders,Yes,15%,525,30,51,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 1,525
NCT75842185,Hepatitis,Hepatobiliary disorders,Yes,10%,525,32,41,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 1,525
NCT75842185,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,525,14,24,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 1,525
NCT75842185,Hepatitis,Hepatobiliary disorders,Yes,10%,525,44,54,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 1,525
NCT75842185,Colitis,Gastrointestinal disorders,Yes,5%,525,7,7,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 1,525
NCT75842185,Hepatitis,Hepatobiliary disorders,Yes,5%,525,21,22,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 1,525
NCT75842185,Hepatitis,Hepatobiliary disorders,Yes,10%,525,48,75,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 1,525
NCT17518948,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,564,38,72,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 1,564
NCT17518948,Hepatitis,Hepatobiliary disorders,Yes,5%,564,23,33,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 1,564
NCT17518948,Colitis,Gastrointestinal disorders,Yes,15%,564,1,1,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 1,564
NCT80331730,Hepatitis,Hepatobiliary disorders,Yes,15%,424,19,22,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 1,424
NCT80331730,Hepatitis,Hepatobiliary disorders,Yes,5%,424,39,54,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 1,424
NCT80331730,Hepatitis,Hepatobiliary disorders,Yes,15%,424,32,49,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 1,424
NCT86459434,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,425,3,4,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 2,425
NCT86459434,Colitis,Gastrointestinal disorders,Yes,15%,425,42,62,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 2,425
NCT86459434,Colitis,Gastrointestinal disorders,Yes,10%,425,31,56,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 2,425
NCT86459434,Colitis,Gastrointestinal disorders,Yes,5%,425,19,38,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 2,425
NCT86459434,Hepatitis,Hepatobiliary disorders,Yes,5%,425,15,18,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 2,425
NCT86459434,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,425,8,10,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 2,425
NCT39967869,Hepatitis,Hepatobiliary disorders,Yes,5%,698,25,31,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 3,698
NCT39967869,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,698,4,6,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 3,698
NCT39967869,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,698,7,9,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 3,698
NCT39967869,Colitis,Gastrointestinal disorders,Yes,10%,698,5,5,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 3,698
NCT39967869,Colitis,Gastrointestinal disorders,Yes,10%,698,1,2,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 3,698
NCT39967869,Hepatitis,Hepatobiliary disorders,Yes,15%,698,47,58,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 3,698
NCT39967869,Hepatitis,Hepatobiliary disorders,Yes,5%,698,44,50,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 3,698
NCT39967869,Colitis,Gastrointestinal disorders,Yes,15%,698,41,50,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 3,698
NCT39967869,Hepatitis,Hepatobiliary disorders,Yes,5%,698,45,87,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 3,698
NCT39967869,Hepatitis,Hepatobiliary disorders,Yes,5%,698,22,44,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 3,698
NCT24341371,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,518,32,62,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 4,518
NCT24341371,Hepatitis,Hepatobiliary disorders,Yes,15%,518,30,38,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 4,518
NCT24341371,Hepatitis,Hepatobiliary disorders,Yes,5%,518,32,48,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 4,518
NCT24341371,Colitis,Gastrointestinal disorders,Yes,5%,518,40,69,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 4,518
NCT24341371,Hepatitis,Hepatobiliary disorders,Yes,15%,518,39,65,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 4,518
NCT24341371,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,518,20,26,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 4,518
NCT24341371,Hepatitis,Hepatobiliary disorders,Yes,15%,518,41,75,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 4,518
NCT32889601,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,922,49,65,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 4,922
NCT32889601,Colitis,Gastrointestinal disorders,Yes,10%,922,46,47,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 4,922
NCT32889601,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,922,33,42,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 4,922
NCT32889601,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,922,7,10,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 4,922
NCT32889601,Hepatitis,Hepatobiliary disorders,Yes,15%,922,37,72,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 4,922
NCT32889601,Colitis,Gastrointestinal disorders,Yes,10%,922,2,3,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 4,922
NCT32889601,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,922,45,85,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 4,922
NCT32889601,Colitis,Gastrointestinal disorders,Yes,10%,922,48,94,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 4,922
NCT32889601,Hepatitis,Hepatobiliary disorders,Yes,10%,922,44,60,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 4,922
NCT32889601,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,922,41,45,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 4,922
NCT32889601,Hepatitis,Hepatobiliary disorders,Yes,15%,922,16,32,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 4,922
NCT32889601,Colitis,Gastrointestinal disorders,Yes,10%,922,47,69,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 4,922
NCT75925533,Hepatitis,Hepatobiliary disorders,Yes,10%,560,20,38,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 4,560
NCT75925533,Hepatitis,Hepatobiliary disorders,Yes,5%,560,48,67,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 4,560
NCT75925533,Colitis,Gastrointestinal disorders,Yes,5%,560,42,70,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 4,560
NCT75925533,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,560,11,17,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 4,560
NCT75925533,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,560,36,42,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 4,560
NCT75925533,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,560,14,15,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 4,560
NCT75925533,Hepatitis,Hepatobiliary disorders,Yes,15%,560,8,11,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 4,560
NCT75925533,Hepatitis,Hepatobiliary disorders,Yes,15%,560,30,60,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 4,560
NCT75925533,Hepatitis,Hepatobiliary disorders,Yes,15%,560,25,33,Treatment Emergent,Nivolumab,Anti-PD-1,Melanoma,Phase 4,560
NCT75925533,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,560,36,47,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 4,560
NCT75925533,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,560,29,48,All Causality,Nivolumab,Anti-PD-1,Melanoma,Phase 4,560
NCT94198799,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,834,44,64,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,834
NCT94198799,Hepatitis,Hepatobiliary disorders,Yes,5%,834,12,16,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,834
NCT94198799,Colitis,Gastrointestinal disorders,Yes,5%,834,37,44,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,834
NCT94198799,Hepatitis,Hepatobiliary disorders,Yes,10%,834,16,17,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,834
NCT94198799,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,834,37,62,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,834
NCT94198799,Hepatitis,Hepatobiliary disorders,Yes,15%,834,27,40,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,834
NCT73617729,Colitis,Gastrointestinal disorders,Yes,5%,762,30,55,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,762
NCT73617729,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,762,18,32,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,762
NCT73617729,Hepatitis,Hepatobiliary disorders,Yes,15%,762,21,37,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,762
NCT15479368,Colitis,Gastrointestinal disorders,Yes,15%,941,25,48,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,941
NCT15479368,Colitis,Gastrointestinal disorders,Yes,10%,941,27,49,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,941
NCT15479368,Hepatitis,Hepatobiliary disorders,Yes,5%,941,36,61,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,941
NCT15479368,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,941,7,14,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,941
NCT15479368,Colitis,Gastrointestinal disorders,Yes,15%,941,1,2,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,941
NCT15479368,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,941,37,52,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,941
NCT15479368,Hepatitis,Hepatobiliary disorders,Yes,10%,941,21,22,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,941
NCT15479368,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,941,31,40,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,941
NCT15479368,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,941,28,56,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,941
NCT15479368,Hepatitis,Hepatobiliary disorders,Yes,15%,941,23,46,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,941
NCT15479368,Hepatitis,Hepatobiliary disorders,Yes,5%,941,10,12,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,941
NCT15479368,Colitis,Gastrointestinal disorders,Yes,5%,941,11,16,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,941
NCT15479368,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,941,27,32,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,941
NCT15479368,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,941,36,49,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,941
NCT15479368,Hepatitis,Hepatobiliary disorders,Yes,5%,941,4,7,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 1,941
NCT97301291,Hepatitis,Hepatobiliary disorders,Yes,10%,929,30,47,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,929
NCT97301291,Colitis,Gastrointestinal disorders,Yes,15%,929,50,59,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,929
NCT97301291,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,929,11,16,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,929
NCT97301291,Hepatitis,Hepatobiliary disorders,Yes,10%,929,39,53,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,929
NCT60553499,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,488,29,34,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,488
NCT60553499,Hepatitis,Hepatobiliary disorders,Yes,15%,488,11,16,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,488
NCT60553499,Hepatitis,Hepatobiliary disorders,Yes,15%,488,35,42,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,488
NCT60553499,Colitis,Gastrointestinal disorders,Yes,15%,488,20,20,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,488
NCT60553499,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,488,14,15,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,488
NCT60553499,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,488,42,69,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,488
NCT60553499,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,488,2,3,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,488
NCT60553499,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,488,16,26,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,488
NCT60553499,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,488,34,54,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,488
NCT60553499,Colitis,Gastrointestinal disorders,Yes,5%,488,37,69,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,488
NCT55268605,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,435,42,70,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,435
NCT55268605,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,435,41,56,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,435
NCT55268605,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,435,19,28,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,435
NCT55268605,Hepatitis,Hepatobiliary disorders,Yes,15%,435,26,27,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,435
NCT55268605,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,435,29,34,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,435
NCT55268605,Hepatitis,Hepatobiliary disorders,Yes,15%,435,26,46,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 2,435
NCT39313364,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,191,15,22,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,191
NCT39313364,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,191,6,11,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,191
NCT39313364,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,191,3,5,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,191
NCT39313364,Hepatitis,Hepatobiliary disorders,Yes,5%,191,6,7,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,191
NCT39313364,Hepatitis,Hepatobiliary disorders,Yes,5%,191,13,13,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,191
NCT39313364,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,191,10,19,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,191
NCT39313364,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,191,6,8,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,191
NCT39313364,Colitis,Gastrointestinal disorders,Yes,10%,191,6,6,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,191
NCT39313364,Colitis,Gastrointestinal disorders,Yes,15%,191,14,19,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,191
NCT39313364,Hepatitis,Hepatobiliary disorders,Yes,10%,191,3,4,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,191
NCT39313364,Hepatitis,Hepatobiliary disorders,Yes,10%,191,1,1,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,191
NCT39313364,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,191,7,7,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,191
NCT39313364,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,191,10,12,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,191
NCT18387314,Hepatitis,Hepatobiliary disorders,Yes,5%,311,9,12,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,311
NCT18387314,Hepatitis,Hepatobiliary disorders,Yes,10%,311,30,57,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,311
NCT18387314,Colitis,Gastrointestinal disorders,Yes,15%,311,25,46,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,311
NCT18387314,Hepatitis,Hepatobiliary disorders,Yes,5%,311,10,12,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,311
NCT18387314,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,311,4,6,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,311
NCT18387314,Colitis,Gastrointestinal disorders,Yes,15%,311,2,2,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,311
NCT18387314,Hepatitis,Hepatobiliary disorders,Yes,15%,311,26,49,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,311
NCT18387314,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,311,2,4,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,311
NCT18387314,Hepatitis,Hepatobiliary disorders,Yes,10%,311,29,58,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,311
NCT18387314,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,311,1,1,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,311
NCT86678181,Hepatitis,Hepatobiliary disorders,Yes,15%,219,6,8,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,219
NCT86678181,Hepatitis,Hepatobiliary disorders,Yes,5%,219,18,33,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,219
NCT86678181,Colitis,Gastrointestinal disorders,Yes,15%,219,10,14,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,219
NCT86678181,Hepatitis,Hepatobiliary disorders,Yes,15%,219,15,17,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,219
NCT86678181,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,219,3,3,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,219
NCT86678181,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,219,14,19,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,219
NCT86678181,Colitis,Gastrointestinal disorders,Yes,10%,219,13,16,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,219
NCT86678181,Hepatitis,Hepatobiliary disorders,Yes,15%,219,7,13,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,219
NCT86678181,Hepatitis,Hepatobiliary disorders,Yes,5%,219,13,24,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,219
NCT86678181,Hepatitis,Hepatobiliary disorders,Yes,15%,219,18,36,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,219
NCT86678181,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,219,2,2,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,219
NCT86678181,Colitis,Gastrointestinal disorders,Yes,10%,219,17,27,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,219
NCT86678181,Hepatitis,Hepatobiliary disorders,Yes,5%,219,10,10,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 3,219
NCT75343369,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,978,1,2,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,978
NCT75343369,Hepatitis,Hepatobiliary disorders,Yes,15%,978,39,69,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,978
NCT75343369,Hepatitis,Hepatobiliary disorders,Yes,5%,978,2,2,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,978
NCT75343369,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,978,16,20,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,978
NCT75343369,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,978,22,41,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,978
NCT75343369,Hepatitis,Hepatobiliary disorders,Yes,10%,978,20,31,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,978
NCT75343369,Colitis,Gastrointestinal disorders,Yes,15%,978,31,45,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,978
NCT75343369,Hepatitis,Hepatobiliary disorders,Yes,5%,978,33,49,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,978
NCT75343369,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,978,50,92,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,978
NCT75343369,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,978,20,31,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,978
NCT75343369,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,978,31,59,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,978
NCT42505109,Colitis,Gastrointestinal disorders,Yes,10%,904,2,4,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,904
NCT42505109,Colitis,Gastrointestinal disorders,Yes,10%,904,15,20,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,904
NCT42505109,Hepatitis,Hepatobiliary disorders,Yes,15%,904,24,47,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,904
NCT42505109,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,904,27,43,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,904
NCT42505109,Hepatitis,Hepatobiliary disorders,Yes,10%,904,9,12,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,904
NCT42505109,Colitis,Gastrointestinal disorders,Yes,5%,904,33,38,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,904
NCT42505109,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,904,21,38,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,904
NCT42505109,Hepatitis,Hepatobiliary disorders,Yes,5%,904,7,8,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,904
NCT42505109,Hepatitis,Hepatobiliary disorders,Yes,10%,904,24,30,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,904
NCT42505109,Colitis,Gastrointestinal disorders,Yes,5%,904,22,27,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,904
NCT42505109,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,904,12,19,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,904
NCT42505109,Hepatitis,Hepatobiliary disorders,Yes,15%,904,41,72,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,904
NCT42505109,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,904,26,45,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,904
NCT42505109,Hepatitis,Hepatobiliary disorders,Yes,15%,904,3,6,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,904
NCT62260047,Hepatitis,Hepatobiliary disorders,Yes,15%,948,18,23,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,948
NCT62260047,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,948,2,3,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,948
NCT62260047,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,948,15,15,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,948
NCT62260047,Colitis,Gastrointestinal disorders,Yes,15%,948,49,79,All Causality,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,948
NCT62260047,Hepatitis,Hepatobiliary disorders,Yes,15%,948,21,42,Treatment Emergent,Nivolumab,Anti-PD-1,Lung Cancer,Phase 4,948
NCT80938625,Colitis,Gastrointestinal disorders,Yes,10%,555,32,59,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 1,555
NCT80938625,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,555,3,6,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 1,555
NCT80938625,Colitis,Gastrointestinal disorders,Yes,15%,555,13,13,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 1,555
NCT80938625,Colitis,Gastrointestinal disorders,Yes,10%,555,27,33,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 1,555
NCT80938625,Colitis,Gastrointestinal disorders,Yes,5%,555,21,26,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 1,555
NCT80938625,Hepatitis,Hepatobiliary disorders,Yes,10%,555,16,23,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 1,555
NCT80938625,Hepatitis,Hepatobiliary disorders,Yes,15%,555,18,22,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 1,555
NCT80938625,Colitis,Gastrointestinal disorders,Yes,15%,555,44,51,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 1,555
NCT80938625,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,555,34,44,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 1,555
NCT80938625,Hepatitis,Hepatobiliary disorders,Yes,5%,555,41,57,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 1,555
NCT80938625,Hepatitis,Hepatobiliary disorders,Yes,15%,555,11,15,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 1,555
NCT80938625,Colitis,Gastrointestinal disorders,Yes,10%,555,12,18,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 1,555
NCT80938625,Colitis,Gastrointestinal disorders,Yes,10%,555,29,38,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 1,555
NCT77308094,Colitis,Gastrointestinal disorders,Yes,10%,626,27,36,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 1,626
NCT77308094,Colitis,Gastrointestinal disorders,Yes,15%,626,1,1,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 1,626
NCT77308094,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,626,32,49,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 1,626
NCT77308094,Colitis,Gastrointestinal disorders,Yes,10%,626,33,61,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 1,626
NCT77308094,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,626,21,25,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 1,626
NCT77308094,Hepatitis,Hepatobiliary disorders,Yes,5%,626,45,81,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 1,626
NCT90762726,Colitis,Gastrointestinal disorders,Yes,5%,525,16,19,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 1,525
NCT90762726,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,525,42,59,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 1,525
NCT90762726,Colitis,Gastrointestinal disorders,Yes,10%,525,20,23,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 1,525
NCT90762726,Colitis,Gastrointestinal disorders,Yes,5%,525,43,51,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 1,525
NCT90762726,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,525,34,51,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 1,525
NCT90762726,Hepatitis,Hepatobiliary disorders,Yes,10%,525,12,12,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 1,525
NCT90762726,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,525,14,15,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 1,525
NCT90762726,Hepatitis,Hepatobiliary disorders,Yes,15%,525,19,34,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 1,525
NCT76046465,Hepatitis,Hepatobiliary disorders,Yes,5%,724,3,5,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 2,724
NCT76046465,Hepatitis,Hepatobiliary disorders,Yes,5%,724,37,63,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 2,724
NCT76046465,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,724,21,23,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 2,724
NCT76046465,Colitis,Gastrointestinal disorders,Yes,5%,724,47,83,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 2,724
NCT76046465,Hepatitis,Hepatobiliary disorders,Yes,15%,724,10,20,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 2,724
NCT76046465,Colitis,Gastrointestinal disorders,Yes,5%,724,45,84,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 2,724
NCT76046465,Colitis,Gastrointestinal disorders,Yes,15%,724,49,92,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 2,724
NCT76046465,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,724,44,88,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 2,724
NCT76046465,Hepatitis,Hepatobiliary disorders,Yes,10%,724,20,28,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 2,724
NCT78929451,Hepatitis,Hepatobiliary disorders,Yes,15%,596,34,53,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 2,596
NCT78929451,Hepatitis,Hepatobiliary disorders,Yes,5%,596,16,29,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 2,596
NCT78929451,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,596,32,37,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 2,596
NCT78929451,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,596,38,56,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 2,596
NCT78929451,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,596,1,2,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 2,596
NCT78929451,Hepatitis,Hepatobiliary disorders,Yes,5%,596,25,28,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 2,596
NCT78929451,Hepatitis,Hepatobiliary disorders,Yes,5%,596,10,11,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 2,596
NCT78929451,Colitis,Gastrointestinal disorders,Yes,10%,596,2,4,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 2,596
NCT78929451,Colitis,Gastrointestinal disorders,Yes,10%,596,24,48,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 2,596
NCT78929451,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,596,42,82,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 2,596
NCT78929451,Hepatitis,Hepatobiliary disorders,Yes,10%,596,36,45,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 2,596
NCT78929451,Hepatitis,Hepatobiliary disorders,Yes,15%,596,40,56,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 2,596
NCT78929451,Hepatitis,Hepatobiliary disorders,Yes,5%,596,47,88,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 2,596
NCT16638362,Colitis,Gastrointestinal disorders,Yes,10%,926,4,6,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 2,926
NCT16638362,Colitis,Gastrointestinal disorders,Yes,15%,926,23,27,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 2,926
NCT16638362,Colitis,Gastrointestinal disorders,Yes,10%,926,37,65,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 2,926
NCT16638362,Hepatitis,Hepatobiliary disorders,Yes,5%,926,39,46,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 2,926
NCT16638362,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,926,32,32,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 2,926
NCT16638362,Colitis,Gastrointestinal disorders,Yes,10%,926,35,54,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 2,926
NCT87218069,Colitis,Gastrointestinal disorders,Yes,5%,504,24,31,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,504
NCT87218069,Colitis,Gastrointestinal disorders,Yes,10%,504,32,62,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,504
NCT87218069,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,504,47,69,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,504
NCT87218069,Hepatitis,Hepatobiliary disorders,Yes,10%,504,35,35,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,504
NCT87218069,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,504,29,48,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,504
NCT87218069,Hepatitis,Hepatobiliary disorders,Yes,10%,504,48,57,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,504
NCT87218069,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,504,13,23,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,504
NCT87218069,Colitis,Gastrointestinal disorders,Yes,15%,504,2,3,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,504
NCT87218069,Colitis,Gastrointestinal disorders,Yes,5%,504,24,26,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,504
NCT87218069,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,504,34,53,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,504
NCT87218069,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,504,13,23,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,504
NCT87218069,Hepatitis,Hepatobiliary disorders,Yes,10%,504,36,58,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,504
NCT85275764,Hepatitis,Hepatobiliary disorders,Yes,10%,104,2,2,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,104
NCT85275764,Hepatitis,Hepatobiliary disorders,Yes,10%,104,10,18,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,104
NCT85275764,Hepatitis,Hepatobiliary disorders,Yes,15%,104,6,11,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,104
NCT85275764,Colitis,Gastrointestinal disorders,Yes,15%,104,9,14,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,104
NCT85275764,Hepatitis,Hepatobiliary disorders,Yes,15%,104,4,7,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,104
NCT85275764,Colitis,Gastrointestinal disorders,Yes,10%,104,9,17,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,104
NCT85275764,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,104,10,12,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,104
NCT85275764,Colitis,Gastrointestinal disorders,Yes,5%,104,8,9,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,104
NCT85275764,Colitis,Gastrointestinal disorders,Yes,15%,104,4,5,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,104
NCT85275764,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,104,3,3,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,104
NCT64596365,Colitis,Gastrointestinal disorders,Yes,15%,253,8,12,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,253
NCT64596365,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,253,23,38,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,253
NCT64596365,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,253,17,17,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,253
NCT64596365,Colitis,Gastrointestinal disorders,Yes,15%,253,6,12,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,253
NCT64596365,Colitis,Gastrointestinal disorders,Yes,5%,253,17,20,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,253
NCT64596365,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,253,16,30,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,253
NCT64596365,Colitis,Gastrointestinal disorders,Yes,15%,253,1,2,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,253
NCT64596365,Colitis,Gastrointestinal disorders,Yes,10%,253,1,2,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,253
NCT64596365,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,253,7,11,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,253
NCT64596365,Colitis,Gastrointestinal disorders,Yes,15%,253,21,37,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,253
NCT64596365,Colitis,Gastrointestinal disorders,Yes,5%,253,9,12,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,253
NCT64596365,Colitis,Gastrointestinal disorders,Yes,15%,253,19,33,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,253
NCT64596365,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,253,23,30,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,253
NCT64596365,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,253,13,19,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,253
NCT64596365,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,253,18,24,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 3,253
NCT81751883,Hepatitis,Hepatobiliary disorders,Yes,10%,227,11,22,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 4,227
NCT81751883,Colitis,Gastrointestinal disorders,Yes,10%,227,2,4,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 4,227
NCT81751883,Hepatitis,Hepatobiliary disorders,Yes,15%,227,6,6,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 4,227
NCT81751883,Colitis,Gastrointestinal disorders,Yes,5%,227,2,2,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 4,227
NCT81751883,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,227,15,27,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 4,227
NCT58789817,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,409,31,40,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 4,409
NCT58789817,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,409,5,6,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 4,409
NCT58789817,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,409,4,8,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 4,409
NCT58789817,Colitis,Gastrointestinal disorders,Yes,15%,409,23,40,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 4,409
NCT58789817,Hepatitis,Hepatobiliary disorders,Yes,10%,409,40,48,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 4,409
NCT53634000,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,282,8,11,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 4,282
NCT53634000,Hepatitis,Hepatobiliary disorders,Yes,15%,282,11,11,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 4,282
NCT53634000,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,282,2,4,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 4,282
NCT53634000,Colitis,Gastrointestinal disorders,Yes,10%,282,22,23,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 4,282
NCT53634000,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,282,8,13,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 4,282
NCT53634000,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,282,22,24,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 4,282
NCT53634000,Hepatitis,Hepatobiliary disorders,Yes,15%,282,25,26,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 4,282
NCT53634000,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,282,15,28,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 4,282
NCT53634000,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,282,27,30,All Causality,Nivolumab,Anti-PD-1,Lymphoma,Phase 4,282
NCT53634000,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,282,9,15,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 4,282
NCT53634000,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,282,25,32,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 4,282
NCT53634000,Colitis,Gastrointestinal disorders,Yes,15%,282,16,28,Treatment Emergent,Nivolumab,Anti-PD-1,Lymphoma,Phase 4,282
NCT90878202,Hepatitis,Hepatobiliary disorders,Yes,10%,939,25,31,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 1,939
NCT90878202,Hepatitis,Hepatobiliary disorders,Yes,5%,939,38,63,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 1,939
NCT90878202,Colitis,Gastrointestinal disorders,Yes,5%,939,22,36,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 1,939
NCT90878202,Colitis,Gastrointestinal disorders,Yes,5%,939,4,5,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 1,939
NCT90878202,Hepatitis,Hepatobiliary disorders,Yes,5%,939,46,89,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 1,939
NCT90878202,Colitis,Gastrointestinal disorders,Yes,15%,939,13,24,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 1,939
NCT90878202,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,939,4,7,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 1,939
NCT90878202,Hepatitis,Hepatobiliary disorders,Yes,15%,939,40,66,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 1,939
NCT90878202,Colitis,Gastrointestinal disorders,Yes,5%,939,5,5,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 1,939
NCT90878202,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,939,20,32,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 1,939
NCT90878202,Hepatitis,Hepatobiliary disorders,Yes,15%,939,42,79,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 1,939
NCT53849951,Colitis,Gastrointestinal disorders,Yes,15%,682,18,34,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 1,682
NCT53849951,Colitis,Gastrointestinal disorders,Yes,15%,682,12,15,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 1,682
NCT53849951,Colitis,Gastrointestinal disorders,Yes,15%,682,33,47,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 1,682
NCT41906780,Hepatitis,Hepatobiliary disorders,Yes,10%,553,34,48,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,553
NCT41906780,Hepatitis,Hepatobiliary disorders,Yes,5%,553,49,50,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,553
NCT41906780,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,553,24,29,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,553
NCT41906780,Hepatitis,Hepatobiliary disorders,Yes,15%,553,42,74,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,553
NCT41906780,Colitis,Gastrointestinal disorders,Yes,15%,553,43,81,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,553
NCT41906780,Hepatitis,Hepatobiliary disorders,Yes,10%,553,33,65,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,553
NCT41906780,Hepatitis,Hepatobiliary disorders,Yes,15%,553,20,30,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,553
NCT15135495,Hepatitis,Hepatobiliary disorders,Yes,15%,326,12,21,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,326
NCT15135495,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,326,11,17,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,326
NCT15135495,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,326,11,14,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,326
NCT15135495,Hepatitis,Hepatobiliary disorders,Yes,5%,326,14,24,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,326
NCT15135495,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,326,8,12,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,326
NCT15135495,Colitis,Gastrointestinal disorders,Yes,5%,326,23,41,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,326
NCT15135495,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,326,7,7,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,326
NCT15135495,Hepatitis,Hepatobiliary disorders,Yes,15%,326,24,43,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,326
NCT15135495,Colitis,Gastrointestinal disorders,Yes,15%,326,14,20,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,326
NCT15135495,Colitis,Gastrointestinal disorders,Yes,15%,326,25,27,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,326
NCT15135495,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,326,28,55,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,326
NCT17616763,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,437,37,73,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,437
NCT17616763,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,437,42,72,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,437
NCT17616763,Colitis,Gastrointestinal disorders,Yes,15%,437,2,3,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,437
NCT17616763,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,437,6,12,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,437
NCT17616763,Hepatitis,Hepatobiliary disorders,Yes,10%,437,39,66,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,437
NCT17616763,Hepatitis,Hepatobiliary disorders,Yes,10%,437,26,42,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,437
NCT17616763,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,437,34,52,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,437
NCT17616763,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,437,29,31,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,437
NCT17616763,Colitis,Gastrointestinal disorders,Yes,10%,437,17,18,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,437
NCT17616763,Colitis,Gastrointestinal disorders,Yes,5%,437,15,19,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,437
NCT17616763,Hepatitis,Hepatobiliary disorders,Yes,5%,437,26,42,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,437
NCT17616763,Colitis,Gastrointestinal disorders,Yes,5%,437,37,66,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,437
NCT17616763,Colitis,Gastrointestinal disorders,Yes,15%,437,17,17,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,437
NCT17616763,Hepatitis,Hepatobiliary disorders,Yes,5%,437,40,70,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,437
NCT17616763,Hepatitis,Hepatobiliary disorders,Yes,5%,437,39,42,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 2,437
NCT90088890,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,391,25,26,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 3,391
NCT90088890,Hepatitis,Hepatobiliary disorders,Yes,5%,391,6,9,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 3,391
NCT90088890,Colitis,Gastrointestinal disorders,Yes,10%,391,13,22,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 3,391
NCT90088890,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,391,12,18,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 3,391
NCT90088890,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,391,30,31,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 3,391
NCT90088890,Hepatitis,Hepatobiliary disorders,Yes,15%,391,7,8,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 3,391
NCT90088890,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,391,31,48,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 3,391
NCT90088890,Hepatitis,Hepatobiliary disorders,Yes,15%,391,27,39,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 3,391
NCT90088890,Hepatitis,Hepatobiliary disorders,Yes,5%,391,9,15,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 3,391
NCT90088890,Hepatitis,Hepatobiliary disorders,Yes,15%,391,9,10,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 3,391
NCT66786008,Colitis,Gastrointestinal disorders,Yes,5%,973,48,65,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 3,973
NCT66786008,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,973,28,31,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 3,973
NCT66786008,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,973,3,4,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 3,973
NCT66786008,Hepatitis,Hepatobiliary disorders,Yes,5%,973,19,30,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 3,973
NCT66786008,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,973,34,42,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 3,973
NCT16562248,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,239,3,5,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 3,239
NCT16562248,Colitis,Gastrointestinal disorders,Yes,10%,239,9,17,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 3,239
NCT16562248,Colitis,Gastrointestinal disorders,Yes,10%,239,5,7,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 3,239
NCT47901988,Hepatitis,Hepatobiliary disorders,Yes,10%,548,26,34,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,548
NCT47901988,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,548,10,13,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,548
NCT47901988,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,548,25,49,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,548
NCT47901988,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,548,5,7,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,548
NCT47901988,Colitis,Gastrointestinal disorders,Yes,10%,548,27,38,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,548
NCT47901988,Colitis,Gastrointestinal disorders,Yes,15%,548,35,47,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,548
NCT47901988,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,548,10,13,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,548
NCT47901988,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,548,9,10,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,548
NCT58062277,Colitis,Gastrointestinal disorders,Yes,5%,474,14,21,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,474
NCT58062277,Colitis,Gastrointestinal disorders,Yes,10%,474,24,33,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,474
NCT58062277,Hepatitis,Hepatobiliary disorders,Yes,10%,474,15,16,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,474
NCT58062277,Colitis,Gastrointestinal disorders,Yes,5%,474,23,27,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,474
NCT58062277,Colitis,Gastrointestinal disorders,Yes,5%,474,29,41,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,474
NCT58062277,Hepatitis,Hepatobiliary disorders,Yes,5%,474,36,66,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,474
NCT58062277,Hepatitis,Hepatobiliary disorders,Yes,10%,474,29,38,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,474
NCT58062277,Hepatitis,Hepatobiliary disorders,Yes,15%,474,41,51,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,474
NCT58062277,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,474,18,26,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,474
NCT58062277,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,474,10,15,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,474
NCT58062277,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,474,36,67,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,474
NCT58062277,Colitis,Gastrointestinal disorders,Yes,10%,474,47,54,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,474
NCT58062277,Colitis,Gastrointestinal disorders,Yes,15%,474,46,68,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,474
NCT65516625,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,693,50,56,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,693
NCT65516625,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,693,9,14,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,693
NCT65516625,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,693,38,41,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,693
NCT65516625,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,693,41,58,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,693
NCT65516625,Colitis,Gastrointestinal disorders,Yes,10%,693,20,21,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,693
NCT65516625,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,693,13,15,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,693
NCT65516625,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,693,46,60,Treatment Emergent,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,693
NCT65516625,Colitis,Gastrointestinal disorders,Yes,15%,693,46,58,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,693
NCT65516625,Colitis,Gastrointestinal disorders,Yes,15%,693,29,51,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,693
NCT65516625,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,693,25,44,All Causality,Cemiplimab,Anti-PD-1,Melanoma,Phase 4,693
NCT29084518,Colitis,Gastrointestinal disorders,Yes,10%,846,33,42,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 1,846
NCT29084518,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,846,24,28,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 1,846
NCT29084518,Colitis,Gastrointestinal disorders,Yes,15%,846,48,51,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 1,846
NCT29084518,Colitis,Gastrointestinal disorders,Yes,15%,846,26,52,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 1,846
NCT29084518,Hepatitis,Hepatobiliary disorders,Yes,5%,846,36,44,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 1,846
NCT44253125,Colitis,Gastrointestinal disorders,Yes,5%,359,26,47,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 1,359
NCT44253125,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,359,10,16,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 1,359
NCT44253125,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,359,11,20,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 1,359
NCT44253125,Hepatitis,Hepatobiliary disorders,Yes,10%,359,9,17,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 1,359
NCT44253125,Hepatitis,Hepatobiliary disorders,Yes,15%,359,28,29,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 1,359
NCT44253125,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,359,30,30,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 1,359
NCT44253125,Hepatitis,Hepatobiliary disorders,Yes,5%,359,9,11,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 1,359
NCT44253125,Hepatitis,Hepatobiliary disorders,Yes,10%,359,33,53,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 1,359
NCT44253125,Hepatitis,Hepatobiliary disorders,Yes,5%,359,30,56,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 1,359
NCT44253125,Colitis,Gastrointestinal disorders,Yes,15%,359,5,9,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 1,359
NCT44253125,Colitis,Gastrointestinal disorders,Yes,5%,359,15,16,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 1,359
NCT44253125,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,359,9,12,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 1,359
NCT44253125,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,359,22,33,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 1,359
NCT44253125,Colitis,Gastrointestinal disorders,Yes,10%,359,20,31,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 1,359
NCT44253125,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,359,23,34,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 1,359
NCT25404073,Hepatitis,Hepatobiliary disorders,Yes,5%,475,4,6,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 2,475
NCT25404073,Colitis,Gastrointestinal disorders,Yes,15%,475,1,2,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 2,475
NCT25404073,Colitis,Gastrointestinal disorders,Yes,10%,475,45,59,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 2,475
NCT68692331,Hepatitis,Hepatobiliary disorders,Yes,15%,779,49,65,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 2,779
NCT68692331,Colitis,Gastrointestinal disorders,Yes,10%,779,31,61,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 2,779
NCT68692331,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,779,9,10,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 2,779
NCT68692331,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,779,24,29,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 2,779
NCT73424244,Hepatitis,Hepatobiliary disorders,Yes,10%,306,11,13,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 2,306
NCT73424244,Colitis,Gastrointestinal disorders,Yes,10%,306,12,24,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 2,306
NCT73424244,Hepatitis,Hepatobiliary disorders,Yes,10%,306,26,27,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 2,306
NCT73424244,Hepatitis,Hepatobiliary disorders,Yes,10%,306,5,5,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 2,306
NCT73424244,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,306,28,49,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 2,306
NCT73424244,Colitis,Gastrointestinal disorders,Yes,10%,306,29,51,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 2,306
NCT73424244,Hepatitis,Hepatobiliary disorders,Yes,10%,306,22,33,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 2,306
NCT73424244,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,306,23,27,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 2,306
NCT73424244,Colitis,Gastrointestinal disorders,Yes,5%,306,30,48,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 2,306
NCT41033207,Hepatitis,Hepatobiliary disorders,Yes,10%,57,3,3,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,57
NCT41033207,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,57,1,1,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,57
NCT41033207,Colitis,Gastrointestinal disorders,Yes,15%,57,3,3,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,57
NCT41033207,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,57,1,2,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,57
NCT41033207,Colitis,Gastrointestinal disorders,Yes,10%,57,2,2,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,57
NCT41033207,Hepatitis,Hepatobiliary disorders,Yes,5%,57,4,5,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,57
NCT41033207,Hepatitis,Hepatobiliary disorders,Yes,5%,57,3,4,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,57
NCT41033207,Hepatitis,Hepatobiliary disorders,Yes,10%,57,1,2,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,57
NCT41033207,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,57,5,9,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,57
NCT41033207,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,57,4,6,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,57
NCT41033207,Colitis,Gastrointestinal disorders,Yes,15%,57,1,2,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,57
NCT41033207,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,57,1,1,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,57
NCT41033207,Hepatitis,Hepatobiliary disorders,Yes,10%,57,1,1,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,57
NCT12959918,Hepatitis,Hepatobiliary disorders,Yes,5%,819,8,16,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,819
NCT12959918,Colitis,Gastrointestinal disorders,Yes,5%,819,27,30,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,819
NCT12959918,Hepatitis,Hepatobiliary disorders,Yes,15%,819,32,33,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,819
NCT12959918,Colitis,Gastrointestinal disorders,Yes,10%,819,8,10,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,819
NCT12959918,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,819,43,75,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,819
NCT12959918,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,819,16,23,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,819
NCT12959918,Colitis,Gastrointestinal disorders,Yes,5%,819,4,8,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,819
NCT12959918,Colitis,Gastrointestinal disorders,Yes,5%,819,2,4,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,819
NCT12959918,Hepatitis,Hepatobiliary disorders,Yes,10%,819,29,34,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,819
NCT12959918,Colitis,Gastrointestinal disorders,Yes,10%,819,4,4,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,819
NCT12959918,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,819,5,9,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,819
NCT12959918,Hepatitis,Hepatobiliary disorders,Yes,10%,819,31,55,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,819
NCT12959918,Hepatitis,Hepatobiliary disorders,Yes,15%,819,20,23,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,819
NCT12959918,Hepatitis,Hepatobiliary disorders,Yes,5%,819,45,76,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,819
NCT24693985,Hepatitis,Hepatobiliary disorders,Yes,15%,448,44,67,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,448
NCT24693985,Hepatitis,Hepatobiliary disorders,Yes,5%,448,16,17,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,448
NCT24693985,Hepatitis,Hepatobiliary disorders,Yes,15%,448,37,69,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,448
NCT24693985,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,448,13,24,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,448
NCT24693985,Colitis,Gastrointestinal disorders,Yes,5%,448,40,75,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,448
NCT24693985,Colitis,Gastrointestinal disorders,Yes,15%,448,7,14,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,448
NCT24693985,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,448,14,14,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,448
NCT24693985,Hepatitis,Hepatobiliary disorders,Yes,5%,448,37,57,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,448
NCT24693985,Colitis,Gastrointestinal disorders,Yes,10%,448,37,64,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,448
NCT24693985,Colitis,Gastrointestinal disorders,Yes,15%,448,9,16,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,448
NCT24693985,Colitis,Gastrointestinal disorders,Yes,10%,448,26,43,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,448
NCT24693985,Colitis,Gastrointestinal disorders,Yes,15%,448,43,84,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 3,448
NCT54177517,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,426,32,46,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 4,426
NCT54177517,Colitis,Gastrointestinal disorders,Yes,15%,426,28,56,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 4,426
NCT54177517,Hepatitis,Hepatobiliary disorders,Yes,10%,426,12,19,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 4,426
NCT54177517,Colitis,Gastrointestinal disorders,Yes,10%,426,38,54,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 4,426
NCT63485508,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,686,45,52,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 4,686
NCT63485508,Hepatitis,Hepatobiliary disorders,Yes,10%,686,33,45,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 4,686
NCT63485508,Colitis,Gastrointestinal disorders,Yes,5%,686,49,91,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 4,686
NCT63485508,Colitis,Gastrointestinal disorders,Yes,5%,686,32,39,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 4,686
NCT63485508,Colitis,Gastrointestinal disorders,Yes,10%,686,27,36,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 4,686
NCT63485508,Colitis,Gastrointestinal disorders,Yes,15%,686,1,2,All Causality,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 4,686
NCT63485508,Colitis,Gastrointestinal disorders,Yes,15%,686,8,11,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 4,686
NCT63485508,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,686,41,70,Treatment Emergent,Cemiplimab,Anti-PD-1,Lung Cancer,Phase 4,686
NCT12530506,Colitis,Gastrointestinal disorders,Yes,15%,803,31,53,Treatment Emergent,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,803
NCT12530506,Colitis,Gastrointestinal disorders,Yes,10%,803,15,15,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,803
NCT12530506,Hepatitis,Hepatobiliary disorders,Yes,5%,803,31,34,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,803
NCT12530506,Hepatitis,Hepatobiliary disorders,Yes,5%,803,17,21,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,803
NCT12530506,Hepatitis,Hepatobiliary disorders,Yes,15%,803,3,6,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,803
NCT12530506,Hepatitis,Hepatobiliary disorders,Yes,5%,803,47,58,Treatment Emergent,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,803
NCT12530506,Colitis,Gastrointestinal disorders,Yes,10%,803,46,48,Treatment Emergent,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,803
NCT12530506,Hepatitis,Hepatobiliary disorders,Yes,10%,803,36,60,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,803
NCT12530506,Hepatitis,Hepatobiliary disorders,Yes,10%,803,15,16,Treatment Emergent,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,803
NCT12530506,Colitis,Gastrointestinal disorders,Yes,5%,803,36,66,Treatment Emergent,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,803
NCT12530506,Hepatitis,Hepatobiliary disorders,Yes,10%,803,15,24,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,803
NCT12530506,Hepatitis,Hepatobiliary disorders,Yes,15%,803,49,52,Treatment Emergent,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,803
NCT12530506,Colitis,Gastrointestinal disorders,Yes,5%,803,41,63,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,803
NCT12530506,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,803,44,64,Treatment Emergent,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,803
NCT12530506,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,803,42,58,Treatment Emergent,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,803
NCT72297871,Colitis,Gastrointestinal disorders,Yes,5%,153,7,9,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,153
NCT72297871,Hepatitis,Hepatobiliary disorders,Yes,10%,153,4,6,Treatment Emergent,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,153
NCT72297871,Colitis,Gastrointestinal disorders,Yes,10%,153,7,8,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,153
NCT72297871,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,153,15,23,Treatment Emergent,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,153
NCT72297871,Colitis,Gastrointestinal disorders,Yes,15%,153,2,2,Treatment Emergent,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,153
NCT72297871,Colitis,Gastrointestinal disorders,Yes,5%,153,1,2,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,153
NCT72297871,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,153,6,8,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,153
NCT72297871,Colitis,Gastrointestinal disorders,Yes,5%,153,11,15,Treatment Emergent,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,153
NCT72297871,Hepatitis,Hepatobiliary disorders,Yes,10%,153,1,2,Treatment Emergent,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,153
NCT24136200,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,70,7,9,Treatment Emergent,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,70
NCT24136200,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,70,6,7,Treatment Emergent,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,70
NCT24136200,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,15%,70,3,4,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,70
NCT24136200,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,70,4,6,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,70
NCT24136200,Colitis,Gastrointestinal disorders,Yes,10%,70,6,10,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 1,70
NCT21710226,Colitis,Gastrointestinal disorders,Yes,10%,495,6,6,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 2,495
NCT21710226,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,495,41,56,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 2,495
NCT21710226,Colitis,Gastrointestinal disorders,Yes,15%,495,4,5,Treatment Emergent,Cemiplimab,Anti-PD-1,Lymphoma,Phase 2,495
NCT21710226,Colitis,Gastrointestinal disorders,Yes,5%,495,45,83,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 2,495
NCT21710226,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,495,7,11,Treatment Emergent,Cemiplimab,Anti-PD-1,Lymphoma,Phase 2,495
NCT21710226,Colitis,Gastrointestinal disorders,Yes,10%,495,29,39,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 2,495
NCT21710226,Colitis,Gastrointestinal disorders,Yes,15%,495,33,58,Treatment Emergent,Cemiplimab,Anti-PD-1,Lymphoma,Phase 2,495
NCT21710226,Colitis,Gastrointestinal disorders,Yes,5%,495,7,8,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 2,495
NCT21710226,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,495,18,26,Treatment Emergent,Cemiplimab,Anti-PD-1,Lymphoma,Phase 2,495
NCT21710226,Colitis,Gastrointestinal disorders,Yes,10%,495,19,38,Treatment Emergent,Cemiplimab,Anti-PD-1,Lymphoma,Phase 2,495
NCT21710226,Hepatitis,Hepatobiliary disorders,Yes,15%,495,10,10,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 2,495
NCT21710226,Hepatitis,Hepatobiliary disorders,Yes,15%,495,31,50,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 2,495
NCT39801497,Hepatitis,Hepatobiliary disorders,Yes,10%,27,2,4,Treatment Emergent,Cemiplimab,Anti-PD-1,Lymphoma,Phase 2,27
NCT39801497,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,27,2,3,Treatment Emergent,Cemiplimab,Anti-PD-1,Lymphoma,Phase 2,27
NCT39801497,Colitis,Gastrointestinal disorders,Yes,5%,27,2,3,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 2,27
NCT39801497,Colitis,Gastrointestinal disorders,Yes,5%,27,1,2,Treatment Emergent,Cemiplimab,Anti-PD-1,Lymphoma,Phase 2,27
NCT39801497,Hepatitis,Hepatobiliary disorders,Yes,10%,27,1,2,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 2,27
NCT39801497,Hepatitis,Hepatobiliary disorders,Yes,5%,27,1,2,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 2,27
NCT39801497,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,10%,27,2,4,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 2,27
NCT67291114,Colitis,Gastrointestinal disorders,Yes,10%,480,4,6,Treatment Emergent,Cemiplimab,Anti-PD-1,Lymphoma,Phase 3,480
NCT67291114,Colitis,Gastrointestinal disorders,Yes,5%,480,27,33,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 3,480
NCT67291114,Colitis,Gastrointestinal disorders,Yes,5%,480,5,9,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 3,480
NCT87668614,Colitis,Gastrointestinal disorders,Yes,10%,347,28,33,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 3,347
NCT87668614,Hepatitis,Hepatobiliary disorders,Yes,15%,347,33,34,Treatment Emergent,Cemiplimab,Anti-PD-1,Lymphoma,Phase 3,347
NCT87668614,Pneumonitis,"Respiratory, thoracic and mediastinal disorders",Yes,5%,347,31,31,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 3,347
NCT25829882,Hepatitis,Hepatobiliary disorders,Yes,10%,530,22,31,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 4,530
NCT25829882,Hepatitis,Hepatobiliary disorders,Yes,15%,530,37,62,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 4,530
NCT25829882,Colitis,Gastrointestinal disorders,Yes,15%,530,48,81,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 4,530
NCT25829882,Hepatitis,Hepatobiliary disorders,Yes,10%,530,15,16,Treatment Emergent,Cemiplimab,Anti-PD-1,Lymphoma,Phase 4,530
NCT25829882,Colitis,Gastrointestinal disorders,Yes,15%,530,48,86,Treatment Emergent,Cemiplimab,Anti-PD-1,Lymphoma,Phase 4,530
NCT25829882,Colitis,Gastrointestinal disorders,Yes,5%,530,23,41,Treatment Emergent,Cemiplimab,Anti-PD-1,Lymphoma,Phase 4,530
NCT25829882,Colitis,Gastrointestinal disorders,Yes,15%,530,23,45,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 4,530
NCT25829882,Hepatitis,Hepatobiliary disorders,Yes,10%,530,1,1,All Causality,Cemiplimab,Anti-PD-1,Lymphoma,Phase 4,530
NCT33583694,Fatigue,General disorders and administration site conditions,No,15%,527,29,56,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,527
NCT33583694,Fatigue,General disorders and administration site conditions,No,15%,527,45,65,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,527
NCT33583694,Fatigue,General disorders and administration site conditions,No,10%,527,38,39,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,527
NCT33583694,Fatigue,General disorders and administration site conditions,No,5%,527,24,36,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,527
NCT33583694,Fatigue,General disorders and administration site conditions,No,15%,527,7,10,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,527
NCT33583694,Fatigue,General disorders and administration site conditions,No,5%,527,26,30,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,527
NCT33583694,Fatigue,General disorders and administration site conditions,No,5%,527,1,1,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,527
NCT33583694,Fatigue,General disorders and administration site conditions,No,5%,527,31,55,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,527
NCT46034490,Fatigue,General disorders and administration site conditions,No,15%,784,38,52,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,784
NCT46034490,Fatigue,General disorders and administration site conditions,No,15%,784,30,39,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,784
NCT46034490,Fatigue,General disorders and administration site conditions,No,5%,784,3,6,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,784
NCT46034490,Fatigue,General disorders and administration site conditions,No,15%,784,49,85,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,784
NCT46034490,Fatigue,General disorders and administration site conditions,No,10%,784,4,8,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,784
NCT46034490,Fatigue,General disorders and administration site conditions,No,10%,784,31,33,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,784
NCT46034490,Fatigue,General disorders and administration site conditions,No,15%,784,13,16,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,784
NCT46034490,Fatigue,General disorders and administration site conditions,No,5%,784,43,65,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,784
NCT46034490,Fatigue,General disorders and administration site conditions,No,15%,784,33,56,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,784
NCT46034490,Fatigue,General disorders and administration site conditions,No,5%,784,6,9,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,784
NCT66716385,Fatigue,General disorders and administration site conditions,No,5%,259,5,5,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,259
NCT66716385,Fatigue,General disorders and administration site conditions,No,10%,259,22,25,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,259
NCT66716385,Fatigue,General disorders and administration site conditions,No,10%,259,2,3,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,259
NCT66716385,Fatigue,General disorders and administration site conditions,No,15%,259,10,18,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,259
NCT66716385,Fatigue,General disorders and administration site conditions,No,15%,259,8,10,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,259
NCT66716385,Fatigue,General disorders and administration site conditions,No,5%,259,10,19,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 1,259
NCT65899919,Fatigue,General disorders and administration site conditions,No,15%,420,7,10,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,420
NCT65899919,Fatigue,General disorders and administration site conditions,No,5%,420,33,36,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,420
NCT65899919,Fatigue,General disorders and administration site conditions,No,5%,420,19,32,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,420
NCT65899919,Fatigue,General disorders and administration site conditions,No,5%,420,40,63,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,420
NCT65899919,Fatigue,General disorders and administration site conditions,No,5%,420,26,47,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,420
NCT65899919,Fatigue,General disorders and administration site conditions,No,5%,420,12,24,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,420
NCT65899919,Fatigue,General disorders and administration site conditions,No,5%,420,14,20,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,420
NCT65899919,Fatigue,General disorders and administration site conditions,No,15%,420,36,55,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,420
NCT65899919,Fatigue,General disorders and administration site conditions,No,10%,420,7,14,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,420
NCT65899919,Fatigue,General disorders and administration site conditions,No,5%,420,36,68,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,420
NCT65899919,Fatigue,General disorders and administration site conditions,No,5%,420,26,33,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,420
NCT65899919,Fatigue,General disorders and administration site conditions,No,5%,420,29,53,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,420
NCT80575300,Fatigue,General disorders and administration site conditions,No,10%,426,12,20,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,426
NCT80575300,Fatigue,General disorders and administration site conditions,No,15%,426,31,35,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,426
NCT80575300,Fatigue,General disorders and administration site conditions,No,15%,426,39,48,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,426
NCT80575300,Fatigue,General disorders and administration site conditions,No,5%,426,11,18,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,426
NCT80575300,Fatigue,General disorders and administration site conditions,No,5%,426,26,51,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,426
NCT80575300,Fatigue,General disorders and administration site conditions,No,5%,426,22,40,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,426
NCT80575300,Fatigue,General disorders and administration site conditions,No,10%,426,40,79,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,426
NCT80575300,Fatigue,General disorders and administration site conditions,No,10%,426,8,14,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,426
NCT80575300,Fatigue,General disorders and administration site conditions,No,5%,426,10,12,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,426
NCT80575300,Fatigue,General disorders and administration site conditions,No,15%,426,30,55,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,426
NCT80575300,Fatigue,General disorders and administration site conditions,No,15%,426,14,28,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,426
NCT80575300,Fatigue,General disorders and administration site conditions,No,10%,426,19,31,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,426
NCT80575300,Fatigue,General disorders and administration site conditions,No,10%,426,15,30,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,426
NCT80575300,Fatigue,General disorders and administration site conditions,No,10%,426,25,49,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,426
NCT80575300,Fatigue,General disorders and administration site conditions,No,5%,426,2,3,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 2,426
NCT75681869,Fatigue,General disorders and administration site conditions,No,5%,552,47,69,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,552
NCT75681869,Fatigue,General disorders and administration site conditions,No,5%,552,14,22,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,552
NCT75681869,Fatigue,General disorders and administration site conditions,No,10%,552,43,74,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,552
NCT75681869,Fatigue,General disorders and administration site conditions,No,15%,552,42,54,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,552
NCT75681869,Fatigue,General disorders and administration site conditions,No,15%,552,29,42,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,552
NCT75681869,Fatigue,General disorders and administration site conditions,No,5%,552,36,41,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,552
NCT75681869,Fatigue,General disorders and administration site conditions,No,5%,552,40,79,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,552
NCT75681869,Fatigue,General disorders and administration site conditions,No,10%,552,30,30,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,552
NCT75681869,Fatigue,General disorders and administration site conditions,No,10%,552,21,34,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,552
NCT75681869,Fatigue,General disorders and administration site conditions,No,10%,552,11,22,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,552
NCT75681869,Fatigue,General disorders and administration site conditions,No,5%,552,22,30,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,552
NCT75681869,Fatigue,General disorders and administration site conditions,No,15%,552,39,67,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,552
NCT75681869,Fatigue,General disorders and administration site conditions,No,5%,552,18,23,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,552
NCT75681869,Fatigue,General disorders and administration site conditions,No,5%,552,18,21,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,552
NCT75681869,Fatigue,General disorders and administration site conditions,No,15%,552,27,27,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 3,552
NCT96504389,Fatigue,General disorders and administration site conditions,No,5%,541,8,14,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 4,541
NCT96504389,Fatigue,General disorders and administration site conditions,No,5%,541,18,25,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 4,541
NCT96504389,Fatigue,General disorders and administration site conditions,No,5%,541,17,33,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 4,541
NCT96504389,Fatigue,General disorders and administration site conditions,No,15%,541,47,79,Treatment Emergent,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 4,541
NCT96504389,Fatigue,General disorders and administration site conditions,No,10%,541,11,19,All Causality,Atezolizumab,Anti-PD-L1,Lung Cancer,Phase 4,541
NCT46042865,Fatigue,General disorders and administration site conditions,No,15%,372,8,10,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,372
NCT46042865,Fatigue,General disorders and administration site conditions,No,15%,372,17,23,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,372
NCT46042865,Fatigue,General disorders and administration site conditions,No,5%,372,9,17,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,372
NCT46042865,Fatigue,General disorders and administration site conditions,No,10%,372,27,48,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,372
NCT46042865,Fatigue,General disorders and administration site conditions,No,5%,372,27,34,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,372
NCT46042865,Fatigue,General disorders and administration site conditions,No,10%,372,27,34,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,372
NCT46042865,Fatigue,General disorders and administration site conditions,No,10%,372,6,12,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,372
NCT46042865,Fatigue,General disorders and administration site conditions,No,15%,372,27,39,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,372
NCT46042865,Fatigue,General disorders and administration site conditions,No,5%,372,2,3,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,372
NCT46042865,Fatigue,General disorders and administration site conditions,No,5%,372,22,31,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,372
NCT46042865,Fatigue,General disorders and administration site conditions,No,15%,372,26,39,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,372
NCT46042865,Fatigue,General disorders and administration site conditions,No,15%,372,17,23,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,372
NCT46042865,Fatigue,General disorders and administration site conditions,No,10%,372,25,26,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,372
NCT46042865,Fatigue,General disorders and administration site conditions,No,5%,372,23,43,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,372
NCT46042865,Fatigue,General disorders and administration site conditions,No,10%,372,14,23,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,372
NCT64054453,Fatigue,General disorders and administration site conditions,No,10%,379,10,19,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,379
NCT64054453,Fatigue,General disorders and administration site conditions,No,15%,379,12,24,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,379
NCT64054453,Fatigue,General disorders and administration site conditions,No,15%,379,20,31,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,379
NCT64054453,Fatigue,General disorders and administration site conditions,No,5%,379,20,22,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,379
NCT64054453,Fatigue,General disorders and administration site conditions,No,5%,379,9,12,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,379
NCT64054453,Fatigue,General disorders and administration site conditions,No,10%,379,24,48,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,379
NCT99658277,Fatigue,General disorders and administration site conditions,No,5%,502,11,21,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,502
NCT99658277,Fatigue,General disorders and administration site conditions,No,10%,502,5,7,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,502
NCT99658277,Fatigue,General disorders and administration site conditions,No,15%,502,31,35,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,502
NCT99658277,Fatigue,General disorders and administration site conditions,No,5%,502,20,39,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,502
NCT99658277,Fatigue,General disorders and administration site conditions,No,15%,502,32,35,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,502
NCT99658277,Fatigue,General disorders and administration site conditions,No,15%,502,2,2,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,502
NCT99658277,Fatigue,General disorders and administration site conditions,No,15%,502,10,16,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,502
NCT99658277,Fatigue,General disorders and administration site conditions,No,15%,502,33,54,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 1,502
NCT88131226,Fatigue,General disorders and administration site conditions,No,10%,913,5,8,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,913
NCT88131226,Fatigue,General disorders and administration site conditions,No,10%,913,37,54,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,913
NCT88131226,Fatigue,General disorders and administration site conditions,No,15%,913,28,46,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,913
NCT88131226,Fatigue,General disorders and administration site conditions,No,5%,913,29,34,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,913
NCT88131226,Fatigue,General disorders and administration site conditions,No,5%,913,7,8,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,913
NCT88131226,Fatigue,General disorders and administration site conditions,No,15%,913,32,51,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,913
NCT88131226,Fatigue,General disorders and administration site conditions,No,10%,913,32,37,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,913
NCT88131226,Fatigue,General disorders and administration site conditions,No,15%,913,17,20,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,913
NCT88131226,Fatigue,General disorders and administration site conditions,No,10%,913,31,46,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,913
NCT88131226,Fatigue,General disorders and administration site conditions,No,5%,913,40,58,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,913
NCT88131226,Fatigue,General disorders and administration site conditions,No,15%,913,28,56,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,913
NCT56751684,Fatigue,General disorders and administration site conditions,No,5%,117,6,12,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,117
NCT56751684,Fatigue,General disorders and administration site conditions,No,10%,117,5,5,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,117
NCT56751684,Fatigue,General disorders and administration site conditions,No,5%,117,2,2,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,117
NCT56751684,Fatigue,General disorders and administration site conditions,No,10%,117,11,12,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,117
NCT56751684,Fatigue,General disorders and administration site conditions,No,5%,117,9,17,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,117
NCT56751684,Fatigue,General disorders and administration site conditions,No,15%,117,1,1,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,117
NCT56751684,Fatigue,General disorders and administration site conditions,No,5%,117,3,4,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,117
NCT56751684,Fatigue,General disorders and administration site conditions,No,10%,117,4,6,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,117
NCT56751684,Fatigue,General disorders and administration site conditions,No,5%,117,1,1,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,117
NCT56751684,Fatigue,General disorders and administration site conditions,No,5%,117,7,7,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,117
NCT91343847,Fatigue,General disorders and administration site conditions,No,15%,85,2,3,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,85
NCT91343847,Fatigue,General disorders and administration site conditions,No,15%,85,4,7,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,85
NCT91343847,Fatigue,General disorders and administration site conditions,No,5%,85,3,5,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,85
NCT91343847,Fatigue,General disorders and administration site conditions,No,5%,85,3,6,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,85
NCT91343847,Fatigue,General disorders and administration site conditions,No,15%,85,7,14,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,85
NCT91343847,Fatigue,General disorders and administration site conditions,No,15%,85,5,7,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,85
NCT91343847,Fatigue,General disorders and administration site conditions,No,5%,85,1,2,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,85
NCT91343847,Fatigue,General disorders and administration site conditions,No,10%,85,6,10,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 2,85
NCT98559134,Fatigue,General disorders and administration site conditions,No,10%,565,13,22,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 3,565
NCT98559134,Fatigue,General disorders and administration site conditions,No,5%,565,8,13,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 3,565
NCT98559134,Fatigue,General disorders and administration site conditions,No,15%,565,22,30,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 3,565
NCT98559134,Fatigue,General disorders and administration site conditions,No,15%,565,41,69,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 3,565
NCT70109965,Fatigue,General disorders and administration site conditions,No,15%,871,22,35,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 4,871
NCT70109965,Fatigue,General disorders and administration site conditions,No,10%,871,44,72,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 4,871
NCT70109965,Fatigue,General disorders and administration site conditions,No,5%,871,29,47,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 4,871
NCT70109965,Fatigue,General disorders and administration site conditions,No,15%,871,37,60,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 4,871
NCT70109965,Fatigue,General disorders and administration site conditions,No,10%,871,45,53,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 4,871
NCT70109965,Fatigue,General disorders and administration site conditions,No,15%,871,29,49,All Causality,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 4,871
NCT70109965,Fatigue,General disorders and administration site conditions,No,15%,871,39,63,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 4,871
NCT70109965,Fatigue,General disorders and administration site conditions,No,5%,871,40,65,Treatment Emergent,Atezolizumab,Anti-PD-L1,Bladder Cancer,Phase 4,871
NCT75862657,Fatigue,General disorders and administration site conditions,No,10%,229,10,10,All Causality,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 1,229
NCT75862657,Fatigue,General disorders and administration site conditions,No,15%,229,16,24,Treatment Emergent,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 1,229
NCT75862657,Fatigue,General disorders and administration site conditions,No,15%,229,7,7,All Causality,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 1,229
NCT76824808,Fatigue,General disorders and administration site conditions,No,5%,152,14,25,All Causality,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 2,152
NCT76824808,Fatigue,General disorders and administration site conditions,No,10%,152,11,21,All Causality,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 2,152
NCT76824808,Fatigue,General disorders and administration site conditions,No,10%,152,5,5,All Causality,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 2,152
NCT76824808,Fatigue,General disorders and administration site conditions,No,15%,152,2,4,Treatment Emergent,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 2,152
NCT76824808,Fatigue,General disorders and administration site conditions,No,10%,152,10,18,Treatment Emergent,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 2,152
NCT25629315,Fatigue,General disorders and administration site conditions,No,15%,21,2,3,All Causality,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 2,21
NCT25629315,Fatigue,General disorders and administration site conditions,No,15%,21,2,2,Treatment Emergent,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 2,21
NCT25629315,Fatigue,General disorders and administration site conditions,No,5%,21,1,1,All Causality,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 2,21
NCT25629315,Fatigue,General disorders and administration site conditions,No,5%,21,1,1,Treatment Emergent,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 2,21
NCT25629315,Fatigue,General disorders and administration site conditions,No,15%,21,2,3,Treatment Emergent,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 2,21
NCT25629315,Fatigue,General disorders and administration site conditions,No,5%,21,2,4,All Causality,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 2,21
NCT25629315,Fatigue,General disorders and administration site conditions,No,15%,21,1,1,Treatment Emergent,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 2,21
NCT25629315,Fatigue,General disorders and administration site conditions,No,10%,21,1,2,Treatment Emergent,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 2,21
NCT25629315,Fatigue,General disorders and administration site conditions,No,10%,21,2,3,Treatment Emergent,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 2,21
NCT32803597,Fatigue,General disorders and administration site conditions,No,10%,955,1,2,Treatment Emergent,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 2,955
NCT32803597,Fatigue,General disorders and administration site conditions,No,5%,955,18,32,All Causality,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 2,955
NCT32803597,Fatigue,General disorders and administration site conditions,No,10%,955,41,59,Treatment Emergent,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 2,955
NCT32803597,Fatigue,General disorders and administration site conditions,No,10%,955,24,26,All Causality,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 2,955
NCT32803597,Fatigue,General disorders and administration site conditions,No,10%,955,6,8,All Causality,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 2,955
NCT32803597,Fatigue,General disorders and administration site conditions,No,10%,955,12,16,All Causality,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 2,955
NCT32803597,Fatigue,General disorders and administration site conditions,No,5%,955,35,61,All Causality,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 2,955
NCT32803597,Fatigue,General disorders and administration site conditions,No,5%,955,36,37,Treatment Emergent,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 2,955
NCT32803597,Fatigue,General disorders and administration site conditions,No,15%,955,6,10,Treatment Emergent,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 2,955
NCT32803597,Fatigue,General disorders and administration site conditions,No,15%,955,28,45,Treatment Emergent,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 2,955
NCT32803597,Fatigue,General disorders and administration site conditions,No,5%,955,28,31,Treatment Emergent,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 2,955
NCT32803597,Fatigue,General disorders and administration site conditions,No,10%,955,15,29,All Causality,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 2,955
NCT67098592,Fatigue,General disorders and administration site conditions,No,5%,849,47,63,All Causality,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 3,849
NCT67098592,Fatigue,General disorders and administration site conditions,No,15%,849,6,9,All Causality,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 3,849
NCT67098592,Fatigue,General disorders and administration site conditions,No,10%,849,14,23,Treatment Emergent,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 3,849
NCT67098592,Fatigue,General disorders and administration site conditions,No,5%,849,12,12,Treatment Emergent,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 3,849
NCT67098592,Fatigue,General disorders and administration site conditions,No,15%,849,47,71,Treatment Emergent,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 3,849
NCT67098592,Fatigue,General disorders and administration site conditions,No,10%,849,7,8,All Causality,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 3,849
NCT88982673,Fatigue,General disorders and administration site conditions,No,15%,934,2,3,Treatment Emergent,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 4,934
NCT88982673,Fatigue,General disorders and administration site conditions,No,15%,934,16,31,Treatment Emergent,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 4,934
NCT88982673,Fatigue,General disorders and administration site conditions,No,10%,934,39,49,Treatment Emergent,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 4,934
NCT88982673,Fatigue,General disorders and administration site conditions,No,10%,934,34,34,All Causality,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 4,934
NCT88982673,Fatigue,General disorders and administration site conditions,No,5%,934,4,6,All Causality,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 4,934
NCT88982673,Fatigue,General disorders and administration site conditions,No,5%,934,36,49,All Causality,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 4,934
NCT88982673,Fatigue,General disorders and administration site conditions,No,10%,934,9,16,Treatment Emergent,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 4,934
NCT88982673,Fatigue,General disorders and administration site conditions,No,15%,934,9,15,All Causality,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 4,934
NCT88982673,Fatigue,General disorders and administration site conditions,No,15%,934,33,45,All Causality,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 4,934
NCT88982673,Fatigue,General disorders and administration site conditions,No,10%,934,31,45,Treatment Emergent,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 4,934
NCT88982673,Fatigue,General disorders and administration site conditions,No,10%,934,19,36,All Causality,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 4,934
NCT88982673,Fatigue,General disorders and administration site conditions,No,15%,934,6,10,All Causality,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 4,934
NCT73325873,Fatigue,General disorders and administration site conditions,No,15%,854,37,59,All Causality,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 4,854
NCT73325873,Fatigue,General disorders and administration site conditions,No,15%,854,32,56,All Causality,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 4,854
NCT73325873,Fatigue,General disorders and administration site conditions,No,5%,854,27,35,Treatment Emergent,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 4,854
NCT73325873,Fatigue,General disorders and administration site conditions,No,5%,854,10,18,All Causality,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 4,854
NCT73325873,Fatigue,General disorders and administration site conditions,No,5%,854,41,52,Treatment Emergent,Atezolizumab,Anti-PD-L1,Breast Cancer,Phase 4,854
NCT69726904,Fatigue,General disorders and administration site conditions,No,10%,419,11,11,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 1,419
NCT69726904,Fatigue,General disorders and administration site conditions,No,10%,419,4,8,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 1,419
NCT69726904,Fatigue,General disorders and administration site conditions,No,10%,419,21,31,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 1,419
NCT69726904,Fatigue,General disorders and administration site conditions,No,10%,419,8,10,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 1,419
NCT69726904,Fatigue,General disorders and administration site conditions,No,5%,419,13,22,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 1,419
NCT69726904,Fatigue,General disorders and administration site conditions,No,15%,419,21,27,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 1,419
NCT69726904,Fatigue,General disorders and administration site conditions,No,15%,419,19,22,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 1,419
NCT69726904,Fatigue,General disorders and administration site conditions,No,5%,419,1,1,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 1,419
NCT53036638,Fatigue,General disorders and administration site conditions,No,10%,345,10,14,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 1,345
NCT53036638,Fatigue,General disorders and administration site conditions,No,5%,345,20,28,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 1,345
NCT53036638,Fatigue,General disorders and administration site conditions,No,5%,345,9,15,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 1,345
NCT53036638,Fatigue,General disorders and administration site conditions,No,15%,345,12,15,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 1,345
NCT53036638,Fatigue,General disorders and administration site conditions,No,15%,345,13,24,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 1,345
NCT53036638,Fatigue,General disorders and administration site conditions,No,10%,345,21,22,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 1,345
NCT85353811,Fatigue,General disorders and administration site conditions,No,15%,541,17,21,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 1,541
NCT85353811,Fatigue,General disorders and administration site conditions,No,5%,541,39,78,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 1,541
NCT85353811,Fatigue,General disorders and administration site conditions,No,10%,541,25,25,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 1,541
NCT85353811,Fatigue,General disorders and administration site conditions,No,10%,541,11,13,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 1,541
NCT21304959,Fatigue,General disorders and administration site conditions,No,5%,888,2,3,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 2,888
NCT21304959,Fatigue,General disorders and administration site conditions,No,5%,888,25,35,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 2,888
NCT21304959,Fatigue,General disorders and administration site conditions,No,10%,888,2,4,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 2,888
NCT21304959,Fatigue,General disorders and administration site conditions,No,10%,888,4,4,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 2,888
NCT77829873,Fatigue,General disorders and administration site conditions,No,10%,899,34,54,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,899
NCT77829873,Fatigue,General disorders and administration site conditions,No,15%,899,20,40,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,899
NCT77829873,Fatigue,General disorders and administration site conditions,No,10%,899,24,46,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,899
NCT77829873,Fatigue,General disorders and administration site conditions,No,15%,899,43,61,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,899
NCT77829873,Fatigue,General disorders and administration site conditions,No,10%,899,23,36,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,899
NCT77829873,Fatigue,General disorders and administration site conditions,No,15%,899,24,46,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,899
NCT77829873,Fatigue,General disorders and administration site conditions,No,15%,899,34,65,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,899
NCT77829873,Fatigue,General disorders and administration site conditions,No,5%,899,30,30,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,899
NCT77829873,Fatigue,General disorders and administration site conditions,No,5%,899,26,37,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,899
NCT77829873,Fatigue,General disorders and administration site conditions,No,10%,899,36,48,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,899
NCT77829873,Fatigue,General disorders and administration site conditions,No,10%,899,48,77,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,899
NCT77829873,Fatigue,General disorders and administration site conditions,No,15%,899,22,35,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,899
NCT77829873,Fatigue,General disorders and administration site conditions,No,15%,899,40,65,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,899
NCT77829873,Fatigue,General disorders and administration site conditions,No,10%,899,45,81,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,899
NCT29437925,Fatigue,General disorders and administration site conditions,No,15%,616,33,48,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,616
NCT29437925,Fatigue,General disorders and administration site conditions,No,15%,616,9,11,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,616
NCT29437925,Fatigue,General disorders and administration site conditions,No,10%,616,44,61,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,616
NCT29437925,Fatigue,General disorders and administration site conditions,No,15%,616,18,32,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,616
NCT29437925,Fatigue,General disorders and administration site conditions,No,15%,616,34,41,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,616
NCT29437925,Fatigue,General disorders and administration site conditions,No,10%,616,41,42,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,616
NCT29437925,Fatigue,General disorders and administration site conditions,No,10%,616,5,10,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,616
NCT29437925,Fatigue,General disorders and administration site conditions,No,15%,616,38,56,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,616
NCT29437925,Fatigue,General disorders and administration site conditions,No,10%,616,18,36,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,616
NCT29437925,Fatigue,General disorders and administration site conditions,No,15%,616,39,68,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,616
NCT29437925,Fatigue,General disorders and administration site conditions,No,10%,616,33,62,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,616
NCT29437925,Fatigue,General disorders and administration site conditions,No,15%,616,28,55,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,616
NCT29437925,Fatigue,General disorders and administration site conditions,No,5%,616,5,5,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,616
NCT29437925,Fatigue,General disorders and administration site conditions,No,10%,616,7,12,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,616
NCT29437925,Fatigue,General disorders and administration site conditions,No,5%,616,10,11,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 3,616
NCT98990326,Fatigue,General disorders and administration site conditions,No,15%,529,29,50,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 4,529
NCT98990326,Fatigue,General disorders and administration site conditions,No,10%,529,17,26,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 4,529
NCT98990326,Fatigue,General disorders and administration site conditions,No,5%,529,26,36,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 4,529
NCT98990326,Fatigue,General disorders and administration site conditions,No,5%,529,36,70,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 4,529
NCT98990326,Fatigue,General disorders and administration site conditions,No,15%,529,40,68,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 4,529
NCT98990326,Fatigue,General disorders and administration site conditions,No,15%,529,46,55,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 4,529
NCT98990326,Fatigue,General disorders and administration site conditions,No,5%,529,35,43,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 4,529
NCT98990326,Fatigue,General disorders and administration site conditions,No,10%,529,8,12,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 4,529
NCT98990326,Fatigue,General disorders and administration site conditions,No,5%,529,45,71,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 4,529
NCT98990326,Fatigue,General disorders and administration site conditions,No,15%,529,32,48,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 4,529
NCT62312552,Fatigue,General disorders and administration site conditions,No,15%,83,2,4,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 4,83
NCT62312552,Fatigue,General disorders and administration site conditions,No,10%,83,2,4,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 4,83
NCT62312552,Fatigue,General disorders and administration site conditions,No,10%,83,7,10,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 4,83
NCT62312552,Fatigue,General disorders and administration site conditions,No,15%,83,3,4,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 4,83
NCT62312552,Fatigue,General disorders and administration site conditions,No,15%,83,5,5,Treatment Emergent,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 4,83
NCT62312552,Fatigue,General disorders and administration site conditions,No,10%,83,4,6,All Causality,Durvalumab,Anti-PD-L1,Lung Cancer,Phase 4,83
NCT10860513,Fatigue,General disorders and administration site conditions,No,15%,102,1,1,Treatment Emergent,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 1,102
NCT10860513,Fatigue,General disorders and administration site conditions,No,15%,102,9,12,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 1,102
NCT10860513,Fatigue,General disorders and administration site conditions,No,5%,102,1,2,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 1,102
NCT10860513,Fatigue,General disorders and administration site conditions,No,15%,102,6,10,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 1,102
NCT10860513,Fatigue,General disorders and administration site conditions,No,15%,102,8,13,Treatment Emergent,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 1,102
NCT10860513,Fatigue,General disorders and administration site conditions,No,5%,102,2,2,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 1,102
NCT10860513,Fatigue,General disorders and administration site conditions,No,5%,102,8,11,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 1,102
NCT10860513,Fatigue,General disorders and administration site conditions,No,10%,102,1,2,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 1,102
NCT10860513,Fatigue,General disorders and administration site conditions,No,10%,102,9,9,Treatment Emergent,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 1,102
NCT10860513,Fatigue,General disorders and administration site conditions,No,15%,102,6,9,Treatment Emergent,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 1,102
NCT10860513,Fatigue,General disorders and administration site conditions,No,15%,102,4,8,Treatment Emergent,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 1,102
NCT10860513,Fatigue,General disorders and administration site conditions,No,5%,102,3,6,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 1,102
NCT10860513,Fatigue,General disorders and administration site conditions,No,10%,102,6,12,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 1,102
NCT10860513,Fatigue,General disorders and administration site conditions,No,5%,102,10,16,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 1,102
NCT65333032,Fatigue,General disorders and administration site conditions,No,5%,871,3,6,Treatment Emergent,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 2,871
NCT65333032,Fatigue,General disorders and administration site conditions,No,15%,871,3,5,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 2,871
NCT65333032,Fatigue,General disorders and administration site conditions,No,15%,871,40,51,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 2,871
NCT65333032,Fatigue,General disorders and administration site conditions,No,15%,871,18,33,Treatment Emergent,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 2,871
NCT65333032,Fatigue,General disorders and administration site conditions,No,15%,871,17,21,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 2,871
NCT65333032,Fatigue,General disorders and administration site conditions,No,15%,871,41,68,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 2,871
NCT65333032,Fatigue,General disorders and administration site conditions,No,10%,871,25,29,Treatment Emergent,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 2,871
NCT65333032,Fatigue,General disorders and administration site conditions,No,5%,871,5,6,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 2,871
NCT65333032,Fatigue,General disorders and administration site conditions,No,10%,871,43,49,Treatment Emergent,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 2,871
NCT65333032,Fatigue,General disorders and administration site conditions,No,10%,871,38,62,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 2,871
NCT65333032,Fatigue,General disorders and administration site conditions,No,10%,871,28,47,Treatment Emergent,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 2,871
NCT65333032,Fatigue,General disorders and administration site conditions,No,10%,871,3,4,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 2,871
NCT70836974,Fatigue,General disorders and administration site conditions,No,5%,352,30,42,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 3,352
NCT70836974,Fatigue,General disorders and administration site conditions,No,10%,352,11,22,Treatment Emergent,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 3,352
NCT70836974,Fatigue,General disorders and administration site conditions,No,5%,352,22,26,Treatment Emergent,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 3,352
NCT70836974,Fatigue,General disorders and administration site conditions,No,5%,352,30,50,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 3,352
NCT70836974,Fatigue,General disorders and administration site conditions,No,15%,352,23,38,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 3,352
NCT70836974,Fatigue,General disorders and administration site conditions,No,10%,352,9,11,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 3,352
NCT70836974,Fatigue,General disorders and administration site conditions,No,10%,352,13,20,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 3,352
NCT50158543,Fatigue,General disorders and administration site conditions,No,10%,721,29,40,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 4,721
NCT50158543,Fatigue,General disorders and administration site conditions,No,15%,721,12,18,Treatment Emergent,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 4,721
NCT50158543,Fatigue,General disorders and administration site conditions,No,15%,721,14,27,Treatment Emergent,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 4,721
NCT50158543,Fatigue,General disorders and administration site conditions,No,5%,721,25,39,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 4,721
NCT50158543,Fatigue,General disorders and administration site conditions,No,5%,721,7,14,Treatment Emergent,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 4,721
NCT50158543,Fatigue,General disorders and administration site conditions,No,15%,721,27,35,Treatment Emergent,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 4,721
NCT50158543,Fatigue,General disorders and administration site conditions,No,15%,721,8,13,Treatment Emergent,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 4,721
NCT50158543,Fatigue,General disorders and administration site conditions,No,10%,721,50,85,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 4,721
NCT50158543,Fatigue,General disorders and administration site conditions,No,15%,721,35,62,Treatment Emergent,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 4,721
NCT16316498,Fatigue,General disorders and administration site conditions,No,15%,795,15,18,Treatment Emergent,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 4,795
NCT16316498,Fatigue,General disorders and administration site conditions,No,15%,795,15,30,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 4,795
NCT16316498,Fatigue,General disorders and administration site conditions,No,5%,795,23,29,Treatment Emergent,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 4,795
NCT16316498,Fatigue,General disorders and administration site conditions,No,15%,795,3,6,Treatment Emergent,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 4,795
NCT16316498,Fatigue,General disorders and administration site conditions,No,5%,795,19,19,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 4,795
NCT99530343,Fatigue,General disorders and administration site conditions,No,15%,398,23,34,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 4,398
NCT99530343,Fatigue,General disorders and administration site conditions,No,5%,398,39,68,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 4,398
NCT99530343,Fatigue,General disorders and administration site conditions,No,10%,398,32,34,Treatment Emergent,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 4,398
NCT99530343,Fatigue,General disorders and administration site conditions,No,15%,398,26,49,Treatment Emergent,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 4,398
NCT99530343,Fatigue,General disorders and administration site conditions,No,15%,398,30,36,All Causality,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 4,398
NCT99530343,Fatigue,General disorders and administration site conditions,No,10%,398,36,54,Treatment Emergent,Durvalumab,Anti-PD-L1,Bladder Cancer,Phase 4,398
NCT58137453,Fatigue,General disorders and administration site conditions,No,15%,584,27,37,Treatment Emergent,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 1,584
NCT58137453,Fatigue,General disorders and administration site conditions,No,5%,584,37,46,All Causality,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 1,584
NCT58137453,Fatigue,General disorders and administration site conditions,No,5%,584,41,64,All Causality,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 1,584
NCT58137453,Fatigue,General disorders and administration site conditions,No,15%,584,30,39,All Causality,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 1,584
NCT58137453,Fatigue,General disorders and administration site conditions,No,15%,584,49,92,All Causality,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 1,584
NCT58137453,Fatigue,General disorders and administration site conditions,No,10%,584,3,3,Treatment Emergent,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 1,584
NCT58137453,Fatigue,General disorders and administration site conditions,No,10%,584,2,2,All Causality,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 1,584
NCT44823892,Fatigue,General disorders and administration site conditions,No,10%,248,5,6,Treatment Emergent,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 2,248
NCT44823892,Fatigue,General disorders and administration site conditions,No,5%,248,4,6,All Causality,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 2,248
NCT44823892,Fatigue,General disorders and administration site conditions,No,15%,248,4,4,All Causality,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 2,248
NCT44823892,Fatigue,General disorders and administration site conditions,No,15%,248,8,9,All Causality,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 2,248
NCT44823892,Fatigue,General disorders and administration site conditions,No,10%,248,6,11,All Causality,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 2,248
NCT44823892,Fatigue,General disorders and administration site conditions,No,10%,248,5,8,All Causality,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 2,248
NCT51078860,Fatigue,General disorders and administration site conditions,No,5%,701,1,2,All Causality,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 3,701
NCT51078860,Fatigue,General disorders and administration site conditions,No,10%,701,15,18,Treatment Emergent,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 3,701
NCT51078860,Fatigue,General disorders and administration site conditions,No,5%,701,41,47,Treatment Emergent,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 3,701
NCT51078860,Fatigue,General disorders and administration site conditions,No,15%,701,26,29,Treatment Emergent,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 3,701
NCT55975214,Fatigue,General disorders and administration site conditions,No,10%,563,38,67,All Causality,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 3,563
NCT55975214,Fatigue,General disorders and administration site conditions,No,5%,563,22,23,Treatment Emergent,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 3,563
NCT55975214,Fatigue,General disorders and administration site conditions,No,10%,563,41,55,Treatment Emergent,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 3,563
NCT34466698,Fatigue,General disorders and administration site conditions,No,15%,944,29,36,Treatment Emergent,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 4,944
NCT34466698,Fatigue,General disorders and administration site conditions,No,10%,944,10,17,Treatment Emergent,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 4,944
NCT34466698,Fatigue,General disorders and administration site conditions,No,15%,944,20,28,Treatment Emergent,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 4,944
NCT34466698,Fatigue,General disorders and administration site conditions,No,10%,944,32,59,All Causality,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 4,944
NCT34466698,Fatigue,General disorders and administration site conditions,No,10%,944,11,13,Treatment Emergent,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 4,944
NCT34466698,Fatigue,General disorders and administration site conditions,No,5%,944,13,18,All Causality,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 4,944
NCT34466698,Fatigue,General disorders and administration site conditions,No,10%,944,34,48,Treatment Emergent,Durvalumab,Anti-PD-L1,Breast Cancer,Phase 4,944
NCT27298431,Fatigue,General disorders and administration site conditions,No,5%,964,37,69,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 1,964
NCT27298431,Fatigue,General disorders and administration site conditions,No,10%,964,14,22,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 1,964
NCT27298431,Fatigue,General disorders and administration site conditions,No,15%,964,34,36,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 1,964
NCT65573035,Fatigue,General disorders and administration site conditions,No,5%,291,28,55,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 1,291
NCT65573035,Fatigue,General disorders and administration site conditions,No,10%,291,10,12,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 1,291
NCT65573035,Fatigue,General disorders and administration site conditions,No,5%,291,11,22,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 1,291
NCT65573035,Fatigue,General disorders and administration site conditions,No,10%,291,3,4,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 1,291
NCT65573035,Fatigue,General disorders and administration site conditions,No,10%,291,27,40,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 1,291
NCT65573035,Fatigue,General disorders and administration site conditions,No,10%,291,26,35,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 1,291
NCT65573035,Fatigue,General disorders and administration site conditions,No,5%,291,18,21,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 1,291
NCT65573035,Fatigue,General disorders and administration site conditions,No,15%,291,6,9,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 1,291
NCT65573035,Fatigue,General disorders and administration site conditions,No,10%,291,10,19,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 1,291
NCT65573035,Fatigue,General disorders and administration site conditions,No,15%,291,18,32,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 1,291
NCT65573035,Fatigue,General disorders and administration site conditions,No,5%,291,10,12,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 1,291
NCT65573035,Fatigue,General disorders and administration site conditions,No,15%,291,1,1,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 1,291
NCT65573035,Fatigue,General disorders and administration site conditions,No,5%,291,16,23,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 1,291
NCT80442267,Fatigue,General disorders and administration site conditions,No,5%,323,7,14,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 1,323
NCT80442267,Fatigue,General disorders and administration site conditions,No,5%,323,24,36,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 1,323
NCT80442267,Fatigue,General disorders and administration site conditions,No,10%,323,11,13,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 1,323
NCT80442267,Fatigue,General disorders and administration site conditions,No,10%,323,5,8,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 1,323
NCT80442267,Fatigue,General disorders and administration site conditions,No,15%,323,20,29,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 1,323
NCT80442267,Fatigue,General disorders and administration site conditions,No,10%,323,23,38,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 1,323
NCT80442267,Fatigue,General disorders and administration site conditions,No,10%,323,29,32,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 1,323
NCT80442267,Fatigue,General disorders and administration site conditions,No,15%,323,22,25,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 1,323
NCT63997255,Fatigue,General disorders and administration site conditions,No,10%,835,28,33,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 2,835
NCT63997255,Fatigue,General disorders and administration site conditions,No,5%,835,50,95,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 2,835
NCT63997255,Fatigue,General disorders and administration site conditions,No,15%,835,17,32,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 2,835
NCT63997255,Fatigue,General disorders and administration site conditions,No,5%,835,4,4,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 2,835
NCT63997255,Fatigue,General disorders and administration site conditions,No,10%,835,10,12,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 2,835
NCT63997255,Fatigue,General disorders and administration site conditions,No,10%,835,33,49,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 2,835
NCT63997255,Fatigue,General disorders and administration site conditions,No,10%,835,8,13,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 2,835
NCT48832433,Fatigue,General disorders and administration site conditions,No,10%,654,37,66,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 3,654
NCT48832433,Fatigue,General disorders and administration site conditions,No,15%,654,7,8,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 3,654
NCT48832433,Fatigue,General disorders and administration site conditions,No,10%,654,28,39,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 3,654
NCT48832433,Fatigue,General disorders and administration site conditions,No,5%,654,44,50,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 3,654
NCT48832433,Fatigue,General disorders and administration site conditions,No,10%,654,34,38,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 3,654
NCT48832433,Fatigue,General disorders and administration site conditions,No,15%,654,17,32,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 3,654
NCT48832433,Fatigue,General disorders and administration site conditions,No,10%,654,16,24,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 3,654
NCT48832433,Fatigue,General disorders and administration site conditions,No,10%,654,31,47,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 3,654
NCT48832433,Fatigue,General disorders and administration site conditions,No,10%,654,37,45,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 3,654
NCT58719623,Fatigue,General disorders and administration site conditions,No,15%,102,2,3,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 3,102
NCT58719623,Fatigue,General disorders and administration site conditions,No,15%,102,2,3,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 3,102
NCT58719623,Fatigue,General disorders and administration site conditions,No,15%,102,10,20,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 3,102
NCT58719623,Fatigue,General disorders and administration site conditions,No,15%,102,6,9,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 3,102
NCT58719623,Fatigue,General disorders and administration site conditions,No,15%,102,1,1,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 3,102
NCT58719623,Fatigue,General disorders and administration site conditions,No,15%,102,6,12,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 3,102
NCT58719623,Fatigue,General disorders and administration site conditions,No,15%,102,3,5,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 3,102
NCT58719623,Fatigue,General disorders and administration site conditions,No,5%,102,3,6,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 3,102
NCT14177472,Fatigue,General disorders and administration site conditions,No,5%,853,6,6,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 4,853
NCT14177472,Fatigue,General disorders and administration site conditions,No,10%,853,12,14,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 4,853
NCT14177472,Fatigue,General disorders and administration site conditions,No,15%,853,43,78,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 4,853
NCT14177472,Fatigue,General disorders and administration site conditions,No,5%,853,28,37,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 4,853
NCT14177472,Fatigue,General disorders and administration site conditions,No,15%,853,12,19,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 4,853
NCT14177472,Fatigue,General disorders and administration site conditions,No,5%,853,36,58,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 4,853
NCT14177472,Fatigue,General disorders and administration site conditions,No,5%,853,49,86,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 4,853
NCT14177472,Fatigue,General disorders and administration site conditions,No,5%,853,30,60,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 4,853
NCT14177472,Fatigue,General disorders and administration site conditions,No,15%,853,32,33,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 4,853
NCT14177472,Fatigue,General disorders and administration site conditions,No,5%,853,8,10,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 4,853
NCT14177472,Fatigue,General disorders and administration site conditions,No,15%,853,9,13,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 4,853
NCT14177472,Fatigue,General disorders and administration site conditions,No,10%,853,44,81,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 4,853
NCT14177472,Fatigue,General disorders and administration site conditions,No,15%,853,10,15,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 4,853
NCT14177472,Fatigue,General disorders and administration site conditions,No,5%,853,41,75,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 4,853
NCT14177472,Fatigue,General disorders and administration site conditions,No,5%,853,28,53,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 4,853
NCT42918888,Fatigue,General disorders and administration site conditions,No,15%,145,2,2,All Causality,Avelumab,Anti-PD-L1,Lung Cancer,Phase 4,145
NCT42918888,Fatigue,General disorders and administration site conditions,No,5%,145,4,4,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 4,145
NCT42918888,Fatigue,General disorders and administration site conditions,No,15%,145,3,4,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 4,145
NCT42918888,Fatigue,General disorders and administration site conditions,No,15%,145,2,3,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 4,145
NCT42918888,Fatigue,General disorders and administration site conditions,No,15%,145,5,6,Treatment Emergent,Avelumab,Anti-PD-L1,Lung Cancer,Phase 4,145
NCT29118784,Fatigue,General disorders and administration site conditions,No,10%,640,38,39,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 1,640
NCT29118784,Fatigue,General disorders and administration site conditions,No,15%,640,21,32,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 1,640
NCT29118784,Fatigue,General disorders and administration site conditions,No,15%,640,32,64,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 1,640
NCT29118784,Fatigue,General disorders and administration site conditions,No,15%,640,11,20,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 1,640
NCT29118784,Fatigue,General disorders and administration site conditions,No,5%,640,35,69,Treatment Emergent,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 1,640
NCT12332652,Fatigue,General disorders and administration site conditions,No,10%,283,5,9,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 1,283
NCT12332652,Fatigue,General disorders and administration site conditions,No,10%,283,21,37,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 1,283
NCT12332652,Fatigue,General disorders and administration site conditions,No,10%,283,25,27,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 1,283
NCT72626465,Fatigue,General disorders and administration site conditions,No,5%,995,29,51,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 1,995
NCT72626465,Fatigue,General disorders and administration site conditions,No,10%,995,18,26,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 1,995
NCT72626465,Fatigue,General disorders and administration site conditions,No,15%,995,42,44,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 1,995
NCT72626465,Fatigue,General disorders and administration site conditions,No,5%,995,25,47,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 1,995
NCT72626465,Fatigue,General disorders and administration site conditions,No,15%,995,22,42,Treatment Emergent,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 1,995
NCT88737941,Fatigue,General disorders and administration site conditions,No,5%,530,47,84,Treatment Emergent,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 2,530
NCT88737941,Fatigue,General disorders and administration site conditions,No,10%,530,16,21,Treatment Emergent,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 2,530
NCT88737941,Fatigue,General disorders and administration site conditions,No,15%,530,6,11,Treatment Emergent,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 2,530
NCT88737941,Fatigue,General disorders and administration site conditions,No,5%,530,11,16,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 2,530
NCT88737941,Fatigue,General disorders and administration site conditions,No,5%,530,12,16,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 2,530
NCT88737941,Fatigue,General disorders and administration site conditions,No,5%,530,11,17,Treatment Emergent,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 2,530
NCT88737941,Fatigue,General disorders and administration site conditions,No,10%,530,45,78,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 2,530
NCT88737941,Fatigue,General disorders and administration site conditions,No,5%,530,19,26,Treatment Emergent,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 2,530
NCT88737941,Fatigue,General disorders and administration site conditions,No,15%,530,3,3,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 2,530
NCT88737941,Fatigue,General disorders and administration site conditions,No,5%,530,42,42,Treatment Emergent,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 2,530
NCT88737941,Fatigue,General disorders and administration site conditions,No,15%,530,9,15,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 2,530
NCT88737941,Fatigue,General disorders and administration site conditions,No,10%,530,49,64,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 2,530
NCT88737941,Fatigue,General disorders and administration site conditions,No,10%,530,13,25,Treatment Emergent,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 2,530
NCT88737941,Fatigue,General disorders and administration site conditions,No,10%,530,33,38,Treatment Emergent,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 2,530
NCT88737941,Fatigue,General disorders and administration site conditions,No,10%,530,34,42,Treatment Emergent,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 2,530
NCT25662679,Fatigue,General disorders and administration site conditions,No,15%,437,42,47,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 2,437
NCT25662679,Fatigue,General disorders and administration site conditions,No,15%,437,20,20,Treatment Emergent,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 2,437
NCT25662679,Fatigue,General disorders and administration site conditions,No,5%,437,31,56,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 2,437
NCT60509361,Fatigue,General disorders and administration site conditions,No,15%,795,2,2,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 2,795
NCT60509361,Fatigue,General disorders and administration site conditions,No,15%,795,28,42,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 2,795
NCT60509361,Fatigue,General disorders and administration site conditions,No,5%,795,46,50,Treatment Emergent,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 2,795
NCT60509361,Fatigue,General disorders and administration site conditions,No,15%,795,18,29,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 2,795
NCT60509361,Fatigue,General disorders and administration site conditions,No,5%,795,32,47,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 2,795
NCT49720492,Fatigue,General disorders and administration site conditions,No,10%,222,2,2,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 3,222
NCT49720492,Fatigue,General disorders and administration site conditions,No,5%,222,18,28,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 3,222
NCT49720492,Fatigue,General disorders and administration site conditions,No,5%,222,15,23,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 3,222
NCT49720492,Fatigue,General disorders and administration site conditions,No,5%,222,10,11,Treatment Emergent,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 3,222
NCT49720492,Fatigue,General disorders and administration site conditions,No,10%,222,8,12,Treatment Emergent,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 3,222
NCT49720492,Fatigue,General disorders and administration site conditions,No,15%,222,21,34,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 3,222
NCT49720492,Fatigue,General disorders and administration site conditions,No,15%,222,7,13,Treatment Emergent,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 3,222
NCT49720492,Fatigue,General disorders and administration site conditions,No,10%,222,14,14,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 3,222
NCT49720492,Fatigue,General disorders and administration site conditions,No,5%,222,3,3,Treatment Emergent,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 3,222
NCT49720492,Fatigue,General disorders and administration site conditions,No,15%,222,15,22,Treatment Emergent,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 3,222
NCT49720492,Fatigue,General disorders and administration site conditions,No,5%,222,8,11,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 3,222
NCT49720492,Fatigue,General disorders and administration site conditions,No,5%,222,4,8,Treatment Emergent,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 3,222
NCT49720492,Fatigue,General disorders and administration site conditions,No,15%,222,8,16,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 3,222
NCT49720492,Fatigue,General disorders and administration site conditions,No,15%,222,7,11,Treatment Emergent,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 3,222
NCT40175824,Fatigue,General disorders and administration site conditions,No,15%,989,47,88,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 3,989
NCT40175824,Fatigue,General disorders and administration site conditions,No,10%,989,36,54,Treatment Emergent,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 3,989
NCT40175824,Fatigue,General disorders and administration site conditions,No,15%,989,42,56,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 3,989
NCT40175824,Fatigue,General disorders and administration site conditions,No,5%,989,37,56,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 3,989
NCT40175824,Fatigue,General disorders and administration site conditions,No,15%,989,1,1,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 3,989
NCT40175824,Fatigue,General disorders and administration site conditions,No,5%,989,42,77,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 3,989
NCT40175824,Fatigue,General disorders and administration site conditions,No,5%,989,15,19,Treatment Emergent,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 3,989
NCT40175824,Fatigue,General disorders and administration site conditions,No,15%,989,3,3,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 3,989
NCT40175824,Fatigue,General disorders and administration site conditions,No,5%,989,13,23,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 3,989
NCT40175824,Fatigue,General disorders and administration site conditions,No,5%,989,23,42,Treatment Emergent,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 3,989
NCT40175824,Fatigue,General disorders and administration site conditions,No,15%,989,37,61,Treatment Emergent,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 3,989
NCT40175824,Fatigue,General disorders and administration site conditions,No,15%,989,1,2,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 3,989
NCT59769233,Fatigue,General disorders and administration site conditions,No,10%,896,16,22,Treatment Emergent,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 4,896
NCT59769233,Fatigue,General disorders and administration site conditions,No,10%,896,39,47,Treatment Emergent,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 4,896
NCT59769233,Fatigue,General disorders and administration site conditions,No,10%,896,49,93,All Causality,Avelumab,Anti-PD-L1,Bladder Cancer,Phase 4,896
NCT57904088,Fatigue,General disorders and administration site conditions,No,10%,797,9,10,All Causality,Avelumab,Anti-PD-L1,Breast Cancer,Phase 1,797
NCT57904088,Fatigue,General disorders and administration site conditions,No,10%,797,2,2,Treatment Emergent,Avelumab,Anti-PD-L1,Breast Cancer,Phase 1,797
NCT57904088,Fatigue,General disorders and administration site conditions,No,15%,797,26,51,All Causality,Avelumab,Anti-PD-L1,Breast Cancer,Phase 1,797
NCT57904088,Fatigue,General disorders and administration site conditions,No,5%,797,8,16,All Causality,Avelumab,Anti-PD-L1,Breast Cancer,Phase 1,797
NCT57904088,Fatigue,General disorders and administration site conditions,No,15%,797,18,20,All Causality,Avelumab,Anti-PD-L1,Breast Cancer,Phase 1,797
NCT46535339,Fatigue,General disorders and administration site conditions,No,15%,183,8,14,Treatment Emergent,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,183
NCT46535339,Fatigue,General disorders and administration site conditions,No,5%,183,17,29,Treatment Emergent,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,183
NCT46535339,Fatigue,General disorders and administration site conditions,No,10%,183,3,3,Treatment Emergent,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,183
NCT46535339,Fatigue,General disorders and administration site conditions,No,10%,183,6,9,All Causality,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,183
NCT46535339,Fatigue,General disorders and administration site conditions,No,5%,183,4,7,All Causality,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,183
NCT46535339,Fatigue,General disorders and administration site conditions,No,10%,183,16,25,All Causality,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,183
NCT46535339,Fatigue,General disorders and administration site conditions,No,15%,183,4,7,All Causality,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,183
NCT46535339,Fatigue,General disorders and administration site conditions,No,10%,183,1,1,Treatment Emergent,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,183
NCT46535339,Fatigue,General disorders and administration site conditions,No,10%,183,13,16,All Causality,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,183
NCT46535339,Fatigue,General disorders and administration site conditions,No,10%,183,14,14,All Causality,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,183
NCT46535339,Fatigue,General disorders and administration site conditions,No,5%,183,9,15,Treatment Emergent,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,183
NCT46535339,Fatigue,General disorders and administration site conditions,No,10%,183,10,17,All Causality,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,183
NCT89225649,Fatigue,General disorders and administration site conditions,No,15%,879,2,3,All Causality,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,879
NCT89225649,Fatigue,General disorders and administration site conditions,No,15%,879,3,5,Treatment Emergent,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,879
NCT89225649,Fatigue,General disorders and administration site conditions,No,5%,879,37,72,All Causality,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,879
NCT59440678,Fatigue,General disorders and administration site conditions,No,15%,61,4,7,Treatment Emergent,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,61
NCT59440678,Fatigue,General disorders and administration site conditions,No,10%,61,2,2,Treatment Emergent,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,61
NCT59440678,Fatigue,General disorders and administration site conditions,No,15%,61,2,2,All Causality,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,61
NCT59440678,Fatigue,General disorders and administration site conditions,No,15%,61,2,2,All Causality,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,61
NCT59440678,Fatigue,General disorders and administration site conditions,No,10%,61,3,5,All Causality,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,61
NCT59440678,Fatigue,General disorders and administration site conditions,No,5%,61,2,3,Treatment Emergent,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,61
NCT59440678,Fatigue,General disorders and administration site conditions,No,10%,61,2,3,Treatment Emergent,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,61
NCT59440678,Fatigue,General disorders and administration site conditions,No,15%,61,5,9,Treatment Emergent,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,61
NCT59440678,Fatigue,General disorders and administration site conditions,No,5%,61,6,7,Treatment Emergent,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,61
NCT59440678,Fatigue,General disorders and administration site conditions,No,5%,61,4,4,All Causality,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,61
NCT59440678,Fatigue,General disorders and administration site conditions,No,15%,61,5,10,All Causality,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,61
NCT59440678,Fatigue,General disorders and administration site conditions,No,15%,61,5,6,All Causality,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,61
NCT59440678,Fatigue,General disorders and administration site conditions,No,10%,61,2,3,All Causality,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,61
NCT59440678,Fatigue,General disorders and administration site conditions,No,15%,61,4,6,Treatment Emergent,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,61
NCT59440678,Fatigue,General disorders and administration site conditions,No,15%,61,2,2,Treatment Emergent,Avelumab,Anti-PD-L1,Breast Cancer,Phase 2,61
NCT37505588,Fatigue,General disorders and administration site conditions,No,15%,497,26,40,All Causality,Avelumab,Anti-PD-L1,Breast Cancer,Phase 3,497
NCT37505588,Fatigue,General disorders and administration site conditions,No,15%,497,24,32,Treatment Emergent,Avelumab,Anti-PD-L1,Breast Cancer,Phase 3,497
NCT37505588,Fatigue,General disorders and administration site conditions,No,10%,497,12,24,Treatment Emergent,Avelumab,Anti-PD-L1,Breast Cancer,Phase 3,497
NCT37505588,Fatigue,General disorders and administration site conditions,No,5%,497,16,29,All Causality,Avelumab,Anti-PD-L1,Breast Cancer,Phase 3,497
NCT37505588,Fatigue,General disorders and administration site conditions,No,10%,497,44,83,Treatment Emergent,Avelumab,Anti-PD-L1,Breast Cancer,Phase 3,497
NCT37505588,Fatigue,General disorders and administration site conditions,No,5%,497,34,34,Treatment Emergent,Avelumab,Anti-PD-L1,Breast Cancer,Phase 3,497
NCT37505588,Fatigue,General disorders and administration site conditions,No,5%,497,4,6,All Causality,Avelumab,Anti-PD-L1,Breast Cancer,Phase 3,497
NCT37505588,Fatigue,General disorders and administration site conditions,No,15%,497,1,2,All Causality,Avelumab,Anti-PD-L1,Breast Cancer,Phase 3,497
NCT37505588,Fatigue,General disorders and administration site conditions,No,15%,497,46,74,All Causality,Avelumab,Anti-PD-L1,Breast Cancer,Phase 3,497
NCT24133250,Fatigue,General disorders and administration site conditions,No,15%,402,11,11,Treatment Emergent,Avelumab,Anti-PD-L1,Breast Cancer,Phase 4,402
NCT24133250,Fatigue,General disorders and administration site conditions,No,10%,402,22,42,All Causality,Avelumab,Anti-PD-L1,Breast Cancer,Phase 4,402
NCT24133250,Fatigue,General disorders and administration site conditions,No,10%,402,1,2,Treatment Emergent,Avelumab,Anti-PD-L1,Breast Cancer,Phase 4,402
NCT24133250,Fatigue,General disorders and administration site conditions,No,10%,402,19,19,All Causality,Avelumab,Anti-PD-L1,Breast Cancer,Phase 4,402
NCT24133250,Fatigue,General disorders and administration site conditions,No,10%,402,35,68,All Causality,Avelumab,Anti-PD-L1,Breast Cancer,Phase 4,402
NCT24133250,Fatigue,General disorders and administration site conditions,No,5%,402,35,43,Treatment Emergent,Avelumab,Anti-PD-L1,Breast Cancer,Phase 4,402
NCT24133250,Fatigue,General disorders and administration site conditions,No,10%,402,38,61,Treatment Emergent,Avelumab,Anti-PD-L1,Breast Cancer,Phase 4,402
NCT24133250,Fatigue,General disorders and administration site conditions,No,15%,402,1,2,Treatment Emergent,Avelumab,Anti-PD-L1,Breast Cancer,Phase 4,402
NCT33373656,Fatigue,General disorders and administration site conditions,No,10%,584,6,7,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,584
NCT33373656,Fatigue,General disorders and administration site conditions,No,10%,584,25,31,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,584
NCT33373656,Fatigue,General disorders and administration site conditions,No,10%,584,2,2,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,584
NCT33373656,Fatigue,General disorders and administration site conditions,No,5%,584,27,40,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,584
NCT33373656,Fatigue,General disorders and administration site conditions,No,10%,584,44,53,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,584
NCT33373656,Fatigue,General disorders and administration site conditions,No,15%,584,44,72,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,584
NCT33373656,Fatigue,General disorders and administration site conditions,No,5%,584,49,87,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,584
NCT33373656,Fatigue,General disorders and administration site conditions,No,15%,584,18,25,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,584
NCT33373656,Fatigue,General disorders and administration site conditions,No,10%,584,45,79,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,584
NCT97104381,Fatigue,General disorders and administration site conditions,No,15%,514,39,39,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,514
NCT97104381,Fatigue,General disorders and administration site conditions,No,15%,514,42,55,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,514
NCT97104381,Fatigue,General disorders and administration site conditions,No,15%,514,24,32,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,514
NCT97104381,Fatigue,General disorders and administration site conditions,No,10%,514,9,14,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,514
NCT97104381,Fatigue,General disorders and administration site conditions,No,15%,514,7,12,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,514
NCT97104381,Fatigue,General disorders and administration site conditions,No,5%,514,37,43,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,514
NCT97104381,Fatigue,General disorders and administration site conditions,No,10%,514,46,81,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,514
NCT97104381,Fatigue,General disorders and administration site conditions,No,5%,514,17,22,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,514
NCT97104381,Fatigue,General disorders and administration site conditions,No,5%,514,14,15,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,514
NCT97104381,Fatigue,General disorders and administration site conditions,No,15%,514,17,22,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,514
NCT97104381,Fatigue,General disorders and administration site conditions,No,15%,514,10,20,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,514
NCT97104381,Fatigue,General disorders and administration site conditions,No,5%,514,6,10,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,514
NCT97104381,Fatigue,General disorders and administration site conditions,No,15%,514,12,22,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 1,514
NCT11931862,Fatigue,General disorders and administration site conditions,No,15%,873,12,17,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,873
NCT11931862,Fatigue,General disorders and administration site conditions,No,5%,873,39,50,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,873
NCT11931862,Fatigue,General disorders and administration site conditions,No,5%,873,45,56,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,873
NCT11931862,Fatigue,General disorders and administration site conditions,No,15%,873,35,37,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,873
NCT11931862,Fatigue,General disorders and administration site conditions,No,15%,873,5,9,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,873
NCT11931862,Fatigue,General disorders and administration site conditions,No,10%,873,16,32,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,873
NCT11931862,Fatigue,General disorders and administration site conditions,No,10%,873,41,47,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,873
NCT11931862,Fatigue,General disorders and administration site conditions,No,15%,873,13,26,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,873
NCT11931862,Fatigue,General disorders and administration site conditions,No,5%,873,40,62,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,873
NCT11931862,Fatigue,General disorders and administration site conditions,No,10%,873,39,76,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,873
NCT11931862,Fatigue,General disorders and administration site conditions,No,10%,873,14,15,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,873
NCT11931862,Fatigue,General disorders and administration site conditions,No,5%,873,33,38,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,873
NCT11931862,Fatigue,General disorders and administration site conditions,No,10%,873,34,36,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,873
NCT11931862,Fatigue,General disorders and administration site conditions,No,5%,873,15,27,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,873
NCT11931862,Fatigue,General disorders and administration site conditions,No,5%,873,9,10,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,873
NCT87230481,Fatigue,General disorders and administration site conditions,No,5%,365,26,33,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,365
NCT87230481,Fatigue,General disorders and administration site conditions,No,15%,365,35,43,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,365
NCT87230481,Fatigue,General disorders and administration site conditions,No,5%,365,18,29,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,365
NCT87230481,Fatigue,General disorders and administration site conditions,No,5%,365,30,34,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,365
NCT87230481,Fatigue,General disorders and administration site conditions,No,5%,365,27,36,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,365
NCT87230481,Fatigue,General disorders and administration site conditions,No,5%,365,18,34,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,365
NCT87230481,Fatigue,General disorders and administration site conditions,No,15%,365,10,14,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,365
NCT87230481,Fatigue,General disorders and administration site conditions,No,10%,365,19,31,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,365
NCT87230481,Fatigue,General disorders and administration site conditions,No,10%,365,10,15,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,365
NCT87230481,Fatigue,General disorders and administration site conditions,No,15%,365,10,14,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,365
NCT87230481,Fatigue,General disorders and administration site conditions,No,15%,365,4,8,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 2,365
NCT16335321,Fatigue,General disorders and administration site conditions,No,5%,965,30,43,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,965
NCT16335321,Fatigue,General disorders and administration site conditions,No,5%,965,28,44,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,965
NCT16335321,Fatigue,General disorders and administration site conditions,No,10%,965,27,41,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,965
NCT16335321,Fatigue,General disorders and administration site conditions,No,5%,965,14,18,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,965
NCT16335321,Fatigue,General disorders and administration site conditions,No,10%,965,22,24,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,965
NCT16335321,Fatigue,General disorders and administration site conditions,No,10%,965,37,45,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,965
NCT16335321,Fatigue,General disorders and administration site conditions,No,5%,965,46,64,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,965
NCT16335321,Fatigue,General disorders and administration site conditions,No,15%,965,38,39,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,965
NCT16335321,Fatigue,General disorders and administration site conditions,No,15%,965,10,20,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,965
NCT16335321,Fatigue,General disorders and administration site conditions,No,10%,965,41,68,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,965
NCT16335321,Fatigue,General disorders and administration site conditions,No,5%,965,9,14,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,965
NCT16335321,Fatigue,General disorders and administration site conditions,No,15%,965,36,65,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,965
NCT28519311,Fatigue,General disorders and administration site conditions,No,5%,479,16,29,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,479
NCT28519311,Fatigue,General disorders and administration site conditions,No,10%,479,40,65,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,479
NCT28519311,Fatigue,General disorders and administration site conditions,No,15%,479,32,32,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,479
NCT28519311,Fatigue,General disorders and administration site conditions,No,10%,479,30,43,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,479
NCT28519311,Fatigue,General disorders and administration site conditions,No,5%,479,1,1,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,479
NCT28519311,Fatigue,General disorders and administration site conditions,No,5%,479,42,77,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,479
NCT28519311,Fatigue,General disorders and administration site conditions,No,10%,479,44,47,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,479
NCT28519311,Fatigue,General disorders and administration site conditions,No,5%,479,15,24,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 3,479
NCT27084854,Fatigue,General disorders and administration site conditions,No,15%,789,24,48,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 4,789
NCT27084854,Fatigue,General disorders and administration site conditions,No,15%,789,45,64,All Causality,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 4,789
NCT27084854,Fatigue,General disorders and administration site conditions,No,10%,789,46,89,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Melanoma,Phase 4,789
NCT64768987,Fatigue,General disorders and administration site conditions,No,5%,647,2,4,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 1,647
NCT64768987,Fatigue,General disorders and administration site conditions,No,15%,647,44,82,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 1,647
NCT64768987,Fatigue,General disorders and administration site conditions,No,10%,647,28,53,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 1,647
NCT64768987,Fatigue,General disorders and administration site conditions,No,5%,647,37,67,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 1,647
NCT92322273,Fatigue,General disorders and administration site conditions,No,5%,851,11,13,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 1,851
NCT92322273,Fatigue,General disorders and administration site conditions,No,15%,851,4,7,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 1,851
NCT92322273,Fatigue,General disorders and administration site conditions,No,15%,851,32,42,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 1,851
NCT92322273,Fatigue,General disorders and administration site conditions,No,5%,851,7,7,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 1,851
NCT92322273,Fatigue,General disorders and administration site conditions,No,5%,851,27,54,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 1,851
NCT92322273,Fatigue,General disorders and administration site conditions,No,15%,851,50,59,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 1,851
NCT92322273,Fatigue,General disorders and administration site conditions,No,15%,851,10,13,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 1,851
NCT92322273,Fatigue,General disorders and administration site conditions,No,15%,851,23,24,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 1,851
NCT92322273,Fatigue,General disorders and administration site conditions,No,15%,851,12,13,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 1,851
NCT92322273,Fatigue,General disorders and administration site conditions,No,15%,851,33,58,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 1,851
NCT92322273,Fatigue,General disorders and administration site conditions,No,10%,851,42,55,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 1,851
NCT92322273,Fatigue,General disorders and administration site conditions,No,10%,851,43,58,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 1,851
NCT92322273,Fatigue,General disorders and administration site conditions,No,5%,851,40,64,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 1,851
NCT92322273,Fatigue,General disorders and administration site conditions,No,15%,851,7,10,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 1,851
NCT92322273,Fatigue,General disorders and administration site conditions,No,5%,851,14,16,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 1,851
NCT90382262,Fatigue,General disorders and administration site conditions,No,5%,576,20,24,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 2,576
NCT90382262,Fatigue,General disorders and administration site conditions,No,10%,576,25,42,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 2,576
NCT90382262,Fatigue,General disorders and administration site conditions,No,15%,576,4,4,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 2,576
NCT90382262,Fatigue,General disorders and administration site conditions,No,15%,576,47,90,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 2,576
NCT90382262,Fatigue,General disorders and administration site conditions,No,15%,576,30,38,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 2,576
NCT90382262,Fatigue,General disorders and administration site conditions,No,15%,576,20,26,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 2,576
NCT90382262,Fatigue,General disorders and administration site conditions,No,10%,576,15,19,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 2,576
NCT50643016,Fatigue,General disorders and administration site conditions,No,5%,332,2,4,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 2,332
NCT50643016,Fatigue,General disorders and administration site conditions,No,15%,332,9,15,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 2,332
NCT50643016,Fatigue,General disorders and administration site conditions,No,5%,332,24,26,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 2,332
NCT50643016,Fatigue,General disorders and administration site conditions,No,15%,332,12,21,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 2,332
NCT50643016,Fatigue,General disorders and administration site conditions,No,5%,332,13,19,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 2,332
NCT60442511,Fatigue,General disorders and administration site conditions,No,5%,244,22,29,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 3,244
NCT60442511,Fatigue,General disorders and administration site conditions,No,10%,244,19,23,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 3,244
NCT60442511,Fatigue,General disorders and administration site conditions,No,15%,244,7,10,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 3,244
NCT60442511,Fatigue,General disorders and administration site conditions,No,10%,244,2,4,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 3,244
NCT60442511,Fatigue,General disorders and administration site conditions,No,10%,244,5,7,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 3,244
NCT60442511,Fatigue,General disorders and administration site conditions,No,10%,244,21,40,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 3,244
NCT60442511,Fatigue,General disorders and administration site conditions,No,5%,244,4,7,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 3,244
NCT60442511,Fatigue,General disorders and administration site conditions,No,5%,244,16,30,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 3,244
NCT60442511,Fatigue,General disorders and administration site conditions,No,15%,244,19,29,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 3,244
NCT60442511,Fatigue,General disorders and administration site conditions,No,10%,244,5,10,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 3,244
NCT37231699,Fatigue,General disorders and administration site conditions,No,10%,422,34,68,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 3,422
NCT37231699,Fatigue,General disorders and administration site conditions,No,15%,422,6,12,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 3,422
NCT37231699,Fatigue,General disorders and administration site conditions,No,5%,422,38,53,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 3,422
NCT37231699,Fatigue,General disorders and administration site conditions,No,5%,422,7,12,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 3,422
NCT37231699,Fatigue,General disorders and administration site conditions,No,15%,422,42,75,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 3,422
NCT91101049,Fatigue,General disorders and administration site conditions,No,5%,728,47,82,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 4,728
NCT91101049,Fatigue,General disorders and administration site conditions,No,10%,728,32,39,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 4,728
NCT91101049,Fatigue,General disorders and administration site conditions,No,5%,728,43,61,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 4,728
NCT91101049,Fatigue,General disorders and administration site conditions,No,10%,728,23,29,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 4,728
NCT91101049,Fatigue,General disorders and administration site conditions,No,5%,728,2,2,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 4,728
NCT91101049,Fatigue,General disorders and administration site conditions,No,10%,728,34,49,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 4,728
NCT91101049,Fatigue,General disorders and administration site conditions,No,15%,728,45,83,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 4,728
NCT91101049,Fatigue,General disorders and administration site conditions,No,5%,728,44,47,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 4,728
NCT91101049,Fatigue,General disorders and administration site conditions,No,5%,728,37,57,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 4,728
NCT91101049,Fatigue,General disorders and administration site conditions,No,10%,728,21,29,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 4,728
NCT91101049,Fatigue,General disorders and administration site conditions,No,15%,728,28,34,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 4,728
NCT91101049,Fatigue,General disorders and administration site conditions,No,10%,728,34,49,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 4,728
NCT91101049,Fatigue,General disorders and administration site conditions,No,10%,728,32,48,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 4,728
NCT57054706,Fatigue,General disorders and administration site conditions,No,15%,21,2,4,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 4,21
NCT57054706,Fatigue,General disorders and administration site conditions,No,5%,21,1,2,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 4,21
NCT57054706,Fatigue,General disorders and administration site conditions,No,10%,21,1,2,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 4,21
NCT57054706,Fatigue,General disorders and administration site conditions,No,10%,21,1,2,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 4,21
NCT57054706,Fatigue,General disorders and administration site conditions,No,5%,21,2,3,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 4,21
NCT57054706,Fatigue,General disorders and administration site conditions,No,15%,21,1,1,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 4,21
NCT57054706,Fatigue,General disorders and administration site conditions,No,10%,21,1,2,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 4,21
NCT57054706,Fatigue,General disorders and administration site conditions,No,15%,21,2,4,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 4,21
NCT57054706,Fatigue,General disorders and administration site conditions,No,5%,21,2,4,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 4,21
NCT57054706,Fatigue,General disorders and administration site conditions,No,10%,21,1,1,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 4,21
NCT57054706,Fatigue,General disorders and administration site conditions,No,15%,21,1,2,All Causality,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 4,21
NCT57054706,Fatigue,General disorders and administration site conditions,No,5%,21,2,2,Treatment Emergent,Ipilimumab,Anti-CTLA-4,Lung Cancer,Phase 4,21
NCT78431036,Fatigue,General disorders and administration site conditions,No,15%,394,24,40,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 1,394
NCT78431036,Fatigue,General disorders and administration site conditions,No,5%,394,33,41,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 1,394
NCT78431036,Fatigue,General disorders and administration site conditions,No,15%,394,17,30,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 1,394
NCT78431036,Fatigue,General disorders and administration site conditions,No,5%,394,20,21,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 1,394
NCT78431036,Fatigue,General disorders and administration site conditions,No,15%,394,17,31,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 1,394
NCT78431036,Fatigue,General disorders and administration site conditions,No,15%,394,26,35,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 1,394
NCT78431036,Fatigue,General disorders and administration site conditions,No,5%,394,29,40,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 1,394
NCT78431036,Fatigue,General disorders and administration site conditions,No,15%,394,11,17,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 1,394
NCT78431036,Fatigue,General disorders and administration site conditions,No,10%,394,29,53,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 1,394
NCT78431036,Fatigue,General disorders and administration site conditions,No,10%,394,28,32,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 1,394
NCT78431036,Fatigue,General disorders and administration site conditions,No,10%,394,29,44,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 1,394
NCT78431036,Fatigue,General disorders and administration site conditions,No,5%,394,37,54,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 1,394
NCT78431036,Fatigue,General disorders and administration site conditions,No,10%,394,24,44,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 1,394
NCT16337078,Fatigue,General disorders and administration site conditions,No,5%,271,4,6,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 1,271
NCT16337078,Fatigue,General disorders and administration site conditions,No,5%,271,24,27,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 1,271
NCT16337078,Fatigue,General disorders and administration site conditions,No,10%,271,11,16,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 1,271
NCT16337078,Fatigue,General disorders and administration site conditions,No,5%,271,25,45,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 1,271
NCT16337078,Fatigue,General disorders and administration site conditions,No,15%,271,14,15,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 1,271
NCT16337078,Fatigue,General disorders and administration site conditions,No,10%,271,12,17,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 1,271
NCT16337078,Fatigue,General disorders and administration site conditions,No,10%,271,14,21,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 1,271
NCT16337078,Fatigue,General disorders and administration site conditions,No,5%,271,27,37,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 1,271
NCT16337078,Fatigue,General disorders and administration site conditions,No,10%,271,7,14,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 1,271
NCT16337078,Fatigue,General disorders and administration site conditions,No,15%,271,19,28,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 1,271
NCT16337078,Fatigue,General disorders and administration site conditions,No,15%,271,10,15,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 1,271
NCT16337078,Fatigue,General disorders and administration site conditions,No,5%,271,15,20,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 1,271
NCT16337078,Fatigue,General disorders and administration site conditions,No,10%,271,8,9,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 1,271
NCT10417905,Fatigue,General disorders and administration site conditions,No,15%,728,36,56,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 2,728
NCT10417905,Fatigue,General disorders and administration site conditions,No,15%,728,6,11,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 2,728
NCT10417905,Fatigue,General disorders and administration site conditions,No,5%,728,30,42,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 2,728
NCT10417905,Fatigue,General disorders and administration site conditions,No,5%,728,2,2,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 2,728
NCT10417905,Fatigue,General disorders and administration site conditions,No,15%,728,26,27,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 2,728
NCT10417905,Fatigue,General disorders and administration site conditions,No,5%,728,28,56,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 2,728
NCT10417905,Fatigue,General disorders and administration site conditions,No,10%,728,31,38,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 2,728
NCT10417905,Fatigue,General disorders and administration site conditions,No,5%,728,30,49,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 2,728
NCT10417905,Fatigue,General disorders and administration site conditions,No,15%,728,41,71,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 2,728
NCT10417905,Fatigue,General disorders and administration site conditions,No,15%,728,49,69,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 2,728
NCT21408995,Fatigue,General disorders and administration site conditions,No,10%,171,2,3,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 2,171
NCT21408995,Fatigue,General disorders and administration site conditions,No,15%,171,11,19,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 2,171
NCT21408995,Fatigue,General disorders and administration site conditions,No,10%,171,17,27,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 2,171
NCT13572258,Fatigue,General disorders and administration site conditions,No,5%,725,6,8,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 2,725
NCT13572258,Fatigue,General disorders and administration site conditions,No,5%,725,25,33,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 2,725
NCT13572258,Fatigue,General disorders and administration site conditions,No,5%,725,9,14,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 2,725
NCT13572258,Fatigue,General disorders and administration site conditions,No,5%,725,2,4,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 2,725
NCT13572258,Fatigue,General disorders and administration site conditions,No,5%,725,48,53,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 2,725
NCT13572258,Fatigue,General disorders and administration site conditions,No,15%,725,37,49,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 2,725
NCT13572258,Fatigue,General disorders and administration site conditions,No,15%,725,44,58,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 2,725
NCT13572258,Fatigue,General disorders and administration site conditions,No,10%,725,18,28,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 2,725
NCT13572258,Fatigue,General disorders and administration site conditions,No,5%,725,50,76,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 2,725
NCT32770173,Fatigue,General disorders and administration site conditions,No,5%,358,20,33,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 3,358
NCT32770173,Fatigue,General disorders and administration site conditions,No,5%,358,30,60,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 3,358
NCT32770173,Fatigue,General disorders and administration site conditions,No,5%,358,8,12,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 3,358
NCT32770173,Fatigue,General disorders and administration site conditions,No,15%,358,18,19,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 3,358
NCT32770173,Fatigue,General disorders and administration site conditions,No,15%,358,11,14,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 3,358
NCT32770173,Fatigue,General disorders and administration site conditions,No,10%,358,7,12,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 3,358
NCT32770173,Fatigue,General disorders and administration site conditions,No,5%,358,9,18,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 3,358
NCT32770173,Fatigue,General disorders and administration site conditions,No,15%,358,29,52,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 3,358
NCT32770173,Fatigue,General disorders and administration site conditions,No,10%,358,26,27,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 3,358
NCT32770173,Fatigue,General disorders and administration site conditions,No,15%,358,31,52,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 3,358
NCT32770173,Fatigue,General disorders and administration site conditions,No,5%,358,29,51,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 3,358
NCT32770173,Fatigue,General disorders and administration site conditions,No,5%,358,31,53,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 3,358
NCT32770173,Fatigue,General disorders and administration site conditions,No,10%,358,6,12,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 3,358
NCT32770173,Fatigue,General disorders and administration site conditions,No,15%,358,23,36,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 3,358
NCT32770173,Fatigue,General disorders and administration site conditions,No,15%,358,14,14,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 3,358
NCT97225414,Fatigue,General disorders and administration site conditions,No,5%,566,22,36,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 4,566
NCT97225414,Fatigue,General disorders and administration site conditions,No,5%,566,5,5,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 4,566
NCT97225414,Fatigue,General disorders and administration site conditions,No,15%,566,26,37,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 4,566
NCT97225414,Fatigue,General disorders and administration site conditions,No,15%,566,3,6,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 4,566
NCT97225414,Fatigue,General disorders and administration site conditions,No,10%,566,22,28,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 4,566
NCT41223122,Fatigue,General disorders and administration site conditions,No,10%,432,40,65,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 4,432
NCT41223122,Fatigue,General disorders and administration site conditions,No,5%,432,22,36,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 4,432
NCT41223122,Fatigue,General disorders and administration site conditions,No,10%,432,24,29,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 4,432
NCT41223122,Fatigue,General disorders and administration site conditions,No,5%,432,1,1,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 4,432
NCT41223122,Fatigue,General disorders and administration site conditions,No,5%,432,15,21,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 4,432
NCT41223122,Fatigue,General disorders and administration site conditions,No,10%,432,37,37,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 4,432
NCT41223122,Fatigue,General disorders and administration site conditions,No,5%,432,21,21,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 4,432
NCT41223122,Fatigue,General disorders and administration site conditions,No,15%,432,42,50,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 4,432
NCT41223122,Fatigue,General disorders and administration site conditions,No,10%,432,6,6,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 4,432
NCT41223122,Fatigue,General disorders and administration site conditions,No,15%,432,11,19,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 4,432
NCT56265315,Fatigue,General disorders and administration site conditions,No,5%,967,8,11,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 4,967
NCT56265315,Fatigue,General disorders and administration site conditions,No,5%,967,30,30,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 4,967
NCT56265315,Fatigue,General disorders and administration site conditions,No,5%,967,38,46,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 4,967
NCT56265315,Fatigue,General disorders and administration site conditions,No,15%,967,17,23,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 4,967
NCT56265315,Fatigue,General disorders and administration site conditions,No,5%,967,1,2,All Causality,Tremelimumab,Anti-CTLA-4,Melanoma,Phase 4,967
NCT16513150,Fatigue,General disorders and administration site conditions,No,10%,419,19,32,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,419
NCT16513150,Fatigue,General disorders and administration site conditions,No,10%,419,34,46,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,419
NCT16513150,Fatigue,General disorders and administration site conditions,No,15%,419,10,13,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,419
NCT16513150,Fatigue,General disorders and administration site conditions,No,5%,419,15,20,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,419
NCT50986875,Fatigue,General disorders and administration site conditions,No,5%,688,31,53,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,688
NCT50986875,Fatigue,General disorders and administration site conditions,No,15%,688,5,10,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,688
NCT50986875,Fatigue,General disorders and administration site conditions,No,10%,688,19,27,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,688
NCT50986875,Fatigue,General disorders and administration site conditions,No,10%,688,22,27,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,688
NCT50986875,Fatigue,General disorders and administration site conditions,No,10%,688,28,44,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,688
NCT50986875,Fatigue,General disorders and administration site conditions,No,10%,688,2,4,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,688
NCT50986875,Fatigue,General disorders and administration site conditions,No,5%,688,17,31,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,688
NCT50986875,Fatigue,General disorders and administration site conditions,No,15%,688,7,13,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,688
NCT50986875,Fatigue,General disorders and administration site conditions,No,10%,688,36,67,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,688
NCT50986875,Fatigue,General disorders and administration site conditions,No,10%,688,13,24,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,688
NCT50986875,Fatigue,General disorders and administration site conditions,No,10%,688,22,22,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,688
NCT50986875,Fatigue,General disorders and administration site conditions,No,10%,688,10,13,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,688
NCT50986875,Fatigue,General disorders and administration site conditions,No,15%,688,14,23,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,688
NCT54799425,Fatigue,General disorders and administration site conditions,No,15%,634,45,78,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,634
NCT54799425,Fatigue,General disorders and administration site conditions,No,10%,634,45,51,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,634
NCT54799425,Fatigue,General disorders and administration site conditions,No,5%,634,13,15,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,634
NCT54799425,Fatigue,General disorders and administration site conditions,No,15%,634,10,11,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,634
NCT54799425,Fatigue,General disorders and administration site conditions,No,15%,634,36,67,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,634
NCT54799425,Fatigue,General disorders and administration site conditions,No,5%,634,9,15,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,634
NCT54799425,Fatigue,General disorders and administration site conditions,No,5%,634,3,4,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,634
NCT54799425,Fatigue,General disorders and administration site conditions,No,10%,634,35,59,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,634
NCT54799425,Fatigue,General disorders and administration site conditions,No,5%,634,45,45,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,634
NCT54799425,Fatigue,General disorders and administration site conditions,No,5%,634,21,21,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,634
NCT54799425,Fatigue,General disorders and administration site conditions,No,10%,634,25,34,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,634
NCT54799425,Fatigue,General disorders and administration site conditions,No,5%,634,46,90,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 1,634
NCT89252381,Fatigue,General disorders and administration site conditions,No,5%,642,7,14,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 2,642
NCT89252381,Fatigue,General disorders and administration site conditions,No,10%,642,6,7,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 2,642
NCT89252381,Fatigue,General disorders and administration site conditions,No,5%,642,33,50,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 2,642
NCT17690425,Fatigue,General disorders and administration site conditions,No,10%,488,26,52,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 2,488
NCT17690425,Fatigue,General disorders and administration site conditions,No,5%,488,19,21,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 2,488
NCT17690425,Fatigue,General disorders and administration site conditions,No,5%,488,10,14,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 2,488
NCT17690425,Fatigue,General disorders and administration site conditions,No,5%,488,12,13,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 2,488
NCT17690425,Fatigue,General disorders and administration site conditions,No,15%,488,27,53,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 2,488
NCT17690425,Fatigue,General disorders and administration site conditions,No,10%,488,38,55,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 2,488
NCT17690425,Fatigue,General disorders and administration site conditions,No,10%,488,20,33,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 2,488
NCT17690425,Fatigue,General disorders and administration site conditions,No,5%,488,10,16,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 2,488
NCT79933371,Fatigue,General disorders and administration site conditions,No,5%,289,18,27,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 2,289
NCT79933371,Fatigue,General disorders and administration site conditions,No,5%,289,14,25,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 2,289
NCT79933371,Fatigue,General disorders and administration site conditions,No,5%,289,24,40,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 2,289
NCT79933371,Fatigue,General disorders and administration site conditions,No,15%,289,14,26,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 2,289
NCT79933371,Fatigue,General disorders and administration site conditions,No,10%,289,24,48,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 2,289
NCT79933371,Fatigue,General disorders and administration site conditions,No,5%,289,1,2,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 2,289
NCT79933371,Fatigue,General disorders and administration site conditions,No,10%,289,17,24,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 2,289
NCT43887240,Fatigue,General disorders and administration site conditions,No,10%,249,2,3,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 3,249
NCT43887240,Fatigue,General disorders and administration site conditions,No,5%,249,24,33,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 3,249
NCT43887240,Fatigue,General disorders and administration site conditions,No,15%,249,14,19,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 3,249
NCT43887240,Fatigue,General disorders and administration site conditions,No,5%,249,15,23,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 3,249
NCT43887240,Fatigue,General disorders and administration site conditions,No,15%,249,22,28,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 3,249
NCT43887240,Fatigue,General disorders and administration site conditions,No,15%,249,23,45,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 3,249
NCT12158858,Fatigue,General disorders and administration site conditions,No,5%,832,49,55,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 3,832
NCT12158858,Fatigue,General disorders and administration site conditions,No,10%,832,50,64,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 3,832
NCT12158858,Fatigue,General disorders and administration site conditions,No,5%,832,46,49,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 3,832
NCT12158858,Fatigue,General disorders and administration site conditions,No,5%,832,22,22,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 3,832
NCT12158858,Fatigue,General disorders and administration site conditions,No,5%,832,19,28,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 3,832
NCT12158858,Fatigue,General disorders and administration site conditions,No,5%,832,39,46,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 3,832
NCT12158858,Fatigue,General disorders and administration site conditions,No,10%,832,33,63,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 3,832
NCT12158858,Fatigue,General disorders and administration site conditions,No,10%,832,24,26,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 3,832
NCT12158858,Fatigue,General disorders and administration site conditions,No,5%,832,27,40,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 3,832
NCT12158858,Fatigue,General disorders and administration site conditions,No,10%,832,8,13,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 3,832
NCT12158858,Fatigue,General disorders and administration site conditions,No,15%,832,12,13,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 3,832
NCT12158858,Fatigue,General disorders and administration site conditions,No,5%,832,36,44,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 3,832
NCT33337016,Fatigue,General disorders and administration site conditions,No,10%,572,30,59,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 3,572
NCT33337016,Fatigue,General disorders and administration site conditions,No,10%,572,10,17,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 3,572
NCT33337016,Fatigue,General disorders and administration site conditions,No,15%,572,40,79,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 3,572
NCT33337016,Fatigue,General disorders and administration site conditions,No,15%,572,44,73,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 3,572
NCT33337016,Fatigue,General disorders and administration site conditions,No,10%,572,9,9,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 3,572
NCT33337016,Fatigue,General disorders and administration site conditions,No,5%,572,27,39,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 3,572
NCT46325025,Fatigue,General disorders and administration site conditions,No,10%,179,17,18,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 4,179
NCT46325025,Fatigue,General disorders and administration site conditions,No,15%,179,5,8,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 4,179
NCT46325025,Fatigue,General disorders and administration site conditions,No,15%,179,8,16,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 4,179
NCT46325025,Fatigue,General disorders and administration site conditions,No,15%,179,13,20,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 4,179
NCT46325025,Fatigue,General disorders and administration site conditions,No,15%,179,1,1,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 4,179
NCT46325025,Fatigue,General disorders and administration site conditions,No,10%,179,4,6,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 4,179
NCT46325025,Fatigue,General disorders and administration site conditions,No,10%,179,9,10,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 4,179
NCT46325025,Fatigue,General disorders and administration site conditions,No,10%,179,16,31,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 4,179
NCT46325025,Fatigue,General disorders and administration site conditions,No,10%,179,6,12,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 4,179
NCT46325025,Fatigue,General disorders and administration site conditions,No,10%,179,12,16,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 4,179
NCT46325025,Fatigue,General disorders and administration site conditions,No,10%,179,9,15,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 4,179
NCT46325025,Fatigue,General disorders and administration site conditions,No,5%,179,1,1,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 4,179
NCT46325025,Fatigue,General disorders and administration site conditions,No,10%,179,9,13,Treatment Emergent,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 4,179
NCT46325025,Fatigue,General disorders and administration site conditions,No,15%,179,5,5,All Causality,Tremelimumab,Anti-CTLA-4,Lung Cancer,Phase 4,179
NCT11007461,Fatigue,General disorders and administration site conditions,No,5%,314,8,9,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,314
NCT11007461,Fatigue,General disorders and administration site conditions,No,5%,314,7,13,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,314
NCT11007461,Fatigue,General disorders and administration site conditions,No,5%,314,7,14,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,314
NCT11007461,Fatigue,General disorders and administration site conditions,No,5%,314,11,11,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,314
NCT11007461,Fatigue,General disorders and administration site conditions,No,5%,314,4,4,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,314
NCT11007461,Fatigue,General disorders and administration site conditions,No,10%,314,20,33,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,314
NCT11007461,Fatigue,General disorders and administration site conditions,No,15%,314,9,11,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,314
NCT11007461,Fatigue,General disorders and administration site conditions,No,10%,314,3,5,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,314
NCT11007461,Fatigue,General disorders and administration site conditions,No,5%,314,22,31,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,314
NCT11007461,Fatigue,General disorders and administration site conditions,No,15%,314,10,20,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,314
NCT11007461,Fatigue,General disorders and administration site conditions,No,10%,314,9,9,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,314
NCT11007461,Fatigue,General disorders and administration site conditions,No,15%,314,16,22,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,314
NCT11007461,Fatigue,General disorders and administration site conditions,No,15%,314,12,23,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,314
NCT11007461,Fatigue,General disorders and administration site conditions,No,5%,314,16,24,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,314
NCT11007461,Fatigue,General disorders and administration site conditions,No,10%,314,3,5,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,314
NCT97748109,Fatigue,General disorders and administration site conditions,No,15%,648,27,41,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,648
NCT97748109,Fatigue,General disorders and administration site conditions,No,5%,648,26,51,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,648
NCT97748109,Fatigue,General disorders and administration site conditions,No,15%,648,10,18,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,648
NCT97748109,Fatigue,General disorders and administration site conditions,No,5%,648,28,30,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,648
NCT97748109,Fatigue,General disorders and administration site conditions,No,5%,648,19,35,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,648
NCT97748109,Fatigue,General disorders and administration site conditions,No,10%,648,3,4,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,648
NCT97748109,Fatigue,General disorders and administration site conditions,No,5%,648,47,61,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,648
NCT35573456,Fatigue,General disorders and administration site conditions,No,5%,500,16,19,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,500
NCT35573456,Fatigue,General disorders and administration site conditions,No,10%,500,26,52,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,500
NCT35573456,Fatigue,General disorders and administration site conditions,No,5%,500,26,52,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,500
NCT35573456,Fatigue,General disorders and administration site conditions,No,10%,500,41,46,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,500
NCT35573456,Fatigue,General disorders and administration site conditions,No,15%,500,43,82,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,500
NCT35573456,Fatigue,General disorders and administration site conditions,No,15%,500,48,75,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,500
NCT35573456,Fatigue,General disorders and administration site conditions,No,5%,500,6,9,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,500
NCT35573456,Fatigue,General disorders and administration site conditions,No,10%,500,49,57,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,500
NCT35573456,Fatigue,General disorders and administration site conditions,No,15%,500,17,20,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,500
NCT35573456,Fatigue,General disorders and administration site conditions,No,15%,500,48,79,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,500
NCT35573456,Fatigue,General disorders and administration site conditions,No,5%,500,44,68,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,500
NCT35573456,Fatigue,General disorders and administration site conditions,No,15%,500,48,69,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,500
NCT35573456,Fatigue,General disorders and administration site conditions,No,15%,500,4,5,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,500
NCT35573456,Fatigue,General disorders and administration site conditions,No,15%,500,11,20,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,500
NCT43966690,Fatigue,General disorders and administration site conditions,No,10%,649,15,27,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,649
NCT43966690,Fatigue,General disorders and administration site conditions,No,15%,649,27,36,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,649
NCT43966690,Fatigue,General disorders and administration site conditions,No,15%,649,11,21,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,649
NCT43966690,Fatigue,General disorders and administration site conditions,No,15%,649,11,18,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,649
NCT85933226,Fatigue,General disorders and administration site conditions,No,10%,929,29,50,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 3,929
NCT85933226,Fatigue,General disorders and administration site conditions,No,15%,929,4,5,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 3,929
NCT85933226,Fatigue,General disorders and administration site conditions,No,15%,929,36,53,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 3,929
NCT85933226,Fatigue,General disorders and administration site conditions,No,5%,929,27,29,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 3,929
NCT85933226,Fatigue,General disorders and administration site conditions,No,10%,929,28,47,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 3,929
NCT85933226,Fatigue,General disorders and administration site conditions,No,5%,929,50,69,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 3,929
NCT85933226,Fatigue,General disorders and administration site conditions,No,5%,929,47,59,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 3,929
NCT85933226,Fatigue,General disorders and administration site conditions,No,15%,929,6,8,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 3,929
NCT85933226,Fatigue,General disorders and administration site conditions,No,5%,929,1,2,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 3,929
NCT85933226,Fatigue,General disorders and administration site conditions,No,15%,929,16,24,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 3,929
NCT85933226,Fatigue,General disorders and administration site conditions,No,15%,929,3,5,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 3,929
NCT85933226,Fatigue,General disorders and administration site conditions,No,5%,929,31,33,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 3,929
NCT85933226,Fatigue,General disorders and administration site conditions,No,15%,929,37,45,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 3,929
NCT85933226,Fatigue,General disorders and administration site conditions,No,15%,929,47,49,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 3,929
NCT85933226,Fatigue,General disorders and administration site conditions,No,10%,929,41,76,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 3,929
NCT92756595,Fatigue,General disorders and administration site conditions,No,10%,345,1,2,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,345
NCT92756595,Fatigue,General disorders and administration site conditions,No,15%,345,25,45,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,345
NCT92756595,Fatigue,General disorders and administration site conditions,No,15%,345,11,20,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,345
NCT92756595,Fatigue,General disorders and administration site conditions,No,5%,345,10,11,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,345
NCT92756595,Fatigue,General disorders and administration site conditions,No,10%,345,11,21,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,345
NCT92756595,Fatigue,General disorders and administration site conditions,No,10%,345,13,23,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,345
NCT92756595,Fatigue,General disorders and administration site conditions,No,15%,345,2,2,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,345
NCT92756595,Fatigue,General disorders and administration site conditions,No,10%,345,12,15,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,345
NCT92756595,Fatigue,General disorders and administration site conditions,No,15%,345,9,11,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,345
NCT92756595,Fatigue,General disorders and administration site conditions,No,10%,345,29,33,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,345
NCT92756595,Fatigue,General disorders and administration site conditions,No,5%,345,23,41,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,345
NCT92756595,Fatigue,General disorders and administration site conditions,No,15%,345,25,27,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,345
NCT92756595,Fatigue,General disorders and administration site conditions,No,10%,345,17,33,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,345
NCT92756595,Fatigue,General disorders and administration site conditions,No,5%,345,32,43,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,345
NCT92756595,Fatigue,General disorders and administration site conditions,No,15%,345,18,22,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,345
NCT99489167,Fatigue,General disorders and administration site conditions,No,10%,734,35,57,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,734
NCT99489167,Fatigue,General disorders and administration site conditions,No,15%,734,8,9,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,734
NCT99489167,Fatigue,General disorders and administration site conditions,No,15%,734,3,6,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,734
NCT99489167,Fatigue,General disorders and administration site conditions,No,5%,734,21,29,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,734
NCT99489167,Fatigue,General disorders and administration site conditions,No,10%,734,13,23,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,734
NCT99489167,Fatigue,General disorders and administration site conditions,No,5%,734,40,78,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,734
NCT99489167,Fatigue,General disorders and administration site conditions,No,15%,734,24,35,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,734
NCT99489167,Fatigue,General disorders and administration site conditions,No,10%,734,17,29,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,734
NCT99489167,Fatigue,General disorders and administration site conditions,No,5%,734,38,42,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,734
NCT99489167,Fatigue,General disorders and administration site conditions,No,15%,734,6,6,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,734
NCT99489167,Fatigue,General disorders and administration site conditions,No,15%,734,28,31,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,734
NCT99489167,Fatigue,General disorders and administration site conditions,No,5%,734,13,20,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,734
NCT99489167,Fatigue,General disorders and administration site conditions,No,15%,734,42,49,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,734
NCT99489167,Fatigue,General disorders and administration site conditions,No,5%,734,12,14,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,734
NCT80682174,Fatigue,General disorders and administration site conditions,No,5%,78,7,13,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,78
NCT80682174,Fatigue,General disorders and administration site conditions,No,15%,78,5,9,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,78
NCT80682174,Fatigue,General disorders and administration site conditions,No,15%,78,3,4,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,78
NCT80682174,Fatigue,General disorders and administration site conditions,No,5%,78,4,6,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,78
NCT80682174,Fatigue,General disorders and administration site conditions,No,10%,78,6,7,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,78
NCT80682174,Fatigue,General disorders and administration site conditions,No,15%,78,2,3,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,78
NCT80682174,Fatigue,General disorders and administration site conditions,No,15%,78,5,8,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,78
NCT80682174,Fatigue,General disorders and administration site conditions,No,15%,78,7,9,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,78
NCT80682174,Fatigue,General disorders and administration site conditions,No,10%,78,6,11,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,78
NCT80682174,Fatigue,General disorders and administration site conditions,No,5%,78,5,10,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,78
NCT80682174,Fatigue,General disorders and administration site conditions,No,10%,78,1,1,All Causality,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,78
NCT80682174,Fatigue,General disorders and administration site conditions,No,5%,78,5,6,Treatment Emergent,Adalimumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,78
NCT24135362,Fatigue,General disorders and administration site conditions,No,15%,511,3,6,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 1,511
NCT24135362,Fatigue,General disorders and administration site conditions,No,10%,511,22,40,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 1,511
NCT24135362,Fatigue,General disorders and administration site conditions,No,15%,511,29,50,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 1,511
NCT24135362,Fatigue,General disorders and administration site conditions,No,5%,511,15,17,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 1,511
NCT24135362,Fatigue,General disorders and administration site conditions,No,10%,511,28,35,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 1,511
NCT24135362,Fatigue,General disorders and administration site conditions,No,15%,511,37,47,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 1,511
NCT24135362,Fatigue,General disorders and administration site conditions,No,10%,511,37,58,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 1,511
NCT24135362,Fatigue,General disorders and administration site conditions,No,5%,511,34,66,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 1,511
NCT24135362,Fatigue,General disorders and administration site conditions,No,15%,511,21,26,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 1,511
NCT24135362,Fatigue,General disorders and administration site conditions,No,5%,511,31,45,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 1,511
NCT24135362,Fatigue,General disorders and administration site conditions,No,15%,511,24,33,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 1,511
NCT94038370,Fatigue,General disorders and administration site conditions,No,5%,126,3,6,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 1,126
NCT94038370,Fatigue,General disorders and administration site conditions,No,5%,126,3,6,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 1,126
NCT94038370,Fatigue,General disorders and administration site conditions,No,5%,126,8,11,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 1,126
NCT94038370,Fatigue,General disorders and administration site conditions,No,10%,126,1,2,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 1,126
NCT50093936,Fatigue,General disorders and administration site conditions,No,10%,499,10,10,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,499
NCT50093936,Fatigue,General disorders and administration site conditions,No,15%,499,34,35,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,499
NCT50093936,Fatigue,General disorders and administration site conditions,No,10%,499,34,47,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,499
NCT50093936,Fatigue,General disorders and administration site conditions,No,10%,499,47,54,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,499
NCT50093936,Fatigue,General disorders and administration site conditions,No,5%,499,25,43,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,499
NCT50093936,Fatigue,General disorders and administration site conditions,No,15%,499,27,50,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,499
NCT50093936,Fatigue,General disorders and administration site conditions,No,5%,499,37,74,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,499
NCT50093936,Fatigue,General disorders and administration site conditions,No,10%,499,10,10,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,499
NCT50093936,Fatigue,General disorders and administration site conditions,No,10%,499,44,85,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,499
NCT50093936,Fatigue,General disorders and administration site conditions,No,5%,499,35,37,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,499
NCT50093936,Fatigue,General disorders and administration site conditions,No,5%,499,36,57,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,499
NCT50093936,Fatigue,General disorders and administration site conditions,No,5%,499,7,14,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,499
NCT50093936,Fatigue,General disorders and administration site conditions,No,10%,499,8,14,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,499
NCT48837019,Fatigue,General disorders and administration site conditions,No,15%,303,29,44,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,303
NCT48837019,Fatigue,General disorders and administration site conditions,No,5%,303,22,44,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,303
NCT48837019,Fatigue,General disorders and administration site conditions,No,10%,303,22,30,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,303
NCT22311693,Fatigue,General disorders and administration site conditions,No,10%,266,7,9,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,266
NCT22311693,Fatigue,General disorders and administration site conditions,No,10%,266,9,13,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,266
NCT22311693,Fatigue,General disorders and administration site conditions,No,15%,266,21,31,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,266
NCT22311693,Fatigue,General disorders and administration site conditions,No,10%,266,4,4,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,266
NCT22311693,Fatigue,General disorders and administration site conditions,No,10%,266,20,23,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,266
NCT22311693,Fatigue,General disorders and administration site conditions,No,10%,266,22,44,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,266
NCT22311693,Fatigue,General disorders and administration site conditions,No,5%,266,5,10,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,266
NCT22311693,Fatigue,General disorders and administration site conditions,No,10%,266,25,37,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,266
NCT22311693,Fatigue,General disorders and administration site conditions,No,10%,266,22,44,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,266
NCT22311693,Fatigue,General disorders and administration site conditions,No,5%,266,20,27,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,266
NCT22311693,Fatigue,General disorders and administration site conditions,No,15%,266,5,8,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,266
NCT22311693,Fatigue,General disorders and administration site conditions,No,5%,266,17,33,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,266
NCT22311693,Fatigue,General disorders and administration site conditions,No,10%,266,1,2,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,266
NCT22311693,Fatigue,General disorders and administration site conditions,No,15%,266,9,16,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,266
NCT22311693,Fatigue,General disorders and administration site conditions,No,10%,266,4,7,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 2,266
NCT74981713,Fatigue,General disorders and administration site conditions,No,10%,371,22,33,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 3,371
NCT74981713,Fatigue,General disorders and administration site conditions,No,5%,371,6,8,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 3,371
NCT74981713,Fatigue,General disorders and administration site conditions,No,5%,371,35,35,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 3,371
NCT74981713,Fatigue,General disorders and administration site conditions,No,5%,371,28,40,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 3,371
NCT74981713,Fatigue,General disorders and administration site conditions,No,10%,371,33,34,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 3,371
NCT74981713,Fatigue,General disorders and administration site conditions,No,15%,371,9,17,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 3,371
NCT74981713,Fatigue,General disorders and administration site conditions,No,15%,371,33,63,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 3,371
NCT74981713,Fatigue,General disorders and administration site conditions,No,15%,371,2,2,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 3,371
NCT74981713,Fatigue,General disorders and administration site conditions,No,5%,371,3,4,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 3,371
NCT74981713,Fatigue,General disorders and administration site conditions,No,5%,371,36,72,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 3,371
NCT74981713,Fatigue,General disorders and administration site conditions,No,15%,371,3,6,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 3,371
NCT74981713,Fatigue,General disorders and administration site conditions,No,5%,371,33,49,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 3,371
NCT80758062,Fatigue,General disorders and administration site conditions,No,15%,863,31,34,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 3,863
NCT80758062,Fatigue,General disorders and administration site conditions,No,5%,863,27,29,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 3,863
NCT80758062,Fatigue,General disorders and administration site conditions,No,5%,863,10,13,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 3,863
NCT80758062,Fatigue,General disorders and administration site conditions,No,10%,863,49,67,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 3,863
NCT80758062,Fatigue,General disorders and administration site conditions,No,5%,863,29,34,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 3,863
NCT80758062,Fatigue,General disorders and administration site conditions,No,10%,863,17,33,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 3,863
NCT80758062,Fatigue,General disorders and administration site conditions,No,5%,863,7,11,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 3,863
NCT80758062,Fatigue,General disorders and administration site conditions,No,15%,863,18,21,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 3,863
NCT80758062,Fatigue,General disorders and administration site conditions,No,15%,863,9,17,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 3,863
NCT80758062,Fatigue,General disorders and administration site conditions,No,5%,863,46,85,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 3,863
NCT80758062,Fatigue,General disorders and administration site conditions,No,10%,863,44,77,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 3,863
NCT80758062,Fatigue,General disorders and administration site conditions,No,15%,863,27,41,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 3,863
NCT80758062,Fatigue,General disorders and administration site conditions,No,15%,863,28,29,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 3,863
NCT80758062,Fatigue,General disorders and administration site conditions,No,5%,863,18,32,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 3,863
NCT80758062,Fatigue,General disorders and administration site conditions,No,15%,863,9,16,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 3,863
NCT80948906,Fatigue,General disorders and administration site conditions,No,10%,510,48,49,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 4,510
NCT80948906,Fatigue,General disorders and administration site conditions,No,15%,510,10,15,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 4,510
NCT80948906,Fatigue,General disorders and administration site conditions,No,5%,510,31,49,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 4,510
NCT80948906,Fatigue,General disorders and administration site conditions,No,15%,510,34,42,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 4,510
NCT37486257,Fatigue,General disorders and administration site conditions,No,15%,433,38,54,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 4,433
NCT37486257,Fatigue,General disorders and administration site conditions,No,15%,433,15,23,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 4,433
NCT37486257,Fatigue,General disorders and administration site conditions,No,10%,433,37,51,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 4,433
NCT37486257,Fatigue,General disorders and administration site conditions,No,5%,433,18,20,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 4,433
NCT37486257,Fatigue,General disorders and administration site conditions,No,5%,433,30,36,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 4,433
NCT37486257,Fatigue,General disorders and administration site conditions,No,5%,433,7,10,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 4,433
NCT37486257,Fatigue,General disorders and administration site conditions,No,15%,433,6,12,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 4,433
NCT37486257,Fatigue,General disorders and administration site conditions,No,15%,433,10,17,All Causality,Adalimumab,Anti-TNF,Crohn's Disease,Phase 4,433
NCT37486257,Fatigue,General disorders and administration site conditions,No,15%,433,23,31,Treatment Emergent,Adalimumab,Anti-TNF,Crohn's Disease,Phase 4,433
NCT96417196,Fatigue,General disorders and administration site conditions,No,10%,625,4,4,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 1,625
NCT96417196,Fatigue,General disorders and administration site conditions,No,10%,625,48,65,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 1,625
NCT96417196,Fatigue,General disorders and administration site conditions,No,15%,625,32,64,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 1,625
NCT96417196,Fatigue,General disorders and administration site conditions,No,15%,625,43,45,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 1,625
NCT96417196,Fatigue,General disorders and administration site conditions,No,10%,625,47,91,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 1,625
NCT96417196,Fatigue,General disorders and administration site conditions,No,15%,625,47,59,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 1,625
NCT96417196,Fatigue,General disorders and administration site conditions,No,15%,625,33,49,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 1,625
NCT96417196,Fatigue,General disorders and administration site conditions,No,5%,625,5,9,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 1,625
NCT96417196,Fatigue,General disorders and administration site conditions,No,10%,625,23,43,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 1,625
NCT96417196,Fatigue,General disorders and administration site conditions,No,10%,625,32,48,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 1,625
NCT96417196,Fatigue,General disorders and administration site conditions,No,5%,625,21,31,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 1,625
NCT96417196,Fatigue,General disorders and administration site conditions,No,5%,625,18,22,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 1,625
NCT44511828,Fatigue,General disorders and administration site conditions,No,15%,246,12,15,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 2,246
NCT44511828,Fatigue,General disorders and administration site conditions,No,15%,246,14,17,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 2,246
NCT44511828,Fatigue,General disorders and administration site conditions,No,5%,246,23,44,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 2,246
NCT44511828,Fatigue,General disorders and administration site conditions,No,5%,246,8,13,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 2,246
NCT44511828,Fatigue,General disorders and administration site conditions,No,10%,246,4,8,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 2,246
NCT44511828,Fatigue,General disorders and administration site conditions,No,5%,246,22,40,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 2,246
NCT44511828,Fatigue,General disorders and administration site conditions,No,5%,246,1,1,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 2,246
NCT44511828,Fatigue,General disorders and administration site conditions,No,10%,246,14,19,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 2,246
NCT44511828,Fatigue,General disorders and administration site conditions,No,5%,246,1,2,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 2,246
NCT44511828,Fatigue,General disorders and administration site conditions,No,15%,246,15,26,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 2,246
NCT44511828,Fatigue,General disorders and administration site conditions,No,15%,246,7,10,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 2,246
NCT44511828,Fatigue,General disorders and administration site conditions,No,10%,246,23,25,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 2,246
NCT44511828,Fatigue,General disorders and administration site conditions,No,5%,246,23,44,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 2,246
NCT44511828,Fatigue,General disorders and administration site conditions,No,15%,246,3,3,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 2,246
NCT44511828,Fatigue,General disorders and administration site conditions,No,10%,246,3,4,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 2,246
NCT32085804,Fatigue,General disorders and administration site conditions,No,15%,950,17,23,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 2,950
NCT32085804,Fatigue,General disorders and administration site conditions,No,10%,950,26,41,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 2,950
NCT32085804,Fatigue,General disorders and administration site conditions,No,10%,950,30,54,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 2,950
NCT32085804,Fatigue,General disorders and administration site conditions,No,5%,950,35,56,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 2,950
NCT32085804,Fatigue,General disorders and administration site conditions,No,15%,950,39,61,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 2,950
NCT32085804,Fatigue,General disorders and administration site conditions,No,15%,950,4,6,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 2,950
NCT32085804,Fatigue,General disorders and administration site conditions,No,15%,950,38,73,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 2,950
NCT32085804,Fatigue,General disorders and administration site conditions,No,5%,950,39,46,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 2,950
NCT32085804,Fatigue,General disorders and administration site conditions,No,10%,950,3,6,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 2,950
NCT32085804,Fatigue,General disorders and administration site conditions,No,5%,950,5,9,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 2,950
NCT32085804,Fatigue,General disorders and administration site conditions,No,5%,950,43,76,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 2,950
NCT32085804,Fatigue,General disorders and administration site conditions,No,10%,950,48,59,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 2,950
NCT32085804,Fatigue,General disorders and administration site conditions,No,15%,950,37,68,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 2,950
NCT32085804,Fatigue,General disorders and administration site conditions,No,5%,950,1,2,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 2,950
NCT92889143,Fatigue,General disorders and administration site conditions,No,15%,925,17,18,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 2,925
NCT92889143,Fatigue,General disorders and administration site conditions,No,15%,925,41,45,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 2,925
NCT92889143,Fatigue,General disorders and administration site conditions,No,5%,925,18,33,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 2,925
NCT92889143,Fatigue,General disorders and administration site conditions,No,5%,925,37,67,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 2,925
NCT92889143,Fatigue,General disorders and administration site conditions,No,10%,925,32,35,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 2,925
NCT92889143,Fatigue,General disorders and administration site conditions,No,15%,925,34,46,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 2,925
NCT92889143,Fatigue,General disorders and administration site conditions,No,15%,925,24,39,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 2,925
NCT92889143,Fatigue,General disorders and administration site conditions,No,15%,925,47,52,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 2,925
NCT15815294,Fatigue,General disorders and administration site conditions,No,10%,247,9,11,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 3,247
NCT15815294,Fatigue,General disorders and administration site conditions,No,15%,247,7,7,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 3,247
NCT15815294,Fatigue,General disorders and administration site conditions,No,5%,247,22,38,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 3,247
NCT15815294,Fatigue,General disorders and administration site conditions,No,10%,247,16,24,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 3,247
NCT15815294,Fatigue,General disorders and administration site conditions,No,15%,247,24,38,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 3,247
NCT15815294,Fatigue,General disorders and administration site conditions,No,5%,247,23,38,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 3,247
NCT15815294,Fatigue,General disorders and administration site conditions,No,15%,247,5,6,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 3,247
NCT15815294,Fatigue,General disorders and administration site conditions,No,10%,247,7,13,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 3,247
NCT15815294,Fatigue,General disorders and administration site conditions,No,10%,247,4,6,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 3,247
NCT15815294,Fatigue,General disorders and administration site conditions,No,5%,247,13,25,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 3,247
NCT15815294,Fatigue,General disorders and administration site conditions,No,15%,247,9,16,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 3,247
NCT68719223,Fatigue,General disorders and administration site conditions,No,5%,346,1,1,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 3,346
NCT68719223,Fatigue,General disorders and administration site conditions,No,10%,346,19,37,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 3,346
NCT68719223,Fatigue,General disorders and administration site conditions,No,15%,346,24,30,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 3,346
NCT68719223,Fatigue,General disorders and administration site conditions,No,5%,346,9,10,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 3,346
NCT68719223,Fatigue,General disorders and administration site conditions,No,10%,346,33,49,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 3,346
NCT68719223,Fatigue,General disorders and administration site conditions,No,5%,346,34,58,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 3,346
NCT68719223,Fatigue,General disorders and administration site conditions,No,5%,346,14,21,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 3,346
NCT30399032,Fatigue,General disorders and administration site conditions,No,15%,749,2,4,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 3,749
NCT30399032,Fatigue,General disorders and administration site conditions,No,10%,749,39,59,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 3,749
NCT30399032,Fatigue,General disorders and administration site conditions,No,5%,749,39,71,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 3,749
NCT30399032,Fatigue,General disorders and administration site conditions,No,10%,749,8,13,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 3,749
NCT30399032,Fatigue,General disorders and administration site conditions,No,10%,749,9,11,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 3,749
NCT30399032,Fatigue,General disorders and administration site conditions,No,5%,749,7,7,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 3,749
NCT79831002,Fatigue,General disorders and administration site conditions,No,15%,273,1,1,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 4,273
NCT79831002,Fatigue,General disorders and administration site conditions,No,5%,273,15,22,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 4,273
NCT79831002,Fatigue,General disorders and administration site conditions,No,15%,273,18,32,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 4,273
NCT79831002,Fatigue,General disorders and administration site conditions,No,5%,273,15,20,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 4,273
NCT49032232,Fatigue,General disorders and administration site conditions,No,5%,29,2,3,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 4,29
NCT49032232,Fatigue,General disorders and administration site conditions,No,5%,29,2,3,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 4,29
NCT49032232,Fatigue,General disorders and administration site conditions,No,5%,29,1,1,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 4,29
NCT49032232,Fatigue,General disorders and administration site conditions,No,5%,29,1,2,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 4,29
NCT49032232,Fatigue,General disorders and administration site conditions,No,15%,29,1,2,Treatment Emergent,Adalimumab,Anti-TNF,Psoriasis,Phase 4,29
NCT49032232,Fatigue,General disorders and administration site conditions,No,15%,29,2,2,All Causality,Adalimumab,Anti-TNF,Psoriasis,Phase 4,29
NCT55167681,Fatigue,General disorders and administration site conditions,No,10%,774,46,63,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 1,774
NCT55167681,Fatigue,General disorders and administration site conditions,No,5%,774,45,58,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 1,774
NCT55167681,Fatigue,General disorders and administration site conditions,No,5%,774,18,19,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 1,774
NCT55167681,Fatigue,General disorders and administration site conditions,No,10%,774,29,40,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 1,774
NCT55167681,Fatigue,General disorders and administration site conditions,No,15%,774,23,41,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 1,774
NCT55167681,Fatigue,General disorders and administration site conditions,No,15%,774,12,20,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 1,774
NCT55167681,Fatigue,General disorders and administration site conditions,No,5%,774,22,23,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 1,774
NCT55167681,Fatigue,General disorders and administration site conditions,No,5%,774,30,49,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 1,774
NCT55167681,Fatigue,General disorders and administration site conditions,No,5%,774,45,49,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 1,774
NCT55167681,Fatigue,General disorders and administration site conditions,No,5%,774,47,73,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 1,774
NCT55167681,Fatigue,General disorders and administration site conditions,No,15%,774,5,10,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 1,774
NCT55167681,Fatigue,General disorders and administration site conditions,No,10%,774,32,40,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 1,774
NCT55167681,Fatigue,General disorders and administration site conditions,No,15%,774,27,34,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 1,774
NCT16019324,Fatigue,General disorders and administration site conditions,No,5%,21,1,1,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 1,21
NCT16019324,Fatigue,General disorders and administration site conditions,No,5%,21,2,2,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 1,21
NCT16019324,Fatigue,General disorders and administration site conditions,No,15%,21,1,1,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 1,21
NCT16019324,Fatigue,General disorders and administration site conditions,No,5%,21,1,2,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 1,21
NCT16019324,Fatigue,General disorders and administration site conditions,No,10%,21,2,2,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 1,21
NCT16019324,Fatigue,General disorders and administration site conditions,No,5%,21,2,4,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 1,21
NCT16019324,Fatigue,General disorders and administration site conditions,No,15%,21,2,4,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 1,21
NCT16019324,Fatigue,General disorders and administration site conditions,No,15%,21,1,1,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 1,21
NCT31936985,Fatigue,General disorders and administration site conditions,No,15%,304,6,8,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 1,304
NCT31936985,Fatigue,General disorders and administration site conditions,No,15%,304,16,30,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 1,304
NCT31936985,Fatigue,General disorders and administration site conditions,No,5%,304,23,39,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 1,304
NCT75611145,Fatigue,General disorders and administration site conditions,No,10%,433,13,13,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 2,433
NCT75611145,Fatigue,General disorders and administration site conditions,No,5%,433,18,31,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 2,433
NCT75611145,Fatigue,General disorders and administration site conditions,No,15%,433,40,63,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 2,433
NCT75611145,Fatigue,General disorders and administration site conditions,No,10%,433,17,31,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 2,433
NCT75611145,Fatigue,General disorders and administration site conditions,No,5%,433,28,28,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 2,433
NCT75611145,Fatigue,General disorders and administration site conditions,No,5%,433,15,19,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 2,433
NCT75611145,Fatigue,General disorders and administration site conditions,No,10%,433,29,45,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 2,433
NCT75611145,Fatigue,General disorders and administration site conditions,No,15%,433,13,23,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 2,433
NCT75611145,Fatigue,General disorders and administration site conditions,No,10%,433,3,3,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 2,433
NCT75611145,Fatigue,General disorders and administration site conditions,No,15%,433,28,31,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 2,433
NCT75611145,Fatigue,General disorders and administration site conditions,No,15%,433,14,21,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 2,433
NCT75611145,Fatigue,General disorders and administration site conditions,No,10%,433,43,86,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 2,433
NCT75611145,Fatigue,General disorders and administration site conditions,No,10%,433,1,2,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 2,433
NCT75611145,Fatigue,General disorders and administration site conditions,No,5%,433,35,42,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 2,433
NCT99787561,Fatigue,General disorders and administration site conditions,No,10%,717,34,35,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 3,717
NCT99787561,Fatigue,General disorders and administration site conditions,No,10%,717,5,10,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 3,717
NCT99787561,Fatigue,General disorders and administration site conditions,No,15%,717,2,4,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 3,717
NCT99787561,Fatigue,General disorders and administration site conditions,No,5%,717,44,57,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 3,717
NCT99787561,Fatigue,General disorders and administration site conditions,No,5%,717,17,30,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 3,717
NCT99787561,Fatigue,General disorders and administration site conditions,No,15%,717,48,64,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 3,717
NCT99787561,Fatigue,General disorders and administration site conditions,No,15%,717,6,12,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 3,717
NCT99787561,Fatigue,General disorders and administration site conditions,No,5%,717,38,67,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 3,717
NCT99787561,Fatigue,General disorders and administration site conditions,No,15%,717,31,34,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 3,717
NCT99787561,Fatigue,General disorders and administration site conditions,No,10%,717,10,14,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 3,717
NCT24208608,Fatigue,General disorders and administration site conditions,No,15%,427,8,11,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 3,427
NCT24208608,Fatigue,General disorders and administration site conditions,No,15%,427,6,11,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 3,427
NCT24208608,Fatigue,General disorders and administration site conditions,No,10%,427,22,32,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 3,427
NCT43982576,Fatigue,General disorders and administration site conditions,No,5%,633,39,77,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 3,633
NCT43982576,Fatigue,General disorders and administration site conditions,No,15%,633,24,34,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 3,633
NCT43982576,Fatigue,General disorders and administration site conditions,No,5%,633,27,39,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 3,633
NCT43982576,Fatigue,General disorders and administration site conditions,No,10%,633,40,64,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 3,633
NCT43982576,Fatigue,General disorders and administration site conditions,No,15%,633,11,15,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 3,633
NCT43982576,Fatigue,General disorders and administration site conditions,No,5%,633,25,38,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 3,633
NCT43982576,Fatigue,General disorders and administration site conditions,No,10%,633,28,31,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 3,633
NCT43982576,Fatigue,General disorders and administration site conditions,No,5%,633,15,22,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 3,633
NCT43982576,Fatigue,General disorders and administration site conditions,No,5%,633,11,18,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 3,633
NCT43982576,Fatigue,General disorders and administration site conditions,No,5%,633,19,38,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 3,633
NCT43982576,Fatigue,General disorders and administration site conditions,No,10%,633,26,27,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 3,633
NCT43982576,Fatigue,General disorders and administration site conditions,No,10%,633,2,4,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 3,633
NCT43982576,Fatigue,General disorders and administration site conditions,No,15%,633,39,49,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 3,633
NCT43982576,Fatigue,General disorders and administration site conditions,No,5%,633,28,44,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 3,633
NCT31344084,Fatigue,General disorders and administration site conditions,No,15%,584,42,47,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,584
NCT31344084,Fatigue,General disorders and administration site conditions,No,10%,584,29,32,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,584
NCT31344084,Fatigue,General disorders and administration site conditions,No,5%,584,3,5,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,584
NCT31344084,Fatigue,General disorders and administration site conditions,No,5%,584,36,65,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,584
NCT31344084,Fatigue,General disorders and administration site conditions,No,10%,584,17,19,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,584
NCT31344084,Fatigue,General disorders and administration site conditions,No,15%,584,31,41,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,584
NCT31344084,Fatigue,General disorders and administration site conditions,No,5%,584,6,9,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,584
NCT31344084,Fatigue,General disorders and administration site conditions,No,5%,584,13,15,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,584
NCT31344084,Fatigue,General disorders and administration site conditions,No,10%,584,27,30,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,584
NCT31344084,Fatigue,General disorders and administration site conditions,No,5%,584,38,44,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,584
NCT31344084,Fatigue,General disorders and administration site conditions,No,15%,584,28,45,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,584
NCT15451654,Fatigue,General disorders and administration site conditions,No,10%,460,35,68,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,460
NCT15451654,Fatigue,General disorders and administration site conditions,No,15%,460,19,30,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,460
NCT15451654,Fatigue,General disorders and administration site conditions,No,15%,460,33,49,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,460
NCT15451654,Fatigue,General disorders and administration site conditions,No,10%,460,9,17,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,460
NCT15451654,Fatigue,General disorders and administration site conditions,No,10%,460,22,44,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,460
NCT15451654,Fatigue,General disorders and administration site conditions,No,10%,460,39,52,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,460
NCT15451654,Fatigue,General disorders and administration site conditions,No,5%,460,15,21,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,460
NCT15451654,Fatigue,General disorders and administration site conditions,No,5%,460,7,13,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,460
NCT15451654,Fatigue,General disorders and administration site conditions,No,5%,460,20,38,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,460
NCT15451654,Fatigue,General disorders and administration site conditions,No,15%,460,24,26,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,460
NCT15451654,Fatigue,General disorders and administration site conditions,No,5%,460,10,18,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,460
NCT15451654,Fatigue,General disorders and administration site conditions,No,15%,460,32,54,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,460
NCT15451654,Fatigue,General disorders and administration site conditions,No,15%,460,27,32,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,460
NCT15451654,Fatigue,General disorders and administration site conditions,No,10%,460,16,32,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,460
NCT15451654,Fatigue,General disorders and administration site conditions,No,10%,460,41,75,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,460
NCT90733242,Fatigue,General disorders and administration site conditions,No,15%,275,26,32,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,275
NCT90733242,Fatigue,General disorders and administration site conditions,No,10%,275,22,26,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,275
NCT90733242,Fatigue,General disorders and administration site conditions,No,10%,275,1,2,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,275
NCT90733242,Fatigue,General disorders and administration site conditions,No,10%,275,24,42,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,275
NCT90733242,Fatigue,General disorders and administration site conditions,No,10%,275,3,5,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,275
NCT90733242,Fatigue,General disorders and administration site conditions,No,15%,275,6,6,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,275
NCT90733242,Fatigue,General disorders and administration site conditions,No,10%,275,23,44,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,275
NCT90733242,Fatigue,General disorders and administration site conditions,No,10%,275,9,17,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,275
NCT90733242,Fatigue,General disorders and administration site conditions,No,5%,275,15,24,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,275
NCT90733242,Fatigue,General disorders and administration site conditions,No,15%,275,5,9,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,275
NCT90733242,Fatigue,General disorders and administration site conditions,No,15%,275,26,37,Treatment Emergent,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,275
NCT90733242,Fatigue,General disorders and administration site conditions,No,5%,275,14,20,All Causality,Infliximab,Anti-TNF,Rheumatoid Arthritis,Phase 4,275
NCT31094512,Fatigue,General disorders and administration site conditions,No,10%,952,21,32,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 1,952
NCT31094512,Fatigue,General disorders and administration site conditions,No,15%,952,35,57,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 1,952
NCT31094512,Fatigue,General disorders and administration site conditions,No,15%,952,43,86,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 1,952
NCT31094512,Fatigue,General disorders and administration site conditions,No,10%,952,34,68,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 1,952
NCT82979804,Fatigue,General disorders and administration site conditions,No,15%,677,50,84,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 1,677
NCT82979804,Fatigue,General disorders and administration site conditions,No,10%,677,24,34,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 1,677
NCT82979804,Fatigue,General disorders and administration site conditions,No,15%,677,45,88,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 1,677
NCT82979804,Fatigue,General disorders and administration site conditions,No,10%,677,45,57,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 1,677
NCT82979804,Fatigue,General disorders and administration site conditions,No,15%,677,42,46,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 1,677
NCT82979804,Fatigue,General disorders and administration site conditions,No,10%,677,23,26,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 1,677
NCT82979804,Fatigue,General disorders and administration site conditions,No,10%,677,21,28,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 1,677
NCT82979804,Fatigue,General disorders and administration site conditions,No,10%,677,8,10,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 1,677
NCT82979804,Fatigue,General disorders and administration site conditions,No,15%,677,47,52,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 1,677
NCT82979804,Fatigue,General disorders and administration site conditions,No,5%,677,18,24,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 1,677
NCT82979804,Fatigue,General disorders and administration site conditions,No,15%,677,43,48,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 1,677
NCT82979804,Fatigue,General disorders and administration site conditions,No,5%,677,25,38,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 1,677
NCT30804216,Fatigue,General disorders and administration site conditions,No,5%,172,7,9,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 1,172
NCT30804216,Fatigue,General disorders and administration site conditions,No,10%,172,7,12,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 1,172
NCT30804216,Fatigue,General disorders and administration site conditions,No,15%,172,15,25,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 1,172
NCT30804216,Fatigue,General disorders and administration site conditions,No,15%,172,6,6,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 1,172
NCT30804216,Fatigue,General disorders and administration site conditions,No,10%,172,7,8,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 1,172
NCT30804216,Fatigue,General disorders and administration site conditions,No,10%,172,15,24,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 1,172
NCT30804216,Fatigue,General disorders and administration site conditions,No,10%,172,13,24,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 1,172
NCT30804216,Fatigue,General disorders and administration site conditions,No,10%,172,11,13,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 1,172
NCT30804216,Fatigue,General disorders and administration site conditions,No,15%,172,16,24,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 1,172
NCT47154172,Fatigue,General disorders and administration site conditions,No,15%,673,29,34,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 2,673
NCT47154172,Fatigue,General disorders and administration site conditions,No,10%,673,42,49,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 2,673
NCT47154172,Fatigue,General disorders and administration site conditions,No,15%,673,37,58,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 2,673
NCT47154172,Fatigue,General disorders and administration site conditions,No,15%,673,43,84,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 2,673
NCT47154172,Fatigue,General disorders and administration site conditions,No,10%,673,38,48,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 2,673
NCT47154172,Fatigue,General disorders and administration site conditions,No,10%,673,5,10,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 2,673
NCT47154172,Fatigue,General disorders and administration site conditions,No,10%,673,4,7,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 2,673
NCT17286189,Fatigue,General disorders and administration site conditions,No,5%,432,41,47,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 2,432
NCT17286189,Fatigue,General disorders and administration site conditions,No,5%,432,31,43,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 2,432
NCT17286189,Fatigue,General disorders and administration site conditions,No,10%,432,12,24,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 2,432
NCT97360248,Fatigue,General disorders and administration site conditions,No,15%,242,5,5,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 2,242
NCT97360248,Fatigue,General disorders and administration site conditions,No,10%,242,11,16,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 2,242
NCT97360248,Fatigue,General disorders and administration site conditions,No,15%,242,17,26,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 2,242
NCT97360248,Fatigue,General disorders and administration site conditions,No,15%,242,10,13,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 2,242
NCT97360248,Fatigue,General disorders and administration site conditions,No,15%,242,2,2,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 2,242
NCT97360248,Fatigue,General disorders and administration site conditions,No,5%,242,21,38,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 2,242
NCT97360248,Fatigue,General disorders and administration site conditions,No,10%,242,6,8,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 2,242
NCT97360248,Fatigue,General disorders and administration site conditions,No,10%,242,2,2,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 2,242
NCT97360248,Fatigue,General disorders and administration site conditions,No,5%,242,8,10,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 2,242
NCT97360248,Fatigue,General disorders and administration site conditions,No,5%,242,24,31,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 2,242
NCT12891154,Fatigue,General disorders and administration site conditions,No,5%,887,34,63,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 3,887
NCT12891154,Fatigue,General disorders and administration site conditions,No,10%,887,41,56,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 3,887
NCT12891154,Fatigue,General disorders and administration site conditions,No,5%,887,43,55,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 3,887
NCT17612082,Fatigue,General disorders and administration site conditions,No,5%,121,3,3,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,121
NCT17612082,Fatigue,General disorders and administration site conditions,No,5%,121,12,15,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,121
NCT17612082,Fatigue,General disorders and administration site conditions,No,10%,121,1,1,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,121
NCT17612082,Fatigue,General disorders and administration site conditions,No,15%,121,9,10,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,121
NCT17612082,Fatigue,General disorders and administration site conditions,No,10%,121,6,12,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,121
NCT17612082,Fatigue,General disorders and administration site conditions,No,15%,121,8,13,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,121
NCT17612082,Fatigue,General disorders and administration site conditions,No,10%,121,10,19,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,121
NCT17612082,Fatigue,General disorders and administration site conditions,No,5%,121,3,3,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,121
NCT17612082,Fatigue,General disorders and administration site conditions,No,10%,121,1,1,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,121
NCT17612082,Fatigue,General disorders and administration site conditions,No,10%,121,6,12,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,121
NCT17612082,Fatigue,General disorders and administration site conditions,No,10%,121,7,11,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,121
NCT17612082,Fatigue,General disorders and administration site conditions,No,5%,121,11,19,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,121
NCT17612082,Fatigue,General disorders and administration site conditions,No,5%,121,7,13,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,121
NCT43370171,Fatigue,General disorders and administration site conditions,No,15%,886,18,29,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,886
NCT43370171,Fatigue,General disorders and administration site conditions,No,15%,886,6,9,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,886
NCT43370171,Fatigue,General disorders and administration site conditions,No,5%,886,5,10,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,886
NCT43370171,Fatigue,General disorders and administration site conditions,No,15%,886,18,30,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,886
NCT43370171,Fatigue,General disorders and administration site conditions,No,10%,886,26,36,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,886
NCT43370171,Fatigue,General disorders and administration site conditions,No,5%,886,47,80,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,886
NCT43370171,Fatigue,General disorders and administration site conditions,No,15%,886,47,62,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,886
NCT43370171,Fatigue,General disorders and administration site conditions,No,15%,886,26,29,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,886
NCT43370171,Fatigue,General disorders and administration site conditions,No,15%,886,28,41,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,886
NCT43370171,Fatigue,General disorders and administration site conditions,No,10%,886,6,12,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,886
NCT93835633,Fatigue,General disorders and administration site conditions,No,15%,450,21,33,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,450
NCT93835633,Fatigue,General disorders and administration site conditions,No,15%,450,15,15,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,450
NCT93835633,Fatigue,General disorders and administration site conditions,No,10%,450,31,55,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,450
NCT93835633,Fatigue,General disorders and administration site conditions,No,5%,450,3,3,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,450
NCT93835633,Fatigue,General disorders and administration site conditions,No,10%,450,11,11,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,450
NCT93835633,Fatigue,General disorders and administration site conditions,No,10%,450,3,6,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,450
NCT93835633,Fatigue,General disorders and administration site conditions,No,10%,450,12,18,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,450
NCT93835633,Fatigue,General disorders and administration site conditions,No,5%,450,13,21,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,450
NCT93835633,Fatigue,General disorders and administration site conditions,No,10%,450,29,34,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,450
NCT93835633,Fatigue,General disorders and administration site conditions,No,15%,450,17,24,All Causality,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,450
NCT93835633,Fatigue,General disorders and administration site conditions,No,5%,450,8,15,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,450
NCT93835633,Fatigue,General disorders and administration site conditions,No,15%,450,2,4,Treatment Emergent,Infliximab,Anti-TNF,Crohn's Disease,Phase 4,450
NCT34886786,Fatigue,General disorders and administration site conditions,No,15%,32,1,2,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 1,32
NCT34886786,Fatigue,General disorders and administration site conditions,No,10%,32,2,4,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 1,32
NCT34886786,Fatigue,General disorders and administration site conditions,No,15%,32,2,2,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 1,32
NCT34886786,Fatigue,General disorders and administration site conditions,No,15%,32,2,3,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 1,32
NCT34886786,Fatigue,General disorders and administration site conditions,No,15%,32,2,4,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 1,32
NCT34886786,Fatigue,General disorders and administration site conditions,No,5%,32,1,2,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 1,32
NCT34886786,Fatigue,General disorders and administration site conditions,No,5%,32,2,3,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 1,32
NCT34886786,Fatigue,General disorders and administration site conditions,No,5%,32,2,2,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 1,32
NCT34886786,Fatigue,General disorders and administration site conditions,No,15%,32,3,6,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 1,32
NCT12508045,Fatigue,General disorders and administration site conditions,No,5%,710,37,63,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 1,710
NCT12508045,Fatigue,General disorders and administration site conditions,No,15%,710,11,21,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 1,710
NCT12508045,Fatigue,General disorders and administration site conditions,No,15%,710,9,11,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 1,710
NCT12508045,Fatigue,General disorders and administration site conditions,No,10%,710,10,17,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 1,710
NCT12508045,Fatigue,General disorders and administration site conditions,No,15%,710,37,53,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 1,710
NCT59756976,Fatigue,General disorders and administration site conditions,No,10%,396,30,35,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 2,396
NCT59756976,Fatigue,General disorders and administration site conditions,No,5%,396,23,34,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 2,396
NCT59756976,Fatigue,General disorders and administration site conditions,No,5%,396,13,20,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 2,396
NCT59756976,Fatigue,General disorders and administration site conditions,No,5%,396,36,39,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 2,396
NCT59756976,Fatigue,General disorders and administration site conditions,No,15%,396,6,6,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 2,396
NCT59756976,Fatigue,General disorders and administration site conditions,No,5%,396,35,36,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 2,396
NCT59756976,Fatigue,General disorders and administration site conditions,No,10%,396,17,33,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 2,396
NCT59756976,Fatigue,General disorders and administration site conditions,No,10%,396,4,6,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 2,396
NCT59756976,Fatigue,General disorders and administration site conditions,No,10%,396,6,10,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 2,396
NCT59756976,Fatigue,General disorders and administration site conditions,No,5%,396,4,7,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 2,396
NCT59756976,Fatigue,General disorders and administration site conditions,No,15%,396,10,18,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 2,396
NCT59756976,Fatigue,General disorders and administration site conditions,No,10%,396,5,10,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 2,396
NCT20102274,Fatigue,General disorders and administration site conditions,No,10%,123,3,3,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 2,123
NCT20102274,Fatigue,General disorders and administration site conditions,No,10%,123,4,7,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 2,123
NCT20102274,Fatigue,General disorders and administration site conditions,No,10%,123,8,8,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 2,123
NCT20102274,Fatigue,General disorders and administration site conditions,No,10%,123,12,15,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 2,123
NCT20102274,Fatigue,General disorders and administration site conditions,No,5%,123,7,8,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 2,123
NCT20102274,Fatigue,General disorders and administration site conditions,No,10%,123,12,12,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 2,123
NCT56010568,Fatigue,General disorders and administration site conditions,No,5%,356,30,40,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 2,356
NCT56010568,Fatigue,General disorders and administration site conditions,No,5%,356,29,36,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 2,356
NCT56010568,Fatigue,General disorders and administration site conditions,No,5%,356,29,52,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 2,356
NCT56010568,Fatigue,General disorders and administration site conditions,No,10%,356,29,45,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 2,356
NCT56010568,Fatigue,General disorders and administration site conditions,No,10%,356,20,31,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 2,356
NCT56010568,Fatigue,General disorders and administration site conditions,No,15%,356,19,34,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 2,356
NCT56010568,Fatigue,General disorders and administration site conditions,No,10%,356,27,31,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 2,356
NCT56010568,Fatigue,General disorders and administration site conditions,No,10%,356,3,4,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 2,356
NCT56010568,Fatigue,General disorders and administration site conditions,No,15%,356,3,4,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 2,356
NCT56010568,Fatigue,General disorders and administration site conditions,No,5%,356,19,19,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 2,356
NCT56010568,Fatigue,General disorders and administration site conditions,No,15%,356,31,50,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 2,356
NCT56010568,Fatigue,General disorders and administration site conditions,No,10%,356,32,33,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 2,356
NCT56010568,Fatigue,General disorders and administration site conditions,No,15%,356,1,2,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 2,356
NCT56010568,Fatigue,General disorders and administration site conditions,No,10%,356,4,6,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 2,356
NCT82942613,Fatigue,General disorders and administration site conditions,No,15%,896,50,70,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 3,896
NCT82942613,Fatigue,General disorders and administration site conditions,No,5%,896,49,72,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 3,896
NCT82942613,Fatigue,General disorders and administration site conditions,No,15%,896,25,32,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 3,896
NCT82942613,Fatigue,General disorders and administration site conditions,No,15%,896,19,27,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 3,896
NCT82942613,Fatigue,General disorders and administration site conditions,No,10%,896,5,9,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 3,896
NCT82942613,Fatigue,General disorders and administration site conditions,No,15%,896,16,27,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 3,896
NCT82942613,Fatigue,General disorders and administration site conditions,No,15%,896,6,10,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 3,896
NCT82942613,Fatigue,General disorders and administration site conditions,No,10%,896,21,40,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 3,896
NCT82942613,Fatigue,General disorders and administration site conditions,No,5%,896,21,37,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 3,896
NCT82942613,Fatigue,General disorders and administration site conditions,No,15%,896,13,17,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 3,896
NCT82942613,Fatigue,General disorders and administration site conditions,No,5%,896,30,47,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 3,896
NCT82942613,Fatigue,General disorders and administration site conditions,No,5%,896,43,47,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 3,896
NCT82942613,Fatigue,General disorders and administration site conditions,No,15%,896,50,92,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 3,896
NCT82942613,Fatigue,General disorders and administration site conditions,No,5%,896,49,62,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 3,896
NCT23874360,Fatigue,General disorders and administration site conditions,No,5%,932,31,47,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 3,932
NCT23874360,Fatigue,General disorders and administration site conditions,No,5%,932,25,25,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 3,932
NCT23874360,Fatigue,General disorders and administration site conditions,No,10%,932,16,30,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 3,932
NCT23874360,Fatigue,General disorders and administration site conditions,No,5%,932,18,22,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 3,932
NCT23874360,Fatigue,General disorders and administration site conditions,No,10%,932,28,52,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 3,932
NCT23874360,Fatigue,General disorders and administration site conditions,No,10%,932,16,20,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 3,932
NCT23874360,Fatigue,General disorders and administration site conditions,No,15%,932,31,61,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 3,932
NCT73100492,Fatigue,General disorders and administration site conditions,No,5%,975,42,58,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 3,975
NCT73100492,Fatigue,General disorders and administration site conditions,No,15%,975,6,9,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 3,975
NCT73100492,Fatigue,General disorders and administration site conditions,No,5%,975,1,2,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 3,975
NCT73100492,Fatigue,General disorders and administration site conditions,No,10%,975,37,69,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 3,975
NCT73100492,Fatigue,General disorders and administration site conditions,No,15%,975,18,19,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 3,975
NCT73100492,Fatigue,General disorders and administration site conditions,No,5%,975,30,37,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 3,975
NCT73100492,Fatigue,General disorders and administration site conditions,No,15%,975,8,14,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 3,975
NCT73100492,Fatigue,General disorders and administration site conditions,No,15%,975,26,31,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 3,975
NCT73100492,Fatigue,General disorders and administration site conditions,No,5%,975,16,28,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 3,975
NCT73100492,Fatigue,General disorders and administration site conditions,No,5%,975,11,15,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 3,975
NCT73100492,Fatigue,General disorders and administration site conditions,No,5%,975,1,1,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 3,975
NCT73100492,Fatigue,General disorders and administration site conditions,No,15%,975,11,14,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 3,975
NCT73100492,Fatigue,General disorders and administration site conditions,No,10%,975,42,46,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 3,975
NCT73100492,Fatigue,General disorders and administration site conditions,No,5%,975,24,44,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 3,975
NCT73100492,Fatigue,General disorders and administration site conditions,No,5%,975,29,57,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 3,975
NCT11972949,Fatigue,General disorders and administration site conditions,No,10%,485,32,35,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 4,485
NCT11972949,Fatigue,General disorders and administration site conditions,No,5%,485,31,40,Treatment Emergent,Infliximab,Anti-TNF,Psoriasis,Phase 4,485
NCT11972949,Fatigue,General disorders and administration site conditions,No,15%,485,28,36,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 4,485
NCT11972949,Fatigue,General disorders and administration site conditions,No,15%,485,46,51,All Causality,Infliximab,Anti-TNF,Psoriasis,Phase 4,485
NCT80399181,Fatigue,General disorders and administration site conditions,No,15%,753,2,2,Treatment Emergent,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,753
NCT80399181,Fatigue,General disorders and administration site conditions,No,5%,753,17,23,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,753
NCT80399181,Fatigue,General disorders and administration site conditions,No,15%,753,3,5,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,753
NCT80399181,Fatigue,General disorders and administration site conditions,No,15%,753,48,81,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,753
NCT80399181,Fatigue,General disorders and administration site conditions,No,15%,753,43,81,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,753
NCT80399181,Fatigue,General disorders and administration site conditions,No,10%,753,19,31,Treatment Emergent,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,753
NCT80399181,Fatigue,General disorders and administration site conditions,No,10%,753,48,60,Treatment Emergent,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,753
NCT80399181,Fatigue,General disorders and administration site conditions,No,15%,753,4,8,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,753
NCT80399181,Fatigue,General disorders and administration site conditions,No,10%,753,28,38,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,753
NCT80399181,Fatigue,General disorders and administration site conditions,No,5%,753,15,28,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,753
NCT80399181,Fatigue,General disorders and administration site conditions,No,5%,753,7,14,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,753
NCT80399181,Fatigue,General disorders and administration site conditions,No,5%,753,21,24,Treatment Emergent,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,753
NCT80399181,Fatigue,General disorders and administration site conditions,No,5%,753,12,16,Treatment Emergent,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,753
NCT80399181,Fatigue,General disorders and administration site conditions,No,10%,753,45,83,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,753
NCT80399181,Fatigue,General disorders and administration site conditions,No,5%,753,34,54,Treatment Emergent,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,753
NCT81449223,Fatigue,General disorders and administration site conditions,No,10%,505,7,9,Treatment Emergent,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,505
NCT81449223,Fatigue,General disorders and administration site conditions,No,15%,505,7,8,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,505
NCT81449223,Fatigue,General disorders and administration site conditions,No,10%,505,25,29,Treatment Emergent,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,505
NCT81449223,Fatigue,General disorders and administration site conditions,No,15%,505,49,74,Treatment Emergent,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,505
NCT95177158,Fatigue,General disorders and administration site conditions,No,5%,706,42,45,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,706
NCT95177158,Fatigue,General disorders and administration site conditions,No,15%,706,46,53,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,706
NCT95177158,Fatigue,General disorders and administration site conditions,No,10%,706,48,54,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,706
NCT95177158,Fatigue,General disorders and administration site conditions,No,5%,706,6,8,Treatment Emergent,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,706
NCT95177158,Fatigue,General disorders and administration site conditions,No,5%,706,29,45,Treatment Emergent,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,706
NCT95177158,Fatigue,General disorders and administration site conditions,No,5%,706,11,19,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,706
NCT95177158,Fatigue,General disorders and administration site conditions,No,15%,706,11,22,Treatment Emergent,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 1,706
NCT15990835,Fatigue,General disorders and administration site conditions,No,15%,970,18,30,Treatment Emergent,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,970
NCT15990835,Fatigue,General disorders and administration site conditions,No,5%,970,1,1,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,970
NCT15990835,Fatigue,General disorders and administration site conditions,No,15%,970,38,67,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,970
NCT15990835,Fatigue,General disorders and administration site conditions,No,10%,970,36,45,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,970
NCT15990835,Fatigue,General disorders and administration site conditions,No,10%,970,5,5,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,970
NCT15990835,Fatigue,General disorders and administration site conditions,No,10%,970,40,44,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,970
NCT15990835,Fatigue,General disorders and administration site conditions,No,10%,970,21,38,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,970
NCT15990835,Fatigue,General disorders and administration site conditions,No,10%,970,43,79,Treatment Emergent,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,970
NCT15990835,Fatigue,General disorders and administration site conditions,No,5%,970,30,58,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,970
NCT15990835,Fatigue,General disorders and administration site conditions,No,10%,970,5,7,Treatment Emergent,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 2,970
NCT62484067,Fatigue,General disorders and administration site conditions,No,15%,266,11,12,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 3,266
NCT62484067,Fatigue,General disorders and administration site conditions,No,15%,266,6,9,Treatment Emergent,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 3,266
NCT62484067,Fatigue,General disorders and administration site conditions,No,10%,266,22,32,Treatment Emergent,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 3,266
NCT62484067,Fatigue,General disorders and administration site conditions,No,5%,266,19,28,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 3,266
NCT76321648,Fatigue,General disorders and administration site conditions,No,5%,961,44,78,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 3,961
NCT76321648,Fatigue,General disorders and administration site conditions,No,15%,961,23,23,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 3,961
NCT76321648,Fatigue,General disorders and administration site conditions,No,15%,961,17,21,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 3,961
NCT11808985,Fatigue,General disorders and administration site conditions,No,5%,888,11,20,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,888
NCT11808985,Fatigue,General disorders and administration site conditions,No,10%,888,28,56,Treatment Emergent,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,888
NCT11808985,Fatigue,General disorders and administration site conditions,No,5%,888,34,63,Treatment Emergent,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,888
NCT11808985,Fatigue,General disorders and administration site conditions,No,15%,888,19,34,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,888
NCT11808985,Fatigue,General disorders and administration site conditions,No,15%,888,21,36,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,888
NCT11808985,Fatigue,General disorders and administration site conditions,No,10%,888,26,48,Treatment Emergent,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,888
NCT11808985,Fatigue,General disorders and administration site conditions,No,15%,888,24,47,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,888
NCT11808985,Fatigue,General disorders and administration site conditions,No,15%,888,46,66,Treatment Emergent,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,888
NCT11808985,Fatigue,General disorders and administration site conditions,No,15%,888,36,58,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,888
NCT11808985,Fatigue,General disorders and administration site conditions,No,5%,888,22,29,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,888
NCT11808985,Fatigue,General disorders and administration site conditions,No,15%,888,42,64,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,888
NCT11808985,Fatigue,General disorders and administration site conditions,No,15%,888,8,12,Treatment Emergent,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,888
NCT46815158,Fatigue,General disorders and administration site conditions,No,5%,31,2,4,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,31
NCT46815158,Fatigue,General disorders and administration site conditions,No,5%,31,3,5,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,31
NCT46815158,Fatigue,General disorders and administration site conditions,No,10%,31,2,3,Treatment Emergent,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,31
NCT46815158,Fatigue,General disorders and administration site conditions,No,10%,31,2,2,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,31
NCT46815158,Fatigue,General disorders and administration site conditions,No,10%,31,1,2,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,31
NCT46815158,Fatigue,General disorders and administration site conditions,No,15%,31,3,6,Treatment Emergent,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,31
NCT46815158,Fatigue,General disorders and administration site conditions,No,15%,31,1,2,Treatment Emergent,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,31
NCT46815158,Fatigue,General disorders and administration site conditions,No,10%,31,3,5,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,31
NCT46815158,Fatigue,General disorders and administration site conditions,No,15%,31,1,2,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,31
NCT46815158,Fatigue,General disorders and administration site conditions,No,5%,31,1,1,Treatment Emergent,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,31
NCT46815158,Fatigue,General disorders and administration site conditions,No,5%,31,3,3,All Causality,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,31
NCT46815158,Fatigue,General disorders and administration site conditions,No,15%,31,2,2,Treatment Emergent,Certolizumab,Anti-TNF,Rheumatoid Arthritis,Phase 4,31
NCT35993705,Fatigue,General disorders and administration site conditions,No,10%,801,29,41,All Causality,Certolizumab,Anti-TNF,Crohn's Disease,Phase 1,801
NCT35993705,Fatigue,General disorders and administration site conditions,No,10%,801,47,81,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 1,801
NCT35993705,Fatigue,General disorders and administration site conditions,No,10%,801,48,57,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 1,801
NCT35993705,Fatigue,General disorders and administration site conditions,No,15%,801,20,37,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 1,801
NCT35993705,Fatigue,General disorders and administration site conditions,No,5%,801,28,56,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 1,801
NCT35993705,Fatigue,General disorders and administration site conditions,No,5%,801,36,67,All Causality,Certolizumab,Anti-TNF,Crohn's Disease,Phase 1,801
NCT35993705,Fatigue,General disorders and administration site conditions,No,5%,801,27,40,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 1,801
NCT85373679,Fatigue,General disorders and administration site conditions,No,15%,537,20,25,All Causality,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,537
NCT85373679,Fatigue,General disorders and administration site conditions,No,15%,537,1,2,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,537
NCT85373679,Fatigue,General disorders and administration site conditions,No,15%,537,18,20,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,537
NCT85373679,Fatigue,General disorders and administration site conditions,No,5%,537,10,10,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,537
NCT85373679,Fatigue,General disorders and administration site conditions,No,15%,537,3,4,All Causality,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,537
NCT85373679,Fatigue,General disorders and administration site conditions,No,15%,537,33,43,All Causality,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,537
NCT85373679,Fatigue,General disorders and administration site conditions,No,10%,537,23,29,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,537
NCT85373679,Fatigue,General disorders and administration site conditions,No,5%,537,43,86,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,537
NCT85373679,Fatigue,General disorders and administration site conditions,No,5%,537,31,36,All Causality,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,537
NCT41165618,Fatigue,General disorders and administration site conditions,No,10%,783,41,69,All Causality,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,783
NCT41165618,Fatigue,General disorders and administration site conditions,No,15%,783,6,9,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,783
NCT41165618,Fatigue,General disorders and administration site conditions,No,10%,783,38,47,All Causality,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,783
NCT41165618,Fatigue,General disorders and administration site conditions,No,10%,783,18,34,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,783
NCT41165618,Fatigue,General disorders and administration site conditions,No,15%,783,18,18,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,783
NCT41165618,Fatigue,General disorders and administration site conditions,No,10%,783,47,67,All Causality,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,783
NCT74965919,Fatigue,General disorders and administration site conditions,No,5%,64,2,4,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,64
NCT74965919,Fatigue,General disorders and administration site conditions,No,5%,64,6,11,All Causality,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,64
NCT74965919,Fatigue,General disorders and administration site conditions,No,15%,64,1,1,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,64
NCT74965919,Fatigue,General disorders and administration site conditions,No,15%,64,2,4,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,64
NCT74965919,Fatigue,General disorders and administration site conditions,No,5%,64,3,4,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,64
NCT74965919,Fatigue,General disorders and administration site conditions,No,10%,64,2,3,All Causality,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,64
NCT74965919,Fatigue,General disorders and administration site conditions,No,10%,64,1,2,All Causality,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,64
NCT74965919,Fatigue,General disorders and administration site conditions,No,15%,64,4,4,All Causality,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,64
NCT74965919,Fatigue,General disorders and administration site conditions,No,10%,64,4,8,All Causality,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,64
NCT74965919,Fatigue,General disorders and administration site conditions,No,5%,64,5,8,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,64
NCT74965919,Fatigue,General disorders and administration site conditions,No,5%,64,4,5,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,64
NCT74965919,Fatigue,General disorders and administration site conditions,No,10%,64,2,3,All Causality,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,64
NCT74965919,Fatigue,General disorders and administration site conditions,No,15%,64,1,1,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,64
NCT74965919,Fatigue,General disorders and administration site conditions,No,10%,64,3,5,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 2,64
NCT70065580,Fatigue,General disorders and administration site conditions,No,10%,979,28,30,All Causality,Certolizumab,Anti-TNF,Crohn's Disease,Phase 3,979
NCT70065580,Fatigue,General disorders and administration site conditions,No,10%,979,13,21,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 3,979
NCT70065580,Fatigue,General disorders and administration site conditions,No,5%,979,42,64,All Causality,Certolizumab,Anti-TNF,Crohn's Disease,Phase 3,979
NCT70065580,Fatigue,General disorders and administration site conditions,No,15%,979,17,19,All Causality,Certolizumab,Anti-TNF,Crohn's Disease,Phase 3,979
NCT70065580,Fatigue,General disorders and administration site conditions,No,5%,979,33,46,All Causality,Certolizumab,Anti-TNF,Crohn's Disease,Phase 3,979
NCT70065580,Fatigue,General disorders and administration site conditions,No,10%,979,35,49,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 3,979
NCT70065580,Fatigue,General disorders and administration site conditions,No,5%,979,20,21,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 3,979
NCT93831616,Fatigue,General disorders and administration site conditions,No,15%,305,18,28,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 3,305
NCT93831616,Fatigue,General disorders and administration site conditions,No,10%,305,6,11,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 3,305
NCT93831616,Fatigue,General disorders and administration site conditions,No,15%,305,10,13,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 3,305
NCT93831616,Fatigue,General disorders and administration site conditions,No,5%,305,30,59,All Causality,Certolizumab,Anti-TNF,Crohn's Disease,Phase 3,305
NCT93831616,Fatigue,General disorders and administration site conditions,No,5%,305,2,4,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 3,305
NCT93831616,Fatigue,General disorders and administration site conditions,No,5%,305,28,56,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 3,305
NCT93831616,Fatigue,General disorders and administration site conditions,No,10%,305,19,29,All Causality,Certolizumab,Anti-TNF,Crohn's Disease,Phase 3,305
NCT71567453,Fatigue,General disorders and administration site conditions,No,10%,800,1,1,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 3,800
NCT71567453,Fatigue,General disorders and administration site conditions,No,5%,800,12,16,All Causality,Certolizumab,Anti-TNF,Crohn's Disease,Phase 3,800
NCT71567453,Fatigue,General disorders and administration site conditions,No,5%,800,48,77,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 3,800
NCT71567453,Fatigue,General disorders and administration site conditions,No,15%,800,47,84,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 3,800
NCT71567453,Fatigue,General disorders and administration site conditions,No,5%,800,9,11,All Causality,Certolizumab,Anti-TNF,Crohn's Disease,Phase 3,800
NCT71567453,Fatigue,General disorders and administration site conditions,No,15%,800,38,57,All Causality,Certolizumab,Anti-TNF,Crohn's Disease,Phase 3,800
NCT71567453,Fatigue,General disorders and administration site conditions,No,5%,800,11,21,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 3,800
NCT71567453,Fatigue,General disorders and administration site conditions,No,15%,800,38,42,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 3,800
NCT71567453,Fatigue,General disorders and administration site conditions,No,15%,800,24,45,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 3,800
NCT71567453,Fatigue,General disorders and administration site conditions,No,5%,800,43,62,All Causality,Certolizumab,Anti-TNF,Crohn's Disease,Phase 3,800
NCT42977990,Fatigue,General disorders and administration site conditions,No,5%,764,17,30,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 4,764
NCT42977990,Fatigue,General disorders and administration site conditions,No,10%,764,49,50,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 4,764
NCT42977990,Fatigue,General disorders and administration site conditions,No,10%,764,45,75,All Causality,Certolizumab,Anti-TNF,Crohn's Disease,Phase 4,764
NCT42977990,Fatigue,General disorders and administration site conditions,No,15%,764,46,68,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 4,764
NCT42977990,Fatigue,General disorders and administration site conditions,No,15%,764,45,73,Treatment Emergent,Certolizumab,Anti-TNF,Crohn's Disease,Phase 4,764
NCT29107906,Fatigue,General disorders and administration site conditions,No,5%,593,48,79,Treatment Emergent,Certolizumab,Anti-TNF,Psoriasis,Phase 1,593
NCT29107906,Fatigue,General disorders and administration site conditions,No,5%,593,14,18,Treatment Emergent,Certolizumab,Anti-TNF,Psoriasis,Phase 1,593
NCT29107906,Fatigue,General disorders and administration site conditions,No,15%,593,4,8,All Causality,Certolizumab,Anti-TNF,Psoriasis,Phase 1,593
NCT29107906,Fatigue,General disorders and administration site conditions,No,15%,593,48,71,Treatment Emergent,Certolizumab,Anti-TNF,Psoriasis,Phase 1,593
NCT29107906,Fatigue,General disorders and administration site conditions,No,15%,593,43,47,Treatment Emergent,Certolizumab,Anti-TNF,Psoriasis,Phase 1,593
NCT29107906,Fatigue,General disorders and administration site conditions,No,10%,593,46,65,Treatment Emergent,Certolizumab,Anti-TNF,Psoriasis,Phase 1,593
NCT29107906,Fatigue,General disorders and administration site conditions,No,10%,593,13,16,All Causality,Certolizumab,Anti-TNF,Psoriasis,Phase 1,593
NCT29107906,Fatigue,General disorders and administration site conditions,No,15%,593,43,57,Treatment Emergent,Certolizumab,Anti-TNF,Psoriasis,Phase 1,593
NCT29107906,Fatigue,General disorders and administration site conditions,No,5%,593,10,10,Treatment Emergent,Certolizumab,Anti-TNF,Psoriasis,Phase 1,593
NCT29107906,Fatigue,General disorders and administration site conditions,No,5%,593,4,4,All Causality,Certolizumab,Anti-TNF,Psoriasis,Phase 1,593
NCT29107906,Fatigue,General disorders and administration site conditions,No,5%,593,22,40,All Causality,Certolizumab,Anti-TNF,Psoriasis,Phase 1,593
NCT89978301,Fatigue,General disorders and administration site conditions,No,10%,53,2,3,Treatment Emergent,Certolizumab,Anti-TNF,Psoriasis,Phase 2,53
NCT89978301,Fatigue,General disorders and administration site conditions,No,10%,53,2,3,All Causality,Certolizumab,Anti-TNF,Psoriasis,Phase 2,53
NCT89978301,Fatigue,General disorders and administration site conditions,No,15%,53,3,5,All Causality,Certolizumab,Anti-TNF,Psoriasis,Phase 2,53
NCT89978301,Fatigue,General disorders and administration site conditions,No,15%,53,3,6,All Causality,Certolizumab,Anti-TNF,Psoriasis,Phase 2,53
NCT89978301,Fatigue,General disorders and administration site conditions,No,10%,53,4,5,All Causality,Certolizumab,Anti-TNF,Psoriasis,Phase 2,53
NCT89978301,Fatigue,General disorders and administration site conditions,No,10%,53,5,5,All Causality,Certolizumab,Anti-TNF,Psoriasis,Phase 2,53
NCT89978301,Fatigue,General disorders and administration site conditions,No,5%,53,1,2,All Causality,Certolizumab,Anti-TNF,Psoriasis,Phase 2,53
NCT89978301,Fatigue,General disorders and administration site conditions,No,15%,53,3,4,All Causality,Certolizumab,Anti-TNF,Psoriasis,Phase 2,53
NCT89978301,Fatigue,General disorders and administration site conditions,No,10%,53,2,3,All Causality,Certolizumab,Anti-TNF,Psoriasis,Phase 2,53
NCT89978301,Fatigue,General disorders and administration site conditions,No,5%,53,1,2,Treatment Emergent,Certolizumab,Anti-TNF,Psoriasis,Phase 2,53
NCT89978301,Fatigue,General disorders and administration site conditions,No,15%,53,2,3,All Causality,Certolizumab,Anti-TNF,Psoriasis,Phase 2,53
NCT63389468,Fatigue,General disorders and administration site conditions,No,10%,146,14,27,Treatment Emergent,Certolizumab,Anti-TNF,Psoriasis,Phase 3,146
NCT63389468,Fatigue,General disorders and administration site conditions,No,5%,146,12,13,All Causality,Certolizumab,Anti-TNF,Psoriasis,Phase 3,146
NCT63389468,Fatigue,General disorders and administration site conditions,No,5%,146,14,18,All Causality,Certolizumab,Anti-TNF,Psoriasis,Phase 3,146
NCT63389468,Fatigue,General disorders and administration site conditions,No,15%,146,5,10,All Causality,Certolizumab,Anti-TNF,Psoriasis,Phase 3,146
NCT63389468,Fatigue,General disorders and administration site conditions,No,10%,146,10,13,Treatment Emergent,Certolizumab,Anti-TNF,Psoriasis,Phase 3,146
NCT63389468,Fatigue,General disorders and administration site conditions,No,5%,146,14,27,Treatment Emergent,Certolizumab,Anti-TNF,Psoriasis,Phase 3,146
NCT63389468,Fatigue,General disorders and administration site conditions,No,5%,146,11,15,Treatment Emergent,Certolizumab,Anti-TNF,Psoriasis,Phase 3,146
NCT63389468,Fatigue,General disorders and administration site conditions,No,5%,146,13,19,Treatment Emergent,Certolizumab,Anti-TNF,Psoriasis,Phase 3,146
NCT94256173,Fatigue,General disorders and administration site conditions,No,15%,982,9,9,All Causality,Certolizumab,Anti-TNF,Psoriasis,Phase 4,982
NCT94256173,Fatigue,General disorders and administration site conditions,No,15%,982,49,75,All Causality,Certolizumab,Anti-TNF,Psoriasis,Phase 4,982
NCT94256173,Fatigue,General disorders and administration site conditions,No,10%,982,48,48,All Causality,Certolizumab,Anti-TNF,Psoriasis,Phase 4,982
NCT94256173,Fatigue,General disorders and administration site conditions,No,10%,982,26,30,Treatment Emergent,Certolizumab,Anti-TNF,Psoriasis,Phase 4,982
NCT94256173,Fatigue,General disorders and administration site conditions,No,10%,982,5,9,All Causality,Certolizumab,Anti-TNF,Psoriasis,Phase 4,982
NCT94256173,Fatigue,General disorders and administration site conditions,No,15%,982,17,18,Treatment Emergent,Certolizumab,Anti-TNF,Psoriasis,Phase 4,982
NCT94256173,Fatigue,General disorders and administration site conditions,No,15%,982,23,45,All Causality,Certolizumab,Anti-TNF,Psoriasis,Phase 4,982
NCT94256173,Fatigue,General disorders and administration site conditions,No,5%,982,29,52,Treatment Emergent,Certolizumab,Anti-TNF,Psoriasis,Phase 4,982
